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Introduction  
A study on human resource management 
practices and learning for innovation 
 
 
 
The use of the systems of innovation framework to study learning and innovation 
dates back to the mid-1980s (Freeman 2002; Lundvall et al., 2002). The most 
immediate roots trace back to three pioneering works:
1
 Freeman’s (1987) study on 
the Japanese innovation system; Nelson’s (1993) analyses of the systems of 
innovation in a number of developed and “dynamic” developing countries from a 
historical perspective; and Lundvall’s (1992) propositions on user-producer 
interactions as bases for the construction of national innovation systems. These 
seminal works have led to substantial research intended to refine the foundations 
and analytical tools of the framework.  
Notwithstanding its newness the concept of systems of innovation is rapidly 
becoming the common language of scholars and policy makers (Lundvall et.al, 2002; 
Smith 2000),
2
 who are adapting and applying it to the study of developing countries. 
In addition to the chapters on Argentina, Brazil, South Korea and Taiwan in Nelson 
(1993), others have conducted research on Latin America (Alcorta and Peres 1998; 
Cassiolato et.al, 2003; Cimoli and Constantino 2000), Asia (Chang and Shih 2004; 
Mani 2002) and Africa (Muchi et.al, 2003). The large and dynamic economies of 
Brazil, Russia, India, China, South Africa (BRICS) and Mexico have received the most 
attention in the literature (IDRC 2007; Dutrénit et al 2010). 
A relevant lesson to emerge from the literature on systems of innovation is that 
learning and innovation are interactive, socially embedded processes that take place 
within particular socioeconomic, institutional and cultural contexts (Gibbons et.al, 
1994; Lundvall 1988 and 1992). Strongly linked to this is the focus on determinants 
of innovation at the micro level and more specifically, the learning processes of 
firms (Edquist and McKelvey 2000; Lundvall 1992; Lundvall et.al, 2002). The quality 
and quantity of human resources is cited among the top factors that contribute to 
this learning and innovation (Barney 1991; Leonard-Barton 1992).  
Researchers have striven to identify and understand the factors that determine 
both the quantity and quality of human resources for science, technology and 
                                                 
1 Freeman (1995) and Lundvall et al., (2002) acknowledge that inspiration for seminal contributions to 
the literature on systems of innovation go back to Adam Smith and notably, the German philosopher 
Friedrich List.  
2 Comprehensive accounts of the factors explaining such rapid diffusion are found in Smith (2000), Lund-
vall et.al, (2002) and Freeman (2002) 
1
innovation (STI). Significant research is conducted on the development and 
performance of universities and other higher education and research organizations. 
This is understandable as sound empirical evidence shows the critical role of such 
organizations to research capacity building and innovation. In such a way those 
organizations significantly shape the functioning of systems of innovation in general 
(Nelson 1991; Pavitt 1998), and developments in labour markets in particular (Lijima 
and Tachiki 1994; Velloso 2002). 
In the case of developing countries, the supply biased approach is applied to 
study the development of human resources for STI. For instance, in his book on 
systems of innovation Nelson argued that the lack of synergy between industry and 
post-secondary institutions in South Korea was a result of the strong teaching 
orientation of its education organizations (Nelson 1993). In the cases of Argentina, 
Taiwan and Brazil attention centred on the performance, development, structure 
and quality of formal education systems (Nelson 1993). More recent research 
addresses education in general and universities in particular, as important 
background in exploring and analysing economic activities and the knowledge 
inputs that lead to industrial innovation (Cassiolato et.al, 2003; Cimoli and 
Constantino 2000). These studies typically carry out international comparisons of 
structures and performance of education and training systems. These works 
underpin what Freeman (1995) called league tables of cross-country rankings of 
average years of schooling; enrolment rates by core knowledge-fields; education 
levels among different cohorts of population and particularly, of the labour force; 
quality as measured through educational attainment and output in a number of S&T 
indicators, among others. Examples are found in Alcorta and Peres (1998); Chang 
and Shih (2004); Lichtenberg (1994); Nelson (1993); Oyelaran-Oyeyinka and Barclay 
(2004) and Valenti and del Castillo (2000).  
By contrast the study of determinants of the demand for human resources 
usually limits to assessing the capacity of an economy, notably private firms, to 
accommodate the supply of highly qualified human resources. Arguably in order to 
develop, absorb and use economic relevant knowledge, shaping strong education 
systems is sine qua non condition for success. Sound empirical evidence and 
theoretical reasons support recurrent concerns regarding the contribution of 
education systems to building the supply of human resources (Nelson 1959; Pavitt 
1998). This narrow focus on the role of supply raises questions as to whether some 
other factors have been overlooked.  
This thesis seeks to explore and identify factors other than academic 
environments that contribute to the effective development of human resources for 
STI. In particular it sheds light on the relationship between human resource 
management practices and learning for innovation in developing countries. To this 
end, the thesis draws heavily on and contributes to three strands of literature, 
namely: (1) systems of innovation, with a specific focus on developing countries; (2) 
2
human resource management practices and innovation performance at the level of 
the firm; and, (3) learning through R&D. These are outlined below. 
First, in relation to the literature on systems of innovation and the economics of 
innovation more generally, this thesis departs from traditional inquiries into the 
strengths of the systems framework, and instead examines some of its 
shortcomings. It emphasizes weaknesses associated with the approaches typically 
used to identify determining factors in the development of human resources for 
scientific and technological activities, notably R&D. To date, research in the field 
focuses narrowly on supply rather than the demand for those human resources.  
Firms are the locus of learning and innovation, how they carry out activities that 
bolster these areas influences the actions of other relevant agents in the 
environment. In other words firms shape and guide the operation of systems of 
innovation (Nelson and Winter 1982). If this is the case, then it is important to 
investigate how firms contribute to the development of human resources for STI. In 
recent works by Lundvall et al. (2002), (White 2002) and Arundel et al. (2007), for 
example, attention is drawn to the role played by human resource management 
practices as mechanisms shaping learning environments and research, capacity 
building within organizations, in fact, the functioning of systems of innovation.  
Second, the thesis draws from recent research on the linkages between human 
resource management practices and performance at the firm level, and specifically, 
studies that emphasize innovation as relevant performance indicator. The thesis 
addresses the influence of management practices on learning and innovation in 
developing countries. This focus represents a major contribution to the field, as 
research in this area has traditionally examined the case of developed countries. By 
exploring developing countries, new insights can be gained regarding the role 
human resource management practices play in fostering absorptive capacities and 
innovation within firms operating in catching up contexts.  
Third, by tapping into research on individual and organizational learning, this 
thesis identifies some relevant factors explaining learning for innovation at the firm 
level. Previous studies have addressed the context in which firms operate, the 
nature of learning and innovation processes inside organizations, and the learning 
objectives firms pursue over time. Consistent with literature on developing 
countries, this thesis interprets R&D as referring to learning, a mechanism that 
promotes absorptive capacity and which supports technology capability-building 
(Dutrénit 2000; Kale and Little 2007). The analysis differs from traditional views of 
innovation that emphasize such outcomes as patent counts, number of 
products/processes and corresponding degrees of novelty, which are unable to 
provide a comprehensive picture of the complex learning processes that firms 
undertake.  
The analytical framework used in this thesis distinguishes between learning as a 
strategy, and learning in terms of the knowledge gained by the firm. Firms pursue 
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diverse objectives during the innovation process, encourage different learning 
strategies, and require distinct types of knowledge flows in order to generate new 
and creative ideas. R&D is a core component of the learning process. Moreover, 
different knowledge requirements associate with distinct R&D outcomes that in 
turn, show distinct degrees of novelty, at least for the firm. Contingent on these 
factors, firms adopt different types of human resource management practices. It 
follows then that the contribution of such practices to innovative performance 
should differ as well.  
This thesis differs from previous studies in the field, as it emphasizes the 
importance of examining learning. It also circumvents some challenges encountered 
in previous research where the intention is to trace direct links between human 
resource management practices and innovation at the firm level. Such studies find it 
difficult to explain how and why management practices underpin innovation. So far 
the role of learning as an intermediary process remains insufficiently explored in 
both the systems of innovation and management literature. While the data collected 
for this study steered the focus of the analysis on learning at the organization level, 
the underlying logic is that such learning reflects and feeds back and forth to 
learning at the individual level. Chapter 1 explains this in detail. 
As an additional contribution to the literature, this thesis seeks to provide a 
clearer understanding of how human resource management practices underpin 
learning for innovation in a single industry. This approach allows for a more in-depth 
appreciation of the context in which such a relationship emerges; in other words, 
how both local and global factors shape a firm’s learning and innovation efforts. For 
instance, the environment impacts business strategies and perspectives, notably 
incentives and directions for investment in R&D. Thus, the analysis that will be 
undertaken here will follow from the predominant view in the literature regarding 
the importance of understanding the characteristics of and differences in innovation 
processes across industries and, arguably, countries (Laursen and Foss 2003; Lorenz 
and Wilkinson 2003; Lundvall et al 2007). This makes it possible to identify the areas 
where countries, firms and ultimately human resource management practices are 
able to contribute to industry learning and innovation.  
This thesis focuses on the pharmaceutical industry; and more specifically on the 
role of human resource management practices as determinants of learning in this 
area. This is an interesting case, as pharmaceuticals have quite significant socio-
economic, health and ethical implications on human beings; the industry invests 
intensively in R&D. It is an industry where distinctions between research and 
development activities result in very specific patterns of specialization in how firms 
and countries contribute to innovation in the industry. Moreover such distinction 
implies that the type of personnel and associated working conditions also differ 
across the different stages of the pharmaceutical innovation process.  
In this context, the presence of a fairly complex pharmaceutical industry in a 
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developing country such as Mexico raises concerns in terms of the capacity of local 
pharmaceutical companies to carry out and profit from their technological efforts 
(Guzmán 2005; Katz et.al, 1997). It also brings into question the extent to which 
such efforts contribute to further advancement of human resources development 
for innovation in the country. In response to these gaps, this thesis addresses the 
following questions: 
 
 Do management practices contribute to learning at the firm level in Mexican 
pharmaceutical firms? If so, how? If not, why? 
 Which practices have the greatest impact on learning, and thus pharmaceutical 
R&D in Mexico? 
 How do management practices shape a pharmaceutical firm’s interaction with 
other agents in the system of innovation during performance of R&D? 
 
In order to examine these questions the thesis is organised as follows: A sub-
stantial literature review in chapter 1 documents how the actions of agents in non-
academic environments, notably firms, contribute to the development of human 
resources for innovation. The chapter discusses the role of human resource man-
agement practices as mechanisms underpinning innovation performance at the 
level of the firm. It also highlights the role of R&D as a learning mechanism support-
ing innovation and innovation capacity building in latecomer firms.  
Following this background, Chapter 2 presents the analytical framework. The 
chapter splits in two main sections. First it highlights the importance of understand-
ing certain environmental factors, including the knowledge base of a firm, and the 
general characteristics of innovation processes framing the activities of the human 
resources involved in learning and innovation. This makes it possible to appreciate 
the context where firms operate, and consequently to understand what is feasible 
for them in terms of learning, innovation and, ultimately, human resource man-
agement practices. The second section outlines six alternative yet complementary 
analytical approaches to conducting research about management practices, learn-
ing and innovation. The discussion here draws attention to the case of Mexico. 
These six approaches inform the empirical analysis of this thesis.  
Chapter 3 splits into two related sections. Based on an extensive literature re-
view, section 1 defines the variables on human resource management practices 
relevant for the analysis. The second section describes the data and data collection 
methods used in this thesis.  
The empirical analysis is structured in two parts. Part 1 is presented in chapters 
4 and 5. Chapter 4 characterises pharmaceutical innovation at a global level. It out-
lines the several stages and corresponding learning processes, and the interesting 
technological trends of recent years. It also identifies the areas within the innova-
tion process where developing countries are more able to participate and how they 
5
do so. The chapter suggests the need to pay more attention to R&D and other inno-
vation-oriented activities carried out at the advanced stages of the innovation cycle, 
which is where developing countries concentrate the bulk of their technological 
efforts. Complex scientific and technological developments in pharmaceuticals, the 
time consuming and burdensome procedures required for new drug testing and 
development attract considerable attention in the literature. This notwithstanding, 
recent initiatives launched by health authorities in the leading American pharma-
ceutical market seek to favour innovation in drug manufacturing. Increased auto-
mation, systematization and enhanced scientific-based management of manufactur-
ing processes expect to enhance efficiency, workplace conditions, and product qual-
ity and safety. The diffusion of such initiatives to developing countries raises inter-
esting issues for research. 
Chapter 5 introduces the pharmaceutical industry in Mexico. The country is an 
interesting case for study, considering the relative influence of its economy in Latin 
America. Moreover, the country is the tenth largest pharmaceutical market in the 
world, and the second largest in Latin America, and is in close proximity to the dy-
namic US pharmaceutical market. By looking at the Mexican experience, some in-
teresting conclusions can be drawn with regard to the role of technology and em-
ployee conditions of the pharmaceutical industry in Latin America. The chapter 
characterises pharmaceutical-related learning and innovation activities in Mexico. 
Hence, it examines the context in which human resource management practices 
come into play during learning and innovation processes in the country. 
Part 2 contains the econometric analyses. Chapters 6 through 8 explore the 
linkages between human resource management practices and learning for innova-
tion. Based on the case of the pharmaceutical industry in Mexico, the work follows 
Delery’s (1998) suggestion as to the importance of looking at how management 
practices influence performance. The three interconnected chapters consider how a 
similar set of human resource management practices underpins distinct learning 
strategies within a firm. Based on traditional transaction costs theory (Williamson 
1975 and 1985), the analysis first focuses on individual choices of learning strate-
gies. In this scenario firms may produce technology based on internal technological 
efforts (chapter 6); alternatively, firms can tap external knowledge sources as an 
exclusive means to acquire technologies (chapter 7). Finally, learning strategies are 
taken as being not mutually exclusive (Veugelers 1999). Knowledge flows obtained 
from external markets for technology, complement learning efforts in-house (chap-
ter 8). 
The three econometric chapters use distinct definitions of R&D, thus implying 
the different knowledge requirements that firms need to fulfil in order to innovate. 
In line with knowledge-based theories of the firm, firms can either exploit 
knowledge available within their customary knowledge base, or seek out knowledge 
thus far unavailable to them. The empirical analyses reveal positive linkages 
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between management practices and learning at the firm level, and indicate that 
relationships are contingent on factors such as the expected outcome from R&D, or 
the novelty of the knowledge required by the firm.  
Chapter 9 concludes with an integrative view of management practices and 
learning for innovation in the pharmaceutical industry in Mexico. Building on the 
empirical analysis, the chapter offers some recommendations for further research 
on the linkages between management practices and learning for innovation in Mex-
ico and other similar developing contexts.  
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Chapter 1  
Development of human resources for innova-
tion: Reappraising the contribution of firms1 
 
 
 
1. Introduction 
 
The introductory chapter argued that the innovation systems approach remains an 
underdeveloped area of research.
2
 There are a number of challenges, particularly 
with regard to studying the case of developing countries. A major weakness stems 
from traditional analyses of the processes supporting development of human 
resources for STI activities, notably R&D. Much attention is paid to investigating how 
learning within educational organizations underpins the supply of such resources. By 
contrast, still relatively little is known about the extent to which other agents, such 
as firms, can also contribute. Further exploring these issues should enhance the 
analytical power of the systems of innovation framework. Potential research topics 
are many, from macro to micro, from public policy to labour markets and firm 
related aspects; section 2 of this chapter addresses these topics in greater detail. 
Section 3 discusses some recent studies on the influence of human resource 
management practices on innovation performance at the firm level; these constitute 
the basic theoretical underpinnings of this thesis. The discussion here highlights 
some issues requiring further research; in particular the role of learning as an 
intermediary process between human resource management practices and 
innovation performance. Addressing firms in a developing country context, section 4 
argues about the importance of looking at R&D as a learning mechanism requiring a 
strong commitment and effort at both the individual and organizational levels.  
 
2. How non-academic environments contribute to the development of human 
resources for science, technology and innovation 
 
There are at least two broad, but to a certain extent, complementary perspectives to 
analyse how non-academic agents contribute to the development of human 
resources for STI (Figure 1.1). On the one hand, the literature indicates the role of 
                                                 
1 This chapter benefited from comments and suggestions by people attending a mid-term progress 
Seminar at UNU-Intech, 2005; participants at the 2nd Globelics Academy, particularly Rui Baptista and 
Pedro Conceição; the 3rd and 4th Globelics Annual Conferences 2005 and 2006, respectively; Gabriel 
Yoguel and Jorge Katz. 
2 Lundvall et al (2002), Freeman (2002) and Malerba (2002) provide more ample discussion. 
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policy interventions, particularly through activities promoting human resource 
development. On the other hand there is the dynamics of labour markets. Each of 
these is discussed in more detail below. 
 
Figure 1.1 Alternative approaches to investigate the role of non-academic factors on the development of human re-
sources for science, technology and innovation. 
Sources of influence: 
Government’s human resource development policy Labour market structure and dynamics 
• Building supply with/without orientation 
(flows of human resources): 
¬ Strategic Areas 
¬ Linked to final user (demand) 
• Incentives to performance (stock of human 
resources): 
¬ Nature of professional activities: research or 
other 
¬ Universities and public research centres as 
main recipients  
¬ Criteria for promotion and reward: scientific 
versus technology and innovation products 
¬ Relative balance in public funding to 
scientific versus technology and innovation 
project 
• At macro level (signals from the environment):  
 
¬ Employment rates by  
professional career 
 
 
¬ (In)formal labour markets 
¬ Average wages  
¬ Social perception 
 
• At the micro (firm) level: 
¬ Firms’ strategic human resource management 
practices as the basis for improved performance: 
what about innovation? 
¬ Relevance of sector/industry affiliation 
Source: author 
 
2.1. The role of public policy 
 
Different rationales support public interventions in STI including the development of 
human resources in the field. The argument of market failures is recurrent. Gov-
ernments compensate for the missing or inadequate investment by the private 
sector in socially relevant areas, but with unattractive rates of return. Alternatively 
public policies compensate for system failures, including coordination and the na-
ture of linkages among agents in systems of innovation (Smith 2000). Adoption of 
an evolutionary perspective hints at the capacity of public policy: (i) to adapt and 
adjust through sequencing and packaging of policy interventions (Kuruvilla et.al, 
2002); and, (ii) to allow for the complementary actions needed to impact on per-
formance, motivations and reactions of the agents involved (Metcalfe 1994; 
Mohnen and Roller 2005).  
With regard to public policy, particularly in support of human resource 
development, research focuses on government’s contribution to building scientific 
and technological capabilities (Mani 2002; Sanz-Menéndez and Cruz-Castro 2005). 
Based on evidence related to postgraduate scholarship programs in countries such 
as Mexico and Spain, Ortega et.al, (2002), Sanz-Menéndez and Cruz-Castro (2005) 
Sector/industry 
differences; occupation; 
education profiles 
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and FCCT (2006) documented how governments assign priorities, or promote the 
development of specific knowledge-fields particularly at the tertiary level. 
Consideration of the demand for human resources often restricts to whether 
government-sponsored programmes meet the requirements of final users. In other 
words, the extent to which supply and demand for qualified human resources 
matches in labour markets (Quinn and Rubb 2006; Teichler 1999; Wei 2005).  
Arguably the contribution from public policy is more complex. Lijima and Tachiki 
(1994), Govinda (1998) and Kuruvilla et.al, (2002) show how public policy 
interventions in some Asian countries have contributed to the supply of human 
resources by coordinating and aligning it with the requirements of other agents, 
notably firms. This approach makes sense as the internal labour dynamics of firms 
ultimately reflect those of the larger labour markets of a country-see section 2.2. 
Governments can guide the activities of researchers in public institutions; even 
transfer part of those resources to the private sector. In this manner public 
organizations contribute to capacity building and the balancing of supply and 
demand for human resources (Sanz-Menéndez and Cruz-Castro 2005). Alternatively 
by implementing differentiated sets of incentives, sanctions and rewards, 
governments can promote particular activities in the labour market, guide further 
development of the stocks of human resources, and to a certain extent, inform 
individuals’ choices of professional careers (Castaños-Lomnitz 2004; Ruíz 2004). This 
is the result of supporting and financing specific research activities, but not others, 
via research grants, competitive funds, enhanced recognition and other pecuniary 
and non-pecuniary incentives (AMC-FCCT 2005). Similar effects stem from the 
definition and application of specific criteria to evaluate research performance. 
People develop different professional paths in response to specific incentives; they 
can do more basic or applied research, or to work on a public research organization 
or an R&D unit within a firm (AMC-FCCT 2005). 
 
2.2. Labour market dynamics and careers in science and technology  
 
Back in 1992 Lundvall’s seminal work on innovation systems recognised the notable 
absence of analyses of national education and training systems (Lundvall 1992). For 
reasons that he unfortunately did not explain, he did not address what he qualified 
as an ‘extremely important’ element of systems of innovation: education systems. 
Lundvall decried the resulting gaps in knowledge about factors influencing the sup-
ply of human resources, namely: the characteristics and determinants of expendi-
ture in education and training, enrolment rates in science and engineering, availabil-
ity of skilled workers, and so on. Lundvall stressed the limited understanding we 
have about formal and informal education and training systems conditioning inno-
vative capabilities across countries, but also about social norms and values repro-
duced through education. He called for the integration of "education and training 
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systems and innovation systems in one single analytical framework” (Lundvall 
1992:14-15).  
A decade later Lundvall and his colleagues observed the persistent lack of in-
depth scrutiny of education systems and, it would appear, a lack of interaction 
between such systems and other agents shaping systems of innovation (Johnson 
and Lundvall 2003; Lundvall et.al, 2002). In response, they highlighted missing 
factors related to the supply of human resources. They also brought attention to, 
without necessarily addressing, the need to increase awareness and understanding 
of market demand and its relationship to the development of human resources for 
innovation. In their view research has ignored the influence of labour market 
dynamics, the organization of and the logic behind processes of knowledge 
creation, learning and human resources development within firms and networks.  
Recent studies point to the absence of systematic research on how the 
functioning of labour markets shape individuals' choice of professional study and 
career (Taczir 2009). There is a need to learn what perceived and existing incentives 
within STI render it an attractive option for prospective students and employees 
(Quinn and Rubb 2006; Velloso 2002); furthermore what draws people to careers in 
engineering versus management. In a study on Portuguese firms, Texeira (2004) 
proposed that factors such as market, product and process strategies, and the 
conscious and intentional behaviour of firms, determine demand for human capital 
and the consequent contribution to performance. These factors are equally or even 
more important than a large pool of educated and skilled labourers.  
The Canberra Manual for the measurement of human resources in S&T clearly 
asserts that students entering into or already attending college or university only 
become part of the stock of human resources in S&T upon graduation (OECD 
1995:32). Educational institutions and labour markets respond to different 
incentives and have distinct working dynamics (OECD 1995 and 1998). 
Consequently, it is pertinent to learn why, when, how, and to track how many 
students choose STI as a path of study and/or employment. Equally relevant is to 
find out why people avoid study (and work) in this field? Low numbers of people 
working in STI in developing countries reflect something more than poor absorptive 
capacity of local labour markets.  
Related to the above, unlike recurrent interest in learning about what factors 
entice students at the tertiary level to a career in science and engineering, so far 
little is known about the conditions and incentives behind the work of industrial 
researchers in developing countries. Literature suggests that different organizations, 
notably industry and universities, have distinct perceptions of knowledge as an 
imperfect public good (Arrow 1962; Nelson 1959; Pavitt 1998; Stephan 1996). It 
makes sense to think that a professional career in industrial research follows a 
different path as compared to one in academic research (Gibbons and Johnston 
1974; NSF 2004; Stephan and Audrestsch 2000). The question is why careers in 
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academic and industrial research differ from each other, what determines their 
attractiveness? Are there any differences in how such research careers develop in 
developed and developing countries?  
 
2.3. Development of human resources for STI in private firms 
 
A third dimension from the perspective of demand confronts the questions of 
whether firms contribute to the development of human resources for S&T and 
innovation, and if so, how they do so. Some of the literature suggests that the 
answer is yes, firms contribute to such a process. Moreover firms do so by means of 
human resource management practices that impact work environments, and in turn 
people’s capacity and willingness to become involved in STI. The view that firms are 
sources of learning and innovation implies that they are producers and not merely 
users of highly qualified human resources. These topics will be explored in more 
depth in the remaining sections of this chapter. 
 
3. Management of human resources and firm’s performance 
 
In his analysis of the spread of Japanese management techniques to developing 
countries, Kaplinsky (1995) criticised economists for their traditionally narrow 
approach to production as a technical outcome of different combinations of 
productive factors. In his opinion such a limited view is problematic as it abstracts 
firms from the richer social context in which they operate. Moreover it fails to 
explain how the application of individual combinations of factors yields very 
different outcomes contingent on the way production is organised (Nelson 1991; 
Wilkens and Pawlowsky 1997). Kaplinsky (1995) further asserts that productive 
inputs are mobilised within particular social structures 
In line with the above, the literature demonstrates increasing interest in 
understanding the alternative knowledge management practices used by firms,
3
 and 
the characteristics of high-performance work-practices in high-performance work-
places.
4
 Scholars address the broad socioeconomic contexts framing the adoption of 
innovative organisational strategies;
5
 practices shaping dynamic work-
environments,
6
 and how they assist in responding to competitive market pressures, 
improve production, productivity, financial performance and so on.
7
 Enhanced work 
practices put great premium on investment in a firm’s intangible assets,
8
 and rely 
strongly on innovative organisational practices and continuous development of 
                                                 
3 Argote et.al, (2003) and Collinson (2001) 
4 Barton and Delbridge (2001), Lorenz and Wilkinson (2003) and OECD (1998) 
5 Doeringer et.al, (2003), Legewie et.al, (2000) 
6 Hemmert (1998), Livesay et.al, (1996), OECD (1998), Terziovski and Morgan (2006) 
7 Bae and Rowley (2004), Bartlett et.al, (2002), Beret et.al, (2003), Ichniowski et.al, (1997), OECD (1999)  
8 Alic (1995) and Sargent and Matthews (1997) 
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human resources.
9
 In summary, management practices assist in organising and co-
ordinating knowledge creation and exploitation in systems characterised by complex 
social relations (Laursen and Foss 2003). At least in part, such is the logic of studies 
linking management interventions to increased efficiency, productivity gains and so 
on.
10
 Nothing prevents the use of this same logic to study the allegedly positive 
relationship between management practices and firms’ innovation performance 
(Laursen and Foss 2003; Michie and Sheehan 1999 and 2003).  
 
3.1. Do management practices influence innovation? 
 
Nelson and Winter (1982) assert that firms are responsible for most innovations. 
Consequently, learning about internal organisation and work practices sheds light on 
how systems of innovation function and are built (Coriat and Weinstein 2002; 
Hemmert 1998). To complement analyses of R&D efforts and other technology 
development processes, it is necessary to investigate the experiences of workers, 
engineers, salesmen, and so on, and their perceptions of daily operations (Hemmert 
1998; Lundvall et.al, 2002). As stated by Lundvall (1992), whenever challenges arise 
in production or post-production, changes need to be made that will ultimately 
shape the firm’s innovative efforts. In his view, workers’ daily experiences contribute 
to signal the direction in which such changes should proceed; organisational 
strategies frame the complex set of interactions taking place within and outside the 
boundaries of a firm (Smith 2000; Zanko et.al, 1998). Arguably these and related 
factors determine the direction and intensity of the innovative practices that firms 
carry out (Lundvall et.al, 2002). Ultimately innovation involves more than the simple 
transfer of knowledge from academic or other connected environments to the 
productive sector (Gibbons et.al, 1994). 
Dynamic work-practices present potential implications for the contribution of 
human resources to innovation systems. Higher job complexity requires greater 
interdependence, communication and feedback among firms and between firms 
and their customer-supply bases (OECD 1998; Okada 2004). This is true at the 'shop-
floor' level, but also for the organisation, management, training, reward for 
continuous creativity, and enhancement of skills featured by innovation-related 
personnel (James 2002; Mumford 2000). In addition to changing education 
requirements, greater weight is placed on continuous learning, training and 
improved performance (Gray et.al, 2004; OECD 1998). Heterogeneity means that 
there are multiple optimal ways to organise human resources to carry out 
innovation (Hemmert 1998; Senge 1990). 
Lorenz and Wilkinson (2003) assert that research still needs to document the 
                                                 
9 Barton and Delbridge (2001), Gray et.al, (2004) 
10 Boseli et.al, (2005), and Ichniowski et.al, (1997) 
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conditions required for high-performance workplaces to become a generalised 
model to manage human resources; what are the consequences of such adoption? 
Subject to debate is the extent to which the dynamic organisational model 
constitutes a new 'best-practice' method that can be adopted across sectors and 
national boundaries; that is, whether it is possible to develop heterogeneous 
models applicable to diverse national and institutional contexts. Research should be 
conducted on how firms’ unique characteristics, the external environment and even 
the internationalisation of activities contribute to the adoption and impact of high-
performance work-practices (Doeringer et.al, 2003; OECD 1998). 
 
3.2. The intermediary role of learning  
 
Few studies have explored the factors linking management practices to innovation 
performance. Thus, there is poor understanding of the mechanisms that can explain 
such a relationship (Laursen and Foss 2003; Lorenz and Wilkinson 2003), and the 
absence of a coherent theory on what Delery (1998) terms the “transmission 
mechanism” from human resource management practices to innovation 
performance. This thesis addresses this gap by examining firms in the context of 
developing countries. It contends that the difficulty in capturing such a transmission 
mechanism derives from customary approaches to research. For instance Lorenz 
and Wilkinson (2003) assert that researchers frequently assume linear relationships-
--from adoption of specific sets of management practices to innovation, leaving little 
room for more heterogeneous organisational strategies within single industries. It is 
customary to look at innovation outcomes---products/processes, and their degrees 
of novelty--radical/incremental; this oversimplifies the richness of the processes 
involved. Underestimated it is the study of the latent processes associated with the 
organisation of innovation-related staff.  
A firm’s human resources constitute both factors of inducement and a limit to 
performance (Leonard-Barton 1992; Penrose 1959). The services those resources 
render to the firm, rather than their presence, is what matters for performance. The 
ways to channel those services are conditioned by how resources are organised and 
used. Building working environments conducive for all these processes to take place 
is imperative for firms wanting to improve performance and, more specifically, their 
capacities to innovate. In this regard Amabile (1996), Mumford (2000) and James 
(2002) argued that research should further explore factors underpinning creativity, 
ways in which creative thinking spreads across groups, organisations and the wider 
environment in which firms operate. This assumes continuous searches for ways to 
organise personnel, particularly those involved in, but not limited to, R&D.  
Alternatively, recent work by Lorenz and Valeyre (2005) and Arundel et.al, 
(2007) on organisational and management practices, learning and innovation, argue 
for the value of examining more carefully the effects of management practices on 
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individuals’ and thereby, organisational learning. Accordingly the main hypothesis in 
this thesis is that learning is one intermediary mechanism between human resource 
management interventions and innovation performance at the firm level. Wright 
et.al, (2001) support this hypothesis; they propose that human capital and 
knowledge are bridging concepts between management systems and firms’ core 
competencies.
11
 Dynamic capabilities in the sense of Teece et.al, (1997), constitute a 
renewal component that ties all those four concepts over time.  
Human capital, as a stock for the firm, constantly changes through the creation, 
transfer, and integration of knowledge flows in ways that are valuable, rare and 
inimitable (Barney 1991). Therefore, “people management systems create value to 
the extent that they impact the stock, flow, and change of intellectual 
capital/knowledge that form the basis of core competencies” (Wright et.al, 
2001:715). Such factors as increased knowledge, skills and abilities need to 
accompany people’s capacity and motivation to perform (Combs et.al, 2006).  
Figure 1.2 depicts the elements of the framework guiding the work in this 
thesis, namely: human resources management practices and the latent learning 
processes linking such practices to innovation performance at firm level. The figure 
suggests that learning processes inside the firm decompose into both individual and 
organisational forms. In terms of the work in this thesis,
12
 the logic is as follows: The 
upper part of Figure 1.2 shows the traditional way to study the linkages between 
human resource management practices and firm’s performance. Based on a 
productivity function, scholars explore how adoption of certain human resource 
management practices—whether individually or in bundles-- contributes to 
innovation performance. As noted earlier, although researchers find positive 
relationships, subject to debate is why this is so.  
By introducing the notion of learning as intermediary process between human 
resources management practices and innovation, brings research onto a longer but, 
arguably, more illuminating path. It is necessary to learn how management practices 
influence cumulative learning processes within organisations. The process starts 
with the learning activities of individuals, subject to management interventions, and 
continues in a cumulative manner throughout the organisation. Individual and 
organisational learning are processes within a series of feedback loops spanning 
different dimensions and instances within and outside the organisation. 
 
                                                 
11 Human capital consists of human (the knowledge skills, and abilities of people), social (the valuable 
relationships among people), and organisational (the processes and routines within the firm) factors 
(Wright et.al, 2001) 
12 At first sight Figure 1.2 looks rather lineal, other arrows, indicating additional and more complex rela-
tions among the different components, can be added. For instance, from innovation performance back to 
individual/organisational learning. Based on the relevant literature this thesis effectively deals with the 
influence of human resource management practices on innovation performance at firm level. Accord-
ingly, the decision was made to keep the graphic representation as simple as possible.  
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Figure 1.2 Schematic representation of a proposed approach to research on human resources and inno-
vation performance at the firm level. 
 
Source: Author 
 
3.2.1. Individual learning 
 
Knowledge creation within organisations is a complex, cumulative, multilayered 
process. It begins at the individual level since employees are the building blocks of 
any organisation (Nelson and Winter 1982; Nonaka 1994; Nonaka and Takeuchi 
1995). Simon (1991) suggests that organisations only learn through their members 
and/or by employing new members who add knowledge previously unavailable. The 
cognitive potential of organisations is, to a considerable extent, determined by 
accumulated skills and knowledge of their individual members (Nelson and Winter 
1982). In this regard, the literature on cognitive and behavioural sciences points out 
that individual learning involves processes of continuous creation, destruction and 
re-creation of cognitive structures (Ambrosini and Bowman 2001; Fiol 1994; Fiol and 
Lyles 1985). Individuals scan the environment for information, select, prioritise and 
adapt what they find, interpret their findings and apply them to their existing 
cognitive structures (Lane and Lubatkin 1998). Fiol (1994) points out that this 
process needs not be conscious or intentional and does not necessarily immediately 
modify behaviour. Rather, it leads to new interpretations or meanings of available 
information. A comparison of different interpretations takes place until a new 
understanding of the issues at stake is achieved. All dimensions of learning feed on 
each other and result in a series of loops and interactions that are difficult to explain 
by individuals within organisations, but which clearly take place. 
Vinding (2006) suggests that the amount, level and quality of knowledge 
available within organisations positively correlate with the size of the stock of 
knowledge feeding organisational learning. This, in turn, allows for better judgement 
in the search, selection and analysis of even newer internal and external 
information. Education is one of the key inputs for building individuals’ expertise, 
Innovation performance HRM practices 
Individual learning 
Organisational learning 
17
some of which can be codified into articles, books, drawings or other forms of 
storable figurative communication. Yet education is not sufficient to build an 
advanced level of individual knowledge. Brusoni (2002) and Loasby (2002) assert 
that the application of the principle of division of labour to knowledge, results in 
specialisations along disciplinary, functional or institutional lines, as well as the 
emergence of scientific knowledge that increases the productivity of knowledge and 
provides frameworks and foci for addressing a variety of issues. The more 
individuals advance in their areas of specialisation, the more expertise they acquire 
and the larger their potential contribution to organisational knowledge. Cohen and 
Levinthal (1990) and Lundvall and Johnson (1994) expand the role of knowledge 
specialisation by arguing that expertise involves not only substantive technical 
know-how, but also capacity to access relevant information. 
Individuals’ knowledge and their learning skills can be substantially augmented 
by what Amabile (1997) calls “something extra”, or creative thinking. Creativity is 
defined as the production of novel ideas in any domain and creative thinking refers 
to a cognitive style favourable to taking new perspectives on problems, an 
application of techniques (or ‘heuristics’) for the exploration of new cognitive 
pathways, and working styles conducive to persistent, energetic pursuit of one’s 
work. Amabile (1997) and Sternberg et.al, (1997) claim that creativity often requires 
being at the forefront of emergent research, combining analytical and practical 
abilities, and possessing traits such as being an independent thinker, having inner 
motivation and drive; and taking risks. They suggest that creativity is best nurtured 
within an environment conducive to exploration.  
The importance of individual knowledge for organisational learning is further 
underscored by the fact that a significant part of the knowledge accumulated by 
individuals is tacit (Nonaka 1994; Nonaka and Takeuchi 1995; Polanyi 1966). Tacit 
knowledge refers to meaning acquired through experience and is difficult to 
formalize or communicate. It emerges during the actions and activities that 
individuals undertake during their lives and relates to the context in which these 
take place. The more diverse the experience the richer the content of tacit 
knowledge; Nonaka (1994) and Nonaka and Takeuchi (1995) state that tacit 
knowledge involves cognitive structures, based on mental models that provide 
overall positive and normative perspective to actions and activities, as well as 
technical elements, based on know-how and practice under specific circumstances.  
Tacit knowledge is the practical foundation of individual skills (Nelson and 
Winter 1982). Nonaka (1994) and Nonaka and Takeuchi (1995) add that individuals’ 
intentionality or willingness to practice the search for meaning in their environment 
in order to understand and improve it, is critical to enhance individual knowledge. In 
their view, intention and freedom are major forces motivating individuals to expand 
their individual knowledge. Kim (1998) complements this view by pointing out that, 
in addition to motivation or, perhaps, a consequence of it, intensity of effort, or the 
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amount of energy individuals use to solve problems, constitutes a major driver in 
the construction of meaning in organisations. In sum, individuals are the beginning 
and a major source of organisational knowledge and learning. Through exploring 
education and training, creative thinking, experiences and beliefs, expertise and 
relationships, intentions and freedoms and intensity of efforts, individuals 
contribute to learning and innovation in organisations. Building suitable working 
environments that nurture these processes is imperative for firms to succeed.  
 
3.2.2. Organisational learning 
 
Economics often depicts organisations as systems that process information in order 
to make the appropriate decision in light of uncertainty (Casson 1990; Nonaka 1994; 
Nonaka and Takeuchi 1995). Neoclassical theories of the firm see knowledge 
creation as an input-output problem-solving activity, which merely requires 
adequate processing to yield unambiguous solutions. However, Nonaka (1994) 
points out that this approach underestimates the nature of the activity at stake; it 
excludes the possibility of explaining the potential of firms to create new 
information and knowledge. To conceptualize organisations as information 
processing entities assumes uniformity of learning processes which is not the case. 
Organisations have cognitive structures and memories; over time, they develop 
behaviours and mental representations that perpetuate their social patterns. Nelson 
and Winter (1982) and Kay (2000) argue that organisational knowledge or 
competencies become embedded in organisational routines, which act as 
organisational memory. These mental representations, or routines, influence 
individuals’ learning within the organisation and transmit organisational memory to 
new personnel. Organisations can possess less knowledge than that of its members 
if there is little or poor internal communication.  
Kessler et.al, (2000), Bierly and Chakrabarti (1996) and Zack (1999) point out 
that organisational learning always involves choices regarding internal and external 
learning; firms often need to decide whether to develop their own knowledge or 
acquire and/or imitate that of others. The main reason to develop internal sources is 
to generate absorptive capacity (Cohen and Levinthal 1989). Absorptive capacity 
refers to the ability to evaluate and use outside knowledge. It is based on the level 
of related knowledge already available in firms, including basic skills as well as 
recent technological and scientific developments in specific fields. The rationale 
behind the notion of absorptive capacity is that the more objects, patterns and 
concepts stored in an organisation's memory, the more readily new information 
about these constructs can be acquired, and the easier it is to use them in new 
settings. This is because learning often takes place through association with 
patterns, situations or events already recorded in organisational memory. 
Absorptive capacity arises out of previous knowledge accumulation and the 
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intensity of current learning efforts by firms and their members.  
External sources of knowledge, in turn, bring fresh thinking and provide a 
benchmark for internal efforts. Sources of external knowledge are not limited to 
other organisations. They include external publications, universities, research 
institutes, government agencies, consultants and professional and personal 
networks. Kim (1998) and Kim and Cha (2000) developed an international dimension 
to this argument, by pointing out that external knowledge acquisition and imitation 
can function across and connect national systems of innovation.  
 
3.2.3. Learning strategies: exploration and exploitation 
 
From the discussion above two important questions emerge: (i) what is it that firms 
need to learn? And (ii) how can this be achieved? Multiple approaches can be used 
to analyze a firm’s learning processes. Cumulative learning experiences involve 
several types of learning: (i) learning-by-doing, which supports efficiency gains in 
production routines; (ii) learning-by-using, which promotes increased efficiency in 
the use of complex systems; and (iii) learning-by-interacting, which involves user-
producer interactions potentially leading to product innovations (Bell 1984; Lundvall 
1992). If attention is given to final outcomes, firms seek knowledge that supports 
cost-reducing innovations in the form of new or improved manufacturing processes. 
Alternatively, knowledge for demand enhancing innovations include improvements 
to existing products or design new ones (Miravete and Pernias 2006). Knowledge 
can also underpin incremental or radical innovations, which help tailor specific 
technological content and the degree of novelty needed, whether in the case of 
firms, markets or the world (OECD 2005). Factors commonly found across these 
interpretations of learning relate to different perceptions of knowledge content, the 
distinct nature and goals of learning strategies. In the spirit of capacity building, as 
opposed to outcomes, Li et.al, (2008) recommend to address learning as a process 
whereby firms mobilise resources with a more or less clear goal in mind.  
Cohen and Levinthal’s (1989, 1990) treatment of the dual role of R&D as a 
learning mechanism traces a link between management practices and R&D. R&D 
generates new information and knowledge underpinning searches for new market 
and technological opportunities through innovation. R&D is equally relevant for 
assimilating and exploiting existing information and knowledge. In other words, it 
helps to build the absorptive capacity by tapping existing knowledge. Cohen and 
Levinthal (1989, 1990) stressed that the contribution of individuals’ cognitive 
processes to accumulate absorptive capacity is contingent on prior knowledge and 
background. These elements impact an individual’s capacity to absorb, assimilate, 
link, analyse and, eventually, create knowledge. The authors also highlighted the 
distinct outcomes expected from R&D. In effect, firms can exploit their existing 
knowledge bases, or engage in exploration and expansion of knowledge bases.  
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From a management perspective, the notions of knowledge exploitation and 
knowledge exploration, as central and distinguishable elements shaping 
organisational learning and capacity-building, are integrated in the so-called 
knowledge-based theory of the firm (March 1991). According to this literature, the 
primary role of firms, which is the basis of organisational capabilities, is to integrate 
specialised knowledge (Grant 1996b). The latter is often interpreted in tacit form, as 
know-how, skills and practical knowledge embedded within individuals considered 
to be core components of an organisation (Barney 1991). 
Learning strategies differ in complexity, uncertainty and risk. They are shaped 
by the type of resources available and how firms mobilise them when seeking to 
accomplish specific goals. According to the knowledge-based theory of the firm, 
learning is a means to further exploit knowledge residing within its cognitive 
boundaries (Grant 1996b); the firm can gain in efficiency and productivity by 
refining, improving and reorganizing available resources. Alternatively, firms can 
engage in more risky and uncertain learning activities compelling them to explore 
outside their cognitive boundaries. This is through more systematic, costly and 
lengthy research and experimentation. That firms develop and use knowledge 
through either exploitation or exploration or both, is an indication of the 
heterogeneous, complex and distinct nature of the learning process. 
In order for a firm to catch-up, learning approaches must be incorporated 
strategically and over a sufficient period of time. Short-term benefits from 
knowledge-sharing cannot sustain long-term expansion strategies without the 
creation of internal knowledge and absorptive capacity to support the acquisition of 
external knowledge (Cardinal and Hatfield 2000). The literature states that, in 
general, dynamic latecomer firms couple local searches, through internal learning 
efforts, with distant searches, knowledge diffusion and assimilation through, for 
instance, reverse engineering. Nelson and Winter (1982) argue that accumulated 
experiences eventually lead firms to develop routines that increase their efficiency 
and productivity in manufacturing and, in general, the management of their product 
portfolios. Improvements in products, processes, or both, are generally based on 
searches within a firm’s accumulated knowledge. Conversely the more alien the 
intended innovation relative to what the firm knows, the larger the need to look 
beyond familiar cognitive boundaries. Management systems influence and play a 
mediatory role in these processes. Such systems influence the organisation and 
mobilization of individuals and their corresponding knowledge (Cohen and Levinthal 
1989 and 1990; Barney 1991). Moreover they assist in the creation, transfer and 
integration of knowledge flows that enrich a firms’ human capital, as a stock (Wright 
et al., 2001), in ways that are valuable, rare and inimitable (Grant, 1996). 
Innovation scholars acknowledge the distinction of knowledge exploration and 
knowledge exploitation (Li et.al, 2008), particularly in relation to product innovation 
(Greve 2007; Rothaermel and Deeds 2004; Yalcinkaya et.al, 2006). Interpretations of 
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the relevant concepts are heterogeneous (Li et.al, 2008). Exploitation refers to 
refining and efficiency, development projects, incremental innovation, strengthening 
existing market positions, deepening existing capacities and so on. Exploitation 
entails shorter perspectives, and more certainty and proximity with regard to 
potential benefits. By contrast exploration is linked with issues such as 
experimentation, research projects, radical innovation, market creation and the 
broadening of technological capabilities. It identifies searches for new knowledge, 
use of unfamiliar technologies, creation of products/services with unforeseen, or, at 
least, difficult to predict, demand (Greve 2007; March 1991). Exploration implies 
long-run thinking and greater uncertainty about future revenues and benefits.  
From managerial and organisational perspectives, exploitation and exploration 
'require different structures, processes, strategies, capabilities and cultures, and can 
have different impacts on an organization’s performance' (Li et.al, 2008:107). 
Although the effects of exploration and exploitation on learning and capability-
building can be complementary, they lead to competing resource allocation, and 
increased risks and tradeoffs in investment decisions. Finding the right balance is 
problematic; either strategy impacts the survival and prosperity of firms: “...Systems 
that engage in exploration to the exclusion of exploitation are likely to find that they 
suffer the costs of experimentation without gaining many of its benefits. They 
exhibit too many undeveloped new ideas and too little distinctive competence. 
Conversely, systems that engage in exploitation to the exclusion of exploration are 
likely to find themselves trapped in suboptimal stable equilibria” (March 1991:71). 
For the purpose of this study, a practical interpretation of exploration and 
exploitation will be used based on the cognitive distance between the searched-for 
knowledge and a firm's existing knowledge base (Benner and Tushman 2002; Li 
et.al, 2008); in other words, the degree of familiarity between new knowledge and 
what the firm 'already knows'. This cognitive distinction between exploration and 
exploitation will be drawn upon to analyse innovation as a process, and as an 
activity involving learning efforts, behaviours, investment and strategies (Li et.al, 
2008). Concepts such as absorptive capacity, technological capacity building and 
catching up become relevant for the analysis (Cohen and Levinthal 1989 and 1990).  
The distinction made in the preceding paragraph is aligned with the view that 
knowledge and by extension, innovation are gradual and cumulative (Grant 1996a). 
Innovation can refer to the production of new knowledge, and of combining, in 
novel ways, already existing knowledge (Lundvall 1992). Innovation is rooted in 
various types of learning processes associated with the actions of many agents 
involved in ordinary economic activities. Such is the essence of potential 
complementary relationships between the two concepts (Levinthal and March 
1993). R&D and other technology acquisition activities can be approached from the 
points of view of either knowledge exploration or exploitation (Li et.al, 2008).  
Another relevant concept to emerge from the theoretical discussion so far is 
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that firms operate within a competitive ecology. This conditions ways in which 
learning occurs and knowledge is used. Firms compete for resources and market 
shares. However they can also engage in informal and formal, contract-based, 
interactions and many other kinds of cooperative learning behaviours with other 
agents in the environment (March 1991). Consequently a firm’s boundaries often 
need to expand to allow internal and external knowledge searches and integration 
according to the goals of exploitation and/or exploration (Grant 1996a). Such 
searches frequently occur outside the physical, geographical and cognitive 
boundaries of the firm (Li et.al, 2008); and condition the nature, success failure in 
learning through networks, mergers and acquisitions, contracted R&D, technology 
alliances and so on (Gilsing 2006; Greve 2007; Rothaermel and Deeds 2004; 
Yalcinkaya et.al, 2006). The concept of knowledge flows indicates that firms are 
agents that can actively guide systems of innovation by launching searches within, 
and eventually nurture the stocks of knowledge outside their physical boundaries.  
 
4. Human resource management practices and learning for innovation in 
developing countries 
 
The discussion so far stressed the importance of understanding the role of the 
learning processes within organisations; in other words, how human resource 
management practices contribute to the development of a firm's innovative 
capabilities. This approach demonstrates the relevance of conducting research on 
human resource management and innovation, particularly from a development 
perspective. Empirical studies show the contribution that organisational practices, 
relating to R&D and innovation, have made toward assisting latecomer firms catch 
up to their competitors. Successful firms evolve as learners by assimilating and 
tapping into existing technologies, eventually developing capacities to generate 
proprietary technologies (Hobday et.al, 2004). Only when latecomer firms start to 
approach the technological frontier, does high quality basic research, more complex 
scientific techniques and instrumentation progressively gain importance to sustain 
productivity and competitiveness (Patel and Pavitt 1994). Transition from 
technology-follower status to that of technology-leader is neither linear nor 
automatic. Hobday et al. (2004) suggest that the transition requires, as 
complementary assets, gaining international brand recognition, strong marketing 
capabilities and control over foreign distribution channels, along with the ability to 
carry out the necessary organisational and structural changes.  
Catching-up involves continuous efforts on the part of firms to mobilise and 
organise the resources they have at hand. In the case of Japan, for example, Odagiri 
(1998) highlighted the importance of building the absorptive capabilities, increasing 
efforts in training and entrepreneurship, and gaining a sound scientific and 
technological understanding, including mastering the production and management 
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of skilled personnel. Hemmert (1998) further underscored such factors in his 
analysis of how Japanese firms have dealt with evolving and often adverse 
macroeconomic environments, and the challenges associated with business 
strategies posed by continuous technological innovation. Firms have had to 
constantly reorganise and restructure R&D in general and the management of R&D 
personnel in particular. Continuous improvement in personnel management has 
underpinned innovative organisational practices to promote incentives, motivation 
and productivity and attract people into R&D (Legewie et.al, 2000). Accordingly, 
Hemmert (1998) and more recently Michie and Sheehan (1999 and 2003) called for 
further investigation of the relationship between human resource management 
practices and firms’ capacity to engage in R&D.  
As an interactive process of knowledge creation, diffusion and use, innovation 
implies the concurrence of a number of factors, internal and external to the firm, 
shaping the competencies or competitive ingredients that allow firms to 
differentiate in the market. This is coupled with the multiple directions in which 
information and knowledge feed back and forth across firms’ departments (Lundvall 
1988 and 1992). A firm’s innovative capacity rests not only on a given set 
(endowment) of material resources, human skills and relevant knowledge, but on 
the way these are organised and co-ordinated in pursuit of the firm’s strategic goals 
(Leonard-Barton 1992; Wilkens and Pawlowsky 1997). Positive effects expected from 
training, for example, can be enhanced if accompanied by appropriate human 
resource management interventions shaping incentive structures, and working 
conditions suitable for employees to implement newly acquired skills (OECD 1998).  
White (2002) advocates the need to understand how management practices 
contribute to research and other technological capabilities in developing countries. 
In his view accumulated capabilities can erode because of inadequate or poor 
human resource management. This conclusion recalls Leonard-Barton’s (1992:117) 
view of management as a double-edged sword for a firm’s learning and innovation 
capacity. She asserted that by incorporating and organizing “unusual blends” of 
skills, and/or fostering beneficial behaviours not found elsewhere in competitive 
firms, managerial systems contribute to the development of innovation and other 
core capabilities. However such practices can turn into handicaps preventing firms 
to confront and overcome new challenges or carry out new projects. 
Several studies document the challenges faced in defining and measuring 
innovation in developing countries (Forbes and Wield 2000; Lundvall et.al, 2002; 
Mytelka and Farinelli 2003). Conceptual ambiguities derive from the historical roots 
of the systems framework, centred on developed countries (Edquist 1997; Smith 
2000). According to Edquist and Johnson (1997), who provide a bird’s eye view of 
different definitions of innovation from a systems perspective, such ambiguity 
should not be problematic since definitions and analytical distinctions are neither 
right nor wrong. Depending on the objective, definitions can be ‘good or bad; useful 
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or not’ (Edquist and Johnson 1997:10). In these authors’ view, the systems literature 
is about technological innovation, organisational and institutional change. In a world 
where “the R&D system was the source of innovation,”
13 
it made sense to build an 
analytical framework based, almost exclusively, on R&D inputs and outputs 
(Freeman 1995:10). However such a standardised procedure entails a rather limited 
interpretation of the sources and consequences of technical change. Formal 
education and R&D are essential pillars for innovation, but there are several others. 
Technical change, productivity and ultimately, economic growth may depend more 
on efficient diffusion than on being first in the market (Freeman 1995). Innovation is 
rooted in various types of learning processes associated with the actions of many 
agents involved in ordinary economic activities (Lundvall 1992). 
The former discussion provided an overview of the distinction between a 
narrow and a broad definition of systems of innovation (Freeman 2002; Lundvall 
1992). Whereas a narrow definition “would include organisations and institutions 
involved in searching and exploring, such as R&D departments, technological 
institutes and universities; "[a broader definition would entail more ample aspects 
of] the economic structure and the institutional set-up affecting learning as well as 
searching and exploring” (Lundvall 1992:12). Activities such as production, 
marketing, and finance become sub-systems where learning takes place and from 
which inputs to innovation flow back and forth (Lundvall 1992; Nelson 1991).  
Recent studies agree that the broader definition of systems of innovation, 
wherein a system that creates and uses both innovation and competencies in 
pursuit of development goals, is best suited to analyse innovation in developing 
countries working behind the technological frontier (Forbes and Wield 
2000;Lundvall et.al, 2002; Mytelka and Farinelli 2003). Such an extended definition 
allows for learning and innovation opportunities in SMEs and traditional industries, 
and searching for creative ways to reduce costs through design, management and 
production systems. Cassiolato et.al, (2003) assert that developing countries can be 
viewed as extended production and competence building systems linking education 
and labour markets to innovation. Technological modernization, the most common 
innovative exercise in developing countries, introduces new, more advanced 
machinery and equipment, or the adoption of enhanced manufacturing and 
managerial techniques. By contrast, formal R&D leading to product/process 
innovation is less frequently used indicator (Cimoli and Constantino 2000; Corona 
1997; Tecanhuey 2002).  
Alternatively, developing countries are perceived as learning systems (Viotti 
2002), where both modernisation through technical change and R&D are potentially 
complementary activities (Hernández et.al, 2002). Based on the discussion in 
Chapter 1, this interpretation is more valid where innovation is approached from the 
                                                 
13 Stress in the original by the authors. 
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perspective of processes, rather than in terms of outcomes (García and Calantone 
2002; Li et.al, 2008). Moreover it calls for a careful appraisal of the nature of 
innovation and, more specifically, the contribution of R&D to a firm’s success. The 
literature shows that although the technological dynamism of firms from developing 
countries generally lags behind that of large multinationals, R&D remains a major 
determinant of firms’ sustainability and growth (Cardinal and Hatfield 
2000;Cattozzella and Vivarelli 2007). Systematic R&D efforts coupled with consistent 
business and technological strategies, and intensive use and development of human 
resources, have enabled some firms operating in developing countries to draw 
closer to their competitors in the developed world (Kim et.al, 1989; Maiti and 
Raghavendra 2007; Meyers 2006). 
Based on Cohen and Levinthal (1989 and 1990), March’s (1991), and recent 
work by Laursen and Foss (2003) and Hobday et.al, (2004), who examine how R&D 
contributes to a firm’s staying power, further research should shed light on 
determinants of business strategies and organisation around learning and 
innovation. This might enable for what Hemmert (1998) and Coriat and Weinstein 
(2002) qualified as a much needed firm-based ‘systemic’ theory of innovation. From 
this perspective firms would no longer be ‘representative firms’, ‘passive black 
boxes’ acted upon by the macro-social environment around them; rather, one would 
consider the diversity of organisational patterns at the firm, sector and national 
level. Within a systemic approach, there is room to explore how firms work, the 
choices they make during production, innovation and so on; how and why they take 
distinct forms, and how they develop over time (Coriat, 2002).  
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Chapter 2  
Analytical framework and methodological ap-
proaches to research on human resource 
management practices for learning and inno-
vation1 
 
 
 
1 Introduction 
 
This thesis proposes the hypothesis that a firm's human resource management 
practices support innovation via the learning processes underpinning the latter 
activities. This chapter begins with a discussion of the main tenets of the analytical 
framework used in this thesis. The framework suggests the need to understand how 
organisational practices influence learning. It also stresses the importance of 
understanding the characteristics of the knowledge bases in which firms operate, 
and how these relate to the knowledge requirements of firms during the innovation 
process. Finally, the framework recognizes that firms do not operate in a vacuum. 
Learning and human resource management practices influence the relationships 
that firms establish with external sources of knowledge.  
This chapter also presents some methodological approaches that have been 
applied or that could be applied in research on human resource management and 
performance at the firm level. Both the analytical framework and the methodology 
build on the management and innovation literature. Emphasis is placed on research 
linking human resource management, learning and innovation in both developed 
and developing countries. The discussion that follows presents the relevant 
variables that will be taken into account in subsequent chapters.  
 
2 Analytical framework 
 
The literature review in this thesis suggests that four interrelated factors shape a 
firm’s innovative performance: (i) the characteristics of R&D and innovation 
management, of which this thesis highlights human resource management 
practices. Such practices underpin individual learning inside the firm; (ii) a firm’s 
                                                 
1 This chapter benefited from comments by participants at the DRUID-DIME PhD Conference Academy 
Winter 2006, particularly Nicolai Foss and Abraham García; staff at the Research Division of the Faculty of 
Business Administration and Accounting, UNAM; and Javier Jasso.  
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internal organisation, including routine production and innovative activities that 
support organisational learning; (iii) the industry or sectoral affiliation which 
conditions the nature of innovation processes and, relatedly, the kind of knowledge 
required, generated, acquired and used within firms; (iv) learning strategies 
including the complex and diverse sets of interactions between firms and other 
agents in their relevant environment, the national innovation system broadly 
defined. Figure 2.1 summarizes the four dimensions around learning and innovation.  
 
Figure 2.1 Interactive dimensions condition a firm’s learning and innovation activities 
 
 
 
 
 
 
 
 
 
 
 
 
Source: Author 
 
From a management perspective Amabile (1996:8-10) proposed a model 
wherein creativity and innovation are framed within a particular social context 
inside the firm: the organisational environment. The schematic representation in 
figure 2.1 takes this a step further, depicting that same organisation within the 
broader socio-economic environment. It proposes that knowledge bases shape and 
support the firm’s learning, as well as its performance in terms of productivity and 
innovation. Moreover in figure 2.1 the notion of creativity, as a latent variable 
conditioning innovation, is replaced with that of learning.
2
 The elements of the 
framework are discussed below. Considering that the discussions in chapters 1 and 3 
address more extensively the role of management practices, attention here centres 
on the remaining three instances, namely organisational practices, knowledge bases 
and the interactions of firms with other agents in the system of innovation. 
 
                                                 
2 By replacing creativity for learning we do not imply these are substituting concepts; rather we suggest 
that at least these are two possible variables likely to explain linkages between human resource man-
agement practices and innovations.  
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2.1 Organisational practices 
 
Lundvall and Valeyre (2007) in the case of Europe, OECD (1998) for the OECD 
countries and Kaplinsky (1995) for developing countries document the interrelation 
between modern management practices and organisational strategies adopted by 
firms. Such strategies correspond to the type of management practices available for 
firms, and shape the environment in which learning takes place (Arundel et al., 
2007). Effective organisational practices are often associated with the Japanese 
management style; they occur in heterogeneous backgrounds, adoption is prone to 
variety across firms and countries (Barton and Delbridge 2001; Kaplinsky 1995). 
Dynamic work practices involve adoption of new, improved and systematic 
organisational strategies such as Integrated Manufacturing (IM) and Total Quality 
Management (TQM). It also indicates the presence of human resource management 
practices to effectively capture, develop and use knowledge to compete in 
international markets. These activities include strategies to (i) expand and exploit 
markets for knowledge, (ii) adopt or develop new technologies requiring higher 
levels of skills, (iii) emphasize variety, service and quality rather than low cost 
(Doeringer et.al, 2003; OECD 1998).  
Michie and Sheehan (1999 and 2003) reported that ‘low road’ management 
practices encouraged by labour market deregulation--short-term or part-time 
contracts, lack of labour union coverage and the unlikelihood of receiving work-
related training--, correlated negatively with R&D levels and adoption of 
innovations. In contrast, flexibility based on ‘high road’ work practices--those 
involving high commitment to the success of the organisation, teamwork, job 
rotation, quality circles, TQM, high levels of training and innovative pay systems--, 
associated with increased investment and innovation. Dynamic human resource 
management practices linked strongly with the adoption of advanced organisational 
and manufacturing practices and technical change more broadly defined (Greenan 
2003). Human resource management interventions need to be consistent with the 
principles guiding such organisational practices.  
The literature about developing countries notes that the adoption of enhanced 
management and manufacturing practices tends to concentrate in large firms or 
those with clear export orientation. Incorporation of such techniques is 
heterogeneous across sectors and countries (Abramo 1997; Govinda 1998; Mertens 
2005). Human resource management interventions are often fragmented and lack 
consistency with regard to modern organisational techniques. Organisational 
changes and modernisation frequently associate with defensive, survival strategies 
(Domínguez and Brown 1998; Gallart 2001; García 2002; Mertens 2005). 
 
2.2 Knowledge bases 
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A firm's knowledge base denotes the technological inputs and underlying 
capabilities required to develop particular products; such requirements determine 
the simplicity or complexity of knowledge bases (Kale and Little 2007). In other 
words knowledge bases are highly localised and specific to product and process 
characteristics (Smith 2000). Production-specific knowledge bases are technically 
and socially shaped and concern the way technical processes fit into firms’ routine 
activities (Lundvall 1988). The latter are associated with firms’ skill-bases, 
production, training and management systems (Hemmert 1998; Smith 2000).  
Based on the discussion in chapter 1, exploitation of a knowledge base refers to 
local searches for familiar, mature, current or proximate knowledge; it builds on 
existing technological capabilities. By contrast, exploration of a knowledge base 
indicates searches for unfamiliar, distant knowledge. This interpretation of 
innovation draws attention to the learning process occurring inside the firm. It 
introduces flexibility to the analysis while capturing traditional views of innovation 
in terms of incremental and radical outcomes (Greve 2007). Whereas local searches 
may lead to incremental innovations, distant searches could lead to radical ones. 
Nevertheless, there is no reason for such a match between knowledge searches and 
innovation outcomes to always occur. Johnson and Lundvall (2003:163) indicate 
that firms need to adopt “new integrated competence building strateg(ies)”
3
 
whereby they build internal competencies and management interventions.  
Smith (2000) asserts that relevant economic knowledge adopts multiple forms:  
 
• It can be highly specific, relative to factual information about specialised areas 
of expertise (‘know-what’);  
• It implies basic scientific principles (‘know-why’) relevant to problem-solving 
during innovation; though there may not always be direct connection between 
scientific capabilities and innovative performance;  
• It can be specific, selectively social when associated with certain personal rela-
tionships, access and/or contacts to key personnel and/or people (‘know-who’) 
• It embodies practical skills and capabilities associated with aspects of produc-
tion, marketing, and so on (‘know-how’) 
 
Contingent on these different forms of knowledge, relevant technological 
knowledge bases may be informal and non-codified, in the form of skills specific to 
individuals or groups of individuals (Smith 2000). Moreover given the tacit nature 
and localized character of knowledge residing in the firm, no matter how competent 
individual firms are in a given area, competencies are bounded, and the ability to 
carry out search processes is limited. In other words, firms frequently face problems 
to perform innovations which require knowledge lying outside immediate areas of 
                                                 
3 Stress in the original by the authors. 
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expertise. In order to adopt and create new technologies, firms must be able to 
interact with and have access to other sources of knowledge. Returning to Smith 
(2000), knowledge bases are:  
 
• Differentiated, multi-layered, involving the systemic integration of many differ-
ent types of knowledge; 
• Highly specific, organised around relatively limited sets of functions which firms 
know well. The system is thus bounded, in terms of both rationality and vision 
(Nelson and Winter 1982); 
• Significantly tacit in their components, and embodied in the skills and back-
grounds of engineers, R&D staff, workers and managers; 
• Cumulative, developed through time as firms gain experience dealing with par-
ticular technologies. Technological knowledge is path-, context-dependant 
(Grant 1996a); 
• Costly as long as development of knowledge bases involve expensive processes 
of searching, learning and adaptation (March 1991); 
• Internally systemic in the sense that knowledge bases are part of heterogene-
ous production and marketing systems (Cassiolato et.al, 2003); 
• Externally systemic, knowledge bases involve and rely on interactions between 
firms and their environment. Reliance on knowledge infrastructure is also criti-
cal (Teubal et.al, 1996) 
 
The notion of knowledge bases leads to an analytical model that considers the 
significance of firms’ industry and sectoral affiliations; this is addressed more 
extensively in chapter 3. It is important to understand regularities, probable 
differences in technological opportunities and consequently, distinct impacts of 
management practices on learning for innovation across industries or sectors 
(Laursen and Foss 2003; Pavitt 1984). This mirrors the distinction between 
knowledge exploitation and exploration to characterize knowledge flows associated 
with firm learning strategies. More importantly it brings to the forefront the 
discussion of what kind of learning and innovation activities developing countries 
are bound to perform.  
 
2.3 Interactions with external agents 
 
2.3.1 Learning from external markets for knowledge  
 
An additional relevant dimension in our analytical framework refers to the 
interactions between firms and the complex set of agents within the system of 
innovation. Discussion of this particular dimension centres on the leading role of 
firms as agents inducing the dynamics and conditioning performance of such system 
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over time (Nelson and Winter 1982). In other words, the analysis takes into account 
how innovative and learning activities carried out by firms in-house eventually give 
rise to the development and functioning of external markets for knowledge (Arora 
et.al, 2001).  
Several factors shape external markets for knowledge, including: (1) the 
temporality of knowledge requirements, whether current or expected; (2) the 
means to transfer knowledge whether in embodied or disembodied form; and, (3) 
the means to acquire technology, whether by direct purchase or developed in 
collaboration with other agents (Arora et.al, 2001). In this regard, Santamaría et.al, 
(2009) indicate that in addition to joint or contracted R&D, activities such as design, 
the use of advanced machinery and so on, contribute to innovation. The impact of 
those activities is especially important in low- and medium technology industries, 
particularly for the achievement of product innovations. Specific activities shaping 
external markets for knowledge include purchases and/or exchanges of technology 
and technological services, contracted and R&D joint ventures, strategic alliances, 
licensing and cross-licensing, etc. (Arora et.al, 2001). Relevant partners include other 
firms, universities, research institutes, government agencies, consultants and 
personal networks. 
The literature documents some of the factors that lead to the promotion of 
technology diffusion and the development of external markets for knowledge; these 
include: (1) the stance of a firm in relation to markets for knowledge, whether as 
supplier or buyer; (2) the importance of external knowledge for a firm’s overall 
learning activities, and (3) the degree of a firm’s technological attainment. These 
three factors combine in multiple ways in order to guide research. In this regard, a 
first line of enquiry assumes a division of labour in markets for knowledge; 
technology, in itself, becomes the item on sale (Arora et.al, 2001). This type of 
research sheds light on how and why firms become specialised technology suppliers. 
Attention centres on factors such as market structure, property rights regimes, 
competition, and other incentives and constraints for trading in technology. 
Relevant work in the field includes Arora et.al, (2001), Cantwell and Kosmopolou 
(2001) and von Zedtwitz and Gassmann (2002), among others. In sharp contrast to 
investigations involving large multinationals or firms from developed countries, 
research on the participation of technology suppliers from developing countries 
seems rare.  
A second body of literature looks at some technologically dynamic, highly 
internationalized firms. These are buyers, or more generally users of technological 
capabilities developed abroad. These firms specialize in the creation of technology; 
at the same time, they actively search for external knowledge sources and 
associated new technological opportunities (Malerba and Orsenigo 2002; Patel and 
Vega 1999; Shiu-Wang and Ruei-Hung 2008). External knowledge complements 
internal efforts to develop and advance technology. Studies on global 
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pharmaceutical firms illustrate this approach. They document that, in recent years, 
the industry has undergone an intense period of mergers and acquisitions, 
formation of joint ventures and so on (Jungmittag et.al, 2000a; Lane and Probert 
2007; Staropoli 1998). Trends in the industry reveal a push towards outsourcing, and 
joint and contracted R&D (Crossley 2004; Piachaud 2002). This has lead to strategies 
such as increasing speed and productivity in new drug development in the face of 
growing competition from generic manufacturers, and entering new business areas 
in fields such as biotechnology and genomics (Arora et.al, 2001; Tapon and Thong 
1999). The activities of global pharmaceutical firms span developed and developing 
countries. They include exploitation of technological capabilities developed in-
house, and intense exploration for new technological opportunities (Gilsing 2006; 
Rothaermel and Deeds 2004). In general, studies in the field refer to dynamic 
multinationals from developed countries.  
A third strand of literature characterises two types of firms. The first group 
relies, almost entirely, on externally acquired technologies; firms adopt a passive 
stance with regard to technology development. Notwithstanding some short-term 
gains in both productivity and competitiveness, the strategy may threaten a firm's 
viability or success (Kim et.al, 1989). Firms can lose some of their internally created 
technological capabilities while increasing their exposure to external technology 
suppliers (Bell 1984). The second group uses external knowledge as a complement 
to domestic technological efforts (Santamaría et.al, 2009). In this case firms need to 
develop the capacity to assimilate and use the new technology. This is, in essence, 
what (Cohen and Levinthal 1989 and 1990) identified as absorptive capacity. Studies 
in the field document the experiences of latecomer firms that start as followers, in 
terms of technological attainment and market position, but that eventually develop 
the capacity to generate and sell technology; in other words, R&D and other 
learning activities gain in complexity over time (Dutrénit 2007; Hobday et.al, 2004). 
Dynamic latecomer firms perceive external knowledge as a source of both 
opportunities and challenges for their operation and sustainability in the market 
(Archibugi and Pietrobelli 2003; Reddy 1997; Singh 2007).  
 
2.3.2 Human resource management and external interactions 
 
Arora et.al, (2001) highlighted the importance of learning about differences in 
technology management derived from the development and operation of external 
markets for knowledge. In their view whenever technology converts into 
merchandise, distinct approaches are needed for the firm to manage its intellectual 
capital. The analysis needs to pay greater attention on tacit knowledge, strategic 
management, organisational structure and changing corporate strategies. Moreover 
human resources, and more specifically their management and organisation, are 
increasingly recognised as core components of the unique, difficult to imitate 
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capabilities of the firm (Leonard-Barton 1992). Human resource management 
practices can enhance opportunities to learn and explore external knowledge 
sources in search of new ideas and technological opportunities (March 1991).  
Zanko et.al, (1998) argue that new methodologies, techniques or approaches to 
management practices connect to and permeate across organisational membership. 
Interventions such as strategic hiring, sabbaticals, subcontracting and professional 
collaborations grant access to strategic sites, materials and, key people. 
Management practices influence the relationships with those individuals from 
external organisations that contribute to the performance of production or research 
teams, the implementation of training programmes, and so on (Florida and 
Goodnight 2005; Okada 2004). The reward to external agents contributing to in-
house R&D or working on productive projects, the pressures and associated 
responses to customers/suppliers span organisational boundaries of a firm 
(Hemmert 1998; Zanko et.al, 1998). 
The kind of organisations that firms interact with equally shapes the nature of 
the knowledge flows involved during the innovation process. Faulkner et.al, (1995) 
and Laursen and Salter (2004) maintain that meaningful interactions are not built 
from scratch; rather, firms guide and develop relationships based on specific 
knowledge requirements, which, in turn, are aligned with the goals set for specific 
projects or activities. Innovative firms proactively search for and evaluate both the 
sources and the types of knowledge obtained from external markets. Thus a firm 
connects with other firms, machinery suppliers, individual consultants, training 
centres and other intermediary agents attached to the industry. These agents 
provide technical and other kinds of knowledge they have acquired in the industry. 
They can be more familiar with productive activities and everyday operations of the 
firm. Alternatively, via universities and public research centres, firms can access 
knowledge on basic science, research techniques, and so on. Often the resulting 
knowledge flows may not fit with the common thinking structures or practices of 
firms. The distinction between partners and associated knowledge flows does not 
imply a hierarchy or specific advantage in linking with any specific partner. 
Innovation is often constrained by the firm’s bounded and incomplete 
knowledge base. Incompleteness leads firms to expand cognitive boundaries, and to 
engage in multiple interactions with external agents. Technology markets promote 
diffusion and more efficient use of scientific knowledge and existing technologies. 
Such markets underpin technological change and provide additional incentives for 
R&D. Accordingly Arora et.al, (2001) call for research to inform corporate strategies, 
and provide guidance to managers on how to behave when external markets for 
technology are available. Nelson (1991) and Smith (2000) further emphasize that 
the effectiveness of interactive learning is conditioned by a firm’s heterogeneous 
organisational structures, and the type and scale of communication and feedback 
with external agents. Distinct ways to organise and mobilise resources condition a 
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firm’s ability to access, assimilate, use and eventually transfer knowledge to and 
from the outside world (Leonard-Barton 1992).  
 
3 Internal, external, combined learning strategies 
 
Research on factors that contribute to a firm’s learning and innovation strategies is 
often approached from the perspective of the boundaries of the firm. Two main 
streams of literature are identified here. Traditional transaction cost theory 
perceives choices of internal and external sources of technology as potentially 
mutually exclusive (Williamson 1975 and 1985). Organisational learning involves 
choices regarding internal and external learning efforts; firms need to decide 
whether to develop (make) their own knowledge or acquire and/or imitate (buy) 
that of others (Bierly and Chakrabarti 1996; Kessler et.al, 2000; Zack 1999). Finding 
the right balance between in-house development and the external acquisition of 
technology allows for optimum resource allocation to alternative learning activities 
(Nakamura and Odagiri 2005). The problem with this approach is that it only 
partially explains the perceived heterogeneity in firms’ learning behaviours, or the 
characteristics of innovation processes in distinct industries or sectors (Arora and 
Gambardella 1990; Liyanage et.al, 1999), thus undervaluing the possibilities and 
importance of combined strategies (Cassiman and Veugelers 2006; Escribano et.al, 
2009), particularly for latecomer firms (Du and Ai 2008; Kim et.al, 1989; Singh 2007).  
An alternative approach arises in Penrose’s seminal book on the growth of the 
firm (Penrose 1959), where she challenges the notion of “make” or “buy” by 
considering the decisions related to learning that stem from more complex 
processes inside the firm. Internal and external learning sources are not mutually 
exclusive; on the contrary there is great potential for complementary relationships 
among the two strategies. Penrose conceptualised firms as a “collection of resources 
bound together in an administrative framework, the boundaries of which are 
defined by the ‘area of administrative coordination’ and ‘authoritative 
communication’” (Penrose 1997:xi). A firm’s performance is determined, to a large 
extent, by its capacity to organise and mobilise resources. This involves dynamic 
processes whereby knowledge accumulates through incentives for further 
expansion and exploration of new and more productive ways to combine those 
resources. The notion of boundaries implies that firms are part of broader systems 
of agents and interactions. Such systems compose of informal and formal (market) 
transactions from which firms can obtain complementary cognitive and productive 
assets. Management plays a crucial role by identifying and mobilising available 
resources, while determining those that the firm leverages from outside.  
Penrose’s argument can easily extend to interpret learning, from both internal 
and external sources, along the dual perspective proposed by Cohen and Levinthal, 
in which learning implies both conscious capability building processes, and strategic 
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searches for new technological and market opportunities. Building adequate 
absorptive capacity assists in the assimilation and use of external knowledge; it can 
give firms substantial bargaining powers in external markets for technology. 
Absorptive capacity builds on the level of related knowledge already available in 
firms, including basic skills as well as recent technological and scientific 
developments in specific fields. It arises out of previous knowledge accumulation 
and ongoing learning efforts by firms and their members. Some additional, albeit 
indirect, benefits of the efforts to build a strong technology base include the ability 
to: (i) search, choose and benefit from collaborative relationships; (ii) increase the 
capacity to sell technology and contribute to the technological base of the 
environment; (iii) detect environmental changes and capture new technological 
opportunities (Cardinal and Hatfield 2000). External sources of knowledge bring 
fresh thinking and provide benchmarks for internal learning efforts.  
Kim (1998) developed an international dimension to this argument by pointing 
out that external knowledge acquisition and imitation can also function across and 
connect national systems of innovation. Recalling the notion of competitive ecology 
in chapter 1, adoption of mixed learning strategies leads firms to mobilise both 
internal and external resources, to expand physical and cognitive boundaries in 
order to accommodate internal and external knowledge searches. Knowledge 
integration proceeds according to the goals of exploitation- and/or exploration-
related innovations (March 1991). Recent research on complementary strategies is 
found in Beneito (2002), Cassiman and Veugelers (2006), Cattozzella and Vivarelli 
(2007), Lane and Probert (2007), Nakamura and Odagiri (2005), Piga and Vivarelli 
(2004), Shiu-Wang and Ruei-Hung (2008), Veugelers (1999). In the case of Mexico, 
Zúñiga et.al, (2007) applied a complementarity framework to study strategies for 
technology acquisition by pharmaceutical firms in the local market. Chapters 7 and 8 
will deal with this in more detail, including the implications of the adoption of 
distinct learning strategies by firms in the presence of external knowledge sources. 
 
4 Human resource management practices and innovation: Methodological 
approaches 
 
This section will document that research on the linkages between human resource 
management practices and innovation is already well established in management 
studies. Some of the more common studies refer to R&D personnel in developed 
countries. Scholars in the field assert that management interventions enhance 
attractiveness, motivation and, ultimately, people’s capacity to carry out innovation 
(Amabile 1996; Katz 1988; Mumford 2000). Closed views on the conditions and 
functioning of individual managerial and organisational practices are useful to guide 
human resource management practitioners. Unfortunately this is insufficient to 
inform broader policy interventions particularly in light of more heterogeneous 
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managerial approaches, distinct organisational and learning strategies, or the 
situated environment in which firms operate (Alic 1995; Lundvall et.al, 2002).  
With regard to innovation studies, chapter 1 referred to the growing interest 
among scholars in the field in understanding the linkages between management 
practices and innovation performance. Recent work critiques traditional 
assumptions and conclusions about the Japanese and American models, which are 
considered, almost exclusively as the two alternatives in organizing R&D personnel 
(Barton and Delbridge 2001; Joonmo 2004). Research seeks to understand the 
sources of heterogeneity and evolution of those models over time (Hemmert 1998; 
Legewie et.al, 2000); or how new and improved organisational practices shape 
dynamic workplaces and learning across firms, industries, and even countries 
(Arundel et.al, 2007; OECD 1998). This Section presents some of the main findings, 
lessons and challenges from the existing literature on management and innovation, 
and suggests some alternative, though not mutually exclusive approaches to 
research on management practices, learning and innovation. The discussion sheds 
light on some areas and issues missing from the literature.  
 
4.1 Six alternative, yet complementary approaches  
 
Based on a comprehensive literature review, this chapter proposes six approaches 
to analysing human resource management practices and their relationship with a 
firm’s (innovation) performance. The approaches are neither mutually exclusive nor 
exhaustive, and they are both static and dynamic. In other words one can study the 
effects of human resource management practices on firms’ performance at a given 
point in time or along a continuum, and/or under certain firm characteristics. In this 
manner, the analysis can focus on: (i) specific geographical, cultural and related 
contexts in which a firm operates (Type 1); (ii) particular management interventions 
or the characteristics of the personnel involved (Type 2); (iii) differences in man-
agement practices across a firm’s departments (Type 3); (iv) the degree of innova-
tiveness of the management interventions in themselves (Type 4); (v) the charac-
terisation of management practices along different stages of the innovation cycle 
within a firm/industry (Type 5); and, (vi) the contribution of management strategies 
depending on the technological and productive profile of a firm (Type 6).  
Type 1 approaches relate to management across cultures along the lines of 
Hofstede (1980) and subsequent studies. Research seeks to understand how cross-
country cultural differences influence adoption of or characterise local managerial 
approaches (Murphy 2006; Tello and Greene 1996). Alternatively, research refers to 
differences in management practices within multinational corporations in both the 
host and the parent countries (Flynn 1994; Forest 1994; Schuler et.al, 1996). 
Literature on Mexico seeks to provide foreign managers, often first-time visitors to 
the country, with knowledge about the ‘do’s’ and ‘dont’s’ of successfully managing 
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an affiliate facility in the country (Martínez and Dorfman 1998). Several studies 
refer to management in ‘maquiladoras’; they stress the obstacles that cultural 
differences impose in terms of the adoption of management practices promoting 
learning, wide participation and active involvement in innovation.  
Work environments in Mexican firms are considered to be reflective of 
traditionally ‘paternalistic’, rigid and hierarchical social structures, where power is 
concentrated at the top. People are often assigned to high-ranking positions based 
on who they know (Forest 1994; Schuler et.al, 1996). These factors run against 
values and principles of dynamic work practices in developed countries, such as the 
United States, which emphasize meritocracy, individualism and trusting 
relationships between managers and employees, supportive, participative 
management, teamwork and other superior human resource management practices 
(Schuler et.al, 1996). Mexican workers are habituated to work environments where 
being submissive and loyal to people in positions of power is the norm, and where 
self-expression, initiative, and autonomy are discouraged (García 2002). Local 
culture is often unfavourable with regard to modern management practices (Tello 
and Greene 1996). However, in the case of Mexico, scholars agree that intensive 
training for both line workers and managers helps to overcome ‘most cultural 
barriers’ between Mexico and the US, thereby increasing the probability of 
successfully introducing US-type management practices in multinational affiliates 
operating in Mexico (Flynn 1994; Forest 1994). 
There are some major flaws in this argument. In general, while scholars tend 
not to question the validity of the categories proposed by Hofstede’s study, Dávila 
and Elvira (2007) suggest there is a need to reconsider the importance of cultural 
differences between Mexico and the US; interaction between the two countries 
might blur the differences, in terms of ‘individualism’ or ‘attitudes toward 
achievement’, that supposedly exist between the two societies (Rao and Teegen 
2001). The authors call for a careful re-interpretation of the characteristics of 
Mexican workers, their resistance to interventions involving teamwork, pay-for-
performance or when given the opportunity and incentives, to actively involve in 
participative management strategies (Dávila and Elvira 2007). Cultural differences 
may imply that things are different but not necessarily better in either context.  
Type 1 approaches often tell little about the impact that cultural differences 
have on performance on either side of the Mexico-US border. They base their 
conclusions on small samples of firms; rely strongly on interviews with managers or 
key experts, but seldom with workers themselves. In addition, the approaches lack 
consideration of possible differences derived from distinct sectoral affiliations, even 
locations of firms (Hise et.al, 2003; Islas 2003; Lenartowicz et.al, 2003; Rao and 
Teegen 2001), or the tendency towards general prescriptions (Hope Pelled and Xin 
1997; Muller and Rowell 1997; Reza et.al, 1998) all weaken their results.  
Type 2 approaches, referred to as specific human resource management 
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practices, are management studies centred on particular management 
interventions, namely teamwork, training, use of dual professional ladders, 
communication and so on. Studies in the field seek to understand how management 
practices underpin learning, job satisfaction, and so on (Ball 1998; Banker et.al, 
1996; Cordero et.al, 1998; Debackere et.al, 1997; Florida and Goodnight 2005; Kim 
and Cha 2000; Livesay et.al, 1996; Lovett et.al, 2004). Unfortunately several of these 
studies suffer from a strong inclination towards description and prescription 
without critically evaluating the contexts and conditions within which management 
practices shape a firm’s performance (Nelson 1991). Hence we learn about how 
specific management practices operate in R&D, for instance, but not necessarily 
how implementation of such practice differs in manufacturing units within the same 
firm. In addition an analysis of concrete performance indicators or how managerial 
variables respond to influences from the environment is limited (Nelson 1991).  
Researchers in the field look for best-practices, or taxonomies of, for example, 
leader’s or inventors’ personality traits, in order to derive pertinent 
recommendations for human resource management practitioners. With regard to 
developing countries, much of the research focuses on some of the most dynamic 
South East Asian economies, and on very specific aspects of the management and 
motivation of R&D personnel (Kim and Cha 2000; Ta-Cheng 1997). The large 
number of management interventions and performance indicators being studied 
makes it difficult to draw general conclusions about individual practices.
4
 
Nevertheless scholars stress that distinct social contexts result in heterogeneous 
managerial approaches within firms; transposing models built on the experience of 
developed countries or large multinationals does not necessarily fit developing 
countries (Kim and Cha 2000). Additional problems arise when scholars fail to 
consider how working environments in the departments under investigation 
influence connections to and interactions with the remaining areas of the firm.  
Type 3 approaches, termed department specific, are subdivided in two groups. 
The first includes organisational studies dealing with management of R&D 
personnel. Here attention is given to practices influencing creativity, attractiveness, 
motivation and productivity of individuals and groups in R&D (Allen 1988; Amabile 
1996; Amabile et.al, 2002; Badawy 1988; Gupta and Singhal 1993; James 2002; 
Mumford 2000). These studies claim that human resource management practices 
influence people’s capacity to conduct R&D; they shape incentives and rewards, 
opportunities to socialise within specific communities, or to develop and put 
creativity and knowledge at work.  
A second strand of literature comprises the bulk of innovation studies; these 
concentrate on firms in developed countries and in industries such as 
                                                 
4 For a more detailed discussion on some specific human resource management practices and how they 
impact on a firm’s learning activities see chapter 3 in this thesis. 
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Pharmaceuticals. Consideration of human resource management interventions is 
often secondary to the analysis of variables such as scale and nature of projects, 
and research productivity in terms of patents or publications (Cockburn and 
Henderson 2001; Cockburn et al., 1999a; Henderson and Cockburn 1994). 
Communication via publication, teamwork, and decision-making related to risk-
taking and the exploration of new ideas, access to advanced equipment, among 
other management interventions, are found to sustain R&D, innovation in general.  
In the case of developing countries, studies about R&D personnel are 
constrained by the lack of a critical mass of R&D departments operated by firms in 
such countries. Instead the work centres on the conditions and determinants of the 
diffusion of Japanese-style management practices (Kaplinsky 1995) and the impact 
of such practices on adoption of quality programs, training provision, or knowledge 
transfer across firms (Bae and Rowley 2004; Okada 2004). Further research is 
needed to shed light on the conditions at the upper levels of the skill-ladder (e.g. 
engineers, staff and managers), and in order to obtain comprehensive views of the 
firm as a more complex entity integrating production, marketing and R&D. 
Taking Mexico as an example, studies following the logic mentioned above, 
show bias towards analyses in the areas of skills and education attainment within 
the labour force, and real wage levels, particularly at lower-ends of the skill-ladder 
in manufacturing and so on (Abramo 1997; Weller 2000). Research here also 
addresses assembly processes within large firms, maquiladoras or other 
multinationals (Carrillo and Ramírez 1997; Dussel 2003 and 2004). The contribution 
of maquiladoras to technological capability building in specific sectors or the 
economy as a whole attracts great attention as well. In such environments, 
creativity, initiative and independent thought are hardly assets firms seek to 
promote (Luthans et.al, 1997; Samstad and Pipkin 2005). Weller (2000) asserts that 
maquiladoras exemplify how precariousness of employment becomes 
institutionalised. Although workers possess formal contracts and social protection, 
lack of security derives from low wages, the duration of shifts, and lack of workers’ 
involvement in decision making. All of these factors accompany business strategies 
with very low emphasis on local technology development; thus, limited interest in 
technological learning, capability building and innovation.  
Type 4 is one of the first approaches where the notion of time becomes 
potentially important for the analysis. It includes analyses of firms’ technological 
and innovative profiles based on human resource management practices. Recent 
contributions along these lines include Ichniowski et.al, (1997), Michie and Sheehan 
(1999 and 2003), Laursen and Foss (2003). The approach focuses on the 
technological profile and corresponding performance of firms across sectors of 
economic activity. Definition of a production or innovation function links to a 
ranking of firms according to different combinations of management practices, from 
most conservative to most dynamic. Studies build on the notion of 
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complementarities among management practices. Although individual interventions 
can enhance performance, and function interdependently, they are more likely to 
impact positively on performance when implemented in bundles as part of coherent 
incentive systems (Ichniowski et.al, 1997; Michie and Sheehan 1999). In line with 
the work of Milgrom and Roberts (1990) the hypothesis is that “If firms adopt work 
practices in a complementary fashion, then empirical tests should consider the 
impacts of groups of practices rather than simply the effects of individual practices” 
(Ichniowski et.al, 1997:295). Clusters of dynamic practices vary in number and range 
from most traditional to most innovative. Firms incorporating the latter activities 
are expected to outperform those featuring more traditional approaches (Michie 
and Sheehan 1999 and 2003). In practice Laursen and Foss (2003) find that this is 
contingent on some technological differences at the sectoral level.  
Approach type 4 also refers to presumed regularities and the characteristics of 
management practices that depend on a firm’s industry or sectoral affiliation. It is 
not obvious why firms with different innovation strategies and operating in 
completely different sectors should gain, equally, from the adoption of comparable 
management practices (Laursen and Foss 2003; Laursen and Mahnke 2001). This 
raises issues for further research; for instance exploring why the identification of 
relevant clusters of management practices is problematic. Clusters span and 
constitute a large number of practices along several categories of human resource 
management practices. Clusters can overlap since no firm necessarily implements 
similar bundles of dynamic management practices. Moreover, since alternative 
relationships are possible among such interventions (Delery 1998), identification of 
systems of practices leading to particular firm performance is problematic.  
In line with the time dimension incorporated in type 4 approach to research, 
Lorenz and Wilkinson (2003:240) criticise these studies for their almost universal 
ranking of enterprises ‘on a one-dimensional scale going from traditional Taylorist 
organisations to modern flexible organisations, based on the penetration rates of 
the stylised set of practices making up the high-involvement model’. In other words, 
heterogeneity in management models is limited by the assumption that as firms 
gain in technological complexity they move from traditional to dynamic 
management systems as well.  
Type 5, labelled product life cycle, offers interesting avenues for research. 
Studies by Kidder (1982), Henderson and Cockburn (1994) and Omta et.al, (1997), 
among others, suggest different kinds of people, with distinct skills, professional 
backgrounds and professional orientations involve, either sequentially or 
simultaneously, along and according to the requirements of different development 
stages of a given product or technology. From a management perspective, 
specialisation means that firms can transfer a great share of the labour 
responsibility onto partner organisations. In the case of the pharmaceutical industry 
for example, the literature proposes differences in managerial approaches 
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supporting drug discovery on the one hand, and drug development on the other. 
Research characterises by unpredictable timing, informality in the structure of work, 
modes of expenditure and uncertain results. By contrast, development features 
more predictable timing for the conclusion of tasks, formality in the organisation 
and the way activities are carried out, and considerably larger expenditure and 
planned results (Chiesa 1996; Datta et.al, 2003).  
Frequently, the split between research and development occurs both at the 
organisational level, and in terms of physical infrastructure; hence, Chiesa (1996) 
indicated that management of each stage differs in terms of culture, organisation 
and types of people involved. People differ in goals, procedures, organisational 
requirements and incentive structures (Hullman 2000). Whereas the key in research 
is “creativity”, the main tenet in development is “organisation” (Chiesa 1996). 
Researchers conducting basic research can hardly be obliged to look for economic 
success; cooperation and leadership are skills of paramount importance. By 
contrast, as an applied research process, development requires a hierarchical 
structure, a more exact definition of instructions about the functions and probable 
effects of medicines, the requirements of the health authorities and estimations of 
success of the new or improved drug (Hullman 2000:74). Accordingly, rewards, 
organisation, hiring, orientation and attitudes towards research, and recognition 
and promotion preferences differ between firms at different stages of the 
technological ladder. Comparative research on the management of human 
resources along different stages of the innovation cycle seems scarce, even 
nonexistent in the case of developing countries. 
Type 6 approaches derive from literature on learning and technological 
capability building in latecomer firms. The approach suggests opportunities to 
incorporate, more explicitly, the human resource management dimension into 
current studies of how firms build capacity to carry out increasingly complex 
processes of learning, technological change and R&D (Dutrénit 2000; Figueiredo 
2003). Differences in learning processes support the construction and accumulation 
of distinct technological profiles; thus, the ability to carry out formal R&D implies a 
need for advanced capabilities (Hobday et.al, 2004). Still missing are more detailed 
accounts of how progression of technological complexity feeds back and forth to 
changes in professional profiles and organisational practices. Evidence remains 
anecdotal, and scattered throughout case studies. Interest lies in the changing 
nature and complexity of the processes that firms are able to perform over time, 
but seldom on the work environments in which people perform such activities. A 
considerable gap remains in our knowledge about ways in which firms in developing 
countries organise R&D personnel. Furthermore, what remains to be address is 
what distinguishes management strategies in innovative and non-innovative firms? 
Related to the above, Kim and Cha (2000) and Laursen and Foss (2003) contend 
that firms with different technological profiles require and mobilise resources 
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differently. This supports the view that more heterogeneous organisational models, 
as compared with those in mainstream literature, are possible. Dávila and Elvira 
(2007) for instance, stress culture, context and history as inducing a different, yet 
functional, form of employer-employee interactions. Equally important is the 
increasing emphasis on the character of innovation and the frequent lack of formal 
R&D units within latecomer firms (Santamaría et.al, 2009). All this widens the gap 
between traditional studies on management practices in manufacturing and those 
on formal R&D departments. 
The pharmaceutical industry is illustrative of the type 6 approaches to research. 
Pharmaceuticals are highly R&D intensive; the capacity to perform R&D determines 
a firm’s viability and prospects to grow in the market. R&D intertwines with the 
capacity to exploit and explore technological and market opportunities. At a basic 
level of technological capabilities, R&D supports the accumulation of some 
knowledge and experience needed to progressively generate more sophisticated 
drugs. Recent studies in India support this argument. Based on a capability building 
model, Kale and Little (2007) argue that “reverse engineering R&D capability –the 
ability to develop products by copying the process-is categorised as a basic 
capability. Generics R&D involves incremental change representing intermediate 
capability while new chemical entity research involves creating new drugs and 
innovative therapies representing advanced capabilities” (p.594).  
Building on the experience of Indian pharmaceutical firms, Kale and Little 
illustrate how each stage of capability accumulation draws from a firm’s knowledge 
base. Over time, local firms use, acquire and accumulate different types of 
knowledge inputs for innovation with increasing degrees of novelty. Progress in 
technology ladder has accompanied the expansion of learning activities outside 
familiar cognitive boundaries, where knowledge searches have become increasingly 
exploratory. Knowledge exploitation, however, remains relevant particularly for 
firms whose business strategies are still based on the extension of life-cycles of 
existing pharmaceutical products. This experience, together with those presented 
by Cardinal and Hatfield (2000) and Kim (1997) for example, show that although the 
technological dynamism of firms focused on catching up to their competitors 
generally lags behind that of large multinationals, R&D remains a core ingredient for 
their success. The major difference is that, in most cases, R&D in developing 
countries leads to incremental innovations.  
From a management viewpoint rapid technological change and market 
dynamics in the pharmaceutical industry have had and are expected to continue 
having interesting implications in terms of labour characteristics and organisational 
practices (Jones 1996). Cockburn et al, (1999a) assert that novel technologies for 
new drug discovery require changes to managerial practices in order to better 
organise and motivate researchers; professionalise personnel and administrative 
management, while keeping the balance between these two activities. Accordingly, 
43
as noted under type 5, differences in managerial approaches supporting drug 
discovery on the one hand, and drug development on the other, have been 
proposed elsewhere in the literature.  
A similar logic supports the need for research on catching-up countries. The 
technological progress that such countries are striving to achieve brings new 
opportunities but also new challenges in terms of personnel requirements and 
management in the local markets. As innovation activities gain in complexity, firms 
need to incorporate new skills, and adopt novel ways to organise, mobilise and 
retain staff. This is one area where bridging the literature on capability building and 
management studies becomes more apparent. Competition in the labour market 
can likewise increase as the new skills required would not necessarily be readily 
available. Unfortunately we still know little about management practices around 
R&D in pharmaceutical firms in developing countries.  
Figure 2.2 illustrates the six approaches to research on human resource 
management, learning and innovation described thus far. This thesis draws from 
these distinct approaches, particularly Types 2, 4 and 6, in somewhat modified form. 
The focus is on the contribution of human resource management to firm’s 
performance; in this case learning through distinct learning strategies. By 
incorporating explicitly such dimension as performance indicator, this thesis 
contributes to the literature in this field. The discussion progressively gains in 
complexity and incorporates in-house R&D and other means to learn from external 
knowledge sources. Although the analysis does not address complementarities 
among human resource management practices, the latter are introduced in bundles. 
In other words, the study reflects on the effects of adoption of specific sets of 
human resource management practices, rather than individual practices.  
The approach likewise assumes that firms conduct learning and innovation 
activities according to their specialisation within the overall industry’s innovation 
processes. Such specialisation reflects the firm’s learning strategy and complexity of 
its technological attainment. It also reflects how firms respond to the general 
conditions of the environment, e.g. quality of research infrastructure, availability of 
human resources and so on. The environment equally provides the background to 
understand which human resource management practices matter for the analysis; 
how and why they do so? A more detailed discussion is presented in Chapter 3. 
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Figure 2.2: Approaches to research on human resource management practices and firms’ performance 
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 Chapter 3 
Research hypothesis, variable definition, data 
and data sources in this thesis 
 
 
 
1. Introduction 
 
Explaining how and why human resource management practices underpin 
innovation introduce innovation scholars into the more ample debate of how and 
why such practices influence firms’ performance more generally. The task is 
complex, Boseli et.al, (2005) and Combs et.al, (2006) assert that huge challenges 
stem from the diversity in the number and possible definitions of indicators on 
human resource management practices, together with the distinct multidisciplinary 
approaches to research. In light of such complexity defining a comprehensive and 
concrete checklist of practices based on a widely accepted theoretical rationale is 
complex; Boseli et.al, (2005) and Combs et.al, (2006) advise pragmatism. Enhanced 
organisational practices often associate with Japanese management style. Hemmert 
(1998) for example, noted that practices that target R&D personnel include: 
scouting, hiring and firing, job rotation and continuity and compensation systems.  
Building on previous work on complementarities among human resource 
management practices, and actual interventions in steel production lines, Ichniowski 
et.al, (1997) identified systems of complementary human resource management 
interventions explaining distinct productive performance of steel finishing lines. 
These systems spanned seven different personnel management areas: incentive and 
compensation plans, recruiting and selection, work teams, employment security, 
flexible job assignments, training, and labour-management communication, 
together with two labour relations indicators: union status and grievance rates. 
Subsequent studies have investigated the effects of these and related variables on 
firm’s innovation performance across industries (Laursen and Foss 2003; Lorenz and 
Valeyre 2004). These studies show that innovative practices occur in heterogeneous 
backgrounds; they vary significantly across firms and countries (Cardon and Stevens 
2004; Vinding 2004). Table 3.1 presents some relevant management variables 
distributed according to seven categories found in the literature. 
In the case of developing countries, relevant human resource management 
practices are associated with adoption of modern organisational techniques, such 
as TQM or JIT, by the firm. The study of factors determining adoption of such 
techniques has received great attention by innovation scholars. Modern 
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organisational approaches include the provision of training, worker’s 
empowerment, payment and staff promotion (Islas 2003; Mertens 2005; Vargas 
2004). Previous research suggests that relative to innovative companies, non-
innovative firms feature larger turn-over rates, and stronger influence by the 
owner/founder on the way businesses run. Poor innovation performers rely more 
on numerical flexibility as opposed to functional flexibility.  
 
Table 3.1: Enhanced human resource management practices and Firm’s (innovation) performance 
 Ichniowski 
et.al, (1997) 
Michie and 
Sheehan 
(1999, 2003) 
Laursen and 
Mahnke 
(2001) 
Laursen 
(2002) 
Laursen and 
Foss (2003) 
Staffing practices 
Strategic hiring 
External market+* 
Internal market+* 
 
 
 
 
 
 
 
 
 
 
 
 
Goal-setting, performance 
appraisal and rewards 
Goal-setting* 
Performance evaluation  
Reward for performance  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


 
 
 


Team-based organisation 
Teamwork practice 
Group Structure Leadership* 
 
 
 
 
 
 
 
 
 
 


 


Integration to the organisation 
Induction Programmes 
Empowerment/politics++ 
  
 
 
 
 
 
 

 
 

Flexibility 
Rotation assignments 
Internal 
External 
 
 
 
 
 
 
 
 
 
 

 

Industrial relations 
Employment security 
Communication manager-
employee 
Unionisation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Training 
Low+++ 
High+++ 
On-the-job 
Off-the-job 
 
 
 
 
 
 
 
 
 
 
 
  
 
 


*Mentioned in management literature but not formally addressed in innovation studies; + Refers to 
whether firms rely on internal promotion or external labour markets to staff their activities; ++ Includes 
supervisor-employee relationships, workers participation in decision making about working conditions, 
goal-setting, and so on; +++ indicates the share of employees participating in training.  
Source: Author based on literature review 
 
Similar to Ichniowski et.al, (1997), the choice of relevant variables in this thesis 
was validated through exploratory interviews with representatives of 
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pharmaceutical companies located in Mexico City—see section 3.2. This thesis 
explores the effects on learning associated with four out of seven categories of 
human resource management practices in table 3.1: the provision of training, 
remuneration for performance, staff hiring and worker’s participation in decision 
making about the work place. 
 
2. Human resource management practices relevant for learning and innovation 
 
2.1. Training  
 
Training assists development of technical and managerial skills among people, who 
are repositories of the tacit knowledge of an organisation (Johnson et.al, 1996). 
Tacit knowledge supports organisational structures, as well as the productive and 
innovation capabilities of a firm. Training improves the capacity of workers to oper-
ate new equipment, adopt new techniques and, in general, to appropriate knowl-
edge available in the environment. In such a way firms can enrich the knowledge 
base of the organisation as a whole. Skills and knowledge tend to be very specific, in 
line with technical requirements of productive and, eventually, innovative processes 
(Bell 1984; Okada 2004). In practice, training goes beyond formal knowledge acqui-
sition, it includes reflection on learning and learning through problem-solving (Gray 
et.al, 2004). Training can contribute to strategies to promote motivation and re-
ward; it can help addressing motivational problems affecting blue-collar workers 
facing extremely low levels of education and limited development opportunities 
(Colmenares 1992; García 2002). 
Training takes, at least, two complementary forms: on-the-job and off-the-job. 
The former is the most common, frequently provided by staff within the 
organisation; it supports learning of routine operations and an understanding of 
basic concepts of internal work processes. The second is usually available for key 
personnel, provided through formal external, classroom, education and linkages to 
external knowledge-producer organisations. External training contributes to 
enhancing the intellectual capital and skills by capturing existing knowledge, that is, 
latest developments in specific knowledge fields, research techniques and so on 
(Hara 2003). These two approaches condition how and how quickly, new knowledge 
and skills are diffused within the firm (Laursen and Salter 2004; Okada 2004). 
Training is one of the main reasons to linking firms with universities and public 
research centres (Casas 2001). Interactions and resulting knowledge flows respond 
to the goals and specific requirements of firms (Laursen and Salter 2004). 
Relationships with external knowledge-producers can grant access to new scientific 
knowledge, improved understanding of specific processes, research techniques and 
so on (Nakamura and Odagiri 2005). Similarly, partnerships with firms and other 
relevant organisations within the industry can provide technologies and other more 
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technical and industry-specific knowledge (Bell 1984; Casas 2001). Likewise Casas 
(2005) points out that a central aspect to study processes of network construction 
between academic organisations and firms is the knowledge that is exchanged and 
how this is assimilated to nurture a firm’s knowledge base. Such knowledge is 
expected to help in the improvement or generation of new products and/or 
processes, in the creation of new technologies or the promotion of innovative 
activities. Training is a relevant mechanism to mobilise scientific and/or 
technological knowledge for problem solving in the production sector, as well as for 
the formation of human resources according to a firm’s knowledge requirements 
(Kuruvilla et.al, 2002; Labarca 1999a). 
Gray et.al, (2004) warn that the influence of training depends on the creation of 
an environment where sufficient returns on investment in such activity can be 
expected. In other words, training needs to be accompanied by pertinent incentives 
and working conditions so that improved skills are adequately used (Laursen and 
Foss 2003). Frequent problems result from poor formalisation of training structures, 
mismatches between training and career development perspectives, independence, 
enhanced authority and responsibility (Domínguez and Brown 1998; Samstad and 
Pipkin 2005). This is accompanied by weak incentives to training, incompatibility 
with work schedules, inappropriate conditions to implement the new skills and high 
turn-over (Carrillo and Ramírez 1997; García 2002; Islas 2003). 
Pharmaceuticals firms are strongly inclined to train personnel across operations 
(BLS-USLD 2007). Training requirements range from a few hours of on-the-job 
training to years of formal education, including job experience. Training includes 
development of general skills, together with those needed to carry out specific 
projects, develop particular processes, conduct specific analyses, handling 
specialised equipment and so on. Firms frequently train in safety, environmental 
and quality control and technological advances. Training in marketing and sales is 
expected to increase the market success of a product. From the above we formulate 
the following hypotheses: 
H1: Training influences positively the likelihood that firms carry out learning ac-
tivities. 
H2: The nature of training and its impact on learning differs depending on the 
nature of the activities carried out by the firm. 
H3: The influence of training varies according to the agent with which a firm 
interacts. 
 
2.2. Remuneration 
 
Management literature contends that the type of incentives firms provide and how 
they are administered condition diverse motivational styles and, whereby, staff 
attitudes towards work (Badawy 1988; Florida and Goodnight 2005). The correct 
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appreciation of individual and professional aspirations promotes commitment 
towards an organisation (Quinn and Rubb 2006). Mumford (2000) contends that 
effective reward systems encourage employees to take risks, pursue the 
development of new products and continuously generate ideas that can be realized. 
Adequate remunerations contribute to skill development cycles by organizing, 
recognizing and rewarding people for their skills, background, expertise and 
intuition (Samstad and Pipkin 2005). Creativity can be encouraged if freedom, 
financial rewards, promotion and other forms of recognition exist (Amabile 1997). 
The literature recommends provision of a mix of intrinsic rewards--such as greater 
autonomy, additional developmental opportunities and public recognition-and 
extrinsic ones-–such as pay increases and promotion opportunities (James 2002; 
Mumford 2000).  
Wages and other compensations respond to the balance between internal and 
external labour market conditions. When firms prioritize the former market, wages 
may be determined internally, somewhat freely of market pressure (Lazear and Oyer 
2004). Offering attractive compensation packages supports strategies aiming to 
increase a firm’s human capital. Remunerations help to strategically attract talent 
from outside; thus minimizing costs of internal development (Labarca 1999b). In 
such a way firms save time and other resources in personnel development 
programs. In the presence of external labour markets however, wages are 
determined by some aggregate process independently of the control of the firms. 
This is particularly relevant in developing countries where critical masses of well-
trained and experience personnel are often scarce. Firms in developing countries 
face strong competition for and high mobility of qualified labour. Sectoral and 
industry differences also reflect distinct dynamics and prospects for specific 
economic activities within and across countries.  
The contribution of remuneration to strategies aiming to retain human capital is 
also important; it prevents the loss or fragmentation of a firm’s knowledge base. For 
example, studies about the maquiladora industry in Mexico show that high turn-
over rates for people at different hierarchy levels constitute major obstacles to 
improved firm performance (Forest 1994; Sargent and Matthews 1997). 
Compensation mechanisms become instrumental to attract, motivate and retain 
personnel (Dussel 2003; Stephens and Greer 1995). In Mexico monthly 
remuneration is the usual practice, with compensation packages usually including 
something more than nominal salaries (Samstad and Pipkin 2005). Non-pecuniary 
‘status enhancing’ perks are highly appreciated particularly at higher levels of 
responsibility and skills (Stephens and Greer 1995; Tello and Greene 1996). 
Setting adequate remuneration systems is complex; creative individuals can 
prefer a challenging and innovation-driven environment over high salaries. For 
instance, Terziovski and Morgan (2006) argue that in science-based industries, such 
as biotechnology, performance-linked rewards might not be as attractive and 
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stimulating as compared to access to sophisticated scientific equipment and 
instruments. The later enable researchers to work while increasing their intellectual 
capital. In the context of developing countries, the use of remunerations as a 
rewarding mechanism finds additional limits. They characterize by tight markets for 
skilled-labour and reliance on wage contention policies to underpin industrial 
competitiveness. These considerations lead to formulate the following hypothesis: 
H4: Adequate compensation and reward for performance positively and 
significantly impact learning activities by firms. 
H5: The influence from remunerations depends on the nature of knowledge 
requirements of the firm. 
H6: The influence of remunerations depends on the type of learning strategy of 
the firm, whether internal or external, or a combination of both those strategies.  
 
2.3. Empowerment 
 
Notable among innovative human resource management practices is 
decentralisation of both decision-making and problem solving rights (Zanko et.al, 
1998). Self-esteem--the feeling of power--is an important determinant of employee 
performance (Gupta and Singhal 1993). Bartlett et.al, (2002) stress that in high-
performance work systems people should be given the opportunity and means to 
tackle new problems, to gain varied experiences, and to be prepared to take on 
more challenging tasks. People may participate in the definition of personal 
objectives or the time they spend at work. Employees can voluntarily request to 
become involved in assignments promoting skills development, or in the 
establishment and management of effective mentoring relationships; in such ways 
firms can foster discovery activities (Mumford 2000).  
Empowerment means opportunities for workers to understand, manipulate and 
master newly acquired technologies (Dutrénit 2000 and 2007). Morgan and Zeffane 
(2003) highlight the positive contribution of direct consultation between employees 
and managers in major change processes at the firm. By empowering employees, 
managers can minimize conflict and resistance to projects involving technical change 
and, consequently, alteration of customary working conditions or labour 
relationships. Successful empowerment often accompanies teamwork and the 
provision of training (Carrillo and Ramírez 1997; García 2002). Bartlett et al. (2002) 
warn that mismatches between increased responsibility, and means and skills to 
perform the job can render empowerment meaningless, even counterproductive.  
In contexts where labour relations are highly hierarchical, power flows top-
down, based on paternalism, links of trust and loyalty between workers and 
immediate supervisors, delegation of responsibility is limited to particular tasks, 
goes without decision-making authority and resistance to follow-up and control 
(Martínez and Dorfman 1998;Schuler et.al, 1996). Such environments, considered as 
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running against learning and innovation, would be frequently found in developing 
countries. This is said to be the case in Mexico and other Latin American countries 
(García 2002; Muller and Rowell 1997). In addition to poor qualification levels, 
workers face trouble to assume higher responsibilities, to participate actively in 
organisational or technical change (Abramo 1997). Nevertheless, as training and 
education attainment increases, workers, notably those working for multinational 
affiliates or high-standard local companies, are less inclined to traditional work 
styles (Flynn 1994). Particularly at managerial levels, people show strong work ethics 
and openness to work long journeys, and assume extraordinary responsibilities 
(Dávila and Elvira 2007; Murphy 2006). 
In science-based organisations such as pharmaceuticals, an adequate 
management of the tension between professional autonomy and organisational 
goals is crucial to minimise potential conflict between professionals and their 
organisations (Randle, Keith 1996; Styhre and Sundgren 2003). For exploratory 
activities autonomy involves capacity to determine working schedules, often beyond 
the time stipulated in contracts or outside normal working hours. It implies capacity 
to join projects and run experiments without or minimum management control, or 
to be able to take leaves from time to time –e.g. sabbaticals, attend congresses 
(Chiesa 1996; Hemmert 1998). By contrast, in drug development settings things may 
be less relaxed. Chiesa (1996) and Hara (2003) noted that drug development 
involves clear definition of authority and responsibilities, together with milestones 
and timeframes to meet the required objectives. First-line managers may receive 
increased autonomy and responsibility regarding management of his/her 
subordinates including recruitment, appraisal, and rewarding. 
Working conditions in the pharmaceutical industry tend to be among the best 
throughout manufacturing (BLS-USLD 2007). As described in chapter 4, 
manufacturing processes and operations, in general, must comply with strict 
sanitary and quality requirements, manufacturing practices and other industry 
standards, and work closely with regulatory authorities. This leads to working 
environments where cleanliness and safety compare positively with other 
industries. As science-based organisations education requirements tend to be high, 
this often traduces in better remuneration packages, even in developing countries. 
Consequently it is customary to find pharmaceuticals firms ranking among the best 
places to work throughout the world, and Mexico is not an exception (GPWI).  
Nonetheless one must acknowledged that, at a global scale, strict regulations 
faced by the pharmaceuticals industry effectively reduce opportunities to modify 
working conditions. Any modification to the drugs and corresponding manufacturing 
processes can lead to burdensome requirements for (re)certification, supervision 
and control by regulatory agencies. In regards to R&D, the literature documents that 
drug development activities, such as those underpinning the formulation of generic 
drugs, are more structured and defined in terms of timing, nature of tasks, formality 
53
in the organisation, conduction of activities, and so on. This could be the situation in 
Mexico were the bulk of R&D leads to obtaining generic products (chapter 6). Based 
on the conflicting evidence from above, one can derive the following research 
hypotheses about worker’s empowerment:  
H7: The influence of empowerment on learning is constrained by the nature of 
the knowledge pursued by the firm. 
H8: The more exploratory nature of the learning activities, the more important 
should worker’s empowerment be. 
 
2.4. Strategic hiring 
 
Strategic hiring, ways to staff the organisation, team building or training 
programmes are means for firms to accumulate technological and other types of 
capabilities. March (1991) identified turnover and staff replacement as mechanisms 
introducing variability in organisations and whereby, renewed opportunities for 
organisational learning. New comers reduce levels of socialization within the firm, 
relative to more experienced staff; consequently, by bringing them in to the 
organisation, firms can induce increased opportunities to exploration and 
knowledge accumulation. In line with this idea Du and Ai (2008) argue that flexible 
hiring facilitates inter-organisational knowledge sharing. It also enables firms to 
overcome the constraints of internalised knowledge searches during the innovation 
processes. A mix of experience and skills, but also clear intention to keep 
consistency with in-house innovation or production teams, with short- and long-
term knowledge requirements constitute relevant criteria to hire new staff (Du and 
Ai 2008; Santamaría et.al, 2009). 
Potential benefits from hiring new staff stem however, from the introduction of 
increased diversity in individual knowledge, rather than on an intrinsic superiority in 
the skills and knowledge of new employees. Organisations can improve innovation 
performance through flexible hiring interventions, by strategically incorporating 
mobile scientists and engineers, specialised consultants, even by capturing the 
expertise residing in a geographically dispersed organisation. Santamaría et.al, 
(2009) stress the importance of external knowledge sources such as the use of 
consultants, the hiring of personnel, collaboration agreements and external R&D. 
Firms can capture and benefit from such knowledge without having to create it from 
scratch (Bell 1984; Lacetera et.al, 2004). Based on these considerations, the working 
hypotheses associated with strategic hiring read as follows: 
H9: Staff hiring supports acquisition of externally generated knowledge. 
H10: The influence of staff hiring on learning is constrained by the nature of the 
knowledge pursued by the firm. 
Hypotheses H1 through H10 inform the empirical analyses in Chapters 7 
through 9. 
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 3. The data in this thesis 
 
This thesis builds on two kinds of data: quantitative and qualitative from both 
primary and secondary sources. The combination of these two methodological 
strategies for data collection makes the analysis much stronger than mere survey 
based research or case studies (Creswell 2003); this is a major departure from 
available literature in the field. Results from the quantitative analyses were 
contrasted with qualitative information about the agents in the pharmaceutical 
industry; hence one can better understand their behaviour in relation to the topics 
under investigation. The main source of primary data for the quantitative study was 
a survey conducted by the Mexican government as described in Section 3.1. The 
anecdotic information was gathered through in-depth interviews with people from 
the pharmaceutical industry and related public and private organisations. Secondary 
data came from extensive searches on archival and other documentary sources, 
attendance to specialised seminars, presentations, Internet and so on.  
 
3.1. Primary Data 
 
3.1.1. Quantitative Data 
 
The core of the empirical discussion in this thesis is presented in chapters 6-8. The 
econometric analyses in those chapters built on data from a survey carried out by 
the Mexican government: the Encuesta Nacional de Empleo, Salarios, Tecnología y 
Capacitación (ENESTYC)
1
. ENESTYC is a survey carried out by the Instituto Nacional 
de Estadística, Geografía e Informática (INEGI)
2
 on behalf of the Secretaría del 
Trabajo y Previsión Social (STPS), Mexico.
3
 ENESTYC’s geographical coverage is at 
national level; hence, it is representative for the whole of the Mexican 
manufacturing sector. Manufacturing is split into non- and maquiladora activities. 
Our focus was on non-maquiladora firms. Classification of manufacturing activities is 
based on the North American Industrial Classification System (NASCI). The 
manufacturing establishment is the unit of analysis. The survey builds on a stratified 
sample based on the establishment’s size as measured by total employment: Large 
251+; medium: 101-250; small: 10-100 and micro: 0-5. ENESTYC follows a 
probabilistic stratification. As for sampling procedures, manufacturing 
establishments with 100 or more employees are all included plus a random sample 
of those with less than 100 employees. Total population is 9,920 non-maquiladora 
manufacturing units. Confidence level is 95 per cent with a relative error of 10 
                                                 
1 National Survey of Employment, Salaries, Technology and Training 
2National Institute for Statistics, Geography and Informatics 
3Department of Labour, Mexico 
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percent. Estimated non-response is 10 percent. There are no fixed time frames to 
run the survey with new questions being incorporated over subsequent waves. The 
latest publicly available edition of ENESTYC corresponds to the event 2001. 
Nevertheless, with a previous commitment to observe all pertinent confidentiality 
requirements by INEGI, personnel from such Institute processed for us preliminary 
data from the event 2005. Information corresponds to 2004. 
This thesis used the module for the pharmaceutical industry (NASCI code 3254) 
which, in practice, constitutes a census of the industry. The module includes 141 
data points with information representative for a total of 388 establishments. Our 
effective working sample, without missing values, is 112 data points. Some firms 
may own more than one establishment; however it is impossible to match data 
points with specific firms. Given the size of the pharmaceutical industry and the 
sampling procedure, staff at INEGI preferred not to merge those establishments 
belonging to a single firm. Consequently the remaining of this thesis uses indistinctly 
the term establishment and firm. 
 
3.1.1.1. Data on learning strategies of pharmaceutical firms 
 
In ENESTYC information about manufacturing units in Mexico include: technological 
and organisational profiles; employment and remuneration levels; some general 
human resource management practices and the provision of training. As for the 
technological performance, ENESTYC contains data on in-house R&D. The variable is 
identified in two manners: first, firms can be classified depending on whether they 
carry out R&D or not. Second, R&D is captured according to the objectives pursued 
by the firm, whether for new/improved process or product innovation. This thesis 
broadly interprets in-house R&D as an internal source of learning.  
ENESTYC also contains information about the participation of pharmaceutical 
firms in external markets for technology. This is through indicators such as 
technology licensing, acquisition of machinery and equipment, performance of joint 
R&D, contracting consultant firms, reading specialised literature and so on. 
Interactive activities underpinning learning from external technology sources are 
also captured through two indicators: One such indicator denotes collaboration 
among firms and exchange of information about the economic and technical 
conditions of the industry. A second variable indicates joint acquisition of 
technology and equipment. These variables are broadly interpreted as learning from 
external sources of knowledge.  
For comprehensiveness of the analysis, indicators on internal and external 
learning efforts are described in greater detail in Chapters 7 and 8, respectively. 
Correlation analyses are also conveniently provided in those chapters.  
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3.1.1.2. Controls on firms’ characteristics 
 
In line with the framework in figure 2.1, the econometric analyses here control for 
variables such as the adoption of modern organisational practices by the firm, the 
firm’s size, the presence of foreign capital ownership and exports. Table 3.2 presents 
the control variables used in this thesis; written in bold are indicators created based 
on the ENESTYC dataset. 
 
Table 3.2: Control variables about pharmaceutical firms in Mexico 
 Mean S.D. Min Max Description 
impor-
tance_totalq 
1.741 1.849 0 8 Ranking of the use of total quality 
management (TQM) practices by a firm, 
from 1 very important through 8 not 
important; 0 if the firm does not use TQM 
impor-
tance_justinti
me 
1.786 2.689 0 8 Ranking of the use of just-in-time (JIT) 
practices by a firm, from 1 very important, 
through 8 not important; 0 if the firm does 
not use JIT 
use_justintim
e 
0.348 --- 0 1 1 if the firm reports the use of just-in-time 
organisational practices irrespective of 
importance; 0 otherwise 
use_totalq 0.634 --- 0 1 1 if the firm reports the use of total quality 
management organisational practices 
irrespective of importance; 0 otherwise 
mod-
ern_practice 
0.670 --- 0 1 1 if the firm reports the use of total quality 
management and/or just-in-time organisa-
tional practices irrespective of actual impor-
tance; 0 otherwise 
Size 1.884 0.888 1 4 Size of the firm 1=Large, 2=Medium, 
3=Small, 4=Micro 
size_firm 1.589 0.494 1 2 Recode of size; hence it is more intuitive to 
see the size of the firm: 1= Medium, small 
and micro, 2= Large  
exports* 72.9 340.9 0 3499.4 Total exports in 2004 
ex-
port_dummy 
0.536 ---- 0 1 1 if the firm reports exports; 0 otherwise 
fdi 0.313 --- 0 1 Share of foreign ownership within a firm’s 
total social capital structure 
foreign_share 25.768 41.922 0 100 1 if the firm has some foreign ownership 
within its total social capital structure; 0 
otherwise 
Notes: Information for the 112 data points in our working sample; * Million Mexican pesos 
Source: Author with information from ENESTYC, 2005; INEGI, Mexico 
 
Organisational environment: Based on the discussion in chapter 2, the 
econometric analyses control for the characteristics of the organisational 
environment inside a firm. This is through a variable denoting the use of modern 
organisational practices such as JIT and TQM. Although ENESTYC captures this two 
variables individually, they were highly correlated with explanatory variables such as 
worker’s empowerment—see below. The use of a new variable, modern_practice, 
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helped to avoid potential multicollinearity problems. This is consistent with the view 
that pharmaceutical firms customarily introduce advanced organisational practices 
as a means to meet strict product safety and quality requirements—chapter 5. 
Participation in export markets: Arora et.al’s (2001) study on external markets 
for knowledge found that competition in markets for goods is an incentive to license 
technology. Kim et.al, (1989) equally highlights export orientation as a competition-
related factor conditioning a firm’s technological behaviour. These considerations 
lead to control for the firm’s participation in export markets. Exposure to external 
competition is expected to positively influence learning from external markets.  
Foreign ownership: Capital ownership conditions decisions on investment in 
technology in developing countries. This is closely tied to how affiliates contribute to 
the overall innovative strategy of the parent firm. In the case of developing 
countries, the concentration of decision making in the parent company suggests 
that foreign ownership can have negative effects on learning from external markets. 
This is particularly so in the case of activities such as R&D for knowledge exploration 
(Nakamura and Odagiri 2005). By contrast foreign ownership is expected to impact 
positively and significantly on learning from external markets in activities other than 
R&D; multinationals invest heavily in plant modernisation in host countries. 
ENESTYC provides information on both the share of foreign capital in the firm’s 
total social capital, and on export behaviour. In order to reduce some collinearity 
problems, while avoiding trouble in the computation of logarithms for entries set at 
zero, the two variables were converted into dummy variables.  
Size: Controlling for scale effects associated with the size of a firm is standard in 
the literature; the pharmaceutical industry is no exception. Large firms are expected 
to show more positive technological behaviours, as compared to smaller businesses. 
More specifically, large firms report enhanced capacity to systematically invest in 
R&D and other innovation-related activities (Cockburn 2004). Such firms can spread 
the risk among a greater number of projects, even across geographical boundaries 
(Cockburn and Henderson 2001). In the context of the pharmaceutical industry, Kim 
et.al, (1989) stressed that the scale of operations may condition, either negatively or 
positively, learning performance of firms in catching up contexts. Size is an 
important factor in Mexico and other developing countries were large 
multinationals often dominate the most dynamic segments of the market—see 
chapter 6. In this regard, by combining scale effects with the variable on worker’s 
remuneration it was possible to eliminate some high and positive correlation 
between the variable on remunerations, fdi and exports. 
 
3.1.1.3. Indicators on management practices 
 
Table 3.3 presents the variables on human resource management practices in 
ENESTYC, 2005. Based on Delery’s (1998) proposition, we used alternative 
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constructs about management variables; indicators in bold are those that were 
created based on the information in the ENESTYC dataset. For comprehensiveness, 
correlations for variables in table 3.3 are provided in chapters 6 through 8.  
 
Table 3.3 Variables on human resource management practices in Mexican manufacturing and available 
through ENESTYC, 2005 
 Min Max Description 
Human resource management practices 
train04 0 1 1 if the firm provided training to its employees in 2004; 0 
otherwise 
training_internal 0 1 1 if training is provided by colleagues in-house; 0 otherwise 
training_pubuniv 0 1 1 if external training was provided by a public university; 0 
otherwise 
training_priuniv 0 1 1 if external training was provided by a private university; 0 
otherwise 
training_firm 0 1 1 if external training was provided by another firm; 0 
otherwise 
training_tradeorg 0 1 1 if external training was provided through a training centre 
of a trade organisation; 0 otherwise 
training_freelance 0 1 1 if external training was provided by an individual 
consultant; 0 otherwise 
training_sup_mac
h 
0 1 1 if external training was provided by a supplier of machinery 
& equipment. 0 otherwise 
external_training 0 1 1 if the firm provides training through external providers 
(specialised public job training centres, public universities, 
private universities, other firms, consultants or the industry’s 
trade organisation); 0 otherwise 
internal_external
_tr 
0 1 1 if the firm provides training both in-house and externally; 0 
otherwise. This is an interaction term between 
training_internal and external_training 
ln_avg_rem 2.67 5.75 Natural logarithm of the average remuneration per worker: 
total remuneration (salaries and benefits) paid in 2004 
divided by total number of employees in the same year 
impor-
tance_empower 
1 8 Ranking set by the firm about importance of workers partici-
pation in decision-making about the workplace; 1 very impor-
tant through 8 not important; 0 if the firm workers do not 
participate in decision-making 
imp_empowerme
nt 
0 2 1 if workers participate in decision making and the firm 
declares that such practice is important; 2 not important; 0 
workers do not participate  
Human resource management policies 
hire_permwork_c
c 
0 1 1 if the firm reports that it governs hiring practices through 
collective contracts; 0 otherwise 
hire_permwork_ir 
0 1 1 if the firm reports an internal regulation, other than collec-
tive contracts, to govern hiring practices; 0 otherwise 
rule_hiring 0 1 1 if the firm regulates hiring staff through either collective 
contracts or other internal negotiations; 0 otherwise  
Notes: Working sample: 112 data points; Variables in bold denote indicators created by the authors.  
Source: Author with information from ENESTYC, 2005; INEGI, Mexico 
 
ENESTYC contains data on management practices relevant for learning and 
innovation. These include the provision of training, the use of rotation assignments 
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and worker’s participation in decision making. In addition, there are some questions 
on the regulation of practices such as staff hiring, staff promotion, remunerations 
and so on. In this regard, Boseli et.al, (2005:74) acknowledged three forms to 
measure human resource management variables: “by its presence (i.e. a 
dichotomous scale for whether it is actually in effect 'yes' or 'no'), by its coverage 
(i.e. a continuous scale for the proportion of the workforce covered by it) or by its 
intensity (i.e. a continuous scale for the degree to which an individual employee is 
exposed to the practice or policy). The overwhelming majority [of studies rely] only 
on measures of presence.” To a large extent, ENESTYC allows performance of the 
latter type of analysis, as in general, variables are measured in terms of adoption by 
the firm. Although this facilitates data collection and analysis, it is possible that 
managers and employee representatives can disagree on the presence and, more 
importantly, the effectiveness of a given practice (Boseli et.al, 2005; Ichniowski et.al, 
1996). Only a few but relevant variables in the ENESTYC dataset reflect intensity of 
practices. A notable example is the indicator on workers’ participation in decision-
making processes; it shows the perceived importance of delegation from the 
perspective of the employer.  
Wright et.al, (2003) and Boseli et.al, (2005) equally warn about the differences 
resulting from the measurement of management variables in terms of either 
policies or practices. Whereas the former reflects an organisation's stated intentions 
regarding management activities; the latter are the actual, functioning, observable 
activities, as experienced by employees. Written policies concerning management 
practices will only lead to performance as individuals perceive them as important for 
organizational well-being. This distinction is clear in the literature on developing 
countries where distinctions are made between stated management styles, and how 
actual management interventions take place (Abramo 1997; Dutrénit 2000).  
ENESTYC contains variables on regulations applicable to management policies; 
however, information about how such rules translate into actual management 
interventions is missing. Consequently, our use of such variables limits to those 
indicators for which our interviews-see section 3.1.2.1- provided some more concise 
information. Hence it was possible to learn about the implementation of the 
relevant practices as necessary condition for effectiveness (Boseli et.al, 2005). This 
was the case of regulations governing the hiring of new staff. 
The empirical analysis in this thesis incorporates variables such as the provision 
of internal and external training, remuneration for performance, staff hiring and 
worker’s participation in decision making about the conditions of the work place. 
The goal is to learn how they contribute to learning by pharmaceutical firms in 
Mexico. In this regard, the variable on external training was split in order to identify 
some specific training providers for which ENESTYC provides information: individual 
consultants, private and public universities, public research centres, machinery 
suppliers and, training centres linked to local trade organisations of the 
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pharmaceutical industry. 
 
3.1.2. Qualitative Data 
 
Collection of primary qualitative data through in-depth interviews informed about 
the environment in which pharmaceutical firms operate in Mexico and abroad. The 
interviews captured the characteristics of the firm, the type of R&D and other inno-
vation activities it carries out in Mexico, if at all, and some factors explaining why 
firms do or do not do R&D in Mexico. Moreover, the interviews explored the differ-
ent areas shaping pharmaceutical innovation: basic research, clinical trials and 
manufacturing—see chapter 4. An additional set of questions targeted the human 
resource management strategy of the firm. Based on Henderson and Cockburn 
(1994) and Ichniowski et.al, (1997), the information thus obtained helped to inter-
pret both the ways and contexts in which human resource management practices 
intervene in processes underpinning learning for pharmaceutical innovation in Mex-
ico. 
 
3.1.2.1. The interviews 
 
The design of the interview guide, in the form of a survey type questionnaire –
Annex 1-, built on the literature review in chapters 1 and 2, and a series of explora-
tory interviews conducted in Mexico and abroad. The interviews took place at three 
different points in time. Exploratory meetings were held in January (Spain) and June 
(Mexico), 2006. Afterwards two rounds of field work took place in Mexico during 
February-August 2007 and October-December, 2007. Additional interviews were 
held in late 2008. The pilot of the interview instrument included several sources, 
namely: the head of the human resource management department and a technician 
from the development unit at a generics drugs manufacturer in Pamplona, Spain. 
Two telephone interviews conducted with people at a European multinational with 
operations in Mexico. Finally, two interviews were carried out at a Mexican firm, 
and one at a US affiliate. The Mexican firm and a contact person at the National 
Trade Organisation of the Pharmaceutical Industry in Mexico (CANIFARMA for its 
name in Spanish) helped to validate the final version of the interview instrument. 
Useful observations, comments and contacts were obtained from researchers at the 
National Autonomous University of Mexico (UNAM for its name in Spanish) and the 
Metropolitan Autonomous University (UAM for its name in Spanish). 
Seizing the pharmaceutical industry in Mexico involved extensive searches 
through several public and private data sources; distinct sources provided different 
numbers of firms shaping the local pharmaceutical industry. The focus was on firms 
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producing drugs and other pharmaceutical products for human consumption.
4
 The 
basic reference was Secretaría de Salud (2005a),
5
 which reported that, in 2005, 200 
pharmaceutical firms were located in Mexico, including 49 multinational affiliates, 
and operated 226 manufacturing plants. Unfortunately, since the document did not 
identify firms by name, additional searches were conducted within the Mexican 
Pharmacopeia
6
, the Hoovers Database, and the websites of the main local trade 
organisations: CANIFARMA, Association of the Industry of Pharmaceutical Research 
(AMIIF for its name in Spanish) and National Association of Drug Manufacturers in 
Mexico (ANAFAM for its name in Spanish).
7
 Snow-bowling and access to a telephone 
directory of the industry identified some additional firms. These search strategies 
allowed identification of 193 pharmaceutical firms, of which 140 were effectively 
approached, most of them through CANIFARMA –Annex 2.
8
 
CANIFARMA distributed the interview guide via email among its affiliates in 
June 2007; a reminder followed in October 2007. Follow up was conducted by the 
author of this thesis and some research assistants from the UNAM. A total of 40 
firms—for a response of 28.6 percent- replied to our request for information, but 
only 26 agreed to participate. Participation was through interviews but, in some 
cases, the firms simply returned the interview instrument together with some 
comments. For reasons of an explicit commitment to confidentiality, identity of 
informants in each participating firm remains anonymous. Table 3.4 presents more 
details about the interviewees. 
The interviews were semi-structured, took an hour long on average and, in 
most cases, were audio-taped and fully transcribed afterwards. Previous to the 
meeting, interviewees were given specific guidance about the objectives and scope 
of the study. Some introductory letters were sent reconfirming the information 
about the study, together with the interview instrument. Normally the initial 
contact was the general director’s office or that of the manufacturing head. 
Sometimes these persons granted the interview, some others they directed us to 
either the human resources, or the development department. In general it was 
possible to adjust the flow of the conversation as interviewees prompted issues 
worth to explore further. Interviews were conducted in Spanish and only 
occasionally, in English. In addition to General Directors, Medical directors, Human 
                                                 
4 Additional items include API manufacturing, veterinary products and health auxiliary devices. 
5 Secretaría de Salud (2005a) is the most recent and comprehensive publication by the Mexican Health 
authorities about the characteristics and operation of the pharmaceutical industry. The document sets 
the general bases of a renewed public policy approach to the local industry. 
6 The pharmacopeia is a public record of pharmaceutical products officially authorized for sale in a given 
country; in this case, Mexico. 
7 CANIFARMA, AMIIF and ANAFAM represent the largest share of pharmaceutical firms in Mexico, with 
affiliation overlapping across the three organisms. Nevertheless CANIFARMA is the largest of the three; 
membership accounts for the bulk of the Mexican pharmaceutical industry in terms of value, employ-
ment and sales, (80 percent or more).  
8 CANIFARMA denied access to the directory of firms arguing confidentiality reasons. 
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resource managers, R&D Heads or Development analysts, interviews were 
conducted at CANIFARMA and AMIIF. People from the local regulatory agency, 
Comisión Federal para la Protección Riesgos Sanitarios (COFEPRIS), the Instituto 
Mexicano del Seguro Social (IMSS)
9
 and the coordinating body of the public 
healthcare and health research centres (CCINSHAE)
10
 were also interviewed. In total 
40 interviews were conducted, 34 of which correspond to 22 firms. 
Several reasons explain unwillingness of firms to take part in this study. The 
majority of them argued internal policies, ethical reasons or difficulties to provide 
confidential information. Other firms insisted that an official request from the local 
regulatory authority had to be submitted with details about the information 
needed. And yet some other firms qualified themselves as too small, hence 
considered that they could provide limited information, barely useful for our 
purposes. Reticence to participate frequently resulted from strict confidentiality 
agreements signed by the employees with the company. Particularly for large firms, 
a policy of fragmenting information across departments and functions complicated 
access to data. This suggests that future studies may need to run in steps following 
the logic of for example, studies type 3 as described in chapter 2; data can be 
gathered for individual departments and then integrated and analysed in the light 
of the broader operation of firms.  
 
3.2. Secondary data sources  
 
Secondary data sources assisted in the overall characterisation of the 
pharmaceutical industry in Mexico, including market structure and dynamics, 
regulatory aspects, employment, sales, exports, R&D expenditure and overall recent 
innovation performance. Important supplements of data were in the form of 
archival searches in the national press, reference texts, academic and medical 
literature, reports by consultant firms and other specialised sources of information 
about the industry, regulatory agencies and the Internet. These sources assisted in 
better understanding operation of the industry at a global scale and in Mexico. 
Additional data stem from attendance to specialised seminars about the industry. 
  
                                                 
9 IMSS and ISSSTE are the two largest public healthcare organizations. They count with 61 million affili-
ates, roughly 58 percent of Mexico’s total population.  
10 A total of twelve Institutos Nacionales de Salud are in place. These are high speciality hospitals that 
provide health-assistance and training across 12 different therapeutic areas. The fundamental mission 
however, is to perform high quality clinical and some basic research.  
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 Table 3.4: General description of interviews carried out as part of this study 
Firm Origin1/ 
Employ-
ploy-
ment 
Sales/2 Years/3 Date Contact Duration/4 
01 F 210 360000 <3 25/Jun/07 Director general 63 
02 F 1100 3119745 >50 11/Jul/07 Plant manager  
     20/Mar/07 Supervisor Manufacturing 75 
     26/Mar/07 Staff Manufacturing 60 
03 M n.a. 281775 >50 17/Jul/07 Plant manager 104 
     17/Jul/07 Development manager 81 
     17/Jul/07 Research director 88 
04 M 421 n.a. ~30 02/Jul/07 CEO 31 
05 M 343 450000 ~40 11/Jun/07 CEO 92 
     19/Jun/07 Plant manager 109 
06 M n.a. 416394 ~40 07/May/07 
Director General 
Development manager 
110 
     04/Jul/07 
Development manager & 
two staff members 
140 
07 F 808 2228675 ~40 02/Apr/07 Director General 34 
     10/Apr/07 Communications manager 55 
     16/Apr/07 
Medical and regulatory 
affairs manager 
32 
08 F 1100 n.a. >50 16/Feb/07 Latin America, Human 
resource management 
affairs 
120 
     13/Mar/07 90 
     16/Mar/07 Technical operations 75 
09 M n.a. n.a. >50 09/Mar/07 Former CEO assistant 60 
10 M n.a. n.a. >50 07/Dec/07 Former Director General 76 
     16/Jul/07 Head R&D department 89 
11 M 770 600000 +30 
27/Jul/06 
27/Feb/07 
Operations director 
120 
75 
12 F n.a. n.a. <4 11/Jul/07 Director General 19 
13 F >1000 n.a. >50 30/Jul/07 R&D director 47 
     30/Apr/07 Development manager 31 
14 M >1000 n.a. >50 23/Nov/07 R&D director 71 
15 F >1000 4583905 >40 26/Jul/06 Human resource technician 60 
165/ M >30 n.a. >20 19/10/07 Director general --- 
175/ F >1000 n.a. >30 14/Aug/07 Medical director --- 
185/ F >1000 n.a. >50 19/Aug/07 Communication director --- 
195/ M >30 11000 >70 14/Aug/07 Director general --- 
205/ F 90 n.a. 3 14/Aug/07 Operations director --- 
215/ F >350 n.a. >70 14/Aug/07 Medical director --- 
225/ M >40 n.a. 4 14/Nov/07 Director general --- 
Trade1 --- --- --- --- 26/Mar/07 Director research 100 
Trade2 --- --- --- --- 03/May/07 Director communications 52 
InsH1 --- --- --- --- 12/Jul/07 Coordination 23 
InsH2 --- --- --- --- 09/Oct/08 Research coordination 90 
InsH3 --- --- --- --- 18/Apr/07 Director 35 
CRO --- --- --- --- 04/Apr/07 Clinical research monitor 60 
Notes: 1/ M= Mexican, F= foreign; 2/ thousand Mexican pesos; 3/ years of operation in Mexico; 4/ in 
minutes; 5/ correspond to firms that returned the interview instrument together with some comments; 
TradeX: Trade organisation; InsHX: National Health Institute; IMSS or Regulatory body; CRO: Contract 
research organisation; n.a. Not available because the firm denied the information or provided only the 
share of products/markets. 
Source: Author based on interviews  
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Chapter 4 
Understanding innovation in pharmaceuticals: 
Processes, knowledge bases and trends 
 
 
 
1. Introduction 
 
The global pharmaceutical industry stands out for its dynamic growth rate, socio-
economic, health and ethical implications. Intensive R&D efforts characterize it as a 
highly science-based industry. Pharmaceuticals systematically rank among the top 
R&D expending sectors throughout the developed world (NSF 2008). Continuous 
exploration for technological opportunities and innovation is vital for competitive-
ness and success of firms. The industry deserves considerable attention from alter-
native research perspectives including, systems of innovation (Cockburn 2004; 
McKelvey et.al, 2004) and capability building (Kim 1997; Singh 2007). 
The literature addresses the factors determining innovation and overall 
performance of the global pharmaceutical industry. This includes the strengthening 
of IPR’s and associated welfare implications as in Arundel and Kabla (1998) and 
Angell (2004); regulatory and competitive issues shaping dynamics of the industry at 
local and global levels;
1
 availability, costs and access to medicines for the poor;
2
 or, 
ethical considerations related to pharmaceutical R&D and patenting activities.
3
 
Research aims to understand recent changes in the processes, technologies and 
knowledge bases supporting R&D;
4
 R&D productivity, skills requirements and so 
on.
5
 These strands of literature approach pharmaceutical innovation from different 
historical, technical, health and socioeconomic perspectives.  
Gaudillière (2004) offers an interesting integrative approach to understand 
pharmaceutical innovation. The author proposes that such activity is simultaneously 
scientific, technical, organisational, institutional and judicial. The process can be 
approached from two distinct but complementary perspectives: that of health and 
medical sciences professionals on the one hand, and that of economists on the 
other. In the first case innovation refers to introduction of new or improved 
                                                 
1 (Dijkema et.al, 2006; DiMasi 2001a and b; DiMasi et.al, 2003; Reichert 2003) 
2 (Grace 2004; Molina and Rivas 1998) 
3 (BHSP 2006; Drennan 2001; Sharma 2004; Santiago 2009) 
4 (Butcher et.al, 2004; Cardinal 2001; Ginsburg and McCarthy 2001; Ulrich and Friend 2002; Walker 2004) 
5 (Beret et.al, 2003; Cockburn et.al, 1999b; Henderson and Cockburn 1994) 
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substances,
6
 medicines, capable of healing or at least, improving conditions of 
people affected by disease. As such innovation comprises two dimensions: capacity 
to discover and create new molecules; and finding clinical applications for them. 
Each of these dimensions can be associated with two types of research activities: 
that of chemists and that of medical doctors (Gaudillière 2004). Accordingly, the 
therapeutic revolution of the last 50-60 years results from the articulation of 
processes such as (i) screening of “libraries” of molecules owned by pharmaceutical 
companies, and (ii) conduction of the required therapeutic tests and studies to 
ensure healing power and safety of new drugs. These processes endure strict 
regulatory controls and legal requirements, particularly to govern interactions 
between firms and medical doctors (Jungmittag et.al, 2000a). 
Gaudillière (2004) asserts that from economics viewpoint the notion of 
innovation has different connotations. At first sight it corresponds to introduction 
into the market of new goods and their corresponding impact on profits, firms’ 
growth or foreign trade dynamics. Factors conditioning innovation are at least, 
twofold: (i) a firm’s structure, its internal organisation and functional divisions; and 
(ii) the regulatory and administrative frameworks framing firm’s performance. 
Pharmaceutical innovation is a process leading to the transformation of medicines 
in merchandise, their adaptation to mass production and commercialization. 
Bearing Gaudillière’s (2004) ideas in mind, this chapter describes the different 
phases of pharmaceutical innovation. It sheds light on the technological processes 
and recent trends conditioning productivity, efficiency and speed of pharmaceutical 
innovation.  
 
2. Pharmaceutical innovation 
 
New Chemical Entities (NCEs) are potentially new drugs which in general represent 
significant therapeutic advances. They are defined as “those products representing 
new chemical structures never previously available to treat particular disease” 
(Reichert 2003). But how do innovative drugs get into the market? Pharmaceutical 
innovation can be summarised in four major and often overlapping phases as shown 
in figure 4.1 (placed at the end of this chapter). The length and sequence of these 
four phases are determined by legal requirements and scientific and economic 
necessities (Jungmittag et.al, 2000b). In general it takes 10 to 15 years to pass 
through all four stages and bring a new drug into market. The first stage includes 
discovery or basic research leading to identification of new molecular targets or 
NCEs, followed by performance of pre-clinical studies. Second, there is the long 
phase of development, when clinical studies are carried out. The latter constitute 
                                                 
6 Gaudillière (2004) considered only new products in his definition of innovation. To be consistent with 
the literature on developing countries, I included the idea of incremental innovation in the sense of 
product/process improvements.  
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the largest share of the time needed to bring new drugs into the market; they 
represent a third or more of the USD$800–900 million estimated investment in the 
entire pharmaceutical innovation process (Boggs et.al, 1999; Maiti and Raghavendra 
2007).  
A third area captures the regulatory processes of evaluation and eventual ap-
proval/rejection of applications for drug testing, development and marketing. In 
fact this third dimension determines much of what happens throughout the phar-
maceutical innovation process. DiMasi (2001a and b) and Kaitin and Healy (2000) 
document some of the debate on the extent regulatory evaluation and approval 
impacts on productivity in pharmaceutical innovation.
7
 Public regulation introduces 
the principles and acceptable practices to conduct new drug-related R&D, from the 
physical movement of chemical and biological substances, to ensuring that research 
involving human beings meets strict requirements of protection of the populations 
involved. 
Secretaría de Salud (2005a) asserts that regulatory interventions should con-
sider: (i) the epidemiological profile of the country and the goals of the national 
pharmaceutical policy; (ii) the goal of ensuring safe, effective and quality medicines; 
(iii) the need to secure access to medicines; and, (iv) the strategies to promote in-
novation and competitiveness of the pharmaceutical industry. Public policy should 
link a process that starts with the detection of particular health problems; follows 
with the search for suitable products to address such need and, hopefully, obtaining 
and manufacturing a new medicine. Last but not least there is the commercialisa-
tion and surveillance for long-term effects of the drug on consumers. Figure 4.2 
illustrates these elements. 
Frequently, innovation scholars restrict their work to understanding the afore-
mentioned stages of discovery, clinical research and regulation. However, what we 
know is that for a new or improved product, service or process to become an inno-
vation, it still has to prove successful in the market. A last stage in the process com-
prises drug manufacturing, marketing and product life-cycle support (Styhre and 
Sundgren 2003). This is congruent with normal regulatory requirements whereby 
(innovative) drugs are subject to continuous surveillance to prevent potential health 
and other sanitary risks. With some notable exceptions of firms in India who start to 
participate, either via joint ventures or by directly performing them, in drug discov-
ery activities (Reddy 1997; Singh 2007), the contribution of developing countries 
concentrates in manufacturing. This is via development of generic drugs, enhance-
ments or improvements of drugs by combining existing molecules, new dosage 
forms, new indications, and formula changes; and new drug delivery systems (DDS).  
 
                                                 
7 FDA (2004b) reports an average of 16.9 months for the FDA to review and approve new drugs in 2003. 
The share of rejected applications has remained constant at about 10-15 per cent. 
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Figure 4.2: Public policy process in Pharmaceuticals 
 
Source: Adapted and translated from Secretaría de Salud (2005a) 
 
The following paragraphs characterise further each instance of pharmaceutical 
innovation. For comprehensiveness with the rest of the thesis, we focus on R&D 
and manufacturing; regulatory issues are introduced throughout the discussion.  
 
2.1. Drug discovery and pre-clinical tests 
 
2.1.1. Drug discovery 
 
The discovery phase aims to identify specific targets, new molecules with desirable 
properties and effects on particular disease; that is to say, promising prospects for 
new medicines. To find a target, literally thousands of compounds, either natural or 
chemically or genetically engineered, must be screened in a series of test tube ex-
periments called “assays”: compounds are added one at a time to enzymes, cell 
cultures, or cellular substances grown in the laboratory. The goal is to find combina-
tions with desired pharmacological effects. Assays lead to the generation of lead 
compounds which in turn, must be modified to increase activity or minimize unde-
sirable side effects, a process called lead optimization (Bush 2004; DHHS et.al, 1998; 
FDA). From a historical perspective one can distinguish two main innovation re-
Basic 
research 
Pre-clinic 
phase 
API Manu-
facturing  
Clinic (de-
velopment) 
 
Surveillance 
 
Sale 
Drug 
manufac-
turing 
Regulato-
ry/health 
authority 
Health Prob-
lem 
 
Therapeutic 
Need 
Prescription 
 
Distribu-
tion 
68
gimes, systems of practices, to carry out the screening and identification of poten-
tially new pharmaceutical products (Gaudillière 2004). 
In the early years the knowledge and experience of pharmacists supported drug 
innovation, namely: preparation, isolation and concentration of active ingredients. 
The process included the isolation and combination of substances according to the 
characteristics of both the substance itself and the disease it intended to treat 
(Gaudillière 2004). Roots of this regime go back to the office pharmacists and publi-
cation of pharmacopoeias, far from manipulation of living beings (Gaudillière 2004). 
Back then drug discovery depended on experimental protocols guided by research-
ers’ informed curiosity and trial-and-error approaches. Compounds synthesized by 
medicinal chemists were tested in experimental animals hoping to obtain some 
desired biological activity and to separate it from unwanted effects by further 
chemical manipulation of the lead structure (Kuhlman 1997). With time, this regime 
eventually gave way to a second one involving the screening and chemical synthesis 
of compounds (Gaudillière 2004).  
In line with literature on technology diffusion, for some time the two innova-
tion regimes coexisted in the industry but, eventually, the second one gained domi-
nance thanks to developments in the chemical and more precisely, the dye industry 
at the end of the XIX Century (Gaudillière 2004). The new regime built up from the 
development of selective chemotherapies based on anti-bacterial properties of 
some dye products, systematic use of intellectual property rights to protect and 
capture monopolistic rents from new products (Gaudillière 2004). Early in the de-
velopment of the new regime, new drugs were generated based on random, seren-
dipitous chemical processes but increasingly from interactions between biologists 
and chemists. These two groups of professionals increasingly seek to understand 
the biochemical mechanisms of action, the biological structures and function of 
novel chemical structures (Drews 2000). 
Drug discovery is perhaps the area of pharmaceutical innovation where many 
of the most interesting changes in technologies, processes and knowledge bases 
have occurred and are currently taking place. This has been guided by develop-
ments in combinatorial chemistry,
8
 pharmacology, microbiology and biochemistry, 
molecular biology, let alone better understanding of the bases of disease, knowl-
edge of the human genome and notably, biotechnology (Malerba and Orsenigo 
2002; Zucker and Darby 1997). These factors are expected to shape the future 
course of drug discovery (Cockburn 2004; Drews 2000). Great expectations result 
from the prospects of advancing towards personalized medicine, a dreamed appli-
                                                 
8 Combinatorial chemistry refers to “The synthesis of a substantial number of structurally distinct com-
pounds using similar reaction conditions. The process encompasses systematic molecular design either 
by linking separate building blocks or by adding substitutes to a core structure” (Kuhlman 1997). Years of 
experimentation have lead to creation of libraries of molecules, synthesis techniques, physiochemical 
properties and so on. 
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cation for the new technologies (Butcher et.al, 2004; Daar and Singer 2005; Gins-
burg and McCarthy 2001; Myers and Baker 2001). New screening methods are un-
der development including, computer-aided molecular modelling systems, and 
other systems biology tools enabling systematic and simultaneous combination of 
literally hundreds of thousands of molecules.
9
  
Today the search for new drugs starts by understanding how the body works, 
both normally and abnormally, at its most basic levels. Hence it is possible to de-
termine how a drug might be used to prevent, cure, or treat disease or medical 
conditions (FDA 2003). Automation through computer-controlled robotic systems 
and the use of combinatorial chemistry accelerates screening of large numbers of 
novel compounds. As scale advantages diminish, small biotech firms are taking the 
lead as a supplier industry in robotics/automation, information technologies, ge-
nomics, combinatorial chemistry and so on (Jungmittag et.al, 2000a; Malerba and 
Orsenigo 2002).  
Unfortunately, the impact of new technologies on productivity of pharmaceuti-
cal innovation remains disappointing (Cockburn 2004; Drews 2000). Further re-
search is needed to explain factors hindering progress; (Drews 2000) argued that 
new screening techniques and processes still need to be optimized. For instance, 
although (ultra) high throughput screening systems make possible to identify thou-
sands of new promising compounds --200-300 compounds per year (Kuhlman 
1997); only a minor fraction can be chemically synthesised (Butcher et.al, 2004). The 
bio-chemical, pharmaceutical, toxicological and other properties of thousands of 
targets need to be known before entering the development stage (Ulrich and Friend 
2002). Complexity in knowledge requirements and lack of experience in new drug-
related basic research limits strongly the ability of developing countries to partici-
pate in drug discovery activities.  
 
2.1.2. Pre-clinical tests 
 
Following identification of suitable drug candidates, lead compounds enter a period 
of years of recurrent scientific, regulatory and economic testing and validation. 
Previous to tests in humans, pre-clinical testing through laboratory (in vitro) and 
animal (in vivo) studies evaluate safety and biological activity of new compounds. 
This can take anywhere from 3-6 years. Core tests include pharmacokinetics, mean-
ing how active ingredients behave in living organisms via processes such as absorp-
tion, distribution, metabolism and excretion.
10
 The tests ensure that substances 
                                                 
9 Butcher et.al, (2004) offer a more ample discussion on this topic 
10 Choices of animal species, mode of administration, dose and dosing interval, and duration of admini-
stration are chosen so that results can be interpreted in connection to pharmacological and toxicological 
investigations. Methodologies employed include high-pressure liquid chromatography, gas chromatogra-
phy, mass spectrometry analysis and radio- or enzyme-immunoassays (Kuhlman 1997)  
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reach intended targets, that pass through and that are properly excreted from the 
body (DHHS et.al, 1998). Safety tests continue after the start of clinical trials with 
the intention to determine any possible long-term adverse effects associated with 
the new compounds.  
In addition to biological tests, a number of chemical studies establish the com-
pound's purity, stability and shelf life. Manufacturing tests identify potential to 
mass produce the prospective medicine. Pharmaceutical development studies ex-
plore optimum dosage, packaging and formulation--e.g. pills, inhalers and injec-
tions; for the new drug (DHHS et.al, 1998). Pre-clinical tests provide the information 
that a firm compulsory needs to submit when filing for a human investigational new 
drug (IND) (FDA).
11
 Such applications must include data about the compound’s 
chemical structure, how it is expected to work in the body; any side effects in ani-
mals, and how compounds are manufactured (FDA 2001). Applicants must detail 
plans of how, where and by whom clinical trials will be conducted (DHHS et.al, 
1998).  
 
2.2. Clinical trials 
 
Notwithstanding progress in drug discovery, boost to pharmaceutical innovation 
remains limited. Of an estimated 250 compounds entering preclinical testing only 
about five will make it to clinical trials (DHHS et.al, 1998). Development of lead 
compounds asks about the potential of the new substance to become more effec-
tive than current therapies, if at all existent; feasibility to mass produce the new 
drug and so on (Bush 2004;DHHS et.al, 1998).
12
 Blinded
13
, random
14
, controlled 
clinical trials are the best designed instrument to determine if the drug is both safe 
for people and an effective treatment for the disease in question (Sheiner 1997; 
Thompson and Vega 2001; Zivin 2000). Tests of manufacturing potential run in par-
allel as successive phases of trials require substantial amounts of the new substance 
to be administered to study subjects. They also inform appropriate methods for 
large scale manufacturing and formulation. The latter may take up to 5 years to 
develop (Styhre and Sundgren 2003). Clinical-pharmacology and biometric studies 
support the planning and evaluation of each individual study (Kuhlman 1997). Clini-
                                                 
11 The IND is a requested exemption from regulations prohibiting that unapproved drugs are shipped and 
moved across a desired location to conduct clinical trials (FDA) 
12 Molecules can have properties that complicate optimal therapy and administration, including low 
bioavailability, chemical instability or low solubility. In addition, there are marketing- and other demands 
in terms of the user–friendliness, design and frequency of administration, including drug delivery tech-
nologies (Styhre and Sundgren 2003) 
13 Ideally neither voluntary participants nor physicians conducting clinical tests should know which sub-
ject is part of either treatment or control groups; whether the test drug is being administered and to 
whom (Zivin 2000) 
14 INDs are exceptionally provided to very ill patients (DHHS et.al, 1998). Normally, participants are 
randomly allocated among control and test groups (Zivin 2000) 
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cal research involves epidemic studies, life-style modifications, prognostic studies, 
health records and tests of non-pharmacology related therapies. However, clinical 
research on new drugs is the most abundant. Trials split as follows: 
Phase I: The compound is tested in a small group (10-100) of healthy volun-
teers, often in a hospital setting, to determine safety profile, including safe dosage 
range (DHHS et.al, 1998). To minimize risks of major negative reactions in the par-
ticipants, initial doses are typically very low compared to those administered during 
animal and non-animal tests; however, these are escalated closer and closer to the 
expected optimum dosage
15
. Similar to the pre-clinical stage, pharmacokinetic stud-
ies examine drug absorption, distribution, metabolization and excretion, and dura-
tion of its action in the human body. Phase I studies last from six months to one 
year and cost about US$10 million (Zivin 2000).  
Phase II: Non- or placebo-controlled Phase II trials involve approximately 100 to 
500 volunteer patients with the target disease. Beyond the mere testing of effec-
tiveness of a medicine prospect, Phase II informs about the characteristics, number 
of study subjects required, dosage and estimated duration of treatment, and other 
experimental conditions for the larger and more complex Phase III tests. This in-
cludes definition of end points, “unambiguous results that indicate exactly what the 
treatment can do”
 16
 (Zivin 2000).
 
Researchers continue to evaluate safety and pos-
sible side effects, determine optimal dose and intake schedules. Phase II studies go 
from six months to two years and cost about US$20 million.  
Phase III: The compound is tested in a significantly larger number of volunteers, 
from some hundreds to several thousands, in hospitals, clinics and/or physician 
offices. This renders statistically significant data about safety and efficacy of poten-
tial new drugs. By this point, at least one group of patients should render meaning-
ful information about how they benefited and the best way to administer treatment 
(Zivin 2000). Phase III can provide authoritative confirmation that a drug works. 
According to Zivin (2000) if analyses prove that the drug candidate is potentially and 
significantly more effective than the control treatment, the trial is called pivotal. If a 
regulatory agency is satisfied with the evidence it may issue new drug marketing 
approval; in practice several trials are needed to inform decision making
17
 (DiMasi 
2000; Peck, Carl 1997). Phase III can take from 1-4 years depending on the disease, 
length of the study, and the number of volunteers; cost may be in excess of US$45 
million (Zivin 2000).  
                                                 
15 If chances are that the new compound will render extremely serious side effects, Phase I tests may be 
conducted in patients with the medical condition intended to treat; hence potential risks are balanced by 
potential benefits. These are considered “compassion” tests (DHHS et.al, 1998)  
16 End points signal changes in the condition of the patient from healing to a reduction in the progression 
of the disease, or whether dead rates have fallen, and by how much (Zivin 2000) 
17 Peck (1997) documented that out of 12 clinical trials, some 25 per cent of all new drug applications in 
the US in 1994-1995, the least number of clinical studies in an approved NDA was 23, while the maxi-
mum exceeded 150. 
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Clinical trials are cumbersomely long, costly and highly uncertain even if ex-
pected results are more or less known beforehand. Ability to undertake quick, rule-
governed, reasonably low-cost, and credible clinical studies is a major asset and 
source of sustainable competitive advantage in the pharmaceutical industry (Styhre 
and Sundgren 2003). These factors help to reduce time-to-market, increase profits 
and enhance product quality. Each day saved in the process, particularly in Phase III, 
brings substantial gains in expected revenues.
18
 Accordingly, outsourcing and off-
shoring of clinical trials has been an increasingly common strategy adopted by 
pharmaceutical firms to try and speed innovation up. As a result clinical trials are 
increasingly run at numerous sites around the world. Pharmaceutical multinationals 
leverage scientific and technical capabilities and other country-specific characteris-
tics in relevant markets while protecting, enhancing or complementing the core 
knowledge developed at corporate level (Kuemmerle 1999; Le Bas and Sierra 2002; 
Patel and Vega 1999). Regulatory changes taking place in relevant markets underpin 
internationalisation of pharmaceutical R&D. In the US for example, the FDA accepts 
data from clinical trials performed abroad to support any new drug application (FDA 
2001). Similarly, firms take advantage of host countries that are able to comply with 
strict international standards on good clinical practices (GCP) and good laboratory 
practices (GLP) respectively,
19
 as this is required to ensure quality and integrity of 
data and more importantly, to safeguard wellbeing of study subjects. 
Developing countries emerge as relevant sites for clinical research. India and 
China appear as preferred destinations, but good prospects are also available for 
Brazil, South Africa and Mexico for example. In addition to large domestic markets, 
such countries have consolidated regional manufacturing and export bases for for-
eign-owned subsidiaries as well as for some domestic firms. Emerging economies 
feature some country specific conditions shaping their attractiveness as investiga-
tive sites. For instance Santiago (2009) mentions heterogeneous and growing popu-
lations, high prevalence of targeted diseases and lower research costs–even for 
similar labour force quality and research conditions relative to developed coun-
tries;
20
 let alone the presence of fairly strong public healthcare systems with large 
population coverage.  
Although firms can benefit from off-shoring clinical trials into developing coun-
tries, this strategy rises strong debate around potential ethical and health implica-
                                                 
18 Boggs et.al, (1999) indicate that each day a successful drug reaches the market earlier may earn up to 
US$200,000 for a company.  
19 Adoption of GCPs in the post-II World War period responded to the need to protect integrity of sub-
jects participating in clinical trials; key practices include informed consent and observance of ethical 
aspects of tests in humans. GLPs in turn, refer to systems of management controls conditioning work in 
laboratories and research organizations ensuring quality, consistency, validity and reliability of test data 
(FDA/ORA)  
20 Maiti and Raghavendra (2007) for example report savings of 30 to 50 per cent in India for comparable 
clinical trials carried out in Europe or the US. 
73
tions, particularly for local populations. As Santiago (2009 and 2010) document, 
subject to research is the extent to which study subjects are aware of and suffi-
ciently protected against inherent risks of participation in drug testing; or, the ca-
pacity of public policy organisations to minimize risks and increase opportunities of 
host countries to benefit from clinical trials. This field is open for research and policy 
analysis. 
 
2.3. Drug manufacturing 
 
Medicines contain two basic elements. On the one hand the active pharmaceutical 
ingredient (API) also known as the chemical entity, or the active molecule or princi-
pal ingredient. APIs are the ultimate outcome of the ten years or more of basic 
research and clinical development. APIs are the substances responsible for specific 
therapeutic actions: they provide relief to the patient. In physical terms APIs make 
up only a small proportion of the final medicine, but constitute the most expensive 
part of the product. On the other hand, the excipients, inactive substances, serve as 
vehicles or media for a drug or any other active substance. Excipients give shape 
and stability to the medicine. Raw materials of the medicine include both these 
elements, together with the materials and substances employed in manufacturing 
but not contained in the final product.  
 
2.3.1. Good Manufacturing Practice 
 
Ensuring effectiveness and safety of pharmaceutical products leads to the careful 
structuring of manufacturing activities so as to avoid any health risks resulting from 
impurities, variations in the amount of active substance or for instance, the dissolu-
tion pattern of a pill (Seiter 2005). In most countries the health authorities tackle 
these issues by implementing comprehensive safeguards and procedures of obliga-
tory observance by drug manufacturers. These procedures are termed Good Manu-
facturing Practice (GMP) which, in simple words, indicates the rules/practices to 
manufacture a drug (Seiter 2005).
21
 GMPs cover layout and functionality of build-
ings, qualification and training of personnel, cleanliness and sanitation, monitoring, 
supervision and many other aspects, from beginning to the end, of drug manufac-
turing (Seiter 2005). GMPs are constantly reviewed and adjusted according to scien-
tific and technological advances; hence, the frequent denomination of “current” or 
cGMPs (FDA 2004b; Seiter 2005). cGMP compliance requires great investment ef-
                                                 
21 In Mexico for example, cGMP’s are regulated by specific national norms issued by the Secretary of 
Health, (Secretaría de Salud. 1998a, b) 
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forts and operating costs.
22
 More importantly, as we discuss latter, cGMPs can con-
dition opportunities for innovation in drug manufacturing. 
 
2.3.2. Manufacturing process
23
 
 
Drug manufacturing can be decomposed into: (i) Primary manufacture or making of 
APIs; and, (ii) Secondary manufacture where formulation of the medicine takes 
place. Drug manufacturing is lot-based; raw materials subsequently pass from one 
process step to the next. Manufacturing processes require complex and fairly ad-
vanced technologies: distillation reactors, systems to recover solvents and dust 
emissions, confined spaces, tablet machinery, and for packaging and labelling, 
among others. Each step processes and transforms the inputs incrementally.  
Primary manufacture: The first stage of making medicines is manufacturing of 
APIs. Two main ways are possible to do so: (i) pharmochemical technology and, (ii) 
biotechnology. Medicines can combine both processes (Dussel 1999). APIs can be 
contained in herbs or homeopathic products. Regarding pharmochemical technol-
ogy, primary manufacture involves chemical reactions to create molecules or 
chemical compounds. Figure 4.3 illustrates the many possible stages to these reac-
tions. Groups of chemists isolate and purify the API from other products using vari-
ety of techniques. Several processes are needed to produce a completely pure sam-
ple of the API.  
 
Figure 4.3: Schematic representation of the primary manufacturing process for biopharmaceuticals 
 
 
 
 
 
 
 
 
 
 
Source: Taken from ABPI (2006) 
 
                                                 
22 Additional items relevant in the cost structure of a pharmaceutical firm include labour costs, cost of 
capital, construction costs, taxes and tariffs, costs for environmental safeguards, insurance, licensing, 
utilities and costs of externally procured goods and services (Seiter 2005)  
23 This section draws heavily from ABPI (2006) 
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In the case of biotechnology, living beings intervene in API manufacturing. Re-
cent techniques, such as genetic engineering, have been adopted to modify the 
genes of bacteria so that they can produce useful proteins or monoclonal antibodies 
(ABPI 2006). Genetic engineering allows scientists to introduce new genes for useful 
proteins into a cell’s DNA, for example bacteria, fungi or cultures of animal cells. 
The modified cells are subsequently grown on a large scale to produce proteins 
called biopharmaceuticals. They can be vaccines, hormones, enzymes or mono-
clonal antibodies. Production of biopharmaceuticals is similar to the primary manu-
facture sequence in figure 4.3. Nevertheless, the nature of raw materials is differ-
ent, the cells or micro-organisms and the culture medium in which they grow. The 
reactor is usually a fermenter. The product is extracted using a series of filters and 
centrifuges and purified by chromatography. The API is customarily provided in vials 
as a solution or as a frozen dried powder, ready for formulation in secondary manu-
facture. 
Secondary manufacture: In this stage the API is processed in order to make it 
suitable for administration to a patient. During this phase firms follow strict codes 
of good manufacturing practice (Secretaría de Salud 1998a and b). APIs are turned 
into medicines by mixing with other substances, excipients. Although the latter 
make up most of the volume of medicines, they have no active role in curing a pa-
tient. Excipients shape medicines, such as tablets or capsules, liquids, topical medi-
cines, inhalers or syrups, and give stability to the API (ABPI 2006). Secondary manu-
facturing entails a series of systematic steps and system technologies, including: (i) 
the manufacturing system; (ii) the tracking system; (iii) information technology 
systems; (iv) delivery systems; (v) control systems; and, (vi) technological systems 
(ABPI 2006).  
The manufacturing system: The manufacturing system considers the process of 
bringing a (new) medicine to the market; it can break down in terms of inputs, 
processes and outputs.  
Inputs: New drug development starts with learning about a particular disease, 
specifications for new potential medicines and a series of resources including fi-
nancing, energy, equipment, raw materials and knowledge and expertise of em-
ployees, together with the regulatory framework determining and setting the limits 
to what is feasible in the process of developing and manufacturing a (new) drug 
(ABPI 2006). The quality of the raw materials is of paramount importance for suc-
cess in manufacturing processes. Raw materials are carefully evaluated for the iden-
tity and purity of the chemical entity; certificates of compliance with cGMP are 
issued by the appropriate health or regulatory authority of the country of origin.  
The processes: Important aspects include the manufacturing cycle itself; the 
production systems (layout and how equipment is grouped and linked); the check-
ing system to ensure that medicines meet proper specifications; the scale and the 
pace of production (whether products are manufactured continuously, or in small 
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or large batches); the organisation of the company; and quality controls. Meeting 
strict safety and quality principles require full time personnel in such functions (BLS-
USLD 2007). 
The outputs: In addition to medicines, there are by-products as waste and the 
means of storing and transporting the medicines to distribution channels.  
The tracking system: As an integral part of the manufacturing system, the track-
ing system seeks to ensure that medicines are manufactured safely. A strategy is to 
make medicines in batches; hence, it is easier and possible to identify when and 
where particular samples were made. A number of tests carried out at each stage 
guarantees that each batch complies with the specifications in the manufacturing 
licence issued by the regulatory authorities–see discussion on sanitary registration 
below. The tests include physical and biochemical characteristics of the product. 
Tests and quality insurance span the entire supply-buyer chain (ABPI 2006). Keeping 
batch registries makes it easier to trace back any problems arising at later dates. 
Strong safety and environmental concerns, both within and off-line are characteris-
tic of the industry.  
Information Technology (IT) systems: The IT systems help in the management, 
handling and retrieval of data needed for daily operation of pharmaceutical firms.  
Control systems: Controls are introduced throughout the manufacturing proc-
ess; these may be automated or based on human actions.  
Technological systems: Technological systems comprise mechanical, electrical, 
microelectronic, hydraulic and pneumatic components to control and automate the 
processes. Production operations characterize by high degree of automation.  
Working Conditions: Compared to most other manufacturing plants, working 
conditions in pharmaceutical shops are better. Strong emphasis is placed on keep-
ing equipment and work areas clean because of the danger of contamination of 
both the product and personnel. Plants usually are air-conditioned, well lighted, and 
quiet. Ventilation systems protect workers from dust, fumes, and disagreeable 
odours. Special precautions are taken to protect employees working with infectious 
cultures and poisonous chemicals. With the exception of work performed by mate-
rial handlers and maintenance workers most jobs require little physical effort (BLS-
USLD 2007).  
 
2.3.3. Innovation in drug manufacturing  
 
The literature frequently privileges the study of innovation and learning processes 
taking place during the R&D phases of pharmaceutical innovation. This is under-
standable considering the impressive technological and organisational changes 
taking place in those activities. Scientific, technological and organisational chal-
lenges seeking increased productivity in drug discovery and development are sig-
nificant. By contrast, considerably less attention is granted to innovation practices 
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at advanced levels of the drug innovation cycle. In particular, innovation in manu-
facturing activities has received very little consideration in the literature. Some 
good reasons support the omission; notably, the strong standardization and con-
trols imposed by sanitary and related regulations on drug manufacturing processes. 
Conventional drug manufacturing proceeds using batch processing with laboratory 
testing conducted on collected samples to evaluate quality. The need to keep con-
sistency and traceability makes difficult to modify manufacturing processes once 
they have been validated and approved by regulatory agencies. Firms may need to 
“carry out a large number of studies to certify that any modification [to the process] 
has no significant impact on the quality of the product” (Interview at trade1). Oth-
erwise firms need to have the new manufacturing process recertified and author-
ised for use by the regulatory agency. Recertification is cumbersome and costly. 
Regulatory uncertainty reduces incentives to introduce innovative systems into drug 
manufacturing (FDA 2004a).  
From the above, regulatory authorities such as the FDA in the US acknowledge 
that significant opportunities exist “for improving pharmaceutical development, 
manufacturing, and quality assurance through innovation in product and process 
development, process analysis, and process control” (FDA 2004b:2). According to 
the FDA, from a public health perspective, strategies to promote innovation in drug 
manufacturing should be promoted. They would contribute to the availability of 
safe, effective, and affordable medicines. With these goals in mind, the FDA has 
promoted the increased use of an integrated systems approach based on science 
and engineering principles for assessing and mitigating risks related to poor product 
and process quality (FDA 2004a and b). Since 2003, the FDA supports adoption of “a 
system for designing, analyzing, and controlling manufacturing through timely 
measurements (i.e., during processing) of critical quality and performance attrib-
utes of raw and in-process materials and processes, with the goal of ensuring final 
product quality” under the name of Process Analytical Technology (PAT). The term 
is comprehensive and includes chemical, physical, microbiological, mathematical, 
and risk analysis conducted in an integrated manner. A core principle is that “quality 
cannot be tested into products; it should be built-in or should be by design” (FDA 
2004b:4).
24
  
The PAT framework is expected to reduce production cycle times and human 
errors by enhancing automation, prevent deviations from the approved process and 
consequently, the risk of product rejects by sanitary authorities. The framework 
should also diminish scrap and reprocessing of materials, while increasing workers 
safety (Albano 2008). Intensive use of information to monitor and process control is 
also notable (Macher and Nicherson 2006). Notwithstanding its newness, some 
evaluations have been undertaken already on the PATs (Macher and Nicherson 
                                                 
24 Bolds included in the original. 
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2006). Although initial results tend not to support PAT adoption,
25
 further research 
should document whether this is because the new tools are ineffective, or because 
they still require some time to be assimilated and positively exploited by firms. It 
seems pertinent to study the evolution of the PATs framework. On the one hand, to 
shed light on the implications of government driven innovation in the most impor-
tant pharmaceutical market in the world, the US. On the other hand because the 
PATs are already diffusing into developing countries via affiliates of US firms. What 
the implications for the industries in the host countries are? To what extent gov-
ernments in developing countries may promote innovation via modernization in 
drug manufacturing? Chaturvedi et.al, (2007) suggest that in India government 
intervention has been key for innovation in pharmaceutical manufacturing. 
Patent expiration and low pipeline productivity hinder financial sustainability of 
innovative pharmaceutical firms. Keeping new drug innovation up and running calls 
for significant investment in terms of time and other resources. It is pertinent to 
take a careful look at complementary strategies implemented by innovative firms in 
the development of generic products; hence we can learn about pharmaceutical 
innovation beyond frontier R&D. The approach is pertinent from a catching up per-
spective. Recent empirical experiences of technological capability building in India, 
for example, suggest that the seeds for successful catching up build up at the shop-
floor of generics and API manufacturers (Joshi 2003; Kale and Little 2007; Reddy 
1997; Singh 2007). By systematically linking R&D and drug manufacturing a firm sets 
the bases for the eventual development of stronger capacities to perform research, 
chemical synthesis and formulation; these capacities underpin subsequent stages of 
drug innovation.  
As this thesis documents there is room to investigate how systematic searches 
for increased efficiency and productivity by pharmaceutical firms contribute to 
human resource development processes. For instance, interviews at firms 02 and 
08, respectively, showed that the search for continuous improvement in manufac-
turing processes leads firms to invest heavily in training, coaching and promotion of 
cooperative activities. Firms promote team-based strategies aimed at reducing cost, 
lower waste, increase safety and protection of both workers and the environment. 
Innovations with more social, rather than purely economic content are frequently 
found in drug manufacturing activities.  
 
2.3.4. Learning through generic drugs 
 
                                                 
25 Macher and Nicherson (2006) found that process analytic tools correspond with increases in the num-
ber of batches failed, increases in raw material deviations and product and process parameter devia-
tions. The authors call for a careful interpretation of results as they do not necessarily indicate causality 
from PAT adoption to actual performance of firms.  
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It is possible to characterize pharmaceutical firms according to the type of intellec-
tual property rights they rely on. There are: (i) “innovator companies”, firms special-
ised in the development and manufacturing of innovator products, protected by 
patents; (ii) generic manufacturers, firms that produce drugs whose patent has 
already expired; and (iii) firms that participate in both markets. In all these cases 
firms have to ensure that products are manufactured in controlled and consistent 
manners in terms of cGMPs, raw materials, processes and validation and so on. 
Regulatory agencies keep a close watch on manufacturers, including physical in-
spection of productive facilities; they require strong capacity to enforce strict sani-
tary regulations. Firms from developing countries specialize in manufacturing and at 
a lesser extent, export of generic drugs.  
A generic drug is a product comparable to an innovative drug, frequently one 
for which a patent has already expired (DHHS et.al, 1998). Generics emulate the 
innovative drug regarding dosage form, strength, route of administration, quality, 
performance characteristics and intended use. A main characteristic of generics is 
that applications for marketing approval do not demand clinical data on safety and 
efficacy, as these parameters have already been established by the innovative drug. 
Development of generics starts a few years before patent expiry of the innovator 
product. Firms have to reproduce the knowledge needed to manufacture it while 
ensuring bioequivalence and bioavailability, thus supporting its characteristic as a 
generic interchangeable drug.
26
 Speed is necessary, to the extent that first movers 
can gain and retain relevant market shares (Caves et.al, 1991; Hollis 2002). In most 
cases, the choice of products is linked to current product portfolios; what firms 
already know. Nevertheless, expected benefits increase if firms are able to enhance 
the characteristics of the innovator drug. Quality enhancement includes relatively 
simple improvements in product packaging, reformulation or recombination of 
existing molecules. New products, in turn, include new applications of existing 
drugs, often in different therapeutic areas. The search for new knowledge may 
relate more to the methods and techniques used to synthesize the components---
biotechnology techniques, for instance---than to the characteristics of the drug 
itself (Kale and Little 2007). 
In the words of the operations manager at a Mexican manufacturer: “Replica-
tion of the knowledge underpinning manufacturing of generic drugs may not re-
quire as costly and advanced infrastructure, scientific equipment, research centres 
and so on; yet there is a fair degree of complexity involved. Firms need be attentive 
to the expiry date of patents. Some 4-5 years previous to expiration a company may 
begin investing in the technologies and infrastructure needed to produce the drug. 
During such period firms have to learn how to manufacture the product, so that by 
                                                 
26 Generic interchangeable (GI) denomination indicates that the reaction to a generic drug in the human 
body is exactly the same as that of an innovator drug. 
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the expiry date, it is ready to launch the new generic” (Interview at firm 11). Based 
on these considerations, the perception is that whereas generic manufacturers base 
competitiveness solely on prices, innovators do so based on differentiation (Dussel 
1999). Yet generics may not be mere copies of branded innovative products. Quite 
the contrary, the former frequently introduce some improvements to the latter. 
Competition is fierce; manufacturers should differentiate and enhance product 
quality. Improvements in drug absorption, more friendly dosages and drug delivery 
systems, reformulation or means to minimize possible side-effects of the original 
product are examples of innovative features added to generic drugs. Licensing is 
possible to manufacture generic drugs, yet this frequently implies technological 
dependence on the licensor firm.  
 
2.4. Ongoing Studies and product life-cycle support 
 
Pharmaceutical innovation does not end with marketing approval of new drugs. A 
period of surveillance and monitoring of long-term effects ensues; this is known as 
pharmacovigilance. During this period regulatory agencies can ask companies to 
conduct additional research, Phase IV or post-marketing clinical studies, to evaluate 
long-term safety and generate more data about how the medicine affects particular 
groups of patients (Becerril 2006; DHHS et.al, 1998; Styhre and Sundgren 2003).  
Product life-cycle support brings opportunities to continue innovating around a 
specific product, or to extend the commercial value of such products. In other 
words companies tap post-marketing studies to submit new marketing applications 
related to incremental innovations. Hence it is possible to see how drugs change in 
the form of administration, in daily dosages, reduce pernicious side effects while 
exploring ways to maximise positive ones. Aspirin®, active ingredient acetylsalicylic 
acid, is a good example of product-life cycle innovations. In more than hundred 
years of existence the product has moved from initial use in pain-relieve and anti-
inflammatory and fever-fighting to applications in heart-related diseases such as 
heart attacks, recurrent heart attacks or angina, stroke prevention and so on.   
 
3. Final comments 
 
This chapter presented the main characteristics of the pharmaceutical innovation 
processes. In so doing it described the heterogeneity of both the stages and the 
corresponding learning, organisational and investment processes involved. The 
dynamics of technological developments, high risk levels and new scientific knowl-
edge content usually attracts significant attention to drug discovery. Drug manufac-
turing features high standardization and routines; this limits interest in research 
about innovation and learning occurring in such activities. We have learned how-
ever, that while all phases of the process are interconnected, significant technologi-
81
cal progress in drug discovery has so far not being accompanied by corresponding 
improvements in subsequent stages. Drug testing and development remains a ma-
jor bottleneck to speed drug innovation up. Firms face more complex and challeng-
ing scenarios to remain profitable, to face growing competition in the market. Gov-
ernment regulation and supervision continues to play important roles in guiding 
behaviour and performance of pharmaceutical firms. Opportunities for further work 
remain significant. The search for increased efficiency, reduced cost, let alone prod-
uct safety and quality calls for careful reappraisal of the value of innovation in drug 
manufacturing. 
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Chapter 5 
Pharmaceuticals in Mexico 
 
 
 
1. Introduction  
 
Emerging markets are expected to significantly influence future developments 
within the global pharmaceutical industry. By the year 2020 they are predicted to 
contribute to more than 50 percent of worldwide pharmaceutical market growth, 
up from just 13 percent in 2001 (IMS-Health). In 2009 China, Brazil, India, South 
Korea, Mexico, Turkey and Russia were expected to grow at a combined rate of 14-
15 percent to reach a collective market worth of US$105-$115 billion. However, the 
expansion of the Latin American region in 2007/2008, as shown in table 5.1, in-
creased 9.0 per cent, which is significantly higher than that of some developed 
countries. Among the (IMS-Health 2009a) factors being cited to explain the growth 
rates in developing countries are greater government spending on healthcare, 
broader public and private funding, and demand for innovative medicines.  
Table 5.1 also shows that Mexico is the world's 10th largest pharmaceutical 
market, and the second largest in Latin America. Together with Brazil, Argentina and 
Venezuela, the country accounts for more than 80% of total sales in the Latin 
American region (Secretaría de Salud 2005a). At the end of 2008 retail sales in the 
Mexican pharmaceutical industry amounted to US$8.6 billion, a figure equivalent to 
a 2% increase from 2007. In Mexico, local infrastructure for manufacturing pharma-
ceutical products is among the most modern in the world, in many cases complying 
with the US-FDA standards; and it provides significant growth potential for the in-
dustry (Andre 2005a and d). The country has real, albeit poorly exploited resources 
to imitate and to generate innovative pharmaceutical products (Guzmán 2005). 
Pharmaceutical firms invest some US$150 million per annum in plant moderniza-
tion, technological upgrading and clinical research (AMIIF). 
This Chapter examines the structure, recent performance and trends observed 
in the Mexican pharmaceutical market. A discussion of some of the factors shaping 
learning and innovation in the local pharmaceutical industry will help build a 
framework for the subsequent econometric analyses in chapters 6-8. The reader 
will note that this chapter poses more questions than it can answer, given its scope 
and the data available. The discussion is based on a thorough review of the litera-
ture, as well as information collected through in-depth interviews conducted with 
representatives of the industry. The rest of the chapter is organised into sections, as 
follows: Section 2 presents a historical account of the development of the pharma-
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ceutical industry in Mexico, which helps shape the framework that will be used to 
analyse the current structure of the industry in section 3. Section 4 examines the 
innovative performance of the industry; followed by a concluding discussion in Sec-
tion 5. 
 
Table 5.1: Pharmaceutical industry: Main global markets, 2008 
(Sales through retail pharmacies) 
US$ billion November, 2008 % Growth/Nov-07  
North America 225.5 2.0 
   USA 208.7 1.0 
   Canada 16.8 6.0 
Europe (Top 5) 114.6 1.0 
    Germany 35.2 4.0 
    France 30.7 1.0 
    Italy 17.2 2.0 
    United Kingdom 16.0 1.0 
    Spain 15.3 4.0 
Japan (including hospital) 66.7 2.0 
Latin America (Top 3) 24.4 9.0 
    Brazil 12.5 11.0 
    Mexico 8.6 2.0 
    Argentina 3.2 22.0 
Australia/New Zealand 7.9 10 
Source: IMS-Health (2009b) 
 
2. Historical account of the Mexican pharmaceutical industry 
 
Origins of the pharmaceutical industry in Mexico trace back to the 1940s, marking 
the beginning of the exploitation of Barbasco (Sc. Name: Wild Yam), a plant contain-
ing phyto (plant-derived) estrogens, in particular the chemical diosgenin, used in the 
preparation of estrogens to replace female hormones and produce contraceptives 
(Dussel 1999). The firm Syntex (1943) was one of the main processors of Barbasco 
and, in Mexico, Laboratorios Senosiain, part of a pharmaceutical chain of the same 
name, became the first pharmaceutical laboratory in the country (Dussel 1999). 
During World War II the halt of supplies from multinationals to Mexican affiliates, 
some of them dating from the 1920s,
1
 led them to replace imports and start manu-
facturing facilities in the country. From some 60 pharmaceutical firms in the 1940s, 
they grew rapidly up to 200 firms by the 1980s (Brodovsky 1997; Dussel 1999). By 
1977 about 35% of all APIs needed by the country were produced locally. The num-
ber of APIs produced locally rose from 6 in the 1960s, to around 90 during the 
1990’s (Dussel 1999). 
Historically public policy has considerably influenced the development of the 
pharmaceutical industry in Mexico. In the post-Second World War period, the gov-
ernment imposed restrictions on imports of any locally produced pharmochemical. 
                                                 
1 In this earlier period foreign firms conducted mostly commercial and distribution activities. 
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In addition, the foreign capital ownership of any firm located in Mexico was re-
stricted to 49 percent maximum. As for public procurement, this required consoli-
dated tenders and was based on purchases of generic products according to a spe-
cific listing of basic drugs: cuadro básico (henceforth basic drugs scheme), for use of 
public healthcare.
2
  
The government promoted price controls through the public healthcare system, 
privileged local manufacturers and high local integration (Dussel 1999). Price con-
trols were the main instrument to promote the pharmaceutical and pharmochemi-
cal industries (Brodovsky 1997; Dussel 1999). Controls aimed to limit benefits ac-
crued by firms; however they had induced negative incentives to invest in capital 
goods and R&D (Brodovsky 1997). The controls led to market distortions, as maxi-
mum prices were often fixed based more on people's ability to lobby policy makers, 
than on the actual technical and economic merits of the products (Brodovsky 1997). 
In the context of a protected market, with fairly ambitious public healthcare pro-
grammes and strict price controls, the pharmaceutical and pharmochemical indus-
tries flourished. In the early 1980s Mexico manufactured most of the medicines 
within its borders. While exports of pharmaceutical products were negligible, im-
ports of pharmochemical accounted for up to 50% of local consumption (Dussel 
1999).  
Then regulatory and macroeconomic environments changed drastically as a re-
sult of the 1982 Mexican economic crisis. A notable shift was the adoption, in 1984, 
of an integral plan for the development of the pharmaceutical and pharmochemical 
industries (SECOFI 1984). The Bill for the Promotion and Regulation of the Pharma-
ceutical Industry set among its goals ensuring self-sufficiency in API manufacturing; 
it also aimed toward national integration of the production of both pharmochemi-
cals and medicines. The intention was to deepen import substitution, increase local 
content of pharmaceutical products, and promote decentralization away from the 
Mexico City area (Dussel 1999). This notwithstanding, it was possible then to import 
medicines provided as part of the basic drugs scheme, and for high-incidence dis-
eases. In 1987 there were 94 pharmochemical firms producing 259 APIs, roughly 67 
percent of the national consumption of these raw materials. The sector enjoyed 
trade surpluses of up to US$40 million. Incentives from public procurement re-
mained important for local producers; up until 1989 public tenders granted five 
more percentage points to participants using locally produced APIs. 
A new shift in the macroeconomic environment resulted from the introduction 
of economic reforms at the end of the 1980’s. In 1986, accession of Mexico to the 
General Agreement on Tariff and Trade (GATT) led to a generalized and unilateral 
reduction in import duties on purchases of non-locally produced raw materials and 
                                                 
2 Creation of Cuadro Básico, presidential decree of 9th April 1975, homogenized drug supplies to the 
public health sector. The use of generic codes, rather than brand names, intends to promote scale 
economies and reduce unitary prices by raising volumes of purchases (Villaseñor 2006)  
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APIs. This was accompanied by a programmed reduction in duties paid on imports 
of inputs produced locally. Authorities levied restriction on imports provided im-
porters had production facilities in Mexico.
3
 Nevertheless, imports of some inter-
mediate products led to the entry of certain duty-taxes into the country (Secretaría 
de Salud 2005a). Up until the early 1980’s, manufacturing processes accounted for 
40 percent of total value added in the industry. High standardization in this area 
demonstrated that cost differentials among firms resulted from distinct production 
scales (Dussel 1999).  
By the end of the 1990’s major transformations were underway, with liberaliza-
tion of the industry, and the subsequent reduction in the protection firms had pre-
viously enjoyed in the local market. Price controls have since been relaxed, yet 
mechanisms to set prices, such as the principle of “precio máximo de venta al 
público” (maximum retail price), remain in place today.
4
 Notwithstanding some 
government attempts to eliminate VAT exemptions on medicines, the rule of zero 
tax rate persists. Public procurement procedures changed, and since the 1990s, 
rather than consolidated purchases, individual tenders are held by each healthcare 
institution and Federal State government—section 3.3 below. In addition to lower 
scale requirements, firms faced increased administrative costs (Dussel 1999).  
The liberalization programme posed additional challenges to the local industry. 
The sector was no longer considered strategic, effectively opening it up to the 
broader participation of foreign capital and greater exposure to competition. Rapid 
and almost generalized reduction in import taxes, the reclassification of several 
product classes under direct control, and elimination of import permits were signifi-
cant (Brodovsky 1997; Dussel 1999). Enactment of NAFTA further deepened the 
liberalization programme. From 1994 onward, import taxes on all products not 
produced in Mexico were eliminated, with programmed cuts instituted over a pe-
riod of ten years. Effectively from 2004, both pharmaceutical and pharmochemical 
products could be imported from within the NAFTA region at a zero tax-rate. Addi-
tionally, new rules of origin, and changed mechanisms for public procurement, were 
also introduced.
5
  
The industry downsized as a result of both reorganisation and changes in the 
regulatory framework. Between 1987 and 1998 some 59 pharmochemical firms 
went out of business, roughly half of those operating in the early 1980s. By 1994 the 
                                                 
3 The net effect of the lower restrictions was increased production capacity and reduction in imports of 
pharmaceutical products. Distributors, wholesalers and retail pharmacies cannot import such products 
(ACHEMAMERICA 2005) 
4 The mechanism of maximum retail price allows manufacturers, in coordination with the Ministry of 
Economy, to propose a maximum price to consumers thereby factually setting a price-cap in the market. 
Distributors and retail pharmacies negotiate profit “margins” by setting a pharmacy price which varies 
according to volumes and time for payment. Commercialization margins, the gap between prices from 
the manufacturer to the distributor, range between 4-15 percent, a high level relative to international 
standards (Secretaría de Salud. 2005a). The margin for the pharmacies is around 21 percent. 
5 For a further discussion on the topics see Dussel (1999) 
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number of APIs produced in the country had fallen to 129, accounting for about 55 
percent of the market. By 2005 there were only 20 companies affiliated with the 
National Chamber for the Manufacturing Industry (CANACINTRA for its name in 
Spanish), and the National Association of the Chemical Industry (ANIQ for its name 
in Spanish). There were also nine firms integrating all stages of production from the 
sourcing of the pharmochemical to its manufacture, and at least another two that 
produced biopharmochemicals in the process (Secretaría de Salud 2005a). The re-
duction in the number of APIs produced locally occurred alongside the centraliza-
tion of the industry in areas like Mexico City, Estado de México, Puebla, Morelos 
and Jalisco (KPMG 2004). Self-reliance in medicine production fell from 60 percent 
in 1988 to about 35 percent in 1994 (Brodovsky 1997). Over recent years prices and 
public procurement have seldom been used as mechanisms to promote the local 
industry. 
 
3. The industry today 
 
Mirroring the typical structure of the industry worldwide, pharmaceuticals in Mex-
ico comprise four main activities: (i) the pharmochemical segment including manu-
facturers of substances or compounds containing the APIs responsible for the 
pharmacological or therapeutic effects; (ii) the manufacture of medicines for human 
consumption; (iii) production of veterinary medicines, and (iv) production of health-
care auxiliary products, such as medical and chirurgic equipment and materials, 
dentistry and toiletries, diagnosis materials, and others. This chapter focuses on the 
first two activities mentioned.  
The value chain of the local industry comprises a complex network of backward 
and forward linkages with other sectors of the economy (Dussel 1999). It integrates 
12 sectors ranging from the manufacturing of APIs and other pharmochemical in-
gredients, to packaging, manufacturing and distributing pharmaceutical products 
through both private and public markets, figure 5.1. 
In this context, according to the Encuesta Industrial Anual (EIA 2004) (Annual 
Industry Survey)
6
, in 2003 there were 480 pharmaceutical establishments, of which 
92.9 percent, or 446 units, were drug manufacturers, (see table 5.2). This figure 
represented 0.1 percent of total manufacturing establishments in the country. 
Gross output was 3.7 percent of the total manufacturing output, and 1.7 percent of 
Mexico’s total GDP. As for direct employment, this stood at 50,780, of which 
47,172, (92.9 percent), corresponded to pharmaceutical manufacturing and the 
                                                 
6 The econometric analyses in this thesis build on data from the Encuesta Nacional de Empleo, Salarios, 
Tecnología y Capacitación (ENESTYC) (Chapter 3), while analysis in this chapter presents information 
from the EIA. This is because, unlike ENESTYC, the EIA distinguishes between Pharmochemical and Phar-
maceutical manufacturers. Considering that the methodology supporting the ENESTYC is similar to that 
of the EIA, the data are comparable.  
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remaining 3,608, 7.1 percent, to the pharmochemical segment. Within the former 
segment, there has been as a rate increase of 2.4 percent per annum since 1994. 
Today employment in pharmaceuticals accounts for 1.3 percent of the total labour 
market in the area of manufacturing. As for the distribution of employment, EIA 
indicates that some 53.4 percent of staff is in management and sales, 46.0 percent 
in production and the remaining 0.6 percent in other functions. The industry re-
quires high specialisation and skills; on average, salaries and remunerations were 
approximately 2.4 times higher than those in other manufacturing industries. 
 
Figure 5.1 Mexico: Structure of the Pharmaceutical industry 
 
Source: Adapted from Dussel (1999) 
 
Table 5.2: Characteristics of the Mexican pharmaceutical industry 2003.  
As a share of total manufacturing  
 Units1 Gross output Sales Employment Avg wage/Month2/ 
Pharmaceutical Industry 0.1 3.7 3.9 1.3 1588.7 
     Raw materials 0.0 0.2 0.2 0.1 1355.4 
     Pharmaceutical products 0.1 3.5 3.7 1.2 1606.7 
Notes: 1/ Number of manufacturing establishments; 2/US$ dollars per month per person; average exchange rate 10.7953 
Mexican pesos per US dollar. This corresponds to the exchange rate used to process foreign currency denominated 
operations (FIX).  
Source: Author based on information from INEGI and Banxico 
 
Today, the pharmaceutical industry in Mexico is strong; it currently fulfils about 
86 percent of local demand, up from the 35 percent figure from 1994. This is 
achieved mainly through the formulation and manufacturing of imported APIs, and 
via imports for the remaining 14.0 percent. The processes used to extract APIs and 
pharmochemicals are fermentation and purification, or by synthesis of chemical 
compounds, as in biotechnology. Seiter (2005) suggests this is typically the most 
complex and value adding part of the process. Mexico produces mainly steroids, 
fermented and semi-synthetic antibiotics, other anti-infectious medicines, non-
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steroidal anti-inflammation, anti-carcinogenic, anti-ulcer, vitamins and bio-
pharmaceuticals (faboterapeutic, interferon, eritroproyetine). Although accurate 
figures are not available, the estimated usage of manufacturing capacity stands at 
some 63 percent; firms have considerable margins whereby they can increase pro-
duction in case of need (Secretaría de Salud 2005a). According to Secretaría de 
Salud (2005a) some challenges that influence the long term performance of the 
industry include: (i) increased competition from abroad, particularly Asia; (ii) high 
investment costs; (iii) low availability of intermediate chemical products needed to 
manufacture medicines; (iv) limited technological development and very rigid and 
disadvantageous contracts for technology transfer; (vi) low incentives for and inter-
est among local producers to search for new products and, (vii) low integration of 
the supply chain. 
 
3.1. The local market 
 
In Mexico drugs are defined as the single substance or combination of substances 
whether natural or synthetic, with therapeutic, preventive or rehabilitative effects. 
These descriptions arise from the characteristics of their pharmacological, physical, 
chemical and biological activity. For instance, food supplements, which are consid-
ered drugs as they include vitamins, minerals, electrolytes or amino acids in concen-
trations greater than those found in nature, are sold in pharmaceutical form and 
have therapeutic, preventive or rehabilitative effects as indicated on the packaging 
(Secretaría de Salud 1984). Approximately 7,000 different types of drugs, presented 
in 19,000 different packages are marketed in the country. Predominant product 
classes are: Alimentary and Metabolism; Anti-infective, Central Nervous System 
(CNS); Respiratory and Cardiovascular, among others (figure 5.2). 
In Mexico the market for drugs shows a dual structure in terms of both quality 
of products and access by the population. The two segments are well defined and 
independent of each other. On the one hand, there is the “institutional” or public 
sector characterized by demand for mostly generic and technologically mature 
products. On the other hand there is the private market dominated by commercial 
trademarks and innovative products (Secretaría de Salud 2005a). Whereas unit sales 
tend to favour the public sector; in terms of value the private sector, which buys the 
more expensive patented brands, takes the lead. Spending in the latter is almost 
seven times greater than that in the public sector, which purchases mostly cheap, 
locally produced generic drugs (O’Boyle 2002), figure 5.3. In 2002 sales in the Mexi-
can pharmaceutical market reached 2,270 million units.  
 
 
 
 
91
Figure 5.2: Main pharmaceutical product classes in Mexico as of July 2006 
Notes: CNS: Central Nervous System; *Systemic hormones, Blood agents, Parasitological, Cytostatics, Diagnostic Agents, 
and Hospital Solutions. Figures on top of each bar indicate the annual rate of growth relative to July, 2005 and in con-
stant dollar terms. 
Source: IMS-Health (2006) 
 
Figure 5.3: Distribution of volumes and values of sales in the Mexican pharmaceuticals by type of market. 
Million units and US$ million 
Source: Andre (2005a) 
 
The generic drugs segment of the private market is expanding rapidly. Factors 
driving this phenomenon include cheaper prices and recent regulatory changes 
intended to increase supply of compounds with the same APIs as branded drugs, 
but for a fraction of the cost. This segment has been the most dynamic over the 
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past years (Dussel 1999), and yet accounts for only three percent or less of total 
sales in the Mexican market. Equally important has been the development of an 
“impulse” market which, in simple terms, results from the exploitation of some 
regulatory voids (Box 1). Consequently, firms can sell copy drugs which contain the 
same API as the innovator drug, but not necessarily in the same concentrations, and 
which have not been proven to work in the same way (O’Boyle 2002). In other 
words, such drugs have never passed tests for bioequivalence and bioavailability 
ensuring interchangeability with the innovator drug. These low-cost medicines are 
sold in dedicated or exclusive pharmacies, or through other informal, often illegal 
channels (Secretaría de Salud 2005a). Recent efforts to reorganise and improve 
governance of the generics market have been constrained by an insufficient capac-
ity to enforce regulatory reforms. In fact counterfeiting continues to distort the 
local market (Interviews with firm 06).  
 
 
 
Box 1: Promotion and regulation of generic drugs in Mexico 
 
Health authorities around the world are faced with the challenge of rising costs of 
medicines, the responsibility of keeping overall healthcare expenditure in check, and the 
need for adequate developments in both the manufacture of generic and innovative 
drugs. Mexico is no exception. Mexican health authorities face many problems in trying 
to ensure adequate provision of healthcare services, and improve the quality and reduce 
the costs of products in the basic drugs scheme. This is, compounded by shortcomings in 
the supply and distribution capacity of public health institutions which, in turn, derive 
from poor logistics, administration, costly and inefficient procurement systems 
(Secretaría de Salud 2005a). Problems are aggravated by poor enforcement capacity of 
eventual regulatory reforms. Next we illustrate some of these issues. 
In Mexico marketing of pharmaceutical products requires Sanitary Registration 
(Registro Sanitario). This document, issued by the local regulatory agency, Comisión 
Federal para la Protección contra Risgos Sanitarios (COFEPRIS), certifies that the firm 
meets strict requirements of safety, efficacy and quality. It describes and validates API 
manufacturing processes performed both in-house and at supplier firms. It also defines 
quality standards for raw materials, manufacturing and distribution processes from the 
beginning to the end, tests to corroborate stabilities and therapeutic power of drugs, 
and so on. These are the equivalent to New Drug certificates granted by the FDA for 
sales of pharmaceutical products in the US. In the past the customary practice in Mexico 
was to grant Sanitary Registries and thereby drug marketing authorization, for indefinite 
periods of time. This eventually led to the presence of outdated registrations for 
products that may fail to comply with current sanitary and related legislations (Andre 
2005d).
 
The regulation was such that firms could hold sanitary registrations for products 
they no longer sell in the market. More importantly, this regulatory void promoted 
development of copy drugs with suspected deficiencies in quality and safety.  
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Box 1: Promotion and regulation of generic drugs in Mexico (Continued) 
 
To address some problems related to quality and availability of drugs, in 1997 a Bill 
was passed requiring that only drugs meeting strict bioavailability and bioequivalence 
tests could be registered and labelled Genéricos Intercambiables, GI (interchangeable 
generics) (Andre 2005d). The new provision, effective 1
st
 January 1998, required medical 
doctors at public organizations to prescribe based on active ingredient rather than on 
brand names (Hayden 2005). 
In 2002 a new provision was passed requiring that public health organizations should 
only buy GI-denominated products. Yet again in 2005 amendments to Article 376 of the 
Health Bill strengthened impulses to the GI market (Secretaría de Salud 2005a). According 
to the new provision by the year 2010 all non-patented pharmaceutical products 
registered and marketed in Mexico should be GI (Luhnow 2005). During the five year 
transition period firms should renovate or regulate Sanitary Registrations backing their 
product portfolio. The task is complex considering that out of some 40,000 products 
registered in Mexico up to September 2005, about 7,000 were commercialized and only 
about 3,109 were GI. 
A core component of this strategy has been the creation of some independent 
laboratories, Terceros autorizados, responsible for performing the required 
interchangeability tests (Secretaría de Salud 1998b;1999). In principle, Secretaría de Salud 
(2005a) indicated that some 40 laboratories or authorized third parties were needed to 
conduct all the tests required over the five year transition period. However creation of 
the laboratories has proceeded at a slow pace, and to date only 30 are in place, including 
firms, public laboratories, universities and other public organizations (COFEPRIS). The 
response from the pharmaceutical firms has also been slow (Anonimous, La Jornada 
2009). By February 2009, about 55.5 percent of the total products in need of certification 
(aproximately 10,500) had concluded the procedure; 23.3 percent were under way and 
the remaining 21.2 percent had not even started the process. The deadline to conclude 
the recertification process was February 2010. 
As for some likely reasons behind the perceived slow response of firms in complying 
with the new regulation for the manufacturing of drugs, exploratory interviews with 
Mexican manufacturers revealed some complaints about inconsistency in terms of 
regulation with the normal operation of firms. About a year after the start of the 
transition period, the representative of a Mexican firm, a pioneer in the conduction of 
local R&D activities, commented that the new rules meant they would be “unable to 
perform the necessary quality controls on their own products; testing safety and efficacy 
is a core component of any drug development process underpinning eventual product 
registration.” Although the government could increase transparency in the tests by taking 
them away from firms, the latter considered this a hindrance to the development of 
quality control and other research capacities. As we discuss in section 4.3 in this chapter, 
people systematicaly involved in quality control often provide the seeds for the 
development of more formal R&D activities. 
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3.2. Prices  
 
In Mexico the price of medicine for consumers has continued to rise over the last 
decade or so; increases have surpassed the country's general inflation (Secretaría 
de Salud 2005a). In 2003 private expenditure in medicines per capita was the high-
est it had been in more than a decade. On average, a Mexican expended US$70.10 
in medicines in the private market, nearly doubling that of the rest of Latin America, 
totalling US$36.50 (Secretaría de Salud 2005a). Regarding specific products, con-
sumer prices benefit innovative drugs. We can see this by comparing prices of “old” 
drugs, those that have been around for 15 years or more; and “new” medicines, 
those that have existed for 10 years or less; in table 5.3. The price gap for each drug 
type is considerable, particularly in the case of antibiotics and immune-suppressors 
(Villaseñor 2006).  
 
Table 5.3 Mexico: Average drug prices to the final consumer for old (>15 years) and new medicines (<10 years); Mexican 
pesos 
Type of medicine Old New % increase* 
Immune-suppressors 271.1 4375.0 1514.0 
Antibiotics 51.1 602.5 1078.6 
Oral Hypoglycaemic 71.9 250.2 247.9 
Anti-osteoporosis 214.2 642.1 199.8 
Anti-depressors 75.7 218.8 189.0 
Blood agents 101.3 272.3 168.8 
Anti-inflammation 97.0 222.2 129.0 
Hypolipemiants 213.0 410.7 92.9 
Insulin 197.9 342.6 73.1 
Antihypertensive 113.6 177.0 55.8 
*Variation in prices between new and old products 
Source: Modified and translated from Secretaría de Salud (2005a) 
 
Rising prices have led to a situation in which, although with regard to volume 
the Mexican market has remained constant (the average growth rate between 1997 
and 2002 was only 1.1 per cent), in terms of value it increased by about 11 per cent 
per annum (Secretaría de Salud 2005a). Performance of prices in the private market 
Box 1: Promotion and regulation of generic drugs in Mexico (Continued) 
 
More interesting is to ask what will happen once the period allotted to carrying out 
tests of interchangeability expires? What will be the implications associated with the 
creation of the third party independent laboratories for the industry? To what extent will 
these laboratories eventually help in building some additional research capacity in the 
country? (Lijima and Tachiki 1994), (Kuruvilla et.al., 2002) and (Sanz-Menéndez and Cruz-
Castro 2005) document the significant contribution that publicly promoted programmes 
may have on the construction of technological capabilities for firms, particularly by 
transferring capacity built within public organizations to private firms. 
Source: Author 
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illustrates this finding. During the period of 1999-2002, prices increased by an aver-
age of 10.0 percent, reaching some US$7.31 per unit in 2003 (Secretaría de Salud 
2005a). Price hikes have nurtured some positive dynamics in the private market, yet 
some concerns exist concerning long term sustainability, as individual income for 
many Mexicans remains very low (Guzmán 2005). Prices in the private market con-
trast sharply with those of the public sector. Approximately half of the medicines, in 
units, are bought and subsequently distributed by public institutions at a third of 
their price in the private market. Domestic firms supply the public sector mostly 
with generic drugs, at very low unit costs. However, such drugs may not necessarily 
have passed through bioequivalence tests (Secretaría de Salud 2005a). Taking into 
account these differentials in quality, Secretaría de Salud (2005a) states that the 
price of medicines in Mexico can fall to about 64 per cent of what they're sold for in 
the private market: e.g. from US$7.3 per unit, to a global US$4.6 per unit. 
 
3.3. Public procurement 
 
In Mexico, government procurement plays an important role in guiding market 
developments in the drug industry, particularly in generics. Procurement is based 
on public tenders according to a basic drugs scheme for first level healthcare (gen-
eral practice, family doctors), and by ingredient listings in the second (regional and 
national hospitals, intermediate care) and third levels of attention (high speciality 
care). Tenders take place around a single event, with prices being the most impor-
tant criteria in terms of granting contracts. The focus on pricing, without further 
consideration of product quality, the use of locally sourced ingredients, or market 
risks faced by suppliers is considered to distort the market (Villaseñor 2006). It in-
duces pernicious competitive practices as firms can bid really low unitary prices in 
order to acquire contracts that ultimately they will be unable to fulfil in time (Inter-
views with trade1 and firms 03 and 06). In order to meet volume requirements, 
public institutions may purchase products that do not comply with the GI criteria 
(Villaseñor 2006). Insufficient transparency and limited participation of the industry 
in the definition of prices for products in the basic scheme further complicates the 
scenario (firms 02 and 06).  
Domestic firms usually complain about the way in which public tenders are car-
ried out. This is understandable considering that their sales structure relies strongly 
on the public market. In such an uncertain environment, incentives to conduct R&D 
are really low (interviews at firms 05 and 06). Survival strategies are based more on 
the capacity to provide large volumes of generic products; in this case the firm privi-
leges modernization and large manufacturing capacity with significant margins re-
maining idle (interview at firm 03). Excess capacity allows firms to respond to unex-
pected requests from the government, for example when a firm is unable to meet 
the terms of a contract. By contrast, multinationals face a rather unique predica-
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ment. On the one hand they may be unwilling or unable to compete against large 
volumes and significantly low unit prices bid by some domestic generic manufac-
tures (interviews at firms 02); on the other hand, they exploit their capacity to offer 
innovative patent-protected products, therefore displacing competitors (interviews 
at firms 01 and 05). In any case, for foreign affiliates the share of sales in the public 
sector is rather modest compared to that of Mexican manufacturers. 
 
3.4. Presence of multinational affiliates  
 
Mexico hosts affiliates of large firms from countries with long traditions in pharma-
ceutical innovation, including the US, Germany, Switzerland and France. Increasingly 
however, the country attracts affiliates from new players such as Spain and notably, 
India. Operations range from marketing and distribution to large scale manufactur-
ing, even some limited R&D efforts with varying degrees of sophistication. Affiliates 
of big multinationals remain the main players in the Mexican pharmaceutical mar-
ket. Investment, technological and research performance differ significantly be-
tween local and multinational firms, with the latter being the most dynamic (Guz-
mán 2005). Affiliates produce and export finished products with quality and safety 
standards comparable to those of developed countries. They centre marketing ef-
forts on the lucrative private retail market where they take the lead in terms of total 
sales; Novartis and Pfizer are the market leaders. Competition remains strong none-
theless with companies holding maximum market shares of around 8.0-9.0 percent, 
table 5.4. Frequently multinationals enter into commercial agreements with local 
firms, the latter are responsible for the import, handling, safety and security of 
products according to local regulations (Secretaría de Salud 2005a).  
 
Table 5.4: Mexico, leading foreign companies, 2005 
Company  Origin Sales1/2/ Share3/ Founded Relevant notes 
Novartis 
Far-
macéutica 
Swiss 450 9 1996 -Active in pharmaceuticals and consumer health 
-Promotion of local generic markets is expected 
to benefit operation of Sandoz, its mature 
product division 
Pfizer US 250 8.5 1951 -Pfizer’s main office for Northern Latin America 
(1997) 
-Controls operations in Central America  
GlaxoS-
mith 
Kline (GSK) 
UK 250 8.5e 
 
1964 -Local subsidiary exports to 12 other Latin 
American countries, over US$30million per 
annum 
-Domestic sales represent 25-30 percent of the 
firm’s major’s total regional sales 
Boe-
hringer-
Ingelheim 
Promeco 
German 350 8 1953 -Exports account for about 24% of total sales 
-Exports to the US were in excess of 
US$200million (2004) 
-In June 2005 announced investment for some 
US$2million in R&D in Mexico 
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Company  Origin Sales1/2/ Share3/ Founded Relevant notes 
Sanofi-
Aventis 
French 600 7e 1973 -Integration between Sanofi-Synthelabo and 
Aventis –begun 2004– is complete in Mexico  
-The two companies merged local clinical 
research operations 
Merck 
KGaA 
German 250 5 1930 -Exports some 30 percent of production to Latin 
America 
-Local affiliate is the firm’s fourth-highest 
earning overseas unit 
Roche-
Syntex 
Swiss 120 4 1948 -November 2005, Indian generics maker Dr 
Reddy’s acquired Roche’s APIs business in 
Mexico (US$59million) 
Eli Lilly US --- 3e 1943 -Local turnover increased above market growth, 
at some 12% per annum 
-Exports from Mexico to over 54 countries 
(chiefly Latin America) 
-Faces several problems associated with coun-
terfeit copies of its products 
Bristol-
Myers 
Squibb 
US 200 6e 1947 -Recent years have seen heavy investments in 
the expansion of local operations, including new 
manufacturing facilities 
Bayer German 700 3 1939 -Local sales account for around 24 percent of 
Bayer total regional turnover 
-Mexico is the company’s second-largest market 
in Latin America 
-Aspirin and Naproxen, have made Bayer the 
leading consumer-care business in the country 
Notes: 1/In US$ million;2/ Figures may appear inconsistent with market shares. Although not explained in the original 
source, this may be due to differences in information reported by firms. Whereas some provide data on sales for the 
human line only, for others data corresponds to sales from all products sold in Mexico; 3/ Market share as percentage of 
total sales in the Mexican market; e. estimate 
Source: Author with information from BMI (2006). 
 
Mexico attracts pharmaceutical companies targeting the local market while si-
multaneously servicing other countries in Latin America. For instance, companies 
such as Boehringer-Ingelheim, through its affiliate Boehringer-Ingelheim Promeco, 
expected Mexico to become a major production hub to serve the US and Canadian 
markets (Andre 2005b). Roche-Syntex Mexico has turned into one of Roche's five 
largest subsidiaries worldwide and one of the largest selling companies in Mexico, 
table 5.4. A large share of the company’s income stems from primary care products 
but is expected to shift slowly towards speciality care such as oncology. Pfizer’s 
subsidiary is the largest in Latin America (Andre 2005c). 
 
3.5. Foreign Trade 
 
Mexico represents some 0.27 percent of the worlds' total export of pharmaceutical 
products (Secretaría de Salud 2005a). Mexican exports target mainly the US and the 
EU; the primary markets in Latin America are Venezuela and Colombia. Limited local 
production of APIs makes Mexico strongly dependent on the import of raw materi-
als, of which more than 50 percent comes from outside the country. Main suppliers 
include the US, Germany, Switzerland, England, France and Italy. By contrast, im-
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ports of final products represent only 8 percent of local consumption (Guzmán 
2005). The US is the leading source, followed by England, Switzerland, Germany, 
France and Italy (KPMG 2004). As for the trade balance, exports have increased at a 
higher rate than imports, 2.8 percent vs. 1.6 percent, respectively, during the last 
decade. In spite of this, Mexico recorded an increase of 1.3 percent in the trade 
deficit over the same period (Secretaría de Salud 2005a). Imports of pharmaceutical 
products amounted to US$1,288 million in 2003. Exports, in turn, reached US$890 
million, equalling a deficit of US$398 million. Purchases of innovative medicines fuel 
the expansion of imports (Secretaría de Salud 2005a).   
The studies by Hikino and Amsdem (1994), Hobday (1995) and Kim (1997) re-
veal that adopting a decisive export orientation was a key strategy by some of the 
dynamic South East Asian economies in terms of catching up to their competitors. 
This approach is also effective for pharmaceutical firms; see for example Kim et.al’s 
(1989) study about South Korean firms. Over the years some Mexican firms have 
managed to adapt to and resist the changing macroeconomic and regulatory envi-
ronments, while still being able to expand their operations. To a large extent, sur-
vival strategies have been associated with export orientations, coupled with techno-
logical, financial and managerial restructuring (Brodovsky 1997). In some cases this 
has accompanied some incipient but decisive R&D efforts, as well as investment in 
technological development (Interviews with firms 05 and 10). Nevertheless, export 
opportunities, particularly to the large US market, remain insufficiently exploited, 
thus limiting Mexico's ability to strategically support technological progress by local 
pharmaceutical firms (Interviews with firms 03, 06, 12 and 14). The high cost of 
obtaining marketing licenses in the US,
7
 absence of a large enough manufacturing 
capacity, let alone the limited power available to generate a constant flow of new 
products based on in-house R&D, were prompted by Mexican manufacturers. In 
some other cases, inexperience or insufficient understanding of market regulations, 
in Europe for example, hinder a more active export strategy (Interview with firm 
06).  
The limited export of Mexican pharmaceuticals contrasts significantly with the 
strategies of some of the larger Indian firms. As stressed by the director of an affili-
ate of Indian origin in Mexico: “...the US market is such that you have to continu-
ously keep launching the products to be able to compete and to retain your place in 
the market. You cannot launch four products and then sleep for the next year, you 
have to continuously launch 10, 15 new products in a year. It requires a whole lot of 
commitment of resources, but also the company has to be geared towards servicing 
the market. And the Mexican companies so far, you know, they are pretty comfort-
able in Mexico; and to be able to service the more dynamic US generic market, I 
                                                 
7 Licenses to manufacture drug in the US are costly, costs vary depending on whether the product is 
innovator or generic; in other cases bails and insurances on compliance can be involved (Secretaría de 
Salud. 2005a). Rights to manufacture effectively serve as entry barriers. 
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don’t think they have the mindset yet” (Interview with firm 12). Chapters 6-8 review 
the importance of exposure to external competition, through exports, in terms of 
driving learning in the local industry. 
 
3.6. The competitive environment 
 
Traditionally, Mexican authorities required firms interested in marketing pharma-
ceutical products in the local market to set up properly authorized manufacturing, 
laboratory and related facilities in Mexico. This was not exclusive to Mexico as sev-
eral countries in Europe and Latin America have similar provisions. As mentioned in 
section 3.4 above, multinationals without local facilities could overcome this regula-
tory requirement by entering into commercial agreements with local manufactur-
ers. A central element of the regulation was the figure of the Responsable Sanitario, 
a designated representative of a pharmaceutical firm legally established and author-
ised to sell drugs in Mexico. Irrespective of where the drugs were manufactured, 
the Responsable Sanitario is responsible for ensuring the quality, stability and safety 
of the products. In the unfortunate event of a negative side effect arising from the 
consumption of a particular drug in Mexico, the Responsable Sanitario is liable to 
any resulting legal or civil sanctions (López 2006; Secretaría de Salud 2005b).  
The requirement of a Responsable Sanitario promoted expansion of manufac-
turing facilities in Mexico. However, on March 30
th
, 2007, the local regulatory 
agency, COFEPRIS, presented a reform to remove this requirement. The initiative 
followed the loss of a trade dispute with El Salvador, Honduras and Guatemala. 
Those countries claimed that the figure of the Responsable Sanitario was effectively 
an unfair non-tariff barrier blocking imports of pharmaceutical products into Mex-
ico. The requirement was finally abolished by Presidential decree on August 5
th
, 
2008, a decision which, after a six month transitory period, entered into force on 
February 2
nd
, 2009. Thus the Mexican government effectively opened up the market 
to imports of vitamins, vaccines, hormonal products of biological origin, and ho-
meopathic drugs, among other products. Liberalization of imports of patented drugs 
and medical devices will follow in August 2010. The mechanism is expected to in-
duce significant price cuts, particularly in specialty drugs such as those used to treat 
HIV-AIDS.  
It is expected that consumers, particularly the largest share served by the public 
sector, will benefit from cheaper and more readily available drug supplies. This 
notwithstanding, the perception among some segments of the Mexican society is 
that elimination of the Responsable Sanitario entails potentially serious threats to 
sanitation. Major concerns result from COFEPRIS’ failure to ensure that imported 
drugs comply with required sanitary standards (Interview with firm 05). “Unlike the 
US and other countries, where local regulatory agencies conduct exhaustive audits 
and inspection visits to manufacturing facilities at the countries of origin, the Mexi-
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can agency is unable to perform such monitoring and certification activities. It sim-
ply lacks the human, material and financial resources to do so” (Interview with firm 
05). Such concerns were shared by some affiliates with manufacturing facilities in 
Mexico (Interview with firm 02). Third party authorized laboratories at Mexican 
public universities and healthcare organisations will assist in the monitoring and 
certification of imported drugs.  
Increased competition is expected as cheaper drugs enter freely into the Mexi-
can market. This point was raised during interviews with directors of multinationals 
operating manufacturing facilities in Mexico; interviewees expressed that it is 
unlikely they will withdraw from the country (Interviews with firms 02 and 07). 
Nevertheless, those with what are so far purely commercial operations, expressed 
intentions to reconsider future investment in green-field facilities in Mexico (Inter-
views with firms 01 and 12). They claimed that the large manufacturing capacity at 
the parent sites would be enough to service the market. It will be interesting to 
observe the extent to which Mexico is able to support a strong pharmaceutical 
industry based on factors such as market size, epidemic profile, capacity to offer a 
sound legal environment and so on. As suggested by Chaturvedi et.al,’s (2007) study 
about India, the challenge for Mexican pharmaceutical firms is to turn increased 
market turbulence, created by public policy, into opportunities to expand and build 
new technology, knowledge and market capabilities. In tackling such challenges the 
authors stressed the value of business strategies that combine research, marketing 
and internationalization.  
 
3.7. Property rights 
 
Patent and trademark protection on chemical products and processes in Mexico has 
recorded cycles of lax and strong protection. The 1976 Patent Law established that 
chemical products and chemical pharmaceutical products were not patentable; they 
could only be protected by means of certificates of invention
8
 (Lorca and Schmidt 
1994). Patents and certificates of invention were granted for a maximum of 10 years 
from the date of issue. The intention of the 1976 Law was to promote R&D 
activities, the overall development of the pharmaceutical and pharmochemical 
industries, together with import substitution in the field (Dussel 1999). However, 
according to Lorca and Schmidt (1994) the 1976 Patent Law led many foreign 
pharmaceutical companies to cease filing patent applications in Mexico. By 1987, 
amendments to the 1976 Law extended the duration of both patents and 
certificates of invention up to 14 years from when they were granted. More 
                                                 
8 “The most important difference between a patent and a certificate of invention was that the owner of a 
patent had an exclusive right to the patented invention, while the owner of a certificate of invention 
indeed had the right to work the invention himself but was also under an obligation to grant a nonexclu-
sive licence to any third party who wished to use the invention” (Lorca and Schmidt 1994) 
101
importantly, they opened the door for patent on previously non-patentable 
activities including: (i) processes for obtaining, modifying or applying chemical 
products or mixtures of them, with the exception of biotechnological process; and 
(ii) processes for obtaining alloys, pharmaceutical products, medicines, in general, 
foods and beverages for animal consumption, fertilizers, pesticides, herbicides or 
fungicides (Lorca and Schmidt 1994). In principle a transition period of 10 years was 
established, rendering patentability effective as of 1997 (Dussel 1999). 
At that time the local legislation was considered already more advanced than 
most other countries in Latin American (Allende 2000); and yet Mexico was the first 
country in the region to adjust local IPR legislation according to current interna-
tional standards. The first occurred in 1991 with the granting of patents for up to 20 
years counted from the date of application. Certificates of invention were removed, 
further extending patenting to include (i) some plant varieties; (ii) inventions relat-
ing to microorganisms, such as those involving their use, those applied to microor-
ganisms or inventions that result from them, covering all types of microorganisms: 
bacteria, fungi, algae, viruses, mycroplasm protozoa and, in general, cells that re-
produce asexually; (iii) pharmaceuticals, chemicals, medicines in general, foods and 
beverages for human or animal consumption, fertilizers, pesticides, herbicides, 
fungicides or products with biological activity, such as vaccines and hormones; and 
(iv) biotechnological processes for obtaining any of the preceding products (Lorca 
and Schmidt 1994). Pipeline protection was granted to inventions already patented 
elsewhere even if they were not produced in or imported to Mexico (Uríbe 2005).  
Considered a rather controversial decision with unfortunate consequences for 
the local industry, the new 1991 Law eliminated, retroactively, the 10 years transi-
tion period stipulation set by the 1987 amendments, and patentability became 
enforced immediately. The 1991 legislation was subsequently reformed in 1994 in 
order to comply with some provisions of TRIPS and NAFTA. Some of these provi-
sions required non-discrimination principles in regards to: (i) the field of technology; 
(ii) the place within the NAFTA area where the invention originates
9
 and, (iii) 
whether products are imported or locally produced (Lorca and Schmidt 1994). A 
major issue was the effective enforcement of patents by prohibiting product imita-
tion, even if the manufacturing process is different. This was considered detrimental 
for the local industry as it seriously constrained the scope of R&D activities (Uríbe 
2005). For instance, under this policy, firms would be forced to enter unfavourable 
technology transfer agreements or licensing contracts (Dussel 1999). Important 
shortcomings in the legislation persist in the areas of non-disclosed information and 
parallel imports (Allende 2000; interview with firm 03). Insufficient funding and 
                                                 
9 Under NAFTA the parties involved most recognise patents granted to pharmaceutical products by each 
member country. They also should grant local protection for a period equal to the remnant validity 
period of such patent in the other countries (Dussel 1999)  
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frequently understaffed operations have also been major constraints for the opera-
tion of patent authorities (Wagner 1998).  
In Mexico, the bulk of patent applications and patents granted correspond to 
products developed abroad. With the aim of increasing congruence between patent 
registration and the compulsory sanitary registration, recently some adjustments 
were made to the regulatory environment, including: 
 
• The possibility to patent new chemical entities with the intention to obtain sani-
tary registration; 
• Authorization of necessary R&D processes supporting application for sanitary 
registration three years before patent expiry. This is known as “Cláusula Bolar” 
(Bolar clause) and prevents artificial extension of protection. Generic manufac-
turers may carry out the bureaucratic procedures and investment needed well 
before the patent expires; 
• Arbitrage introduced as a dispute mechanism to solve conflicts; 
• Creation of a public listing of patents of innovative molecules with the goal of 
making it coincident with the sanitary registration (Secretaría de Salud 2005a). 
 
Pending challenges include the persistence of entry barriers to generic drug 
markets. There are no established mechanisms to file complaints in relation to the 
granting of patents. Whenever third parties are subject to damage after the grant-
ing of a patent, there is little room and few mechanisms to dispute such a patent 
(Secretaría de Salud 2005a). Also missing are rules for Data Protection. “In the US 
such rules are already in place and, in Canada, have recently been introduced. Pro-
tection varies from 3-6 years depending on the country. [By contrast, absence of 
such procedures in Mexico implies that] you can now file a patent application using 
own data, arguing that they are already in the public domain (...) There should be an 
additional period of protection from the date of patent expiry” (Interview with firm 
02). Currently firms protect themselves by means of internal control systems such 
as confidentiality agreements and by fragmenting information; or by entering into 
specific agreements and codes of practice negotiated through trade organisations 
such as CANIFARMA and AMIIF. Partner research organisations, for instance public 
hospitals conducting clinical research, should adhere to such principles and proce-
dures (Interview with firms 01, 05, 11 and Trade2, Insh1 and InsH2). 
 
4. Learning and innovation  
 
As noted in Chapter 4 learning and innovation are core ingredients for the sustain-
ability and eventual success of global pharmaceutical firms. Firms in developing 
countries are not exception to this. Major differences result in the kind of innova-
tive activities that pharmaceutical firms carry out in either develop or developing 
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countries. Learning in developing countries aims mainly to the development and 
manufacturing of generics drugs. Based on the Mexican experience, the following 
sections document that such specialisation results from a mix of firm’s strategic 
decisions and the influence of factors external to the firm.   
 
4.1. General environment around R&D 
 
Guzmán (2005) and Secretaría de Salud (2005a) maintain that considerations such 
as the size of the local pharmaceutical market, and its integration into the interna-
tional market, imply Mexico's potential as an important centre for innovation. Un-
fortunately, to date this potential remains largely unrealized. The dynamism of the 
industry seldom translates into significant R&D efforts (Dussel 1999; Secretaría de 
Salud 2005a). Major challenges include an unsuitable environment in which to carry 
out R&D, weaknesses in health and sanitary regulations, and dated legislation in the 
area of health research (Santiago 2009; Secretaría de Salud 2005a). Equally chal-
lenging is the low support to R&D and interactivity within the system of innovation. 
Moreover, effective plans to promote the development of the industry are missing 
(Interviews with firms 05, 06 and 11 and Trade1). These factors worsen the effects 
of the high cost of basic infrastructure, including energy (Secretaría de Salud 2005a), 
and the tight price controls, macroeconomic risks and uncertainty about public 
policy.  
In Mexico, the overall macroeconomic environment around S&T activities re-
mains a source of concern. In 2005, the country’s total R&D expenditure repre-
sented 0.46 per cent of GDP; just below the 0.88 percent recorded by Brazil, the 
largest economy and pharmaceutical market in Latin America (CONACYT 2007). 
Public investment in S&T in turn, comprised 0.36 per cent of GDP, with 6.2 percent 
allocated to the area of health. More important is the slow pace of growth in overall 
expenditure in S&T and in particular, R&D-table 5.5. Despite this, prospects for the 
health sector look better than in other areas. The average growth rate of public 
expenditure in health-related S&T has been the most dynamic over the last eight 
years or so. Unfortunately, stagnant total public expenditure results in trade-offs 
between expanding investment in health and reducing support to other sectors.
10
 
Encouraging though are the recent dynamics of private expenditure in R&D. Since 
1997 private investment has increased at a pace of 19.0 percent per annum. From a 
share of 16.9 percent in 1997, it reached 41.5 percent of total R&D in 2005 (CONA-
CYT 2007). 
Major efforts are needed to improve the contribution from within the country’s 
human resource base as well. Secretaría de Salud (2005b) reports that the propor-
tion of researchers in the field of health per 1000 inhabitants is considerably below 
                                                 
10 FCCT (2006) presents a more ample discussion about the expenditure in S&T in Mexico. 
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that of developed countries; in fact, only 20 percent of health research-related 
personnel are employed full-time in this area.
11
 In Mexico there is debate concern-
ing the adequacy of incentives for researchers to work towards applied research, to 
take patents or develop new products (AMC-FCCT 2005). Researchers may ignore 
the potential benefits of participating in applied research (Interview with firm 05 
and Trade2). Those benefiting from public programmes such as the National System 
of Researchers (NSR),
12
 regard publication and being cited in international scientific 
journals, as core curricular activities (AMC-FCCT 2005). Nevertheless, some recent 
measures in the fields of medical and health sciences grant increased importance to 
technological developments as criteria for promotion. Valid performance evaluation 
criteria in relation to technological developments include patents, prototypes, spe-
cialised software, technical reports, industrial secrets, copyrights, and so on; and 
supporting new technologies and applications in the health and biomedicine fields 
(Secretaría de Salud 2005a). 
 
Table 5.5: Mexico: Expenditure in Science and Technology activities by selected sectors, 1997-2005 
 Average Growth1/ 
FES&T2/ 1.5 
    Public Education -3.9 
    Energy -5.4 
    Health 13.7 
    Agriculture 0.3 
    Other3/ 3.3 
GERD 6.7 
    Private 18.9 
    Public 0.0 
1/ at constant prices of 2006; FES&T: Federal expenditure in S&T; GERD: Gross expenditure in R&D; 2/ the ordering of the 
components of FES&T indicate the relative importance of each item within total public investment; 3/ includes the 
Secretaries of Economy, Environment, Navy, Communications, Justice, Social Development and others not specified in 
the source.  
Source: Author with information from CONACYT (2007) 
 
Noteworthy is that a small but world class research community already in Mex-
ico. About half of the total national scientific production is related to clinical disci-
plines, in particular immunology and neurosciences (Secretaría de Salud 2005a). 
Medical publications have been growing and gaining credibility during the last 15 
years (de la Fuente et.al, 2004); Mexican publications in pharmacology, for example, 
represented some 0.9 per cent of world scientific publications in the field during 
                                                 
11 de la Fuente et.al, (2004) argue that figures may underestimate the actual number of researchers in 
health, as they exclude people that classify themselves in areas other than medical research but that 
carry out activities related to health, for instance, physiology and biochemistry.  
12 The National System of Researchers (SNI for its name in Spanish) is one of the instruments supporting 
S&T activities with the longest tradition in Mexico. Since inception in 1984, the SNI promotes the forma-
tion, development and consolidation of a critical mass of researchers at the highest level, mostly within 
the public system of higher education and research. Member researchers receive both pecuniary (a 
monthly compensation) and non-pecuniary stimulus (status and recognition) based on the productivity 
and quality of their research.  
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2002-2006 (CONACYT 2007). Mexico faces opportunities to decentralize research 
capacities; currently such capacities concentrate in the main universities and public 
hospitals located in Mexico City (FCCT 2006).  
The pharmaceutical industry has gradually gained recognition within total R&D 
in Mexican manufacturing. CONACYT (2007) states that pharmaceutical R&D grew 
at an average rate of 43.9 percent between 2000 and 2005 (see table 5.6). This is 
greater than that of total manufacturing R&D (27.5 percent); or those from other 
industries relevant for the Mexican economy: Motor vehicles, (2.8 percent); Elec-
tronic devices such as televisions, radio and telecommunications equipment, (26.9); 
and Petrol related products, (22.2 percent). In the same period the share of phar-
maceutical R&D, relative to total R&D in manufacturing, went from 5.8 percent to 
10.7 percent. As a share of gross national expenditure in R&D, pharmaceutical R&D 
went from 3 percent in 2000, to 8.6 percent in 2005.  
 
4.2. Drivers of pharmaceutical R&D in Mexico 
 
Under Mexican law companies can file an application for a new Registro Sanitario 
and start development of a new generic drug three years before patent expiration. 
Hence by the time protection ends, the firm should be ready to launch the new 
generic product (KPMG 2004). Although this action was expected to further support 
development of the local generics market, the process is much more complex as a 
large number of complementary assets are needed. For instance Kim et.al, (1989) 
and Hobday et.al, (2004) agree on the need to understand the strategic orientation 
of firms and, more specifically, the role played by learning strategies based on in-
house R&D. According to interviews with firms 03, 06, 10 and 11, incentives for 
Mexican pharmaceutical firms to invest in R&D are twofold: On the one hand there 
is the desire to gain independence from suppliers of raw materials; and, on the 
other, the desire to address eventual market opportunities, specifically with regard 
to generics within the private sector. Regarding the former, firms intend to reduce 
costs as import prices of raw materials increase. Alternatively, they try to shake-off 
some unfavourable conditions imposed by suppliers via contracts, or marketing 
restrictions with regard to final products outside Mexico. Local firms try to 
strengthen vertical integration by incorporating manufacturing of APIs and to a 
lesser extent, other raw materials and inputs.  
As noted earlier, strengthening vertical integration is a strategy similar to that 
employed by firms in India and China where integration and control of API manufac-
turing facilitate technology developments: “Entrepreneurship, you know, you have 
to constantly keep launching the products, 10 to 15 products, NDA’s, which require 
a lot of in-house support from R&D, backup studies have to be done, data have to 
be collected, backward integration of API has to be there. All that in Mexico is....[not 
really going on]. Whereas in India and China it is possible because you have a lot of 
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API manufacturers also; so getting access is easier. And companies like Ranbaxy, Dr. 
Reddy, SipLab; they also have a lot of API manufacturing of their own. So they’re 
back in control of their own APIs” (Interview with firm 12). 
 
Table 5.6: Mexico: Gross Expenditure in R&D by main industry, 2000-2005 
Industry field 2000 2005 2005/2000
/1 
Agriculture 0.0 0.0 --- 
Mining 0.8 0.4 1.5 
Manufacturing 50.5 80.8 27.5 
    -Food, beverages and tobacco 6.4 15.5 38.7 
          Food and beverages 6.4 15.5 38.7 
    -Textiles, apparel and leather products 3.8 5.1 22.8 
          Textiles 3.6 1.6 -1.7 
          Apparel and leather 0.0 2.3 224.8 
          Leather and footwear manufacturing 0.2 1.2 64.8 
    - Wood products, paper, and printing 0.6 1.3 35.9 
    - Petroleum and coal, nuclear energy, chemicals, rubber and plastic 11.5 26.5 37.1 
         Petroleum and coal products manufacturing, and nuclear energy 0.2 0.2 22.2 
         Chemical manufacturing 10.0 18.1 30.6 
                 Chemical products (except pharmaceuticals) 7.1 9.5 23.0 
                 Pharmaceuticals 3.0 8.6 43.9 
         Rubber and plastic products 1.3 8.2 66.7 
    - Non-metallic mineral product manufacturing 1.9 4.6 38.0 
    - Basic metals 1.0 1.5 26.2 
    - Metal manufacturing (except machinery and equipment) 0.8 6.6 77.4 
    -Machinery and equipment including transport  20.1 19.3 15.1 
         Computer, electronic, office and accounting product manufacturing 0.0 2.2 --- 
         Electrical equipment manufacturing 0.8 3.2 54.8 
        Electronic equipment (radio, TV. and communications)  0.1 0.6 58.0 
        Motor vehicles  17.4 9.5 2.8 
    - Furniture and Related Product Manufacturing 4.3 0.4 -100.0 
    - Electricity, gas and water (public utilities) 2.0 0.5 -13.0 
Construction 0.3 0.0 -40.8 
Services 46.3 18.2 -3.7 
    -Communications 14.2 1.6 -25.1 
        Telecommunications 14.0 1.6 -25.0 
    - Financial and insurance services  6.7 3.6 2.4 
    - Real Estate and Rental and Leasing 0.0 0.1 53.9 
    - Community, social and personal services 16.7 9.0 2.6 
Total 100 100 16.1 
Note: Totals may not add up due to rounding; *Constant MX Pesos, 2006=100; /1 Avg Growth. 
Source: Author with information from INEGI-Conacyt, Encuestas sobre Investigación y Desarrollo Tecnológico 2002, 
2004 y 2006.  
 
With regard to the second strategy, firms literally try to escape from the gov-
ernment’s monopsonistic power (Interviews with firms 05 and 06). They seek to 
capture some of the benefits accruing from the generic segment of the private mar-
ket. To a lesser extent, firms have targeted the generic market in the US, or have 
looked at the market for so-called 'Orphan' drugs (Interview with firm 09).
13
 Per-
                                                 
13 Orphan drugs are products that treat a rare disease or condition affecting some relatively small group 
of consumer. In the US for example, these refer to diseases affecting fewer than 200,000 Americans 
(FDA. 2001)  
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ceived dynamics of prices, and demand and revenues from these markets make 
investment in more formal and systematic R&D more attractive.  
Business strategies based on more systematic in-house R&D are far from easy 
to implement. As suggested by Kim et.al, (1989), and more recently by Forbes and 
Wield (2000) and Hobday et.al, (2004), major strategic changes are needed in the 
mindset and organisation of activities within latecomer firms. Interviews revealed 
that some Mexican pharmaceutical firms begin this sort of transition by shifting the 
balance of power between development activities on the one hand, and manufac-
turing and quality control on the other (Interviews with firms 03, 06, 10 and 11). 
Indeed, development and eventually, R&D departments, need flexibility and auton-
omy within the organisation. Furthermore, they need to be empowered with the 
time and resources to carry out their activities. It is difficult to progress when devel-
opment, manufacturing and quality control compete for infrastructure inside the 
firm (Interviews with firms 05, 06, 10 and 11). For instance, Firms 05 and 06 men-
tioned that although development staff needs to perform tests on compression and 
other properties of a new tablet, in order to access the required machinery they 
have to stand in the line until it becomes available.  
As R&D gains momentum, further advancements will depend upon the effec-
tive development of human resources, in clinical research for instance, -if only for 
the testing of new applications and reformulations (Interviews with firms 06 and 
11). However limited, performance of clinical research compels firms to comple-
ment sound understanding of the physics and biochemistry of compounds, with 
knowledge about medical conditions and the intricacies of drug testing in humans. 
In practice, this means that skilled and knowledgeable staff with sufficient under-
standing and experience in clinical research should be hired. At the same time, or-
ganisational practices need to change in order to accommodate the needs of per-
sonnel with diverse profiles and interests. Interviews with Mexican generic manu-
facturers revealed that firms are not always ready to undertake these tasks. 
 
4.3. R&D performance 
 
Chapter 2 discussed alternative definitions of innovation in the context of develop-
ing countries. On the one hand, technological modernization denotes introduction 
of new, more advanced machinery and equipment, or adoption of enhanced manu-
facturing and managerial techniques. This is considered the most common innova-
tion exercise in such countries. On the other hand, studies document formal R&D 
efforts leading to successful adoption of product/process innovations with different 
degrees of novelty. In 2005, total expenditure in innovation-related activities in the 
Mexican pharmaceutical industry was US$132-148 million; figure 5.4. Machinery 
and equipment, and R&D represented the areas with the largest investment with 
combined shares of 80 per cent of total expenditure. Nevertheless, R&D represents 
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the largest component of innovation-
design or prototype plants is also an area of considerable interest for pharmaceut
cal firms. By contrast, acquisition of software and other external technolog
resent a larger share of investment by manufacturing firms. Expenditure on innov
tion-related training is negligible in terms of investment in technology acquisition. 
 
Figure 5.4: Mexico, distribution of investment in innovation activities by 
Notes: Average exchange rate 10.8939 Mexican pesos per US dollar. This corresponds to the exchange 
rate used to process foreign currency denominated operations (FIX). 
Source: CONACYT (2007) and Banxico. 
 
Figure 5.5 depicts the share of investment 
ing global pharamaceutical innovation. It distinguishes the different instances where 
Mexico participates more actively. Some
sponds to drug discovery and preclinical studies up to the stage of toxicity testing. 
These are areas where Mexico make
documented in Chapter 4, the most expensive and longest component of pharm
ceutical innovation corresponds to clini
cent of total investment. Chapter 4 equally noted that dosage, formulation and 
stability, together with drug manufacturing development are the activities most 
frequently carried out by developing countries. These 
cent, respectively, of total investment in pharmaceutical innovation. 
Figure 5.5 shows that Mexico characterises by limited performance of research 
underpinning drug discovery. The country’s contribution to global pharmaceuti
innovation begins with galenic development and sustainability of active ingredients. 
As discussed later, in line with global trends of the pharmaceutical industry, clinical 
research is growing in the country. Most technological contributions remain in 
manufacturing or post-marketing stage of the pharmaceutical innovation cycle. This 
is through incremental innovations with degrees of technological complexity ran
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ing from limited to moderate (Interview at Trade1 and firms 04 and 05). Innovative 
activities are geared mostly to pharmaceutical development including, analytic 
methods, new drug delivery systems, new applications or reformulations of existing 
molecules, development of new dosage forms, and generics; firms may also create 
new or new combinations of excipients (Interview at firm 05).  
 
Figure 5.5: Distribution of R&D investment among the different phases of the development of a new drug: where does 
Mexico stand? 
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Drug development takes two main forms. First, firms replicate existing drug 
manufacturing processes in order to obtain marketing approval by Mexican authori-
ties. Secondly, efforts are made to enhance product quality and performance. Do-
mestic firms are quite active in these latter activities. There are in addition, firms 
such as Silanes, Probiomed and Alpharma, which have a capacity to explore some 
NCEs based mostly on biotechnology tools and relatively closer interaction with 
public and private research organisations in Mexico and abroad. Domestic manufac-
turers perceive biotechnology as a viable though still expensive and demanding way 
to start building formal R&D efforts (Interviews with firms 03, 06 and 10). 
As for the contribution of multinationals to technological activities in Mexico, 
the picture is rather mixed, depending on where such investment occurs. To a large 
extent multinationals are responsible for the highest levels of modernization and 
automation of the local industry. US affiliates for example, are already introducing 
some of the advanced monitoring and manufacturing techniques under the PAT 
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framework—see chapter 4. Hence, compared to local firms, multinationals tend to 
take the lead when it comes to technology. In terms of R&D the conclusion is 
somewhat different. Firms such as Schering-Plough have established fully-fledged 
R&D facilities in support of their global innovation strategies, with a somewhat 
limited capacity to perform original research.
14
 In general however, R&D by multina-
tionals remains concentrated in the formulation of new applications or niche prod-
ucts tailored to the Mexican market (Interviews with firms 07 and 13). Merck KGaA 
in Mexico for example, developed a vitamin supplement tailored specifically for the 
large diabetic population. The product has rapidly diffused to other markets world-
wide. Alternatively, multinationals increasingly carry out clinical research in partner-
ship with local research organisations, mainly public hospitals (Interview with 
Trade2). 
Zúñiga and Combe (2002) argue that it is difficult to expect significant increases 
in R&D expenditure by multinationals in developing countries. This is complicated 
even following patent reforms, considering the nature of the pharmaceutical indus-
try, with a traditional concentration of corporate R&D laboratories in the countries 
of origin. Other factors are needed for multinationals to relocate R&D facilities, 
including: (i) more coherent science and technology policies; (ii) linking better aca-
demic and industry R&D efforts, and (iii) direct promotion of stronger R&D activities 
in the pharmaceutical industry. 
 
4.4. R&D outcomes 
 
According to the latest Community Innovation Survey 2006 (CONACYT 2007), some 
59.1 percent of pharmaceutical firms in Mexico performed in house R&D, the ma-
jority of which, 94.8 percent, obtained some kind of result, table 5.7. Mirroring 
global trends in the industry, pharmaceutical firms in Mexico have a larger propen-
sity to invest in R&D than the rest of the manufacturing sector. In terms of out-
comes, product innovations are the most frequent; almost all firms performing in-
house R&D obtained such innovations. Firms performing R&D and obtaining some 
kind of results (181) introduced, on average, 16.8 new or improved pharmaceutical 
products between 2004 and 2005. The number of firms introducing new or im-
proved processes is considerably lower (75); yet, on average firms introduced some 
15.7 process innovations.  
In line with the discussion in Chapter 1, the incremental nature of pharmaceuti-
cal R&D in Mexico is reflected in the large number of innovations that are new to 
the country and, to a lesser extent, the firm. Local firms mostly tap into available 
knowledge in order to adapt products and/or processes to the local market. Despite 
this, some firms operating in Mexico have managed to obtain some radical innova-
tions in the sense that they are completely new to the world. However, sales reve-
nue makes little distinction between new and improved products; though new 
products represent about 53.0 percent of total sales. The figure differs significantly 
                                                 
14 It is uncertain what will happen with those R&D facilities after the merger of Schering-Plough and 
Merck, Co. 
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with those for the whole of the manufacturing sector. Although pharmaceutical 
firms report a larger R&D focus in terms of sales, expected sales revenue from the 
new or improved products is lower than those from R&D in the manufacturing in-
dustry.  
 
Table 5.7: Innovative performance of the Mexican pharmaceutical industry, 2004-2005 
 Pharmaceuticals Manufacturing  Pharmaceuticals Manufacturing 
Total firms 323 16398 Distribution of sales by novelty of product (%) 
Carried out R&D1/  New 24.2 31.8 
Yes 191 4,090 Improved 28.8 36.4 
With results 181 4,040 No change 47.0 31.8 
No 132 12,307 Total 100 100 
Results from R&D Patents 
Products 3,043 35,471  Applied Granted 
Yes1/ 181 3,891 Mexico 64 22 
% of total firms 56.3 23.7 Abroad 56 11 
Processes 1,178 9,444 Total 119 33 
Yes1/ 75 2,001 Linkage activity in pharmaceuticals1/ 
% of total firms 23.2 12.2  Product/Services Process 
Innovations by degree of novelty (per cent) In house 138 69 
Firm Country World 
Research 
Centres 
10 4 
21.4 77.6 1.0 Universities 15 0 
   Other firm 18 2 
   Total 181 75 
Notes: 1/ Number of firms 
Source: Author with information from CONACYT (2007) 
 
Chapters 7 and 8 offer a more extensive analysis of the propensity of pharma-
ceutical firms in Mexico to acquire technological knowledge from external markets; 
licensing in particular, is among the mechanisms preferred by firms. This situation 
can partly explain the larger number of patents established in Mexico by multina-
tional, compared to domestic firms. By applying for patents in Mexico, multination-
als support the marketing of innovative drugs, particularly to the benefit of private 
market. In such a way those firms capitalize on the improved local environment 
around IPRs following Mexico’s endorsement of the TRIPS agreement. By contrast, 
the low patenting activity of local agents reflects the limited learning activities they 
carry out. In effect Guzmán (2005) reports that the bulk of pharmaceutical patents 
by Mexican agents correspond to individuals or research organisations; only a minor 
share are proposed by domestic firms and transformed into marketable products. 
The few patents that Mexican firms file abroad concentrate in the European Union.  
The literature stresses that one of the more disquieting features of the Mexican 
system of innovation is that low levels of R&D are accompanied by limited or poor 
interactions among agents shaping such systems (Cimoli 2000; Cimoli and Constan-
tino 2000). Casas (2001) asserts that firms rely almost exclusively on internal learn-
ing efforts to fulfil knowledge requirements. This situation is exemplified by the 
Mexican pharmaceutical industry. Nearly three quarters of firms that introduced 
product innovations did so without interacting with other agents. The lack of con-
nection is even more evident in the case of process innovation.  
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Recent efforts to promote interactivity in the system by CONACYT, the agency 
responsible for S&T policy in Mexico, have achieved some modest results. Over the 
last years, CONACYT has funded projects carried out jointly by firms and other or-
ganisations. In 2006, investment in such projects added up to MX$3,999.8 million, 
roughly US$366.9 million, (table 5.8). Some 481 firms were involved, carrying out 
1,616 projects; the two latter figures more than tripled compared to those observed 
in 2001. The presence of pharmaceutical firms increased considerably between 
2001 and 2006, but the figures suggest some inconsistency in terms of resource 
allocation. More detailed information about the number of applicants and corre-
sponding funding requirements is missing. Nevertheless, one can see that although 
the number of both pharmaceutical firms and projects has increased, investment 
per project has not. The number of pharmaceutical firms supported by CONACYT is 
a minor fraction of those that could potentially participate, table 5.8.   
 
Table 5.8: Conacyt’s investment in projects involving interactions of firms and other agents, 2001-2006 
 2001 2002 2003 2004 2005 2006 
Pharmaceutical industry 
Firms1/ 9 16 27 35 50 48 
Projects1/ 31 95 132 202 278 273 
Investment2/ 3.1  3.2  5.7  11.6  17.9  29.0  
Inv/project3/ 100.8  33.2  43.1  57.2  64.3  106.1  
Share in total 
Firms1/ 6.3 7.4 11.4 9.8 8.2 10.0 
Projects1/ 6.1 11.5 15.1 15.4 13.3 16.9 
Investment2/ 6.5 5.0 10.1 9.5 6.2 7.9 
Total       
Firms1/ 142 216 236 357 608 481 
Projects1/ 506 824 873 1308 2083 1616 
Inv/project3/ 95.2 76.1 64.8 93.0 137.4 227.1 
Notes: 1/ Number; 2/US$ million, 2006=100; 3/US$ Thousand  
Source: Author with information from CONACYT 
 
4.5. Basic research 
 
Mexico has facilities to perform new drug-related research; yet activity in such ar-
eas is only in its early stages. Basic research happens mostly at universities and 
public research centres with limited links to the industry. Nevertheless BMI (2006) 
reports that GSKs Rotarix, a novel, orally administered two-dose vaccine for rotavi-
rus infection in infants, was one of the first drug discoveries to be made in Mexico; 
and the product was partly developed at the local affiliate.
15
  
One of the main questions of this chapter, is why firms, particularly multina-
tionals, do not conduct basic research in Mexico? Interviews with firm representa-
tives revealed that there are several reasons to explain this. In line with literature 
on internationalization of R&D (von Zedtwitz and Gassmann 2002), the most fre-
quent answer was that from a business strategy point of view, Mexico is mostly a 
                                                 
15 In July 2004 GSK announced that COFEPRIS had approved Rotarix. Therefore the product was launched 
in Mexico even before obtaining approvals from the US or European authorities. The drug is expected to 
generate annual sales of up to US$1.8 billion, and royalty payments of US$1-2 million. More importantly, 
Mexico became the starting point for a promising new business for GSK (BMI 2006) 
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manufacturing location and consumer market, but not a major R&D centre. This 
was the case even for affiliates of Indian origin.  
Mexico lacks the technical infrastructure, an attractive and conducive research 
environment, and a sufficiently experienced human resource base. A few public 
research centres meet world-class standards and possess adequate research meth-
odologies and procedures. However, they lack sufficient equipment, both in terms 
of the quantity and degree of sophistication required to carry out the massive 
amount of biological and chemical tests underpinning new drug discovery. “Tests 
should often run simultaneously and at considerable precision and speed. [Mexican 
researchers have little or no experience in] conducting lead discovery projects, un-
derstanding of the physicochemical structure of the processes under research; for 
instance, to test for systemic or crossed effects of lead targets, particularly when 
processes of hypothesis testing involve combinations or simultaneous analysis of 
different molecules or substances” (Interview with firm 13). Whereas the bulk of 
local R&D activities currently focus on inter-changeability tests, multinationals are a 
few steps ahead “exploring, testing and solving new hypotheses” (Interview with 
firm 13).  
An important question to pose, considering, most new drug-related basic re-
search happens at universities, limited though it may be, is why firms do not capital-
ise on those activities. Efforts to bridge the gap between firms and academic institu-
tions have rendered limited results; the two agents operate according to different 
incentives and motivations, where 'publish or perish' clashes with 'time to market' 
incentives and rewards (Interview with firms 05, 06 and 11). This classic dichotomy 
is widely documented in the literature (Pavitt 1998; Stephan 1996; Stephan and 
Audrestsch 2000). Additional obstacles stem from inadequate handling of IPRs 
within academic organisations, which hinders access to research with potential 
pharmaceutical use. It is problematic to negotiate technology transfer or joint de-
velopment projects when no one owns the technology (Interview with firms 06 and 
13).  
In some other cases, researchers disregard or fail to appreciate the many pro-
cedures required by law to test, develop, improve, manufacture and market new 
drugs. These require time, advanced facilities, laboratories, pilot plants and person-
nel -resources that are not readily and widely available at Mexican public research 
organisations. Failure to value potential technologies would be an additional obsta-
cle. Limited interactivity occurs not only between firms and research organisations 
but among the latter, and between these and government institutions. For instance, 
the leader of the R&D department at firm 13 commented that, “Although diabetes 
is one of the most prevalent diseases in Mexico, so far there are no specific mecha-
nisms whereby public health and S&T organisms, healthcare institutions, research 
organisations and firms may join forces to develop new drugs or other products for 
such population. Everybody is working on his/her own agenda without proper as-
sessment of how research results may be applied and translated into new prod-
ucts”.  
The business environment is also an area of concern (Secretaría de Salud 2005). 
In a best case scenario, firms sponsor research projects at universities or research 
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centres; alternatively firms award prizes and recognition to interesting basic re-
search projects in the areas of health, medicine and pharmacology, through organi-
sations such as CANIFARMA. In general though, such projects never make it to the 
development stage; researchers are either not interested in pursuing further devel-
opment, applicability in the real world is not immediately obvious, or linkages to the 
industry are weak (Firms 05, 11 and Trade1). According to Trade1 between 2000 
and 2006 some 160 projects competed for the CANIFARMA Award in health- and 
pharmaceutical-related research, but only around eight projects were successful. Of 
those successful projects no more than two have been made into usable products. 
Pharmaceutical innovation is a matter of creating critical masses of projects, mobi-
lizing resources, cultivating an environment of collaboration between different 
research organisations, including the sharing of assets; Mexico is still weak in all of 
these areas.  
Uncertainties regarding whether large manufacturers of innovative products 
will be willing to commercialise molecules developed by local API manufacturers 
may also help explain the lack of appeal related to basic R&D (Secretaría de Salud 
2005a and Interview with firm 06). This is compounded further by factors such as 
the absence of linkages between health problems and R&D; inadequate regulation 
preventing public research organisations from receiving funding and equipment 
from private organisations; few linkages between public scholarship programmes 
and the on-the-ground needs of industry in terms of human resources; insufficient 
funding for R&D, and the enduring uncertainty surrounding pharmaceutical re-
search (Secretaría de Salud 2005a).  
In the case of biotechnology, Bolívar (1997) reported that a major obstacle to 
develop industrial applications has been the strong teaching or research orientation 
of graduate programmes in the field; they have little or no connection at all with 
industry needs. Such problems are aggravated by “the inadequate interpretation of 
the concept of biotechnology by Mexican policy makers. Because authorities take it 
as a generic sector, they tend to ignore differences in the development of applica-
tions for agriculture, food and pharmaceutical industries" (Interview with firm 05). 
 
4.6. Clinical research 
 
Countries such as Mexico are increasingly being considered as potential sites for 
drug development activities, mostly via the off-shoring of clinical research by multi-
national firms. Santiago (2009) maintains that multinationals benefit from the pres-
ence of effective and sufficiently equipped healthcare organisations with experience 
and well established procedures to deal with patients and regulations. Equally im-
portant are factors such as the presence of a large pool of experienced clinical re-
searchers; an effective ethics committee, and superior evaluation and supervisory 
mechanisms to ensure that research protocols occur in a relatively efficient, trans-
parent and speedy manner. Mexico is an attractive site as it fulfils many of these 
requirements (Santiago 2009). It complies with principles established by the Inter-
national Conference on Harmonisation (ICH) on Good Clinical Practices. The country 
has positioned itself as one of the leading sites for clinical trials in Latin America 
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with research protocols in more than 20 therapeutic areas and more than 1,000 
institutions and 43,000 patients involved in 2005 alone (AMIIF). Despite this, there 
are some factors hindering success, such as regulatory shortcomings in, for in-
stance, authorization and supervision of trials by both ethics committees and 
COFEPRIS (Interviews with trade2, Insh2, Insh3 and CRO); and the lack of experi-
enced researchers to conduct clinical research (Secretaría de Salud 2005a).  
 
5. Concluding remarks 
 
The introductory section to this chapter argued that the climate surrounding the 
pharmaceutical industry in Mexico discourages learning and innovation, particularly 
by domestic firms. A number of factors stand out from the analysis. Historically, 
public policy seems to struggle finding the middle ground between strict 
protectionism and extreme liberalisation. In either case government intervention 
has been somewhat ineffective in setting the stage for the advancement of the local 
industry. Rather public policy tends to nurture cautious behaviour by domestic 
firms; firms reluctantly seek business strategies based on more ambitious plans to 
develop proprietary technologies. Studies on Korea and India show that strategies 
based on intensive domestic learning require long-term approaches; hence it is 
possible to more systematically undertake uncertain and risky R&D activities (Kim et 
al, 1989; Kale and Little 2007).  
Incentives to invest in innovation and learning derived from traditional market 
mechanisms, such as prices, are equally hindered by conflicting policy goals. When it 
comes to public procurement of basic drugs, consumer protection and reduction of 
healthcare costs result in price structures that privilege low cost over quality and 
novelty. In such a context market specialisation of domestic and multinational firms 
places the former in precarious positions; they depend strongly on the low profit, 
large volume public market. Most domestic firms concern more about survival than 
growing market shares via increased in-house technological efforts. Their capacity to 
tackle the more profitable private sector is limited by low R&D performance.  
The analyses in chapter 6-8 reinforce the perception that strategies to develop 
the pharmaceutical industry based on capturing knowledge from foreign firms are 
also questionable. Mexico still ranks very low as suitable location for multinational 
firms to carry out some of their more advanced R&D activities. Reform and 
increased market orientation have been poorly conducive for the development of 
the local pharmaceutical industry. Such efforts seldom accompany more decisive 
actions to strengthen whatever technological base is in place in the domestic 
industry. Moreover, the agents in the relevant system of innovation are unable to 
complement each other’s efforts, or to support more rapid and sustained 
construction of technological capabilities by domestic firms.  
The pernicious macroeconomic context around pharmaceutical innovation in 
Mexico accompanies an equally limited learning environment inside pharmaceutical 
firms. The econometric analyses in Chapters 6-8 documents the limited influence 
that organisational arrangements and related human resource management 
practices have on learning performance of pharmaceutical firms in Mexico.  
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Chapter 6 
Human resource management practices 
for learning through in-house R&D: 
pharmaceuticals in Mexico1 
 
 
 
1. Introduction 
 
This chapter contributes to the literature on human resource management practices 
and learning for innovation in the context of developing countries. In-house R&D is 
broadly interpreted as learning at firm level. Based on the notions of knowledge 
exploitation, and knowledge exploration, the research hypotheses here is that the 
influence of human resource management interventions on learning depends on 
two factors: first, the nature of the knowledge required; and second, the expected 
goals from the learning activities carried out by the firm–see chapters 1 and 3. The 
underlying logic is that human resource management practices influence innovation 
by stimulating, first, learning and capacity-building through in-house R&D. 
To the best of our knowledge, this is one of the first systematic analyses of the 
sway of human resource management over learning through R&D in developing 
countries. Focus on the Mexican pharmaceutical industry illustrates the importance 
of carefully considering the contexts in which management practices work. Overall 
macroeconomic conditions and the social environment around R&D conditions 
what can be expected from human resource management interventions. In 
particular, the effects of such practices on performance depend on how countries 
get involved and contribute to global innovation processes in specific industries.  
From a methodological perspective, the chapter illustrates the potential 
benefits of research on the latent processes linking human resource management 
practices to innovation, in this case, learning. This kind of approach is quite familiar 
for management scholars interested in comprehending how management practices 
affect creativity and creative thinking for example. In this manner this chapter paves 
the way towards better understanding how human factors and their organisation 
                                                 
1Earlier versions benefited from comments by Gabriela Dutrénit; Nobuya Haraguchi; Wilfred Dolfsma, 
Branka Urem, Jojo Jacob and members of the research group on Innovation, global business strategies 
and host country development at UNU-MERIT; Leonel Corona, Javier Jasso and staff of the División de 
Investigación, Facultad de Contaduría, Administración e Informática of the National Autonomous Univer-
sity, Mexico. Suggestions by Martin Shrolec and other participants at the 7th Annual conference of the 
Globelics network are appreciated. Maria Fermie helped in editing and correcting previous versions. A 
paper based on this chapter is currently under review by the Journal Structural Change and Economic 
Dynamics; this will be a special issue with contributions to the 7th Globelics conference. I appreciate 
comments by two anonymous referees to the journal. 
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inside firms contribute to the building and operation of systems of innovation. The 
chapter proceeds as follows: Section 2 defines the dependent variables and 
research strategy used in this chapter; they denote different types of in-house R&D 
performed by pharmaceutical firms in Mexico. Section 3 provides results. Finally, 
section 4 presents some discussion and conclusions. 
 
2. Variable definition 
 
Data used in this chapter were extracted from the ENESTYC dataset--chapter 3.  
 
2.1. Dependent variables  
 
ENESTYC includes detailed questions on the R&D activities performed by pharma-
ceuticals firms in Mexico. To begin with, ENESTYC enquires if firms perform R&D, at 
all. This is captured by the variable rd_inhouse, item (1) in table 6.1. A novel feature 
of this study is the identification of the objectives pursued by the firm through R&D. 
ENESTYC identifies R&D supporting cost-reducing innovations through: (2) im-
provements in existing drug manufacturing processes (rd_improve_process); (3) 
improvement or design of new machinery and equipment for the firm’s own use 
(rd_design_meq). This second is interpreted as R&D for new process innovation. 
Other R&D variables capture demand-enhancing innovations including: (4) quality 
improvements on existing pharmaceutical products (rd_drug_improvement); and 
(5) design of new pharmaceutical products (rd_drug_design). The novelty of the 
R&D outcomes is defined taking the firm as reference; innovations may be new to 
the firm but not necessarily to the Mexican market or the world.  
 
Table 6.1: Indicators on in-house R&D performance by pharmaceutical firms in Mexico  
 Variable Definition 
(1) rd_inhouse The firm carries out R&D in-house 
(2) rd_improve_process The goal of R&D is to improve existing manufacturing processes 
(3) rd_design_meq The goal of R&D is to improve or design new machinery and equipment for 
the firm’s own use 
(4) rd_drug_improvement The goal of R&D is to improve existing pharmaceutical products 
(5) rd_drug_design The goal of R&D is to design new pharmaceutical products 
(6) rd_exploit The firm performs R&D for knowledge exploitation 
(7) rd_explore The firm performs R&D for knowledge exploration 
Source: Author with information from ENESTYC, 2005 
 
Items (2) and (4) in table 6.1 identify knowledge exploitation activities; 
improvement in pharmaceutical products and/or processes leads to searches within 
the firm’s familiar knowledge bases. By contrast, the introduction of some new 
manufacturing processes or new drugs, indicators (3) and (5), relate to knowledge 
searches outside familiar cognitive, including physical and geographical, boundaries 
of the firm.
2
 This distinction coincides with Kale and Little’s (2007) differentiation of 
pharmaceutical firms, based on their accumulated technological capabilities. Based 
                                                 
2Similar interpretations in the context of biotechnology and pharmaceuticals are found in Rothaermel 
and Deeds (2004), Gilsing (2006) and Kettler and Modi (2001) 
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on the logic of exploitation and exploration, variables (2)-(5) were combined to 
generate two new indicators on R&D. By combining (2) and (4) a variable on R&D 
for knowledge exploitation, rd_exploit, is obtained. Likewise, by combining (3) and 
(5) the variable on R&D for knowledge exploration, rd_explore, is obtained.  
Chapter 5 documented that, in general, firms in Mexico pursue imitative, 
incremental innovations based on the exploitation of knowledge already available 
in-house. Quality enhancements of pharmaceutical products denote changes in 
formulations so that the products meet the requirements of bioequivalence and 
bioavailability of the API. Firms may also improve product packaging. New products, 
in turn, include new vaccines, development of new applications of existing drugs by 
combining excipients, reformulating or recombining existing molecules--often in a 
different therapeutic area; and designing novel medical devices. Some of the more 
dynamic local firms have capacity to developed new generics and excipients based 
on the use of biotechnology.  
Correlation analysis in table 6.2 lends support to some of the previous 
arguments; it reveals that knowledge exploitation, particularly for the improvement 
of drugs already in a firm’s product portfolio, is what drives R&D of pharmaceutical 
firms in Mexico.
3
 There is high and statistically significant correlation between 
variables on R&D for knowledge exploitation. By contrast, the weakest correlations 
relate to R&D for the design and improvement of machinery and equipment for the 
firm’s own use.  
 
2.2. Explanatory and control variables 
 
Table 6.2 presents the explanatory and control variables used in this paper. Sections 
2 and 3.1.1 in Chapter 3 discussed the theoretical underpinnings and the 
construction of the variables based on the ENESTYC dataset, respectively. The 
chapter highlighted the difficulties to identify, based on concrete theoretical 
grounds, the human resource management practices that matter the most for firm 
performance. The decision was to include some practices adopted by both 
innovation scholars, and available studies on human resource management 
practices in Mexico. Thus the analysis includes distinct forms of remunerations, 
training and worker’s participation in decision making –variables 8-14 in Table 6.2. 
Likewise we control for firm’s characteristics such as adoption of organisational 
practices, exports, foreign ownership–variables 8-14 in Table 6.2. Scale effects are 
captured in interaction with remunerations to personnel. 
 
2.3. Research strategy 
 
                                                 
3 To further identify factors driving pharmaceutical R&D in Mexico exploratory factor analysis was con-
ducted including rd_process_improvement, rd_design_meq, rd_drug_improvement and rd_drug_design; 
from the analysis one single factor was retained. Within such factor, rd_drug_improvement had the 
largest factor loading, albeit somewhat close to those for rd_drug_improvement and rd_drug_design. 
For the sake of simplicity of the analysis this chapter reports only results from the correlation analysis. 
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This chapter explores the likelihood that a pharmaceutical firm carries out different 
types of in-house R&D. A suitable approach for studying this type of binary decision 
variables is a probability model, such as binary probit regression (Greene 2003). The 
dependent variable can be expressed as: 
 
 
y =         (6.1) 
 
 
The function linking the vector of dependent variables Y and the explanatory 
variables x's can be represented as:  
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Given the binary nature of Y, one can express the linkage function between Y 
and X in a more general fashion as η . Hence, a probit model is a generalised linear 
model with a probit link: 
 
µη 1−Φ=       (6.3) 
 
Where Φ  is the standard normal cumulative density function (CDF) in the form 
of a standardized variable or Z score, expressed in probability terms (Liao 1994). 
Probit analysis assumes a binomial distribution of the dependent variable and a 
normal distribution in the errors term, ε .  
The analysis started with the construction of a basic model that explores the 
extent to which the variables in the analysis explain the likelihood that a firm 
performs in-house R&D.
4
 Then, the definition of the dependent variable was 
iteratively changed.
5
 As for variables in the right hand side of the equation, 
normalizing the log of remunerations with respect to firm's size (rem_size) 
corrected problems of high and positive correlations between ln_rem_avg and the 
variables on fdi and exports, respectively (table 6.2). It also captured some scale 
                                                 
4 Several checks were performed to ensure accuracy and robustness of results. Models were included, 
first where each dependent variable was regressed on the explanatory human resource management 
variables only; then compared to full specification models; and second, full specification models. Equa-
tions were also run including only those explanatory and control variables that revealed some statistical 
significance, at 5 per cent or less, in the full specification model. The results from such models were 
consistent with those reported here. 
5 Note a minor difference in the definition of training used in models with rd_design_meq as the de-
pendent variable. The majority of pharmaceutical firms reported to have provided training during 2004. 
Consequently, models with train04 had problems to converge, the variable predicted perfectly the prob-
ability that a firm performs such type of R&D (Long and Freese 2006). The choice was for the alternative, 
internal_external_tr, which denotes interactions between internal and external training. As section 4 
reports, individual effects of internal and external training, respectively, were tested on the remaining 
definitions of R&D. 
1, if y* > 0 
 
0, otherwise 
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effects associated with firm size (Cockburn 2004). A similar situation occurred in the 
case of the variable on adoption of JIT techniques. The use of the variable 
modern_practice eliminated high correlation with the indicator on worker’s 
empowerment. Results from models including only the TQM were similar to those 
presented here.  
 
3. Empirical results  
 
3.1. Learning behaviour of pharmaceutical firms in Mexico 
 
Table 6.3 summarizes the learning behaviour of pharmaceutical firms in Mexico. It 
shows that 74.1 per cent of firms performed R&D in 2004, with some 63.4 per cent 
and 70.5 per cent focusing on process and product innovations, respectively. Of 
those conducting R&D for process innovation, 25.3 per cent did so to improve or 
design machinery for their own use, while some 63.4 per cent to improve produc-
tive processes. As for demand-enhancing innovations, some 61.1 per cent of firms 
pursued new products, and some 66.1 per cent focused on improvements in exist-
ing drugs. In this context, indicators such as sales and employment show that, on 
average, R&D performers slightly outperform those reporting no R&D. For instance, 
average employment, total sales and sales per employee are, respectively, 1.4, 1.6 
and 1.1 times larger in firms with active learning strategies.  
Indicators on capital origin and export orientation tend to favour non-R&D 
performers. Some 70 per cent of firms carried out either knowledge exploitation or 
exploration. The corresponding figures on employment, sales and so on, are very 
close among each group, yet with a slight advantage for active learners. Some 60 
per cent of firms in the sample participated in export markets. However, since the 
average share of exports in total sales of the industry is rather modest, one can 
argue that pharmaceutical firms are oriented to serving the local market. In line 
with the cGMPs requirement, ENESTYC reports an extensive adoption of modern 
manufacturing practices in the pharmaceutical industry. 
Table 6.4 presents the independent and control variables used in this chapter 
by type of learning strategy selected by the firms in our sample. The table shows the 
great propensity of pharmaceutical firms in Mexico to provide training to 
employees. Note also that training is more frequently provided by firms with R&D 
for knowledge exploitation, and by those pursuing drug improvements. Firms make 
use of combinations of both internal and external sources of training, whereby 
documenting the search for synergistic effects between the two types of training. 
The pharmaceutical industry in Mexico restrains worker’s participation in decision 
making about working conditions. Even in those occasions where workers have a 
voice, the practice is reported as having little importance for the company. 
Interviews with several Mexican manufacturers revealed that R&D staff frequently 
subordinates to the needs of manufacturing and quality control units. 
 
3.2. Human resource management and learning through in-house R&D 
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3.2.1. Knowledge exploitation or exploration  
 
This chapter contends that knowledge exploration, in the sense of research, ex-
perimentation and technological capability-building; associates with stronger exi-
gencies on human resource management practices. This section explores this hy-
pothesis. Table 6.5 presents estimates from the econometric analysis. Model (1) 
corresponds to in-house R&D, irrespective of the goal pursued by the firm. Model 
(2) captures R&D for knowledge exploitation (rd_exploit) and finally, model (3) iden-
tifies R&D for knowledge exploration (rd_explore). Each model in the table splits in 
four sections: models with human resource management variables only, and then 
those with the full set of explanatory and control variables. In order to ensure that 
correlation between fdi and export_dummy does not cause major problems, a third 
column includes models with an interaction term between such variables 
(fdi_expt).
6
 Finally, the computation of marginal effects for the model with the full 
set of explanatory variables is presented. The Wald tests for the value of X
2
, which is 
different from zero, confirm that the models are statistically significant at standard 
confidence levels. The count R
2 
for each of the models shows that, in general, their 
individual predictive power is acceptable (Liao 1994). Similarly, the values of the 
Cragg-Uhler R
2
 suggest that the models adequately explain the probability that a 
firm does R&D. 
Individual estimates reveal that training has the strongest and most significant 
effect on learning through R&D. This is indicated in models with human resource 
management variables only. In terms of the specific dependent variable, the effect 
looks stronger for knowledge exploitation than for knowledge exploration. 
Remunerations in turn, show positive impact on rd_explore but the effect seems 
not to be robust. Export participation and foreign ownership in turn, report relevant 
influences on R&D performance. The effects, however, run in opposite directions. 
Whereas export participation induces learning, foreign ownership inhibits it. In fact, 
the influence of capital ownership is stronger than that of exports. This is evident by 
looking at models with fdi_expt as explanatory variable. Scale effects are also 
captured by the variable on remunerations, as it is normalized by the firm's size. 
Adoption of modern_practice and worker’s empowerment do not reveal any 
specific effect on learning. Overall, the estimates suggest a passive learning 
behaviour of the pharmaceutical industry in Mexico. The constant term is 
consistently negative and statistically significant. If all right-hand side coefficients 
were set at zero, the probability that a firm carries out R&D is rather low. 
A complementary way to look at results from probit models is to compute the 
marginal effects derived from modifications in the value of a given explanatory 
                                                 
6 We evaluated performance of models in Tables 6.5 and 6.6, respectively, with and without the interac-
tion term fdi_export without leaving out any of the control variables. Unfortunately estimations including 
all three variables, fdi, export_dummy and fdi_expt, were problematic as they tended to predict perfectly 
the learnimg behavior of firms. Based on Long and Freese (2006) we corrected by droping the observa-
tions creating problems. But then considering the relatively small size of the working sample, colinearity 
problems increased. In STATA the practical solution to colinearity is to automatically drop the redundant 
variable from the equation, in this case fdi_expt. The chapter report models with and withouth fdi_expt. 
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variable (Christofides et.al, 1997; Christofides et.al, 2000). A fourth column for each 
model in table 6.5 presents the marginal and discrete probability changes for the 
variables in the full specification models. Estimates confirm that the provision of 
training has the largest positive and statistically significant impacts on learning. If all 
remaining variables in the equation are left constant, in this case at the mean value, 
the shift from non- to provision of training increases, by some 48 per cent, the 
probability that a firm carries out in-house R&D. Once the notions of knowledge 
exploitation and exploration are taken into account, stronger effects of training are 
associated with knowledge exploitation than with R&D for knowledge exploration. 
Contrary to our research hypothesis, so far the findings in table 6.5 suggest that the 
influence of management practices on the likelihood that a pharmaceutical firm 
does R&D is rather limited. Moreover, it is difficult to perceive how distinct types of 
learning activities associate with different management practices adopted by a firm. 
Based on the discussion in section 2.1, in what follows a further distinction is made 
on the expected innovation outcomes from the R&D carried out by the firm. 
 
3.2.2. Learning through different kinds of R&D  
 
Table 6.6 presents the results from models that incorporate the distinct goals pur-
sued through in-house R&D. Models (1) and (2) include cost-reducing R&D, while 
models (3) and (4) relate to demand-enhancing R&D. For convenience of the analy-
sis, the table excludes the computation of marginal effects; these are presented in 
table 6.7. Customary indicators on goodness of fit corroborate the adequacy of the 
models. As expected, the more detailed definitions of R&D provide better informa-
tion on the distinct contribution of human resource management practices on 
learning. Relevant practices vary both in number and strength of the perceived 
effect. This supports the idea that firms with dissimilar learning and innovation 
strategies should gain differently from adoption of even comparable human re-
source management practices (Laursen and Foss 2003; Laursen and Mahnke 2001). 
Estimates for individual practices indicate that the provision of training remains 
the most significant practice across learning activities; the strongest contribution 
corresponds to new drug designs. Variables on remunerations and worker’s 
empowerment also gain in statistical significance. Remunerations are important for 
exploratory R&D supporting new manufacturing process or new drug designs. 
Worker's empowerment has positive effects on R&D for the design or improvement 
of machinery and equipment. Export_dummy and fdi continue to play relevant 
roles, albeit with effects running in opposite directions, for rd_design.  
Table 6.7 presents the computation of marginal effects for the variables in the 
basic models of table 6.6. Unlike the analysis in table 6.5 this new exercise is much 
more detailed. Estimates confirm training as the intervention with the largest 
positive and statistically significant impact on the likelihood that a firm performs 
R&D. In fact, the largest effect of training is on rd_drug_design, 43.7 per cent. By 
contrast, the lowest influence, some nine percent, is in the case of rd_design_meq. 
The latter variable is also the one where worker’s empowerment has perceptible 
and positive contributions to learning. Marginal increases in remunerations have 
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positive and statistically significant influence on knowledge exploration. This result 
lends support to the expectation that as firm grow, so does their capacity to carry 
out R&D, and to pay more attractive remunerations to personnel in such activities.  
Interpretation of discrete probability changes should be handled with care, as 
they are meaningful only for variables spanning over a sufficiently large range of 
values (Long and Freese 2006). A pertinent case is that of remunerations. Column 
(1) in table 6.7 reveals that a change in the log of remunerations, equivalent to an 
increase from minimum to maximum, raises the likelihood that a firm conducts 
rd_drug_design by some 0.341. Changes in remunerations are stronger for demand-
enhancing R&D than for cost- reducing activities. Similarly, the impact from changes 
of half a standard deviation in the log of remunerations, column (4), are larger for 
rd_design than for any other type of process R&D. Interestingly, except for 
rd_design_meq, worker’s participation in decision-making seems to impact 
negatively the likelihood of R&D performance. We come back to this in section 4. 
 
3.3. Effects from different types of training  
 
The analysis so far documents that the provision of training has positive and robust 
influences on the likelihood that a firm does R&D. In order to extract some more 
meaningful conclusions, more disaggregated measures on the actual nature of 
training were introduced. Chapter 3 identified two complementary forms: internal 
(on-the-job) and external (off-the-job). The former was expected to support knowl-
edge diffusion and sharing within the organisation, as it would be more closely re-
lated to exploitation strategies. By contrast, external training would support the 
expansion of knowledge bases through interaction with other knowledge producers 
(Casas 2005). In order to explore this dual nature of training, two additional vari-
ables, namely, training_internal and external_training, were brought into the analy-
sis. Table 6.8 contains estimates for models where train04 is replaced by the two 
new variables.
7
 The Wald tests show that, with the exception of 
rd_drug_improvement, the remaining models are statistically significant at conven-
tional confidence levels.
8
 Estimates in table 6.8 confirm that the provision of inter-
nal training is more closely related to knowledge exploitation. By contrast, the train-
ing provided via interactions with external agents impacts more directly on knowl-
edge exploration, particularly rd_drug_design. Note that remunerations and 
worker’s empowerment lose the explanatory power found in tables 6.5 and 6.6. 
Exposure to competition through participation in export markets stimulates learn-
ing, particularly for (new) product innovation. 
 
                                                 
7 The analysis excluded the variable on rd_design_meq because training_internal tended to predict 
perfectly the probability that a firm performs this specific activity. In the presence of perfect prediction 
STATA drops the problematic variables out from the equation (Long and Freese, 2006).  
8 Although not included in table 7.8, we also ran models where the variables fdi and export_dummy 
where replaced by the interaction term, fdi_expt. Results from such models corroborate the conclusions 
presented here. 
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4. Discussion and concluding remarks 
 
Chapter 1 in this thesis established that a consistent theory on the relationship 
between human resource management practices and innovation performance at 
firm level is at an early stage, since the linkages between those variables are yet to 
be comprehended. This chapter investigated the influence of human resource man-
agement practices on the likelihood that a firm performs in-house R&D. In the con-
text of the pharmaceutical industry in Mexico, R&D was broadly interpreted as 
conscious learning activity promoting and supporting technology capability building 
processes in latecomer firms. The literature recognizes this as absorptive capacity 
building.  
Based on the notions of knowledge exploitation and knowledge exploration, 
respectively, the analysis considered distinct definitions of in-house R&D, each of 
them implying distinct knowledge requirements that firms need to fulfil in order to 
innovate. Firms carry out in-house R&D with at least two clear goals in mind: they 
can exploit their existing knowledge base, or enter more complex explorations for 
knowledge residing outside it. Different knowledge requirements, in turn, relate to 
specific R&D outcomes along the different stages of the innovation process 
characteristic of an industry, even a country. In this case, our discussion in chapter 5 
indicated that Mexican pharmaceuticals concentrate in the segment of generic 
drugs. R&D therefore needs to be interpreted in terms of incremental innovations 
on existing drugs, pharmaceutical products more broadly defined. 
The empirical analysis revealed some positive linkages between human 
resource management practices and learning at firm level. Differences in the nature 
of R&D lead to distinct knowledge requirements and consequently, demands and 
roles for the human resources shaping an organisation. The number of relevant 
practices and their corresponding influence diverged contingent on both the 
novelty of the knowledge required by the firm, and the expected outcomes from 
R&D. In line with the literature on human resource management and new product 
development, R&D for new drug designs was positively associated with training and 
remunerations (Christensen and Lundvall 2004). Those studies stress that in the 
context of new product development, human resource management approaches 
condition creativity, risk taking and exploration. Such approaches assist in 
channelling and enhancing knowledge and skills of the personnel involved.  
In addition to the above, this chapter disclosed some positive impacts of human 
resource management practices on R&D for new process innovation, technical 
change more broadly defined (Greenan 2003). The provision of training, worker’s 
remuneration and incorporation of workers into decision making supported R&D for 
the design or improvement of machinery for the firm’s own use. To the best of our 
knowledge, this is one of the first studies documenting this issue in the context of 
developing countries. The structure of our data prevented further investigation into 
this finding; nevertheless, it is relevant considering that process innovations enjoy a 
significant share of innovations in developing countries. Even in contexts where 
most innovation activities are perceived as incremental, management strategies can 
contribute to learning and capability building. 
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As for the specific personnel management interventions, and in light of the 
hypotheses presented in chapter 3, some relevant findings are as follows: The 
provision of training systematically exerts positive effects on the likelihood that a 
firm pursues R&D; hence hypothesis H1 is confirmed. This result was robust to 
changes in either the construction of the variable on training, or on the model 
specification. The finding supports Domínguez and Brown’s (1998) and Samstad and 
Pipkin’s (2005) views on that training and general qualifications of the labour force 
dictate the type of management practices that are needed and that can be 
implemented in countries such as Mexico. Raising skill levels facilitates adoption of 
advanced management systems by Mexican firms. The empirical results equally 
support the pertinence of promoting interactions between firms and other external 
agents, at least for the provision of R&D-relevant training. External provision of 
training is a relevant mean for firms to acquire new knowledge and expand existing 
knowledge bases. Further research should shed light on the nature of the 
knowledge flows being actually involved. However, the interviews conducted 
among Mexican firms suggest that interactions are broad; they include learning 
about new excipients and formulations, to methodologies for the synthesis of 
chemical ingredients (Interviews with firms 06). For some firms however, external 
training increasingly provides understanding of advanced research methodologies 
and applications, particularly in areas such as biotechnology (Interviews with firms 
03 and 10). Overall, hypothesis H2 was confirmed. 
The literature review in the first part of chapter 3 highlighted that adequate 
compensation and reward for performance are core ingredients of strategies 
promoting enhanced performance. Estimates in this chapter revealed that raising 
remunerations increases the probabilities that a firm does R&D, particularly for 
knowledge exploration; however, the effect was not robust. Consequently, whereas 
hypothesis H3 is only partially supported, hypothesis H4 seems more plausible. 
Remunerations underpin learning but only under certain conditions and for specific 
types of R&D. However difficult to corroborate based on data used here, a possible 
explanation results from the frequent limits imposed on pecuniary remunerations, 
more specifically wages, in countries such as Mexico. Interviewees at both Mexican 
and multinational pharmaceutical firms expressed that beyond certain threshold, 
subsequent wage increases for an individual can alter the overall compensation 
structure of the firm. The local environment contributes to wage stickiness; the 
pharmaceutical industry in Mexico is already one of the industries with the best 
wages and overall compensation.  
Factors such as enhanced training and/or promotion opportunities become 
equally or even more relevant as reward mechanisms. This is in either foreign 
affiliates or Mexican pharmaceutical firms. Some firms accept to sponsor specialised 
postgraduate training, for up to a year in private universities, for key personnel 
(Interviews with firms 08 and 11). In other cases, remunerations act more as 
mechanisms determining labour mobility within the pharmaceutical industry; thus 
promoting a continuous transfer of research capabilities, however limited, within 
the industry (Interviews with firms 05, 10 and 13). In the aggregate, the positive 
effects on the firm attracting the employee cancel out by the negative impact on 
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the one loosing him/her. 
Somewhat inconclusive results were drawn in the case of worker’s 
empowerment. The practice was positive only in the case of exploration-related 
R&D underpinning adoption of new drug manufacturing processes. This is at odds 
with previous literature where delegation of decision-making capacity is key 
ingredient for new product development; empowering people fosters creativity and 
discovery (Mumford 2000). A possible explanation relates to the traditional 
perception that paternalistic work environments, rigid and hierarchical 
organisational structures, such as those generally found in Mexico and other similar 
countries, hinder good performance.  
Nevertheless, as stressed in chapter 4, the nature of drug manufacturing 
processes introduces some limits to a worker’s capacity to influence the way R&D is 
pursued. Concerns over product quality and safety lead to close scrutiny and 
approval, by sanitary authorities, of practically every step of the drug manufacturing 
process. Sanitary regulations limit the capacity to change both existing drugs and 
the corresponding manufacturing processes. Any alteration in either of them can 
lead to additional reviews and need to obtain approval by regulatory authorities. 
FDA (2004a, b) recognizes that this can be cumbersome for the firm; and a major 
barrier for process innovation in the pharmaceutical industry. In the context of 
countries specialised in the manufacturing of generic drugs, development of such 
products is restricted by the need to comply with specific parameters and qualities 
set by the drug innovator. If firms are required only to reproduce the knowledge 
behind such products, it makes little sense to empower workers and allow them to 
play around with the technology. 
Some final comments in relation to the control variables are noteworthy. The 
findings here contradict the usual perception that foreign firms are more 
technologically dynamic than domestic firms. After all, the literature documents the 
frantic behaviour of global pharmaceutical firms regarding technology acquisition 
and new drug development. However, the choice of the relevant performance 
indicators is important. In terms of R&D, a careful reflection points to the position 
that developing countries, such as Mexico, occupy within overall business and 
innovation strategies of multinationals. Affiliates maintain a low profile; rather they 
assist in the exploitation of knowledge generated at the parent location or 
elsewhere in the developed world (von Zedtwitz and Gassmann 2002). The new 
knowledge demanding R&D activities are seldom carried out in developing 
countries. Affiliates in developing countries maintain a low, indeed modest, profile 
when it comes to R&D performance.  
By contrast, exposure to external competition and larger market opportunities 
was found to increase the likelihood that domestic firms pursue R&D. The strongest 
effect was associated with new drug designs. In line with Kale and Little’s (2007)’s 
findings in the case of India, the managing director of an affiliate of Indian origin in 
Mexico stressed the significant boost that Indian firms have received from their 
decisive export orientation. He argued that “Success requires strong commitment of 
financial and human resources, particularly in research. The goal is to develop a 
portfolio of products to be launched in export markets over a significant time 
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horizon”. In the case of Mexican pharmaceutical firms, strong reliance on the local 
pharmaceutical market inhibits incentives to innovate; human resource 
management strategies aim largely to increase productivity and efficiency. In other 
words, adoption of modern organisational practices simply contributes to the 
making of what Cimoli (2002) identifies as a “global modern manufacturing centre”. 
The analysis presented in this chapter is only a partial one. As documented in 
Chapters 4 and 5, respectively, innovation in the pharmaceutical industry is highly 
globalised; firms cannot afford to rely, exclusively, on internal technological efforts. 
Rather, firms increasingly interact with and attract knowledge from external 
sources. These observations raise questions about the extent to which the results in 
this chapter remain once firms are allowed to participate in external markets for 
knowledge. Chapter 7 and 8 address this question. The analysis is as follows: first 
chapter 7 looks at the extreme case in which firms transfer responsibility for 
technology development to external agents; firms assume a passive stance vis-à-vis 
learning and innovation. Then, chapter 8 introduces further reality by bringing 
together internal and external learning strategies adopted by pharmaceutical firms 
in Mexico. Against these alternative backgrounds we examine the contribution of 
human resource management variables.  
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Table 6.3: Summary statistics for the Pharmaceutical industry in Mexico, 2004 
 Mean Std Dev Min Max 
R&D in-
house 
R&D3  
(I) 
No R&D4 
 (II) (I)/(II) (I) (II) (I) (II) (I) (II) 
Employment  475.7 331.2 1.4 555.2 259.1 1.1 63 3391.5 1158.4 
Total sales1  694.1 433.0 1.6 1270.9 694.9 2.4 12.1 6958.0 2297.0 
 Domestic 
sales 609 394.5 1.5 1055.3 634.7 2.4 0 6334.5 2069.8 
 Export share  .07 .08 0.9 .13 .20 0 0 .69 1 
Share of FDI  .30 .34 0.9 .46 .48 0 0 1 1 
Age2 33.2 27.5 1.2 19.4 16.6 1 0 74 70 
rd_improve_process R&D5 No R&D6 (I)/(II) (I) (II) (I) (II) (I) (II) 
Employment  492.5 344.3 1.4 589.2 261.3 1.1 63.0 3391.5 1158.4 
Total sales1  7414.9 427.5 1.7 1354. 641.4 2.4 12.1 6958.0 2297.0 
 Domestic sales 656.7 375.3 1.8 1120.7 583.4 2.4 0.0 6334.5 2069.8 
 Export share  0.1 0.1 0.6 0.1 0.2 0.0 0.0 0.6 1.0 
Share of FDI  0.3 0.3 0.9 0.5 0.5 0.0 0.0 1.0 1.0 
Age2 33.2 29.2 1.1 20.6 15.1 1.0 0.0 74.0 70.0 
rd_design_meq R&D7 No R&D8 (I)/(II) (I) (II) (I) (II) (I) (II) 
Employment  655.0 388.3 1.7 804.2 386.7 2.2 1.1 3391.5 2852.9 
Total sales1  1140.1 508.0 2.2 1808.1 914.3 31.9 2.4 695.8 6772.2 
 Domestic sales 919.5 469.3 2.0 1307.2 856.1 31.9 0.0 4359.9 6334.6 
 Export share  0.1 0.1 1.4 0.2 0.1 0.0 0.0 0.6 1.0 
Share of FDI  0.3 0.3 0.9 0.5 0.5 0.0 0.0 1.0 1.0 
Age2 39.2 30.0 1.3 17.7 18.7 16.0 0.0 74.0 72.0 
rd_drug_improveme
nt R&D9 No R&D10 (I)/(II) (I) (II) (I) (II) (I) (II) 
Employment  496.6 324.7 1.5 577.4 261.5 1.1 63.0 3391.5 1158.4 
Total sales1  738.0 409.4 1.8 1328.8 653.9 2.4 7.8 6958.0 2297.0 
 Domestic sales 654.1 358.1 1.8 1101.8 587.8 2.4 0.0 6334.5 2069.8 
 Export share  0.1 0.1 0.6 0.1 0.2 0.0 0.0 1.0 1.0 
Share of FDI  0.3 0.3 0.9 0.5 0.5 0.0 0.0 1.0 1.0 
Age2 34.2 26.8 1.3 19.8 15.9 1.0 0.0 74.0 70.0 
rd_drug_design R&D11 No R&D12 (I)/(II) (I) (II) (I) (II) (I) (II) 
Employment  526.1 297.4 1.8 592.1 238.0 2.2 1.1 3391.5 1158.4 
Total sales1  765.7 403.3 1.9 136.8 631.2 2.4 7.8 695.8 2297.0 
Domestic sales 676.5 356.6 1.9 1134.4 564.4 2.4 0.0 6334.5 2069.8 
Export share  0.1 0.1 0.7 0.1 0.2 0.0 0.0 0.7 1.0 
Share of FDI  0.3 0.3 0.8 0.5 0.5 0.0 0.0 1.0 1.0 
Age2 34.6 27.1 1.3 19.9 16.2 1.0 0.0 74.0 70.0 
R&D_exploitation R&D13 No R&D14 (I)/(II) (I) (II) (I) (II) (I) (II) 
Employment  475.9 344.3 1.4 560.7 276.6 1.12 63 3391.5 1158.4 
Total sales1  708.4 421.9 1.7 1291.8 665.5 2.4 
12.
1 695.8 2297.0 
Domestic sales 626.2 372. 1.7 107.1 607.8 2.4 0 6334.5 2069.8 
Export share  .1 .1 1 .1 .2 0 0 .6 1 
Share of FDI  .3 .4 0.7 .4 .5 0 0 1 1 
Age2 33.3 27.7 1.2 19.7 16.1 1 0 74 70 
R&D-exploration R&D15 No R&D16 (I)/(II) (I) (II) (I) (II) (I) (II) 
Employment  488.1 319.0 1.5 565.6 249.1 1.12 63 3391.5 1158.4 
Total sales1  705.5 437.6 1.6 1292.8 693.5 2.4 7.7 6958.0 2297.0 
 Domestic sales 620.6 393.4 1.6 1073.9 623.6 2.4 0 6334.5 2069.8 
 Export share  .1 .1 1 .1 .2 0 0 .7 1 
Share of FDI  .3 .3 1 .5 .5 0 0 1 1 
Age2 33.6 27.2 1.2 19.4 16.7 1 0 74 70 
Firms in sample: 112; 1. Million Mexican pesos; 2. difference between the year in which a firm started operations in 
current business and the year of the survey, 2004; Number of firms: 3. (83); 4. (29); 5. (71); 6. (41); 7. (21); 8. (91); 9. 
(74); 10. (38); 11. (69); 12. (43); 13. (80); 14. (32); 15. (79); 16. (33). 
Source: Author with information from ENESTYC 2005, INEGI   
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Table 6.4: Frequency analysis of the explanatory and control variables included in the analysis 
 
rd_inhouse 
rd_design 
_meq 
rd_improve 
_process 
rd_drug 
_design 
rd_drug_impro
vement 
rd_exploi
t 
rd_explor
e 
 no yes no yes no yes no yes no yes no yes no yes 
train04               
No 8 4 12 0 9 3 9 3 8 4 8 4 9 3 
Yes 21 79 79 21 32 68 34 66 30 70 24 76 33 67 
inter-
nal_external_tr               
No 8 4 12 0 9 3 9 3 8 4 8 4 9 3 
Internal 5 11 14 2 7 9 9 7 6 10 5 11 9 7 
External 3 9 12 0 5 7 4 8 4 8 4 8 4 8 
Both 13 59 53 19 20 52 21 51 20 52 15 57 20 52 
imp_empowerm
ent               
Not implemented 20 50 63 7 29 41 30 40 25 45 21 49 30 40 
Very important 5 8 8 5 7 6 7 6 6 7 6 7 6 7 
Not important 4 25 20 9 5 24 6 23 7 22 5 24 6 23 
ln_avg_rem 4.5 4.8 4.7 4.9 4.6 4.8 4.5 4.9 4.5 4.8 4.6 4.8 4.5 4.8 
rem_size  6.31 7.03 6.6 8.1 6.5 7.0 6.1 7.3 6.2 7.2 6.4 7.0 6.2 7.2 
modern_practice               
No 12 25 31 6 18 19 18 19 14 23 12 25 17 20 
Yes 17 58 60 15 23 52 25 50 24 51 20 55 25 50 
export_dummy               
No 17 35 44 8 21 31 26 26 20 32 17 35 25 27 
Yes 12 48 47 13 20 40 17 43 18 42 15 45 17 43 
fdi               
No 19 58 62 15 27 50 28 49 25 52 20 57 27 50 
Yes 10 25 29 6 14 21 15 20 13 22 12 23 15 20 
Total 29 83 91 21 41 71 43 69 38 74 32 80 42 70 
Source: Author with information from ENESTYC, 2005; INEGI 
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Table 6.7: Changes in probabilities and marginal effects for models in Table 6.6 
 (1) min->max (2) 0->1 (3) -+1/2 (4) -+sd/2 (5) MargEfct1 (6) MargEfct
2,a 
rd_impr_proc      0.642 
train04 0.418 0.418 0.394 0.127 0.412 0.418(0.146)*** 
rem_size 0.199 0.025 0.024 0.070 0.024 0.024(0.019) 
imp_empowerment -0.101 -0.050 -0.050 -0.035 -0.050 -0.050(0.080) 
modern_practice 0.192 0.192 0.187 0.089 0.189 0.192(0.123) 
export_dummy 0.103 0.103 0.103 0.052 0.103 0.103(0.117) 
fdi -0.265 -0.265 -0.255 -0.120 -0.260 -0.265(0.128)** 
rd_design_meq      0.124 
Internal_external_tr 0.188 0.027 0.093 0.099 0.092 0.092(0.035)*** 
rem_size 0.218 0.008 0.023 0.069 0.023 0.023(0.011)** 
imp_empowerment 0.420 0.154 0.152 0.106 0.151 0.151(0.050)*** 
modern_practice -0.062 -0.062 -0.059 -0.028 -0.059 -0.062(0.081) 
export_dummy 0.042 0.042 0.042 0.021 0.042 0.0420.071) 
fdi -0.160 -0.160 -0.197 -0.091 -0.195 -0.1600.062)** 
rd_drug_imp      0.672 
train04 0.387 0.387 0.354 0.113 0.366 0.387(0.152)** 
rem_size 0.295 0.039 0.036 0.107 0.036 0.036(0.019)* 
imp_empowerment -0.093 -0.045 -0.045 -0.032 -0.045 -0.045(0.076) 
modern_practice 0.057 0.057 0.057 0.027 0.057 0.057(0.119) 
export_dummy 0.112 0.112 0.111 0.056 0.111 0.111(0.117) 
fdi -0.283 -0.283 -0.269 -0.127 -0.274 -0.283(0.132)** 
rd_design      0.642 
train04 0.437 0.437 0.413 0.134 0.433 0.437(0.161)*** 
rem_size 0.341 0.042 0.042 0.124 0.042 0.042(0.021)** 
imp_empowerment -0.092 -0.045 -0.045 -0.032 -0.045 -0.045(0.079) 
modern_practice 0.181 0.181 0.176 0.084 0.177 0.180(0.121) 
export_dummy 0.368 0.368 0.364 0.187 0.377 0.368(0.123)*** 
fdi -0.510 -0.510 -0.484 -0.238 -0.518 -0.510(0.136)*** 
Min->Max: change in predicted probability as x changes from minimum to maximum; 0->1: change in predicted prob-
ability as x changes from 0 to 1; -+1/2: change in predicted probability as x changes from 1/2 unit below base value to 
1/2 unit above; -+sd/2: change in predicted probability as x changes from 1/2 standard deviation below base to 1/2 
standard deviation above; MargEfect: partial derivative of the predicted probability/rate with respect to a given inde-
pendent variable. 1. Computed based on the method of discrete changes; 2. Computed based on the method of mar-
ginal changes; robust standard errors in parentheses; ***,**,* denote significance at the 1%, 5% and 10% levels, respec-
tively; a changes for binary variables from 0 to 1.  
Source: Author based on information from ENESTYC, 2005. 
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Table 6.8: Testing the influence of internal and external training on performance of in-house R&D 
Variable rd_inhouse rd_exploit rd_explore rd_improve 
_process 
rd_drug 
_design 
rd_drug 
_improvement 
training_internal 0.58* 0.70** 0.31 0.59* 0.24 0.40 
 (0.33) (0.32) (0.33) (0.32) (0.33) (0.32) 
external_training 0.63** 0.46 0.79** 0.50* 0.75** 0.35 
 (0.31) (0.31) (0.32) (0.31) (0.32) (0.31) 
rem_size 0.020 0.043 0.061 0.030 0.075 0.076 
 (0.060) (0.057) (0.058) (0.053) (0.058) (0.055) 
imp_empowerment -0.11 -0.15 0.035 -0.12 -0.11 -0.11 
 (0.24) (0.23) (0.22) (0.22) (0.22) (0.21) 
modern_practice 0.31 0.22 0.34 0.54* 0.52* 0.21 
 (0.35) (0.34) (0.31) (0.32) (0.32) (0.32) 
export_dummy 0.71** 0.42 0.99*** 0.23 1.01*** 0.28 
 (0.33) (0.34) (0.33) (0.32) (0.33) (0.31) 
fdi -0.94** -0.89** -1.31*** -0.63* -1.29*** -0.69* 
 (0.38) (0.38) (0.40) (0.35) (0.41) (0.36) 
Constant -0.56 -0.57 -1.21*** -0.90** -1.32*** -0.68* 
 (0.44) (0.43) (0.44) (0.42) (0.45) (0.41) 
Observations 112 
Log Likelihood Full -55.5 -59.3 -60.9 -65.9 -60.9 -66.4 
Χ
2 [7] 23.2*** 15.6** 30.1*** 14.1*** 29.3*** 11.5 
Cragg-Uhler R2 0.207 0.185 0.287 0.135 0.295 0.127 
Count R2 0.777 0.741 0.696 0.705 0.723 0.688 
Notes: Robust standard errors in parentheses, *** p<0.01, ** p<0.05, * p<0.1; Degrees of freedom within squared 
brackets.  
Source: Author with information from ENESTYC, 2005. 
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Chapter 7 
Learning from external markets for 
technology: Is there a role for human 
resource management practices? 
 
 
 
1. Introduction 
 
Chapter 3 argued that learning and innovation are interactive dimensions spanning 
both the physical and cognitive boundaries of a firm. It is therefore not surprising to 
find scholars being interested in exploring how firms, including those in developing 
countries, respond to both the challenges and opportunities associated with 
external markets for technology (Arora et al. 2001; Archibugi and Pietrobelli 2003). 
The task is complex, as interactions differ in nature--they range from cooperation to 
purely market based transactions--and imply different degrees of commitment by 
the firm. Distinct relationships require the mobilization of different kinds of 
resources by the firm.  
From the above, this chapter addresses the questions of whether human 
resource management practices contribute to learning from external markets for 
technology, and how they do so. Based on the discussion in chapter 1, the research 
hypothesis is that human resource management practices support innovation by 
conditioning, first, the way it learns from external knowledge sources; hence the 
pertinence to look at a firm’s interactions with external knowledge sources. In the 
spirit of chapter 6, relevant human resource management interventions are 
expected to vary depending on the type of knowledge pursued by the firm. This is 
one of the first systematic efforts to investigate this topic, particularly by adopting 
the perspective of developing countries (Chung-Jen, and Jing-Wen, 2009). 
The empirical analysis here abstracts from any formal learning efforts carried 
out in-house by the firm; it focuses exclusively on learning from external markets. In 
other words, as discussed in chapter 3, this chapter addresses the extreme case in 
which firms rely exclusively on external sources of technology.
1
 The remainder of 
the chapter proceeds as follows: Section 2 presents the data, the variables 
definitions and the research strategy. Section 3 contains the empirical results. 
Empirical evidence refers to the pharmaceutical industry in Mexico. The 
                                                 
1 The case when markets for technology are perceived as sources of supplementary knowledge inputs for 
a firm’s internal learning efforts is the subject matter of chapter 8. 
137
presentation is split into two sections. First, some descriptive statistics are provided 
about the pharmaceutical firms in Mexico based on two criteria: on the one hand, 
the table presents characteristics such as size, sales, employment and so on. On the 
other hand, the table identifies the type of human resource management practices 
adopted by firms. A second section contains the results from the econometric 
analysis. Section 4 discusses the results and presents the conclusions.  
 
2. Variable definitions and research strategy 
 
2.1. Dependent variables  
 
Data used in this paper come from the ENESTYC dataset described in chapter 3. The 
dependent variables, as originally defined in ENESTYC, are presented in table 7.1, 
part A. Based on Cassiman and Veugelers (2000 and 2006) some such variables were 
subsequently combined to generate three new generic indicators on external 
markets for knowledge– table 7.1, part B. Criteria for the aggregation was the form 
in which technology is acquired, whether embodied in physical artefacts or in a non-
physical form.  
 
Table 7.1: Means for technology acquisition from external markets: pharmaceutical firms in Mexico 
Variable Definition 
Part A:Variables in ENESTYC, 2005 
1. extrel_rd Firms carry out R&D in collaboration with other agents 
2. licensing Firms license technology 
3. tech_package Firms acquire technology packages 
4. tech_consultant_firm Firms hire consultant firms as a source of technology 
5. tech_literature Firms consult literature as a source of knowledge 
6. extrel_learn_inds Firms collaborate with other firms to learn about the conditions of the business envi-
ronment and other characteristics of the industry 
7. extrel_acq_machin Firms acquire machinery and equipment in collaboration with other firms in the industry 
Part B: Redefinition of variables for the econometric analysis 
8. external_mkt Firms acquire technology through at least one of the items 1-7 in Part A 
9. embodied  Firms acquire technology in an embodied form; includes items 3,4 and 7 
10. disembodied  Firms acquire technology in a disembodied form; includes items 1,2,5 and 6  
Source: Author based on information from ENESTYC, 2005 
 
External R&D: Innovation scholars pay considerable attention to contracted or 
joint performance of R&D as learning mechanism. This is the best proxy for what 
Arora et.al, (2001) and DOJ-FTC (6th April 1995) term the market for future technol-
ogy, the market for innovations. In this context, the literature documents some 
trend towards off-shoring of R&D activities by global pharmaceutical firms (Crossley 
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2004); internationalization is increasingly in the form of clinical research (Piachaud 
2002; Santiago 2009). Mexico and other developing countries face opportunities to 
participate mostly as investigative sites hosting clinical research (Interviews with 
trade2 and Insh3). As discussed in chapter 4 although clinical research is carried out 
mostly by foreign affiliates, some firms in host countries have also the capacity to do 
some such activities in connection with local hospitals and other specialised re-
search organisations. Last but not least, and even if this remains rather limited, 
some joint R&D is carried out between local companies and research institutions in 
connection to development or improvement of generic drugs and other pharmaceu-
tical products. The variable extrel_rd captures the performance of joint R&D by 
pharmaceutical firms in Mexico. Unfortunately, it does not specify the specific type 
of R&D the firm carries out with external agents. 
Technology licensing: Technology licensing, particularly of patents, is among the 
most common means to acquire technology. Depending on the conditions of the 
negotiation between the licensee and the licensor, the new knowledge can be used 
as input for further technological developments. Development however is 
conditioned by the relative distance between the new piece of knowledge and the 
licensee’s technological capabilities (Leone and Reichstein 2009). In other cases 
contracts limit the use of the new technology, effectively prohibit any modification 
by the licensee. Taking into account the importance of patents and licensing of 
technologies for the pharmaceutical industry (Nakamura and Odagiri 2005), analysis 
in this chapter introduces licensing as dependent variable. This is interpreted as a 
component of the market for existing knowledge (Arora et.al, 2001; DOJ-FTC 6th 
April 1995).  
Other external markets: Part A of table 7.1 includes some additional indicators 
on external markets. In general, the variables denote the acquisition of packaged 
technologies, tech_package; or the purchase of machinery in collaboration with 
other firms, extrel_acq_machin. The table also includes variables denoting the 
hiring of consultancy firms, tech_consutant_firm; access to specialised literature, 
tech_literature; and some collaborative learning activities among firms in the 
industry, extrel_learn_inds, for example via participation or in partnership with 
trade organisations.  
Generic variable on external markets: Merging both extrel_rd and licensing with 
the rest of indicators in Part A of table 7.1, generates a new variable, external_mkt, 
which denotes the participation of a firm in external knowledge markets. The 
variable takes the value of one if the firm carries out at least one of the activities 1-7 
in table 7.1. Otherwise, the variable is set to zero. The new variable indicates that 
the firm seeks to tap knowledge from external markets (Cassiman and Veugelers 
2000 and 2006). 
(Dis)embodied technologies: A frequent definition of technology acquisition 
considers its mode of transfer, whether in physical or ‘virtual’ form. In other words, 
whether the knowledge is incorporated in a tangible artefact, or separated from the 
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thing itself (Cassiman and Veugelers 2000). In the first case, we talk about embodied 
technologies; in the second, of disembodied technologies. Embodied technologies 
come in the shape of products, instruments, machinery and equipment, software or 
prototypes. Disembodied technologies, in turn, reflect trading of intangibles such as 
intellectual property rights. These allow the use of blueprints, designs, formulas, or 
contracted R&D. Depending on the nature of contracts disembodied technologies 
can sustain either the mere replication of whatever knowledge is obtained, or the 
mobilisation of resources to develop the technology further. Based on these 
considerations, the analysis in this chapter includes two new variables created using 
the information from the ENESTYC: embodied and disembodied (Cassiman and 
Veugelers 2000). The first variable merges items 3, 4 and 7 in table 7.1, and denotes 
acquisition of technologies in physical form. The second variable captures the 
acquisition of knowledge in disembodied form, items 1, 2, 5 and 6 in the same table.  
 
2.2. Independent variables 
 
Human resource management variables: This chapter explores the effects on learn-
ing from external markets associated with management practices such as the provi-
sion of training, remuneration for performance, worker’s participation in decision 
making about the work place, and the hiring of new staff. The definition of these 
variables and how they can impact on learning are described in chapter 3 in this 
thesis. Section 3.2 in chapter 3 explains variable constructions. 
Control variables: This Chapter controls for some firm characteristics including: the 
adoption of modern management practices; capital ownership, participation in 
export markets and size.  
 
2.3. Research Strategy 
 
The dependent variables used in this chapter are binary; they identify some means 
for pharmaceutical firms in Mexico to tap external knowledge. A suitable econo-
metric approach to study this type of decision variables is probit regression (Greene 
2003; Liao 1994). The analysis proceeded as follows: a basic model specification was 
identified using external_mkt as dependent variable. This is the reference to com-
pare results from models including other variables on learning from external 
sources. Similar to the analysis in chapter 6, we then iteratively changed the defini-
tion of the dependent variable. Considering the importance that the literature 
grants to R&D, licensing and the acquisition of embodied and disembodied tech-
nologies, the empirical analysis incorporates these variables.  
As for variables in the right hand side of the equation, similar to Michie and 
Sheehan (1999) and Laursen and Foss (2003), our analysis considered whether the 
provision of training was carried out by a staff member in-house (internal training), 
140
or by linking to some external provider (external_training). This alternative was 
preferred to using a general indicator on training, train04, as it rendered some finer 
information about the characteristics of the training provided. Nevertheless, 
introducing train04 in the regressions rendered similar results to those reported in 
section 3. Finally, a series of models enquired about the influence of human 
resource management interventions once we distinguish the specific partner 
assisting the firm in the provision of external training. This chapter reports models 
where external training is provided by individual consultants, private and public 
universities, public research centres, machinery suppliers, and training centres 
linked to local trade organisations of the pharmaceutical industry. Each of these 
variables was combined with internal_training. The exercise served two goals. First, 
it suggested the kind of knowledge flows obtained through external training. 
Second, it shed light on the robustness of results. 
This chapter also reports the computation of marginal effects for the models in 
the analysis. Additional checks were performed to ensure accuracy and robustness 
of results. First, each dependent variable was regressed on the human resource 
management variables only; this tested the extent to which such variables capture 
the learning behaviour of pharmaceutical firms in Mexico. Likewise, we ran models 
including only the explanatory and control variables showing some statistical 
significance, at a maximum 5 per cent confidence level, in the basic model for each 
dependent variable.
2
  
 
3. Empirical results 
 
3.1. Participation in external markets for knowledge 
 
Table 7.2 presents the learning behaviour of pharmaceutical firms in Mexico. The 
industry shows a fairly diversified use of external sources of knowledge. In 2004 
some 60.7 percent of firms participated in such markets. However, the most fre-
quent learning mechanism was technology acquisition in disembodied form. Within 
this, the most important item was consulting specialised literature with about a 
third of firms reporting that activity. After specialised literature, performance of 
joint R&D and technology licensing ranked second and third as sources of disem-
bodied knowledge, with some 25.9 and 18.8 percent of firms, respectively. Limited 
joint R&D and licensing indicate the low efforts aimed at building learning capacities 
by pharmaceutical firms in Mexico. In fact collaboration, particularly for the per-
formance of R&D, is rather low in the local industry. The latter characterises by 
                                                 
2 For reasons of space, the results from models including variables with significance at the 5 percent level 
or lower are omitted from presentation. However, estimates were similar to those reported here.  
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limited interactions underpinning the capacity to generate future knowledge flows 
and potential innovations. This finding coincides with the discussion in Chapter 6. 
As for the acquisition of embodied technology, this was carried out by some 
35.6 percent of firms in the sample. In this case, the most important type was the 
purchase of packaged technology, 26.8 percent of firms. Hiring consultant firms and 
acquisition of machinery and equipment through collaborative relations followed. 
Some 25.0 percent and 13.4 percent of firms, respectively, made use of these 
mechanisms.  
Table 7.2 also identifies pharmaceutical firms based on indicators such as 
employment, sales, exports, foreign ownership, size and age. Moreover, firms are 
classified by type of external market. Larger firms, in terms of both size and sales, 
participate actively in markets for technology. Sales per employee for this group of 
firms are 1.2 times larger than those corresponding to firms reporting no external 
technology acquisition at all. The bulk of sales for both groups of firms stem from 
the domestic market.  
Table 7.2 suggests that exports are of little relevance as factor motivating 
learning from external markets; sales of pharmaceutical firms are directed mostly to 
the Mexican market. Exports are equal to only 10 percent of total sales. This 
notwithstanding, one should remember that the econometric analysis in Chapter 6 
revealed that exports stimulate knowledge exploration—particularly for new drugs; 
through in-house R&D. Would exports condition learning from external markets in 
particular ways? 
Table 7.2 suggests that foreign capital ownership conditions negatively learning 
activities in the pharmaceutical industry in Mexico. In general, the share of foreign 
capital is larger for firms reporting no learning activities, about 40 percent. Notable 
exception is learning via licensing where foreign owned firms are more active. 
Chapter 5 suggested commercial reasons as being among the main drivers for 
technology licensing; foreign affiliates take patents that back sales of innovative 
drugs in the Mexican market. The strengthening of IPRs following endorsement of 
the TRIPS Agreement by Mexico, may have increased the cost of licensing, affecting 
negatively incentives for investment in R&D and productive capacity by domestic 
firms (Guzmán et.al, 2005). Firms that license technology reported sales which are 
considerably larger relative to those of firms that do not license technology at all. 
Unfortunately, neither the ENESTYC nor the interviews provided evidence about the 
characteristics of licensing contracts established by pharmaceutical firms in Mexico. 
Hence, it is difficult to conclude anything about how likely are firms in the local 
industry to subsequently enhance the licensed technology. 
Table 7.3 presents the correlation analysis of the variables on external markets 
used in this chapter. The table corroborates the perceived importance of 
disembodied technologies for pharmaceutical firms in Mexico. Reading of 
specialised literature accounts for most of the learning in disembodied form. Joint 
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R&D and licensing come second and third within this specific kind of learning 
strategy. Overall, table 7.3 shows that the different sources of external technology 
are poorly correlated among themselves. The strongest correlation is observed 
between the acquisition of packaged technologies and the hiring of consultant 
firms. This finding suggests that interactions between pharmaceutical firms and 
technology suppliers in Mexico occur mostly via market transactions. Purchases of 
technology require specialised assistance to install and ready the new machinery 
and equipment. Joint R&D is poorly connected to the rest of technological activities 
in the local industry. 
 
3.2. Human resource management practices by source of external knowledge 
 
Table 7.4 presents the independent and control variables used in this chapter ar-
ranged according to the distribution of firms among types of external learning 
strategies. The table corroborates the high frequency with which pharmaceutical 
firms in Mexico provide training to staff. The likelihood that training takes place by 
means of both internal and external knowledge providers is high as well. Internal 
knowledge diffusion is supplemented with external knowledge through training. 
Interviewees at firm 03 and 06 suggested that suppliers of APIs and other raw mate-
rials contribute significantly to learning; they provide knowledge about new sub-
stances, possible combinations and how they can be used to expand development 
and formulation opportunities. This is together with knowledge about new machin-
ery and equipment.  
Chapter 1 argued that by capturing part of the supply of human resources 
available in the market, firms influence developments in S&T-related labour 
markets. Table 7.4 reveals that firms that participate in external technology markets 
tend to adopt some specific regulation to govern hiring practices. Interviews with 
firms in the industry showed that as firms grow larger and particularly for positions 
requiring higher skill levels, staffing processes become more systematic and 
carefully conducted (Interviews with firms 08 and 15). Prospective employees 
undergo long and strict selection processes, some time spanning several months 
and entailing several interviews with different people within the hiring organisation. 
One can also perceive that acquisition of disembodied technologies coincides with 
the largest frequency of firms that have specific regulations to guide staffing 
practices. At the same time, firms performing joint R&D or technology licensing 
report some of the lowest propensity to regulate staffing practices. These 
observations do not imply causality between these variables. 
Table 7.4 shows that adoption of modern organisational practices is frequent 
for firms that use external sources for knowledge. The largest frequency 
corresponds to firms that incorporate disembodied technologies. Note that there is 
no evident difference in the distribution of firms, by size, according to export 
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behaviour. Nevertheless, firms that both export and carry out some kind of learning 
activity are relatively fewer in number.  
 
3.3. Econometric results  
 
Table 7.5 presents the findings from the econometric analysis. The Wald tests for 
the value of X
2
 different from zero confirm that the models are statistically signifi-
cant at standard confidence levels. The values of the count R
2
 scalar, which is a brief 
indication of the predicting power of the models, are also adequate (Long and 
Freese 2006). As a final indication on the goodness of fit, the values of the Cragg-
Uhler R
2
 suggest that the models with the full set of explanatory variables suffi-
ciently explain the learning behaviour of firms (Long and Freese 2006). The excep-
tion is the models for acquisition of technologies in embodied form; those models 
failed to provide statistically meaningful information about the learning behaviour 
of pharmaceutical firms. 
Model (1) in table 7.5 shows the isolated effects of the human resource 
management variables on external acquisition of technology. Workers’ 
empowerment and adoption of specific rules to govern staff hiring, respectively, 
seem to influence learning. By contrast, none of the training indicators provides 
meaningful information about their influence of learning. Incorporation of the full 
set of variables, model (2), results in the control variables taking the explanatory 
power. Estimates for individual management variables indicate that neither has 
perceptible effects on learning. This holds even in the case of the provision of 
training. These results fail to support the expectation—see chapter 3--; that human 
resource management practices will positively and significantly affect learning. 
Computation of marginal effects for the full specification model leads to similar 
conclusions. Notwithstanding these disappointing results, by looking at the more 
detailed definitions of markets for technology, the findings become somewhat more 
revealing. This is presented in the next paragraphs. 
 
3.3.1. Embodied and disembodied knowledge acquisition 
 
Table 7.5 presents the results for models including technology acquisition in either 
embodied or disembodied forms. Since the models including embodied 
technologies obtained non-statistically significant results, the discussion focuses on 
the estimates for models with acquisition of disembodied technologies as 
dependent variable. The Models are statistically significant at the one percent level; 
their predictive power is also acceptable (Cassiman and Veugelers 2006). These 
results reflect the previous finding that incorporation of disembodied technologies 
is the preferred external source of knowledge of pharmaceutical firms in Mexico.  
Individual estimates show that both adoption of modern organisational 
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practices and exports impact positively on learning from external sources. By 
contrast, foreign ownership reduces the probability that a firm learns by means of 
disembodied knowledge. Estimates for the variables on human resource 
management practices indicate that rule_hiring is the single variable with 
statistically significant effects on learning. Adoption of formal procedures to regulate 
staffing practices increases the likelihood that a pharmaceutical firm incorporates 
disembodied technologies. Unfortunately, none of the remaining management 
practices reported statistically significant effects; computation of marginal effects 
corroborates these conclusions. We explored further these findings by looking at the 
indicators on joint R&D and technology licensing.  
 
3.3.2. Markets for innovation: joint R&D  
 
Table 7.5 contains the results for models with joint R&D as dependent variable. The 
models reveal a good explanatory power across the alternative model specifications. 
In line with the notion of knowledge exploitation, estimates for individual variables 
indicate that foreign ownership influences negatively the propensity to learn via 
engagement in collaborative R&D. R&D in general, and collaboration for R&D are 
not relevant components of business strategies of multinational affiliates in Mexico. 
Neither exports nor the adoption of modern organisational practices provided some 
statistically meaningful information. By contrast, regulation of staffing practices 
revealed some positive and statistically significant effects on joint R&D. 
Computation of marginal effects corroborates these results.  
 
3.3.3. Markets for technology: licensing 
 
Models (9) and (10) in table 7.5 present results for models with licensing as 
dependent variable. Estimates show that adoption of modern organisational 
practices has no perceptible effect on licensing. Surprisingly, and contrary to our 
expectations, the control for capital ownership rendered no statistically significant 
information. By contrast, exports reported positive and significant impacts on 
licensing. The variables on human resource management variables indicate that 
remunerations and staff hiring mechanisms are the most influential on learning. The 
effect however, is no robust to inclusion of the control variables; when the latter 
enter the equation, the variables on human resource management report no 
perceptible influence on learning from external markets. The computation of 
marginal effects confirmed these findings. The enquiry of the extent to which 
technology licensing is accompanied by internal learning efforts is postponed to 
chapter 8. 
The analysis so far reveals that human resource management variables have 
limited influence on the learning from external knowledge sources by 
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pharmaceutical firms in Mexico. We observe that the variables denoting a firm’s 
characteristics seem to explain learning from external markets. Particularly 
intriguing is the lack of statistical significance of variables such as the provision of 
external training. In the innovation literature, including that about Mexico, external 
training usually stands out as the main reasons for manufacturing firms to 
collaborate with education and research institutions. In order to explore further this 
issue, the variable on external training was split into some different training 
providers a firm can associate with. Results are presented in the following section. 
 
3.3.4. Learning from distinct training providers 
 
This section explores the effects of the linkages of pharmaceuticals with 
organisations such as universities, public research centres, other firms, and 
individual consultants. The analysis focuses in the provision of R&D-relevant 
training.
3
 The results from these models are presented in tables 7.6-7.9 at the end of 
the chapter. In general the models turned out statistically significant at customary 
confidence levels; nevertheless, those where acquisition of embodied technologies 
was used as dependent variable failed to provide meaningful results.
4
 Consequently, 
the following comments concentrate on the former group of models. 
Models with external_mkt as independent variable (table 7.6), revealed that 
the variables on adoption of modern organisational practices and foreign ownership 
systematically influence learning from external markets. However, the 
corresponding individual effects show opposite signs. Regarding management 
practices, rule_hiring was positive and statistically significant whenever training is 
provided in connection with centres attached to local trade organisations. The 
marginal effects associated with adoption of the latter variable were also relevant. 
Strikingly, none of the training variables identifying traditional knowledge producers, 
universities and research centres, provided statistically meaningful information to 
explain learning by firms. By contrast, the hiring of individual consultants supported 
learning from external markets. 
Models using the variable on acquisition of disembodied technologies, table 
7.7, corroborated some of the results presented in section 3.3.1. Both the adoption 
of modern organisational practices and exposure to external competition through 
exports motivate firms to acquire technology. The opposite effect is observed in the 
case of foreign ownership. Among the variables on human resource management, 
rule_hiring and training in connection with individual consultants were the only 
variable with some statistically significant effects on learning.  
Turning to joint performance of R&D, the models showed that management 
                                                 
3 During the analysis two distinct sets of models were run; the main difference was the presence or 
absence of internal training provision. Results were similar to those reported here. 
4 Full results are available from the author upon request. 
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practices have really poor explanatory power, with the exception of rules governing 
hiring practices—table 7.8. Foreign ownership revealed negative and statistically 
significant effect on the likelihood that a firm performs external R&D.  
In the case of technology licensing –table 7.9, the estimates revealed that 
whereas foreign ownership lost the statistical significance observed in previous 
models, exposure to competition through exports gained relevance to explain 
licensing by pharmaceutical firms in Mexico. From a management perspective, 
regulations applicable to hiring practices increase the likelihood of technology 
licensing. Regarding the provision of training, none of the variables used in the 
analysis turned out statistically significant. 
 
4. Discussion and concluding remarks 
 
Firms face difficulties to internalise all the resources and efforts needed to produce 
and commercialize new technology. A firm’s innovative capacity is constrained by its 
ability to interact with external organisations offering some complementary assets. 
Thus the interest in learning about factors conditioning the development and 
functioning of external markets for knowledge. Previous research documents the 
complexities involved in setting straight boundaries between different types of, 
transmission channels and ways to appropriate knowledge. External markets are 
heterogeneous; they include activities with different degrees of technological 
content and proprietary rights, from specialised literature and acquisition of modern 
machinery and equipment, to technology licensing. Firms can perform R&D to 
jointly explore new markets, tackle promising technological and business 
opportunities, or develop new knowledge underpinning innovation. Cooperative 
and purely market-based interactions mediate knowledge exchanges within and 
across systems of innovation. 
External markets for knowledge involve firms with different levels of 
technological capabilities. Considerable attention focuses on firms that act as both 
producers and consumers in external markets for knowledge. Such firms tap into 
existing knowledge stocks while contributing to advancement of the technological 
frontier in specific sectors or industries. To a large extent, available studies involve 
large multinationals in high-technology industries such as electronics, 
pharmaceuticals and biotechnology. However the literature documents that in 
alternative contexts, firms can also benefit from technology markets. Arguably, 
those markets open windows of opportunities for improved performance and 
growth of firms in catching up modes. External markets provide complementary 
assets for latecomer firms facing more limited technological capabilities and 
learning efforts (Santamaría et.al, 2009).  
In this context, this chapter documented that during 2004 approximately two 
thirds of pharmaceutical firms in Mexico made use of external technology markets. 
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Whereas this seems positive, a careful look at individual activities revealed that the 
complexity of learning activities of the local pharmaceutical industry is relatively 
limited. Most activities involve knowledge exploitation; firms learn by replicating 
existing knowledge, or by adapting and incorporating technologies developed 
elsewhere into everyday processes. External markets support searches for short-
term efficiency gains with limited demands and incentives to expand a firm’s 
customary knowledge base (March 1991).  
Learning by pharmaceutical firms in Mexico usually takes place through the 
reading of specialised literature. In such a way development staff gets acquainted 
with new ways to synthesize and replicate knowledge supporting manufacturing of a 
given drug (Interview with firms 05 and 06). Particularly in the case of off-patent 
drugs, consulting professional journals, blue-prints and other specialised literature 
grants knowledge about analytical methodologies, the pharmochemical and 
biological properties of the compound-- parameters such as dissolution, absorption 
and excretion curves--; the characteristics of excipients and other raw materials 
required to (re)formulate the drug. This strategy often leads companies to build 
libraries in-house, subscribe to specialised journals or to actively promote Internet 
usage. In such context, personnel characteristics such as experience and educational 
background constitute key ingredients to adequately perform learning activities. 
In line with traditional transaction cost theory, this chapter assumed firms to 
adopt external learning strategies independently of domestic technological efforts; 
firms avoid the risks and costs involved in developing new technologies. Next we 
enquired about the contribution of management practices to learning. The results 
from the econometric analysis indicated both the limited explanatory power of the 
models, and the difficulties to conclude on the influence of management practices 
on learning. In fact, firm characteristics had a stronger explanatory power. This 
notwithstanding, it is possible to draw some conclusions from the analysis. 
Based on the literature, the expectation is that firms with stronger learning 
behaviours should perform better than those revealing more passive stances. Our 
analysis suggests this needs a careful interpretation. Pharmaceutical firms that 
participated in technology markets tended to perform better, in terms of sales and 
employment, than those with no learning activities; nevertheless, the advantage 
was modest. Major differences corresponded to firms reporting the use of 
technology licensing as learning mechanism. In those cases, total sales, and more 
specifically those leveraged from the local market, were nearly three times larger 
than those recorded by firms that do not license technology. It seems that it all 
depends on the kind of learning activities and how these are carried out by the firm. 
Bell (1984) for example, distinguished two possible ways for individuals and 
organisations to learn. Learning can involve dynamic processes of acquisition and 
accumulation of technical knowledge and skills, firms constantly nurture their 
knowledge bases. Alternatively, learning can reflect “patterns of change in the 
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performance of production activities”
5
 (p. 187). (Increased) efficiency in task 
performance, productivity gains and so on, indicate that learning in the first sense is 
occurring. However Bell (1984) qualified this conclusion as potentially misleading. 
Observed improvements may arise out of knowledge accumulation taking place 
elsewhere along the supply chain; good performance occurs without enrichment of 
a firm’s knowledge base. Technology acquisition can lead to short-term efficiency 
and productivity gains, while masking processes of slow disarticulation of 
technological capabilities in the local industry (Kim et.al, 1989). Such processes 
potentially hinder future development prospects of the industry; by giving up 
internal learning efforts, firms preclude future capacity to explore and tackle 
technological and business opportunities.  
We also found that foreign ownership systematically and negatively influences 
learning by pharmaceutical firms in Mexico. The exception was the case of learning 
through technology licensing where fdi provided no statistical significance. In 
principle, this is an intriguing result considering the weight of multinationals in the 
Mexican pharmaceutical market. However, the information in table 7.4 showed that 
only a limited number of firms reporting FDI licensed technology.  
The positive effects of exports on the propensity to license technology are more 
important. However limited as a share of total sales of pharmaceutical products, 
estimates in table 7.5 showed that export behaviour explains better the propensity 
of a firm to license technology. Kim et.al, (1989) documented a similar situation in 
the case of Korea; a firm’s size induced positive effects on learning, particularly 
through licensing, when combined with export behaviour. Arora et.al, (2001) in turn, 
pointed out that competition in markets for goods can positively drive licensing. The 
finding is interesting as table 7.4 documents that licensing is not strongly connected 
to exports in Mexico, only a small number of firms reported participation in both 
those activities.  
The analysis in this chapter built on the notion that learning from different 
types of external markets requires distinct ways to mobilise a firm’s resources. 
Among the latter, the organisation of human resources was stressed as an area 
deserving more attention than is common in the literature. Accordingly, the 
discussion of results pertaining to variables on firms’ characteristics provided some 
context to interpret findings for those on human resource management. The 
analysis of the latter variables showed the relatively limited power they have to 
explain learning by pharmaceutical firms.  
In regard to individual variables, the regulations applicable to new staff hiring 
were the sole factor with a positive and statistically significant contribution to 
external learning. The finding is intuitive because hiring new staff normally assumes 
movements of knowledge embodied in people; in itself staff hiring is a mechanism 
                                                 
5 Stress in the original by the author. 
149
to acquire knowledge from external sources. The limited size of the Mexican market 
for skilled labour leads to strong competition for talent in the industry; firms 
frequently complained about the high labour mobility across firms. Introducing 
adequate and well defined guidelines to incorporate new staff becomes sort of 
prerequisite to learn from external sources (Interviews with trade2, firms 03, 05, 11 
and 13). By incorporating some sufficiently skilled and knowledgeable people firms 
can access, assimilate and implement new knowledge. There might be a lag 
between the moment of hiring and that in which actual organisational learning 
takes place. Based on the previous considerations, we positively confirm the 
research hypotheses H9-H10. 
As for the provision of training, it is intriguing the lack of statistical significance 
that, in general, was obtained from this variable. Literature on skill bias indicates 
that technical change frequently motivates training interventions in order to 
accommodate newly acquired technologies. This of course frequently implies some 
conscious learning efforts carried out internally by the firm. This is a dimension that 
chapter 8 will further explore; hence some more concrete conclusions are expected 
from the analysis there.  
Equally relevant from tables 7.6-7.9 was the dearth of a perceptible 
contribution of training from universities and research centres. As FCCT (2006) 
documents, those organisations carry out most research and technologically related 
activities in Mexico; some such knowledge can be transferred to firms via the 
provision of training (Casas 2005). Based on our interviews, we suggest some 
possible interpretations for these findings. A mismatch in orientation of both firms 
and public universities is frequently involved. Particularly in the case of public 
universities, bureaucratic burdens hinder flexibility and ability to respond to training 
requirements, especially when these do not necessarily lead to academic degrees 
(Interview with firms 05 and 06). In extreme cases, the mismatch reflects what Ruíz 
(2004) identified as a low esteem, even reticence of some major Mexican public 
universities to design study programmes by contacting and gaining feedback from 
the productive sector.  
By contrast, the findings point out that, under certain conditions, training 
provided by independent consultants, or through specialised centres related to 
some trade organisations, reported some positive results. This is symptomatic of the 
incremental nature of learning activities of pharmaceutical firms in Mexico; they 
obtain relevant knowledge by interacting with agents more directly connected to 
the industry. This was frequently found during our interviews. Firms prefer to 
interact with agents that are able to understand the nature of processes and 
development activities carried out in the industry (Interviews with Trade1, firms 03, 
05 and 15). Theoretical or more abstract contents are seldom relevant for training 
programmes in the industry. Overall, these results confirmed only partially 
hypotheses H1-H3. 
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The effects on learning associated with worker’s empowerment were also 
difficult to perceive in the statistical analysis. This is of concern as it prevents to 
meaningfully conclude on the importance of granting workers increased capacity to 
participate in decision making. This is something suggested in the literature. For 
example, Dutrénit (2000) and Dutrénit (2007) documented the positive effects on 
learning whenever firms grant workers the opportunity to manipulate and ‘play 
around’ with newly acquired technologies. Conclusions related to hypotheses H7-H8 
need further exploration; this is done in chapter 8.  
The lack of statistical significance of variables such as remunerations and 
worker’s empowerment suggests the lack of reinforcing effects among management 
practices as well. Perhaps this explains the high mobility among personnel within 
the industry. The dynamism of organisational practices is limited by the strategic 
orientation towards strong reliance and transfer of responsibility to perform 
technological efforts onto parent companies, or supplier firms. Whenever incentives 
to acquire new, increasingly more complex knowledge are low, the potential 
contribution of human resource management practices is also limited. The capacity 
of the industry to sway over the functioning of labour markets underpinning 
technological development looks pretty low. Chapter 8 explores further some of 
these issues. 
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Table 7.2: Learning from external markets: Pharmaceutical industry in Mexico, 2004 
 Mean SD1 Min Max 
External_mkt 
(I) 
Exter-
nal4  (II) No 5  (I)/ (II) (I) (II) (I) (II) (I) (II) 
Employment  467.2 393.6 1.2 525.4 456.7 1.1 63.0 3391.5 2852.9 
Total sales2  720.9 480.8 1.5 1.2 1074.8 2.4 7.7 6958.0 6772.2 
 Domestic 
sales 631.2 433.9 1.5 937.1 1008.4 2.4 0.0 4359.9 6334.5 
 Export share  0.1 0.1 1.0 0.1 0.2 0.0 0.0 0.6 1.0 
Share of FDI  0.3 0.4 0.8 0.5 0.5 0.0 0.0 1.0 1.0 
Age3 34.4 27.6 1.2 19.5 17.0 1.0 0.0 74.0 72.0 
embodied 
Embod-
ied10 No 11  (I) (II) (I) (II) (I) (II) 
Employment  547.5 377.6 1.4 650.5 382.0 1.1 42.0 3391.5 2852.9 
Total sales  870.6 491.0 1.8 
1435.
1 945.0 31.9 2.4 6958.0 6772.2 
 Domestic 
sales 754.0 442.4 1.7 
1085.
6 881.2 31.9 0.0 4359.9 6334.5 
 Export share  0.1 0.1 1.0 0.1 0.2 0.0 0.0 0.5 1.0 
Share of FDI  0.2 0.4 0.5 0.4 0.5 0.0 0.0 1.0 1.0 
Age 35.2 29.8 1.2 19.4 18.3 1.0 0.0 74.0 72.0 
disembodied 
Disem-
bodied12 No 13  (I) (II) (I) (II) (I) (II) 
Employment  471.2 398.9 1.2 543.0 442.0 2.2 1.1 3391.5 2852.9 
Total sales  724.6 509.3 1.4 
1242.
7 1034.2 2.4 7.7 6958.0 6772.2 
 Domestic 
sales 628.3 464.5 1.4 964.4 970.0 2.4 0.0 4359.9 6334.5 
 Export share  0.1 0.1 1.0 0.1 0.2 0.0 0.0 0.6 1.0 
Share of FDI  0.3 0.4 0.8 0.5 0.5 0.0 0.0 1.0 1.0 
Age 33.2 30.0 1.1 19.0 18.6 1.0 0.0 70.0 74.0 
extrel_rd 
External 
R&D6 No 7  (I) (II) (I) (II) (I) (II) 
Employment  528.6 406.7 1.3 644.9 436.8 42.0 1.1 3391.5 2852.9 
Total sales  788.3 570.0 1.4 1465.8 1025.5 2.4 7.7 6958.0 6772.2 
 Domestic 
sales 646.63 521.2 1.2 994.2 9601.0 2.4 0.0 4359.9 6334.5 
 Export share  0.1 0.1 1.0 0.1 0.2 0.0 0.0 0.5 1.0 
Share of FDI  0.1 0.4 0.3 0.4 0.5 0.0 0.0 1.0 1.0 
Age 34.9 30.6 1.1 20.4 18.2 1.0 0.0 67.0 74.0 
licensing 
Licens-
ing8 No 9  (I) (II) (I) (II) (I) (II) 
Employment  690.0 380.2 1.8 745.2 406.4 217.3 1.1 3391.5 2852.9 
Total sales  1350.7 459.5 2.9 1764.7 891.9 126.1 2.4 6958.0 6772.2 
 Domestic 
sales 1133.9 419.8 2.7 1278.0 831.6 125.9 0.0 4359.9 6334.5 
 Export share  0.1 0.1 1.0 0.1 0.2 0.0 0.0 0.5 1.0 
Share of FDI  0.5 0.3 1.7 0.5 0.4 0.0 0.0 1.0 1.0 
Age 36.8 30.5 1.2 19.9 18.5 1.0 0.0 70.0 74.0 
Notes: Number of firms in sample: 112; 1. standard deviation; 2. Million Mexican pesos; 3. difference between the year 
in which a firm started operations in current business and the year when the survey was collected, 2004; 4. 68 firms; 5. 
44 firms; 6. 29 firms; 7. 83 firms; 8. 21 firms; 9. 91 firms.  
Source: Author with information from ENESTYC 2005, INEGI 
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 Table 7.4: Mexico: Human resource management practices and control variables included in the analysis by type of 
external market for technology 
 external_mkt embodied disembodied extrel_rd licensing 
train04 no Yes no yes no yes no yes no Yes 
No 8 4 10 2 10 2 12 0 11 1 
Yes 36 64 62 38 41 59 71 29 80 20 
internal_external_tr           
No 8 4 10 2 10 2 12 0 11 1 
Internal 8 8 14 2 8 8 13 3 15 1 
External 4 8 8 4 4 8 7 5 9 3 
Both 24 48 40 32 29 43 51 21 56 16 
imp_empowerment           
Not implemented 35 35 46 24 40 30 53 17 60 10 
Not important 5 24 18 11 7 22 21 8 24 5 
Very important 4 9 8 5 4 9 9 4 7 6 
rule_hiring           
No 29 30 41 18 35 24 49 10 53 6 
Yes 15 38 31 22 16 37 34 19 38 15 
rem_size* 7.1 6.4 7.4 6.6 7.0 6.7 7.2 6.7 8.6 6.4 
modern_practice           
No 23 14 24 13 27 10 29 8 34 3 
Yes 21 54 48 27 24 51 54 21 57 18 
export_dummy           
No 23 29 33 19 28 24 39 13 50 2 
Yes 21 39 39 21 23 37 44 16 41 19 
fdi           
No 28 49 45 32 33 44 52 25 66 11 
Yes 16 19 27 8 18 17 31 4 25 10 
Total 44 68 72 40 51 61 83 26 91 21 
Notes: *In logarithms, MX$/person/month. 
Source: Author with information from ENESTYC, 2005; INEGI  
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Chapter 8 
Do human resource management 
practices contribute to combined learning 
strategies in developing countries?  
 
 
 
1. Introduction 
 
This thesis investigates how human resource management practices influence 
learning for innovation by pharmaceutical firms in Mexico. Chapters 6 and 7 
analyzed the extreme cases where firms choose between two mutually exclusive 
learning strategies: a firm learns by means of internal R&D efforts only (chapter 6). 
Alternatively, firms rely, exclusively, on external markets for technology (chapter 7). 
Chapters 6 and 7 thus documented that the contribution of human resource 
management practices is somewhat limited as compared to that of variables on 
firm’s characteristics. However limited, such findings suggested that the 
contribution of management practices is contingent on the choice of either of the 
two learning strategies. Divergences resulted from the specific outcome pursued by 
the firm and consequently, from the nature of the knowledge requirements. Based 
on the discussion in chapter 1, learning is associated with either knowledge 
exploitation or exploration. This chapter takes a step forward to document the 
influence of human resource management practices when internal and external 
learning strategies are deployed together. The chapter thus follows a well-
established literature on technology acquisition at firm level (section 2.3, chapter 2).  
 
1.1. Dual learning strategies in the pharmaceutical industry 
 
At a global scale the pharmaceutical industry stands out for its technological 
dynamism and intensive use of internal and external knowledge sources by firms. In-
house R&D is key element of success particularly at times of increased competition 
from generic manufacturers, and a relatively low pace in new drug innovation. 
Internal technological efforts are insufficient to respond, in a timely manner, to 
current market conditions. Mergers and acquisitions, outsourcing and off-shoring of 
R&D and other innovation-related activities increasingly guide business strategies of 
global pharmaceutical firms.  
The literature equally documents that latecomer pharmaceutical firms can tap 
into both internal and external sources of knowledge; successful catching up 
involves strategic combinations of these two approaches. Kim (1997) identified 
three main channels for firms in developing countries to develop new products: (1) 
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by developing new raw materials in-house, hence they can substitute parts of the 
manufacturing process of patented drugs; (2) by relying on multinationals as source 
of technology through licensing or technical assistance; and (3) by purchasing active 
ingredients and excipients in open markets. In any of these three cases, some 
systematic domestic R&D efforts are needed to build up the capacities required to 
manufacture the final drug.  
As firms gain in technological complexity and innovation capacity, internal 
learning activities play increasingly relevant roles moderating the process of learning 
from external markets (Cattozzella and Vivarelli 2007; Escribano et.al, 2009). In the 
study about the differences in technological strategies and corresponding 
innovation behaviours of 37 pharmaceutical firms in Korea, Kim et.al, (1989) 
categorized firms according to scale of operations and technological capabilities. 
Large firms with significant technological capabilities used external knowledge to 
complement domestic technological efforts. They exhibited the highest degree of 
innovativeness. By contrast, large firms with relatively lower capabilities relied on 
external knowledge to improve short-term profitability. Finally, smaller firms 
showed a dual behaviour: On the one hand, firms that had developed some fair 
technological capabilities relied, almost exclusively, on domestic research efforts; 
they enjoyed the highest rates of growth. On the other hand, small firms with low 
capabilities tended to imitate products with relatively limited technological 
complexity. Mobility of personnel constituted their preferred channel to capture 
external knowledge.  
Recently Singh (2007) documented the progression in the innovative capacity of 
Indian drug manufacturers. Starting as bulk generic suppliers, Indian firms 
increasingly contribute to drug discovery and clinical research. Notable in this 
process has been formation of alliances with large US and European 
pharmaceuticals, efforts to capture and benefit from knowledge and experience of 
highly qualified Indian expatriates and significant export orientation (Meyers 2006; 
Reddy 1997). In addition to some firm and context specific factors, Kim et.al, (1989), 
Reddy (1997) and Meyers (2006) stressed the contribution that human resources 
have had for successful catching up of pharmaceutical firms in South Korea and 
India, respectively. Such contribution was linked to the availability of resources, 
corporate goals and notably, managerial preferences. Good engineering and 
research skills, the entrepreneurial orientation of management, dynamic 
organisational practices and engineering leadership, among other factors, 
contribute to successful catching up by latecomer firms.  
In a study about Mexico, Zúñiga et.al, (2007) looked at in-house R&D and 
technology transfer over the period 1994 and 2000. They built on data from the 
national manufacturing census, which is similar to the dataset used in this thesis.
1
 
Furthermore, the analytical framework of Zúñiga and colleagues was analogous to 
the one used here: they adopted a catching up perspective. The authors concluded 
                                                 
1 The first waves of the ENESTYC were embedded within the manufacturing census. Notwithstanding 
some differences in the kind of information captured by each of the surveys, their methodological un-
derpinnings are directly comparable. 
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that internal and external learning strategies are exogenous in the Mexican 
pharmaceutical industry. In-house R&D has little bearing on external acquisition of 
technology; at the same time, technology purchases only marginally affect 
corporate decisions to invest in R&D. The authors indicated that the observed low 
probability of complementarities could be explained by two divergent technological 
objectives of firms. Market exposure, through exports for example, drives R&D. By 
contrast, external procurement of technology responds to searches for increased 
productivity, capital intensity and company size. This notwithstanding international 
diversification, through exports, could lead to complementary learning strategies.  
This chapter re-examines some of the conclusions by Zúñiga et.al, (2007). In 
order to do so the analysis incorporates additional information so as to better 
explain the learning processes occurring inside the firm. Major differences with 
Zúñiga et.al,’s (2007) study include our finer definitions of the dependent variables: 
they looked only at whether firms performed R&D or not, or the participation of 
pharmaceutical firms in technology licensing. By contrast, this chapter combines 
some of the finer definitions of internal and external learning indicators (chapters 6 
and 7). In addition, the inclusion of the human resource management variables 
sheds light on how pharmaceutical firms mobilise the human resources involved in 
distinct combinations of learning activities. Since dissimilar combinations of 
strategies require distinct forms of organizing personnel, relevant management 
practices should differ as well. The chapter proceeds as follows: Section 2 presents 
the variable definitions, the data and the subsequent research strategy. Section 3 
examines the extent to which pharmaceutical firms in Mexico combine internal and 
external learning strategies. Section 4 presents the econometric analysis. The 
discussion is guided by the research hypotheses in chapter 3. Finally, section 5 
provides some discussion and conclusions of results.  
 
2.  Data and research strategy 
 
Data used in this paper come from the ENESTYC dataset described in chapter 3. The 
variables on internal and external learning were presented in chapters 6 and 7, 
respectively. Based on those chapters, seven indicators on internal learning 
strategies are used here (tables 6.1). The external strategy, in turn, is captured by 
five distinct indicators (tables 7.1).  
Human resource management variables: Based on the discussion in chapters 2 
and 3, this chapter incorporates the following human resource management 
interventions: the provision of training, remunerations, worker’s empowerment and 
rules governing staff hiring. In addition, a pertinent distinction was made between 
internal and external provision of training.
2
 Alternative variables serving to identify 
the actual external training provider were also considered in the analysis. 
Remunerations were normalized by taking into account the firm’s size; this reduced 
                                                 
2 The results from models with the provision of training, train04, were no significantly different com-
pared to those presented here. However, in some cases the distinction between types of training helped 
to avoid some specification troubles preventing the models to converge.  
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potential collinearity problems and captured scale effects.  
Control variables: This chapter controls for a firm’s characteristics including: 
adoption of modern management practices; capital ownership and participation in 
export markets. Tables 6.2 and 7.2 provided correlation analyses for the 
explanatory and control variables used in this chapter.  
 
2.1. Research strategy 
 
The dependent variables in this chapter are binary; they reflect alternative choices 
of learning strategies made by the firm. The analysis assumes that learning 
strategies can be deployed together. Such interrelation suggests the presence of 
some unobservable characteristics of the firm that influence the selection of 
learning strategies. If modelled inadequately, for example through independent 
univariate equations, the results can render inconsistent (biased) estimates of the 
influence of management practices on the choice of learning strategies. A suitable 
econometric approach to deal with these issues is bivariate probit analysis.
3
 As an 
extension of probit regression, bivariate analysis allows the running of two 
simultaneous equations with expected correlation in their disturbance terms 
(Greene 2003). The resulting system of equations looks as follows:  
 
y1i* and y2j* are latent variables, such that:  
y1i*= Different types of in-house R&D  
y2j*= Diverse indicators on external markets for technology 
M = Vector of management variables that influence the probability of choosing 
among learning strategies internal and external 
X = Vector of firm characteristics (control variables) that influence the probability of 
choosing among learning strategies 
iε , iν = Vectors of disturbances  
 
iXuMy i εβ ++= 1'*1 , Finternali=1, if 0*1 >y , 0 otherwise  (8.1) 
iXuMy j νδ ++= 2'*2 , Fexternalj=1, if 0*2 >y , 0 otherwise (8.2) 
With i=1,...,9 and j=1,..,5 
 
Where the sub-indexes i and j in internali and externalj change according to the 
distinct definitions of the internal and external learning strategies. In other words, 
internali captures inhouse_rd, rd_explore, and so on; similarly, externalj refer to 
extrel_mkt; extrel_rd and so on.  
 
                                                 
3 Multinomial logit regression is an alternative methodology (Greene 2003). However, it was unsuitable 
considering the limited size of our working sample. More importantly, the perceived interrelation be-
tween internal and external learning strategies could lead to violation of the critical assumption of inde-
pendence of irrelevant alternatives (IIA) (Long and Freese 2006; McFadden 2000). In simple terms, all 
else being equal, the availability of internal learning strategies influences the adoption of external learn-
ing strategies.  
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The approach assumes: 
 
0),/(),/( == xmExmE νε , 
1),/(),/( == xmVarxmVar νε , 
ρνε =),/,( xmCov
 
 
In order to test for the adequacy of the bivariate specification, estimates were 
contrasted with those from equivalent univariate probit equations. In particular, we 
examined the value and statistical significance of the errors correlation term, ρ, for 
the bivariate models. A positive and significant test indicates that the learning 
strategies are interrelated; univariate models will capture only partial information 
and render biased results (Greene 2003).  
Modelling proceeded as follows: First, the chapter identified a basic model 
specification for the pair of dependent variables on in-house R&D, rd_inhouse, and 
external knowledge acquisition, extrel_mkt, respectively. Second, the definition of 
the dependent variables was changed iteratively while keeping the structure on the 
right hand side of the equation. In such a way the distinct indicators on in-house 
R&D paired with distinct specifications of external markets. The exercise 
documented the different influence of the explanatory variables on the distinct 
goals and means to acquire technology. Several checks were performed on the 
robustness of results. First, based on Cassiman and Veugelers (2006), each pair of 
internal and external learning strategies was regressed on the control variables only. 
Second, we ran full specification models and compared results. As we comment 
later, this procedure is an indirect way to test for complementary relationships 
between learning strategies. Once the basic structure of the models was identified, 
we ran an additional bivariate specification, this time including only those 
explanatory variables that showed statistical significance, at the five percent level or 
lower, in the basic model. For reasons of space and feasibility of the analysis, results 
from all those equations are omitted from presentation; nevertheless, they are 
available from the author upon request.  
As a complementary way to look at results from probit regression, chapters 6 
and 7 reported the computation of marginal effects for the models included in the 
corresponding analyses. Considering the scope of this chapter, here we report the 
conditional probability that a firm performs an external learning strategy provided 
that it is already conducting some kind of learning efforts in-house (Long and Freese 
2006). Hence, the analysis identifies how external knowledge sources supplement 
internal learning activities.  
 
3. Empirical results 
 
The discussion of the main results from the empirical analysis splits into two 
sections: First, we describe the propensity of pharmaceutical firms in Mexico to 
adopt dual learning strategies. Then we present results from our econometric 
analysis.  
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3.1. Learning and technology acquisition  
 
Table 8.1 summarizes the learning behaviour of pharmaceutical firms in Mexico. It 
shows that internal and external learning strategies are positively and significantly, 
albeit weakly, correlated: 0.48. The strongest correlation between external_mkt and 
the detailed R&D variables corresponds to improvement of drug manufacturing 
processes, 0.53. By contrast, the weakest correlation is found with learning from 
external sources supporting new process innovations, 0.17. It is evident that 
acquisition of disembodied technologies complements efforts to improve drug 
manufacturing processes. 
 
Table 8.1: Mexico: Correlation analysis for the choice of joint learning strategy by pharmaceutical firms  
 rd_inho
use 
rd_design 
_meq 
rd_improve 
_process 
rd_drug 
_design 
rd_drug 
_improvement 
rd_exploi
t 
rd_explor
e 
external_mkt 0.484 0.340 0.527 0.455 0.427 0.462 0.472 
tech_package 0.312 0.329 0.334 0.312 0.391 0.338 0.344 
tech_consultant_firm 0.294 0.409 0.310 0.201 0.370 0.320 0.234 
tech_literature 0.415 0.392 0.376 0.398 0.303 0.360 0.426 
extrel_learn_inds 0.100 0.026 0.156 0.098 0.142 0.114 0.093 
extrel_acq_machin 0.173 0.281 0.190 0.149 0.226 0.191 0.196 
extrel_rd 0.349 0.186 0.449 0.341 0.381 0.374 0.374 
licensing 0.075 0.179 0.128 0.144 0.103 0.051 0.136 
embodied 0.356 0.358 0.373 0.282 0.455 0.389 0.308 
disembodied 0.442 0.301 0.496 0.421 0.367 0.414 0.440 
Notes: For presentation purposes, the correlations table was truncated in those sections that had been presented 
already in chapters 6 and 7. Figures in bolder fonts denote correlations different from zero at 1% level of significance  
Source: Author based on data from ENESTYC, 2005, INEGI 
 
Table 8.2 reveals that a significant number of pharmaceutical firms in our 
sample pursued joint learning strategies, 55.4 percent. More specifically, 53.6 
percent of firms adopted dual strategies to exploit existing knowledge. As for the 
behaviour of each pair of detailed definitions of both in-house R&D and external 
technology acquisition, 50 percent or more of the pharmaceutical firms implement 
dual learning strategies. The exception is rd_design_meq with merely 17.9 percent 
of firms interacting with other agents during design or improvement of machinery 
and equipment. This latter finding reflects the separation between drug 
manufacturers and firms producing capital goods for such industry. The values of the 
Pearson X
2 
tests failed to accept the null hypothesis of independence between each 
pair of learning strategies. This clustering suggests some complementarity among 
learning strategies in the sense that doing more of one increases the expected 
return on the other (Arora et.al, 2001). Nevertheless such complementarity is week. 
A look at indicators on employment, domestic sales and exports and so on, 
revealed that firms that involve in joint learning efforts tend to outperform those 
reporting no learning activities at all. For instance, the first group of firms reported 
average employment, total sales and sales per employee that are about 1.5, 3.0 and 
2.4 times larger than those of firms in the second group. By contrast, the average 
shares of both FDI and exports were lower for firms implementing joint learning 
strategies (25 percent and 6.0 percent, respectively), than those for firms reporting 
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no learning activities (30.0 percent and 8.0 percent, respectively). In both these 
cases the bulk of sales target the local market. 
 
Table 8.2: Frequency of learning strategies of pharmaceutical firms in Mexico 
Internal External (Extrel_mkt) 
rd_inhouse No Yes Total Pearson X2(1) 
No 23(20.5) 6(5.4) 29(25.9) 26.2825*** 
Yes 21(18.7) 62(55.4) 83(74.1) 
Total* 44(39.3) 68(60.7) 112(100.0) 
rd_improve_process     
No 30(26.8) 11(9.8) 41(36.6) 31.1339*** 
Yes 14(12.5) 57(50.9) 71(63.4) 
rd_design_meq     
No 43(38.4) 48(42.9) 91(81.2) 12.9154*** 
Yes 1(0.90) 20(17.9) 21(18.8) 
rd_impr_drugs     
No 26(23.2) 12(10.7) 38(33.9) 20.4684*** 
Yes 18(16.1) 56(50.0) 74(66.1) 
rd_design     
No 29(25.9) 14(12.5) 43(38.4) 23.1984*** 
Yes 15(13.4) 54(48.2) 69(61.6) 
rd_exploit     
No 24(21.4) 8(7.1) 32(28.5) 23.9572*** 
Yes 20(17.9) 60(53.6) 80(71.4) 
rd_explore     
No 29(25.9) 13(11.6) 42(37.5) 24.9554*** 
Yes 15(13.4) 55(49.1) 70(62.5) 
Notes: Categories are exclusive; sample includes only firms without missing values, n=112; *** significant at 1% level of 
confidence; percentage share of each cell relative to total firms in sample within parentheses  
Source: Author with information from ENESTYC, 2005 
 
Table 8.3: Characterisation of human resource management variables  
included in the analysis, by type of learning strategy 
Variable Learning strategy 
 Internal External Internal & external 
   Yes No 
training_internal 70 56 53 9 
external_training 68 56 53 9 
rem_size* 7.0 7.1 6.9 5.7 
imp_empower     
   Not implemented 50 35 34 
   Very important 8 9 6 
   Not important 25 24 22 
rule_hiring 42 38 34 28 
* Refers to the minimum and maximum average remuneration in MX$1000.  
Sample without missing values =112 
Source: Author with information from ENESTYC, 2005 
 
Table 8.3 presents the human resource management variables included in the 
analysis according to the choice of joint learning strategies. One observes that a 
large share of firms adopting dual approaches to learning provided training to 
employees during 2004; training was both internal and external. In line with the 
findings in previous chapters, firms performing joint learning strategies report 
compensation levels above those of firms with more passive stances towards 
learning. By contrast, worker’s participation in decision-making about the workplace 
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is either not adopted or not important. Finally about a third of firms implementing 
joint learning approaches reported that they regulate staffing practices through 
either collective contract, internal regulations of both. The figures are relatively 
lower than those of firms that adopt single learning strategies. 
 
3.2. Econometric results 
 
3.2.1. Basic model: Joint internal and external learning strategies 
 
Table 8.4 presents estimates for bivariate probit models corresponding to the 
combination of rd_inhouse and external_mkt. The table reveals that the models are 
statistically significant at the one percent level of confidence; the variables included 
in the analysis adequately explain learning strategies of pharmaceutical firms in 
Mexico. The Wald tests on the value of the errors correlation term, ρ, are positive 
and statistically significant at the one percent confidence level. This supports the 
superiority of bivariate over binary probit specifications.  
 
Table 8.4: Bivariate probit models for joint adoption of internal and external learning strategies 
VARIABLES rd_inhouse external_mkt rd_inhouse external_mkt cond_prob 
training_internal   0.60* 0.02 -0.10 
   (0.33) (0.33) (0.09) 
external_training   0.65** 0.38 0.04 
   (0.31) (0.31) (0.11) 
rem_size   0.022 0.069 0.02 
   (0.058) (0.053) (0.02) 
rule_hiring   0.091 0.44* 0.15* 
   (0.29) (0.26) (0.09) 
imp_empowerment   -0.14 0.28 0.13* 
   (0.24) (0.21) (0.07) 
modern_practice 0.34 1.02*** 0.31 0.86*** 0.31*** 
 (0.28) (0.28) (0.35) (0.33) (0.12) 
export_dummy 0.70** 0.57* 0.70** 0.47 0.07 
 (0.32) (0.30) (0.33) (0.31) (0.11) 
Fdi -0.67* -0.84*** -0.97** -1.16*** -0.31** 
 (0.35) (0.32) (0.39) (0.34) (0.14) 
Constant 0.30 -0.41 -0.59 -1.27***  
 (0.25) (0.25) (0.40) (0.44)  
Observations   112   
Log Likelihood Full  -115  -105  
Χ
2  [6]23.9***  [16]64.4***  
ρ  0.71  0.78  
Wald test, ρ=0  [1]17.79***  [1]19.80***  
Notes: ***,**,* significant at the 1, 5 and 10 percent confidence level; robust standard errors in parentheses; Degrees 
of freedom within squared brackets; marginal effects correspond to changes in conditional probabilities that a firm 
adopts an external learning strategy provided that it already carries out internal learning efforts. In other words, these 
are probabilities for combinations of (external=1| internal=1), see STATA manual for further reference; variable defini-
tions in Chapter 3. 
Source: Author based on information from ENESTYC, 2005. 
 
Individual estimates reveal that participation in export markets has positive and 
statistically significant effects on the likelihood that a firm carries out in-house R&D. 
By contrast, learning from external markets is positively determined by adoption of 
modern organisational practices. Foreign ownership produced negative effects on 
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the two learning strategies. As for management variables, the only perceptible, 
positive effect derives from the provision of external training linked to internal 
learning. The rest of variables rendered little information on their impact on the 
adoption of joint learning strategies. Overall, the preliminary conclusion is that 
human resource management plays a limited role as a factor underpinning learning 
activities of pharmaceutical firms in Mexico. 
 
3.2.2. Changing definitions of internal and external learning strategies 
 
As a subsequent step in the analysis alternative models were run in which 
rd_inhouse and external_mkt were replaced, one at a time, by each of the finer 
definitions for R&D and external markets, respectively. Thus the analysis captured 
the association of human resource management practices with different combina-
tions of learning strategies; distinct innovation outcomes and diverse types of 
knowledge pursued by the firm. This is as follows: 
In-house R&D for improved/new process/product: Table 8.5 contains results for 
models that identify in-house R&D according to the outcome pursued by the firm. 
The table reveals that human resource management variables have no perceptible 
contribution on learning underpinning improvements in either existing drugs or 
drug manufacturing processes. Such contribution is more and more noticeable as 
knowledge searches increase in their exploratory scope. The provision of training, 
particularly from external sources, underpins new drug designs and development of 
new drug manufacturing processes.  
Estimates for the control variables equally showed a rather mixed behaviour. 
Whereas adoption of modern organisational practices is positively and significantly 
associated with external learning, exports positively induce new drug designs. 
Finally foreign ownership remains a negative determinant of technological learning.  
The computation of conditional probabilities that a firm uses external 
knowledge, when it already performs in-house R&D, hints at the poor connection 
between internal and external learning strategies. In such contexts, the role of 
human resource management practices is also rather limited. The use of worker’s 
empowerment contributes positively to joint learning strategies connected with 
improvements in drug manufacturing processes. Introducing regulations to guide 
staffing practices is also positive and significant in the case of learning for new drug 
design. As for the control variables, the conditional probabilities for 
modern_practice were positive and significant when associated with product and 
process improvements. Similar conclusions can be obtained in the case of new drug 
designs. Finally, whereas fdi conditions negatively learning activities, exports did not 
show perceptible effects. 
Knowledge exploitation and exploration: Table 8.6 depicts the results for two 
new sets of models: in-house R&D for knowledge exploitation and exploration, 
respectively. In both these cases the variable external_mkt remained unchanged. 
Indicators on the goodness of fit revealed that the models are statistically significant 
at customary confidence levels. The Wald tests on the value of the errors 
correlation term, ρ, equally support the adequacy of the bivariate specification.  
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In the case of learning for knowledge exploitation, individual estimates show 
that modern_practice and fdi influence learning from external sources; however the 
effects run in different directions. By contrast those same variables reported no 
perceptible effects on in-house R&D. Inclusion of management variables revealed 
that internal training influences knowledge exploitation via in-house R&D. In levels 
the remaining variables on human resource management provided no meaningful 
information. However, computation of conditional probabilities show that worker’s 
empowerment influences positively and significantly the use of external knowledge 
as supplement of in-house R&D. Similar effect results from modern_practice. Finally, 
fdi leads to negative learning behaviours.  
Turning to the models on knowledge exploration, results corroborated that 
exports and foreign ownership have opposed effects on learning. Whereas the 
former is positive, the latter is negative. The variable modern_practice remains 
relevant for external learning. As for the human resource management practices, 
again, the results render very limited information. However, one can perceive that 
the provision of external training increases the likelihood that firms perform in-
house R&D. Regulations governing staff hiring have positive and statistically 
significant influences on the conditional probability of using external knowledge 
when an internal learning strategy is already in place.  
Knowledge exploitation and exploration with embodied and disembodied 
technologies: Table 8.7 presents estimates for models where the variable on 
external knowledge was also modified. The variable is replaced by those on 
technology acquisition in either embodied or disembodied form. Consequently, the 
table shows models that distinguish how pharmaceutical firms in Mexico tap into 
embodied or disembodied technologies to supplement knowledge exploitation and 
knowledge exploration, respectively. Results in table 8.7 show that the models are 
statistically significant at customary confidence levels. The values of the errors 
correlation term, ρ, indicate that the bivariate specification adequately explains the 
adoption of dual learning strategies by pharmaceutical firms.  
Individual estimates show that the provision of internal training supports 
knowledge exploitation combined with the acquisition of embodied technologies. 
This positive influence is offset by the impact of foreign ownership. The remaining 
variables on human resource management practices and firm characteristics 
reported no perceptible effects on learning.  
Table 8.7 equally shows that knowledge exploitation and acquisition of 
disembodied technologies are better explained by firm characteristics. Exports and 
adoption of modern organisational practices have positive effects, but fdi remains 
negative. As for the human resource management variables, the presence of rules 
on staff hiring supports the incorporation of disembodied technologies. 
Chapter 7 documented that pharmaceutical firms in Mexico acquire more 
frequently disembodied technologies than embodied alternatives. This finding is 
reflected in the models investigating how embodied and disembodied technologies 
associate with knowledge exploration. Estimates show that firm characteristics are 
those that better explain adoption of joint learning strategies. In fact the more 
notorious effects correspond to combinations including rd_explore and 
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disembodied knowledge. Although the human resource management variables 
provide limited information on the adoption of dual learning strategies, it is evident 
that the provision of external training contributes to R&D for knowledge 
exploration. Similarly, rules_hiring underpins adoption of disembodied technology.   
Finally, the computation of conditional probabilities revealed a very limited 
interaction between internal and external learning. In particular changes in the 
presence of management practices explain very little of the shifts in the probability 
that firms combine knowledge exploitation or exploration with the acquisition of 
either embodied or disembodied technologies. An interesting exception was the 
combination of rd_explore and disembodied knowledge. In that case rules_hiring 
and imp_empowerment were positive and statistically significant. A similar 
conclusion applies for modern_practice. By contrast, the conditional probability 
associated with foreign ownership remained negative and statistically significant.  
Knowledge exploitation and/or exploration; contracted R&D and technology 
licensing: The literature grants considerable attention to understanding how firms 
tap into contracted or external R&D and technology licensing to complement 
internal learning efforts (Leone and Reichstein 2009; Nakamura and Odagiri 2005). 
In view of the importance that both these activities have for the pharmaceutical 
industry, this chapter explored these issues in the context of Mexico. In practice, 
the variables on rd_external and licensing where coupled with searches supporting 
either knowledge exploitation or knowledge exploration. Results are presented in 
table 8.8. According to the Wald tests on the errors correlation term, ρ, the 
bivariate specification was inadequate to analyse the combination of external R&D 
and licensing with R&D for knowledge exploitation. These activities are independent 
from each other; the equations can be run separately. The analysis will take us back 
to the analyses in chapters 6 and 7. A similar finding occurred in the case of joint 
learning strategies involving rd_explore and licensing. In light of these results, the 
discussion here focuses on models where external R&D was combined with R&D for 
knowledge exploration.  
Estimates revealed that participation in export markets induces positive 
incentives for knowledge exploration through R&D. The opposite effect is derived 
from foreign capital ownership on both internal and external learning efforts. 
Inclusion of human resource management indicators confirmed some previous 
findings in the case of knowledge exploration. The provision of external training 
generates positive and significant effects on in-house R&D. Rule_hiring, in turn, 
increases the likelihood that a firm contracts R&D.  
Computation of conditional probabilities indicates that the only meaningful 
changes are associated with the variables rules_hiring and fdi. As has been the case 
so far, foreign ownership is a negative determinant of learning in the 
pharmaceutical industry in Mexico.  
Changing definitions of external training providers: Firms can interact with 
several agents in the external environment. Given the scope of this thesis, the focus 
has been on organisations taking part in the provision of external training. This 
section reports the results for models that identify each of those specific partners. 
The analysis distinguished R&D for either knowledge exploitation or exploration in 
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combination with external_mkt. Results are presented in tables 8.9 and 8.10.  
Models in tables 8.9 and 8.10 are statistically significant at customary 
confidence levels. In addition, the values of the errors correlation term, ρ, indicate 
that the bivariate specifications adequately explain adoption of dual learning 
strategies by pharmaceutical firms. Individual estimates tell us that the presence of 
modern organisational practices and foreign ownership consistently influence 
learning, particularly from external sources. As has been the case so far, the effects 
from each variable run in diverging directions. By contrast, exports report a more 
mixed behaviour for either knowledge exploitation or knowledge exploration. On 
the one hand, the variable renders no significant information as determinant of 
combinations of rd_exploit and external_mkt. On the other hand, exposure to 
competition in external markets drives positively exploratory R&D.  
Turning now to the variables on human resource management practices, the 
results in tables 8.9 through 8.10 corroborate the limited contributions that 
practices such as remunerations and worker’s empowerment have on learning by 
pharmaceutical firms in Mexico. On the contrary, the provision of training, and to a 
lesser extent the regulation of staffing practices, reported some meaningful 
information. In the case of models with R&D for knowledge exploitation and 
external_mkt, the findings indicate that firms rely on their own staff to provide R&D-
relevant training; firms tap existing knowledge for that purpose. Nevertheless, 
internal training lacks relevance as factor sustaining R&D for knowledge exploration.  
Perhaps more interesting is confirmation of the finding -see Chapter 7- that 
none of the traditional knowledge producers, universities and public research 
centres, provides meaningful information about their contribution to R&D-relevant 
training. Pharmaceutical firms in Mexico tend to lean on independent consultants 
and/or training centres attached to the industry. Arguably, the contribution of those 
two agents increases as knowledge searches take a more exploratory nature. It is in 
the context of training through specialised centres attached to the pharmaceutical 
industry that rule_hiring gains relevance as a means to learn from external 
knowledge sources. Interviews with pharmaceutical firms in Mexico hint at some 
reasons for this; this is part of the discussion in section 4 below. 
The conditional probabilities that a firm uses combined learning strategies were 
computed for the models with a specification for each external training partner; 
these are shown in table 8.11. The marginal probabilities corroborated that a firm’s 
characteristics are the main determinants of learning activities in the 
pharmaceutical industry in Mexico. More specifically, the more relevant variables 
are the adoption of modern organisational practices and foreign ownership. As for 
export_dummy, the variable rendered no statistically significant information.  
The analysis of conditional probabilities for the variables on human resource 
management practices revealed that changes in worker’s empowerment is positive 
and statistically significant for learning strategies underpinning knowledge 
exploitation. In other words as opportunities to participate in decision-making rise, 
so does the likelihood that firms implement joint learning strategies. The provision 
of training in partnership with external consultants is relevant for joint strategies 
supporting knowledge exploitation. As for exploration-related activities, rule_hiring 
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remains the most significant human resource management practice. Finally, none of 
the remaining management practices provided consistent information about their 
influence on the adoption of joint learning strategies.  
 
4. Discussion and concluding remarks 
 
This chapter set out to investigate the influence of human resource management 
practices on the joint implementation of internal and external learning strategies by 
pharmaceutical firms in Mexico. Firms can develop technology by performing some 
domestic efforts, notably R&D. At the same time, firms can tap into knowledge 
already available in technology markets; hence they gain complementary assets, 
additional knowledge inputs to underpin innovative efforts. This perspective was 
inspired by recent literature on complementarity between learning strategies; more 
specifically it built on studies on absorptive capacity building by pharmaceutical 
firms in catching up contexts. Those studies show that in general, combined 
approaches should produce larger returns as compared to individual strategies.  
As a learning activity, in-house R&D was distinguished by specific innovation 
outcomes--whether for product or process--, and the corresponding learning 
processes undertaken by the firm--weather for knowledge exploitation or 
knowledge exploration. A further distinction was made by specific external market 
from which a firm can acquire technology. The emphasis was put on technology 
acquisition in either embodied or disembodied form. Hence, this chapter 
investigated how learning processes differ depending on the goals and activities 
pursued during the innovation processes. In this regard, among the several factors 
that influence organisational learning, we focused on the management of human 
resources. The empirical evidence referred to pharmaceutical firms in Mexico. 
The analysis revealed that, in general, pharmaceutical firms in Mexico pursue 
combined learning strategies. In principle, this is positive as it indicates that internal 
knowledge generation in the industry accompanies active absorption of external 
knowledge. Arguably, knowledge exchanges between pharmaceutical firms and 
external agents should contribute to advance the technological complexity of the 
local industry and eventually, the overall economic environment. Identification of 
some explanatory variables whose effects are specific for a particular learning 
strategy coincides with some previous innovation studies on complementarity –see 
chapter 2. In the presence of learning strategies A and B, some variables will 
influence strategy A provided that strategy B is already in place, and vice versa.  
However, the perceived complementarity between learning strategies in the 
pharmaceutical industry in Mexico is rather week. This is evident by looking at the 
creation of capacity to generate future knowledge flows via exploration activities. 
Arguably, in-house R&D and technology licensing are independent from each other, 
notably for activities that emphasize knowledge exploration. Our results are 
therefore in line with those in Zúñiga et.al, (2007). Pharmaceutical firms in Mexico 
make limited use of licensing as a means to leap their technological capabilities. 
Licensing merely provides manufacturing rights, but seldom the consent to enhance 
the technology incorporated in the product. As for domestic firms, these prefer to 
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wait for patent expiration so that they can proceed with the development and 
manufacturing of a generic drug.  
A note of caution is pertinent here. In order to draw stronger conclusions about 
the nature of complementarity between learning strategies more direct tests are 
needed, together with finer gradations of both the dependent and explanatory 
variables. In the literature at least two approaches are available to test for 
complementarity. According to Athey and Stern (1998), the most “direct” way is to 
use a productivity function where an indicator of innovation performance is 
regressed on a defined set of explanatory variables. In general, such approaches 
have been developed for models where dependent variables are continuous. 
Alternative models for categorical variables -see Miravete and Pernias (2006) and 
Cattozzella and Vivarelli (2007)-, impose strong data and computing requirements 
that face considerable limitations for relatively small datasets. Our dataset faces 
strong limitations in both these fronts. ENESTYC lacks information about customary 
indicators of R&D output, i.e. patent counts, product launches, share of sales of 
innovative products and so on. The relatively small size of the pharmaceutical 
industry in Mexico limits the possibility to carry out the necessary tests. 
An alternative approach to research is to perform “indirect”, albeit weaker tests 
for complementarity based on the notion of clustering (Athey 1998). This eliminates 
the need for proper performance indicators such as those required in more direct 
tests (Cattozzella, 2007). This type of indirect approach is the one used in this study 
and by Zúñiga et. al, (2007). The limitations of the approach are not of particular 
concern for this study as our interest was in understanding innovation more as a 
process than as concrete outcomes. The goal was to shed light on how human 
resource management practices influence adoption of distinct combinations of 
learning strategies. Our results are consistent with these objectives. 
From the above, some of the best results from our models corresponded to 
those combining in-house R&D for knowledge exploration with acquisition of 
disembodied knowledge. This is consistent with some findings in chapter 7; 
pharmaceutical firms in Mexico actively consult specialised literature as a means to 
learn from external sources. Reading of specialised biotechnology journals was 
quoted as customary by companies at some advanced stages of technological 
capabilities; meaning those conducting some formal in-house R&D (Interviews with 
firms 03, 05 and 10). Certainly the emphasis is in development more than on 
research. In addition to specialised literature, the variable disembodied includes 
items such as R&D and licensing. These two, in themselves, are mechanisms of great 
relevance to acquire technology in the industry. 
This study was able to identify some management practices that support 
adoption of joint learning strategies by pharmaceutical firms in Mexico. The 
provision of training and to a lesser extent, regulations on staff hiring are relevant 
for learning. Under very specific conditions, i.e. knowledge exploration, worker’s 
participation in decision-making rendered some positive results as well. By contrast, 
the effects of the variable on remunerations were not statistically significant. Overall 
the contribution of human resource management is contingent on the goals 
pursued and corresponding knowledge requirements of the firm.  
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Estimates associated with the adoption of dual strategies involving knowledge 
exploitation revealed that only the provision of internal training influenced in-house 
R&D. The conclusion held almost irrespectively of the specific definitions of external 
markets for technology. If firms limit learning activities to those underpinning 
efficiency and/or productivity gains, they only need to search within their cumulated 
knowledge bases. A firm self-fulfils its knowledge requirements profiting from staff 
experience and expertise.  
Worker’s empowerment was relevant only when the analysis distinguished 
among external training providers. In fact, the effect was perceptible only via the 
computation of the conditional probability that a firm uses external knowledge 
when an internal learning strategy is already in place. This result is appealing as it 
pertains to a variable that was measured in terms of its perceived importance for 
the firm –see chapter 3. As workers gain in decision-making capacity, more evident 
contributions to learning can also be obtained; the practice facilitates absorption 
and assimilation of new knowledge. Dutrénit (2006) for example documented that 
learning activities can be enhanced if workers are given the opportunity to 
manipulate and ‘play around’ with the newly acquired knowledge. Learning is 
potentiated if staff are allowed to try-out new machinery, experiment with novel 
excipients and so on. Interviews at a Mexican manufacturer revealed that from the 
perspective of a development analyst, great learning opportunities were associated 
with the capacity to call excipients’ suppliers, to interact with them and to get 
acquainted with whatever new products or ingredients were available in the market 
(Interviews with firm 06).  
As for strategies involving knowledge exploration in the pharmaceutical 
industry in Mexico, these characterise by an increased importance of practices such 
as the provision of external training, and rules to guide new staff hiring. The 
relevance of external training hints at the fact that as innovation gains in complexity, 
firms need to access alternative knowledge sources searching for inputs otherwise 
unavailable in-house. Interactions with specialised agents assist efforts to enrich 
knowledge available in-house, particularly for the performance of unfamiliar 
activities (Okada and Kawara 2004). Interactions do not arise from scratch, they take 
time, require commitment and sustained efforts; interactions are constantly 
evaluated. Relevant partners can change over time according to the knowledge 
requirements and technological attainment of a firm. Firms 11 and 14 provide good 
examples. As they gained in technological capabilities the firms started to interact 
more actively with local research organisations, including specialised institutes 
affiliated to the UNAM in Mexico. Today both these firms have well established 
relationships with the Center for Disease Control (CDC) in the US, and universities 
and research organisations abroad. 
Intriguingly our analysis in this chapter corroborated the findings in chapters 6 
and 7, namely that universities and other traditional knowledge producers are of 
little relevance for the learning of pharmaceutical firms in Mexico. Learning through 
linkages with third parties within the industry, including consultants and research 
centres were more relevant. ENESTYC lacks detailed information on the exact nature 
of the knowledge flows exchanged between pharmaceutical firms and their partner 
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organisations; hence, explaining this finding is problematic. Nevertheless, our 
interviews indicated that training by consultants and training centres attached to the 
industry is preferred because these agents are better acquainted with the structure, 
technological attainment and operation of the industry (Interviews with Trade2). By 
contrast, researchers at universities tend to be rather abstract, generalist and with 
serious difficulties to translate research findings into practical solutions (Interviews 
with firms 03, 06 and 13).  
The limited reliance on universities as a source of training reflects some 
deficiencies faced by those organisations to meet the industry’s requirements. Both 
Mexican and multinational firms expressed dissatisfaction about the lack of 
adequate infrastructure at the universities (Interviews with firms 03, 06 and 13); 
hence “it is hard to replicate and learn about the most modern synthesis and 
analytical techniques, manufacturing and laboratory practices used by the industry” 
(Interview at firm 03). This is compounded by the “absence of faculty with sufficient 
experience and understanding of the industry” (Interview at firm 03), or the 
difficulties to observe all the confidentiality requirements of the firm (Interview at 
firms 03 and 06). In other occasions, traditional disconnections between basic 
research carried out at universities and the actual needs of the industry were also 
stated. Firms and knowledge producers in Mexico seem to evolve at different pace 
and diverging directions.  
In the literature remunerations and reward for performance are usually part of 
comprehensive management and learning systems. Consequently our inability to 
obtain meaningful information about the impact of remunerations on learning 
strategies is intriguing. Exploring this issue further is difficult given the limited 
information available in our dataset. Nevertheless some hypotheses stemming from 
our literature review and interviews can be considered. In principle, management 
studies argue that raising remuneration levels is not all what it takes to promote 
enhanced performance of Mexican workers (Tello and Greene 1996). Motivation, 
commitment and drive towards improved performance require the creation of work 
environments where incentives to learning are accompanied by the means, 
resources and opportunities for continuous professional development. This is 
consistent with literature suggesting that in science-based industries, R&D staff 
prefer, as remuneration mechanism, opportunities to further develop intellectual 
capital over performance-linked rewards. Arguably, in environments where 
opportunities to conduct R&D as a professional activity are scarce, people interested 
in such a career can work for companies that allow them to do even if salaries are 
not really attractive. This hypothesis takes us back to the discussion in chapter 1 
about the incentives provided by labour markets for the development of R&D.  
As discussed in chapter 7 an alternative explanation for the lack of statistical 
significance of the variable on remunerations results from the frequent mark-up on 
pecuniary remunerations observed in Mexico. Remunerations function as 
mechanisms to retain personnel but seldom as means to motivate learning of new 
abilities and skills. No surprisingly our interviewees frequently decried that the 
pharmaceutical industry records high staff turn-over and strong competition for 
human resources, particularly at managerial and technical positions (Interviews with 
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firms 02, 03, 10 and 13). People move to places where compensation is closer to 
what they perceive is fair for their knowledge. The interviewees stressed that 
offering financial support to participate in external training helps to overcome some 
limitations to increase wages. In general, training will be undertaken at private 
universities and will not necessarily lead to obtaining a new degree. 
A brief note on estimates for the control variables is obliged, as firm’s 
characteristics seem to account for most of the explanatory power of the models in 
this and previous chapters. Indeed, such variables have a more notorious 
explanatory power than that of human resource management practices. To begin 
with, the descriptive analysis in this chapter signalled relatively low or negligible 
differences in learning behaviours associated with indicators such as foreign capital 
ownership or exports. This is why we find subsequent estimates rather interesting. 
Foreign ownership systematically impacted negatively on learning. Elsewhere in this 
thesis we have proposed that this reflects the position that Mexico occupies in the 
business strategies of global pharmaceutical firms. Local performance of systematic 
R&D efforts falls short from the objectives of multinational affiliates, except for 
outsourcing of clinical trials to local research organisations. Basically multinationals 
‘exploit’ local research capacities and country specific conditions offered by Mexico. 
As clinical trials are normally undertaken through contracts with public hospitals or 
individual medical doctors; no managerial responsibility other than adequate 
compensation link firms to those agents. 
This chapter corroborated that participation in export markets induces 
knowledge exploration. Competition in external markets for goods, in this case 
pharmaceutical products, compels firms to search for knowledge outside familiar 
knowledge bases (Arora et.al, 2001). This finding recalls the very much debated and 
often controversial implementation of liberalisation programmes in Mexico and 
other Latin American countries. In principle one would agree that increased 
competition promotes incentives for enhanced technological profiles among 
pharmaceutical firms. However, competition does not limit to the domestic market. 
Parallel implementation of more decisive policies to promote exports by local firms 
can encourage domestic firms to implement more decisive efforts to innovate. The 
literature shows that successful catching up in South East Asia involved countries 
where domestic economic activities leaned strongly towards export markets. 
Last but not least, adoption of modern organisational practices was positive 
and statistically significant particularly for external learning strategies. In our view 
this reflects the reputation that Mexico has gained as a modern drug manufacturing 
centre. As discussed in chapter 5, multinational firms operating in the domestic 
market are already incorporating some of the most novel manufacturing techniques 
such as Process Automated Technologies (PATs), which require investment in 
machinery and enhanced organisational techniques. Nevertheless, their impact on 
technological efforts involving in-house R&D remains negligible. Opportunities to 
tap into some of the country’s capacities, in drug manufacturing, generic drug 
development and in the use of biotechnology to build stronger R&D bases, remain 
largely unexplored and unexploited.  
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 Table 8.6: Bivariate probit models for internal and external learning strategies underpinning knowledge exploitation and 
exploration activities 
Variables rd_exploit external_mkt Cond Prob rd_explore external_mkt Cond Prob 
training_internal 0.67** -0.004 -0.108 0.31 0.03 -0.034 
 (0.31) (0.33) (0.093) (0.34) (0.34) (0.091) 
external_training 0.47 0.41 0.079 0.80** 0.41 0.022 
 (0.30) (0.32) (0.107) (0.32) (0.32) (0.097) 
rem_size 0.046 0.07 0.018 0.065 0.067 0.014 
 (0.06) (0.05) (0.017) (0.057) (0.054) (0.017) 
rule_hiring 0.30 0.44* 0.132** -0.15 0.44* 0.099 
 (0.28) (0.26) (0.066) (0.29) (0.27) (0.064) 
imp_empowerment -0.15 0.29 0.116 0.014 0.29 0.170** 
 (0.23) (0.22) (0.084) (0.22) (0.22) (0.079) 
modern_practice 0.15 0.87*** 0.322*** 0.35 0.88*** 0.278** 
 (0.35) (0.33) (0.115) (0.33) (0.33) (0.112) 
export_dummy 0.36 0.48 0.125 1.00*** 0.47 0.022 
 (0.34) (0.32) (0.111) (0.33) (0.32) (0.110) 
fdi -0.84** -1.16*** -0.326** -1.35*** -1.18*** -0.222 
 (0.38) (0.33) (0.138) (0.40) (0.35) (0.149) 
constant -0.64* -1.27***  -1.16*** -1.29***  
 (0.39) (0.44)  (0.42) (0.44)  
Observations     112  
Log Likelihood Full  -109   -113  
Χ
  [16]57.8***   [16]68.5***  
ρ  0.73   0.65  
Wald test, ρ=0  [1]17.84***   [1]15.12***  
Notes: ***,**,* significant at the 1, 5 and 10 percent confidence level; degrees of freedom in parentheses; degrees of 
freedom within squared brackets. For variable definitions see Chapter 4. 
Source: Author with information from ENESTYC, 2005 
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 Table 8.8: Bivariate probit models for learning strategies including knowledge exploration and external R&D  
VARIABLES rd_explore extrel_rd Conditional Probability 
training_internal 0.29 0.11 0.007 
 (0.34) (0.40) (0.142) 
external_training 0.81** 0.55 0.099 
 (0.32) (0.41) (0.132) 
rem_size 0.07 0.10* 0.031 
 (0.06) (0.06) (0.020) 
rule_hiring -0.17 0.61** 0.261*** 
 (0.28) (0.27) (0.101) 
imp_empowerment -0.01 0.17 0.069 
 (0.23) (0.23) (0.081) 
modern_practice 0.38 0.22 0.035 
 (0.34) (0.37) (0.130) 
export_dummy 1.04*** 0.37 0.011 
 (0.33) (0.31) (0.123) 
fdi -1.39*** -1.46*** -0.334*** 
 (0.40) (0.40) (0.102) 
constant -1.18*** -2.26***  
 (0.45) (0.53)  
Observations  112  
Log Likelihood Full  -108  
Χ
  [16]46.5***  
ρ  0.66  
Wald test, ρ=0  [1]11.12***  
Notes: ***,**,* significant at the 1, 5 and 10 percent confidence level;  
degrees of freedom within squared brackets. For variable definitions, see Chapter 4. 
Source: Author with information from ENESTYC, 2005 
 
 
 
181
1
8
2
 
Ta
b
le
 8
.9
: B
iv
ar
ia
te
 p
ro
b
it
 m
o
d
el
s 
fo
r 
in
te
rn
al
 a
n
d
 e
xt
e
rn
al
 le
ar
n
in
g 
st
ra
te
gi
es
 u
n
d
er
p
in
n
in
g 
kn
o
w
le
d
ge
 e
xp
lo
it
at
io
n
 a
n
d
 le
ar
n
in
g 
th
ro
u
gh
 e
xt
er
n
al
 m
ar
ke
ts
, B
y 
ex
te
rn
al
 t
ra
in
in
g 
p
ro
vi
d
er
 
V
ar
ia
b
le
s 
rd
_e
xp
lo
it
 e
xt
er
n
al
_
m
kt
 r
d
_e
xp
lo
it
 e
xt
er
n
al
_
m
kt
 r
d
_e
xp
lo
it
 e
xt
er
n
al
_
m
kt
 r
d
_e
xp
lo
it
 e
xt
er
n
al
_
m
kt
 r
d
_e
xp
lo
it
 e
xt
er
n
al
_
m
kt
 r
d
_e
xp
lo
it
 e
xt
er
n
al
_
m
kt
 r
d
_e
xp
lo
it
 e
xt
er
n
al
_
m
kt
 
tr
ai
n
in
g_
in
te
rn
al
 
0.
80
*
**
 
0.
12
 
0.
70
*
*
 
-0
.0
9
0
 
0.
79
*
*
 
0.
10
 
0.
79
*
*
 
0.
12
 
0.
77
*
*
 
0.
13
 
0.
71
*
*
 
0.
07
4
 
0.
77
*
*
 
0.
05
7
 
 
(0
.3
1)
 
(0
.3
3)
 
(0
.3
0)
 
(0
.3
4)
 
(0
.3
1)
 
(0
.3
3)
 
(0
.3
1)
 
(0
.3
2)
 
(0
.3
1)
 
(0
.3
3)
 
(0
.3
4)
 
(0
.3
7)
 
(0
.3
1)
 
(0
.3
1)
 
tr
ai
n
in
g_
fi
rm
 
-0
.0
3
 
-0
.0
2
1
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(0
.2
7)
 
(0
.2
9)
 
 
 
 
 
 
 
 
 
 
 
 
 
tr
ai
n
in
g_
fr
ee
la
n
ce
 
 
 
0.
45
 
0.
69
*
*
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(0
.2
9)
 
(0
.2
9)
 
 
 
 
 
 
 
 
 
 
 
tr
ai
n
in
g_
p
ri
u
n
iv
 
 
 
 
 
0.
03
 
0.
09
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(0
.3
6)
 
(0
.3
5)
 
 
 
 
 
 
 
 
 
tr
ai
n
in
g_
p
u
b
u
n
iv
 
 
 
 
 
 
 
0.
54
 
0.
41
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(0
.4
7)
 
(0
.3
7)
 
 
 
 
 
 
 
tr
ai
n
in
g_
p
u
b
ce
n
t 
 
 
 
 
 
 
 
 
0.
16
 
-0
.1
2
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(0
.3
9)
 
(0
.3
7)
 
 
 
 
 
tr
ai
n
in
g_
su
p
_m
ac
h
 
 
 
 
 
 
 
 
 
 
 
0.
17
 
0.
08
2
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(0
.3
0)
 
(0
.3
1)
 
 
 
tr
ai
n
in
g_
tr
ad
eo
rg
 
 
 
 
 
 
 
 
 
 
 
 
 
0.
87
*
*
 
0.
67
*
*
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(0
.3
7)
 
(0
.3
2)
 
re
m
_s
iz
e
 
0.
06
 
0.
08
 
0.
06
 
0.
10
*
 
0.
06
 
0.
08
 
0.
06
 
0.
08
 
0.
06
 
0.
08
 
0.
06
 
0.
08
2
 
0.
05
 
0.
07
0
 
 
(0
.0
6)
 
(0
.0
6)
 
(0
.0
6)
 
(0
.0
5)
 
(0
.0
6)
 
(0
.0
6)
 
(0
.0
6)
 
(0
.0
5)
 
(0
.0
5)
 
(0
.0
5)
 
(0
.0
6)
 
(0
.0
5
3)
 
(0
.0
6)
 
(0
.0
5
4)
 
ru
le
_
h
ir
in
g 
0.
29
 
0.
44
*
 
0.
20
 
0.
30
 
0.
29
 
0.
43
*
 
0.
29
 
0.
42
 
0.
29
 
0.
44
*
 
0.
29
 
0.
44
*
 
0.
49
 
0.
61
*
*
 
 
(0
.2
8)
 
(0
.2
6)
 
(0
.2
9)
 
(0
.2
6)
 
(0
.2
8)
 
(0
.2
6)
 
(0
.2
8)
 
(0
.2
6)
 
(0
.2
8)
 
(0
.2
6)
 
(0
.2
8)
 
(0
.2
6)
 
(0
.3
1)
 
(0
.2
8)
 
im
p
_e
m
p
o
w
e
rm
e
n
t 
-0
.1
4
 
0.
30
 
-0
.1
7
 
0.
27
 
-0
.1
4
 
0.
30
 
-0
.1
4
 
0.
31
 
-0
.1
4
 
0.
30
 
-0
.1
5
 
0.
30
 
-0
.1
8
 
0.
27
 
 
(0
.2
3)
 
(0
.2
2)
 
(0
.2
4)
 
(0
.2
2)
 
(0
.2
3)
 
(0
.2
2)
 
(0
.2
3)
 
(0
.2
2)
 
(0
.2
3)
 
(0
.2
2)
 
(0
.2
3)
 
(0
.2
2)
 
(0
.2
4)
 
(0
.2
2)
 
m
o
d
er
n
_
p
ra
ct
ic
e 
0.
21
 
0.
89
*
**
 
0.
19
 
0.
92
*
**
 
0.
21
 
0.
89
*
**
 
0.
21
 
0.
90
*
**
 
0.
21
 
0.
89
*
**
 
0.
18
 
0.
88
*
**
 
0.
13
 
0.
86
*
**
 
 
(0
.3
4)
 
(0
.3
2)
 
(0
.3
4)
 
(0
.3
3)
 
(0
.3
4)
 
(0
.3
2)
 
(0
.3
5)
 
(0
.3
2)
 
(0
.3
4)
 
(0
.3
2)
 
(0
.3
4)
 
(0
.3
2)
 
(0
.3
4)
 
(0
.3
3)
 
ex
p
o
rt
_d
u
m
m
y 
0.
34
 
0.
47
 
0.
25
 
0.
32
 
0.
33
 
0.
45
 
0.
26
 
0.
41
 
0.
34
 
0.
48
 
0.
32
 
0.
46
 
0.
28
 
0.
44
 
 
(0
.3
4)
 
(0
.3
1)
 
(0
.3
4)
 
(0
.3
2)
 
(0
.3
3)
 
(0
.3
4)
 
(0
.3
3)
 
(0
.3
2)
 
(0
.3
4)
 
(0
.3
1)
 
(0
.3
4)
 
(0
.3
2)
 
(0
.3
5)
 
(0
.3
1)
 
fd
i 
-0
.8
7*
*
 
-1
.2
0*
**
 
-0
.8
7*
*
 
-1
.2
4*
**
 
-0
.8
6*
*
 
-1
.1
8
**
*
 
-0
.8
5*
*
 
-1
.1
9*
**
 
-0
.8
4*
*
 
-1
.2
1*
**
 
-0
.8
4*
*
 
-1
.1
8
**
*
 
-0
.8
6*
*
 
-1
.1
7*
**
 
 
(0
.3
8)
 
(0
.3
3)
 
(0
.3
7)
 
(0
.3
4)
 
(0
.3
8)
 
(0
.3
4)
 
(0
.3
8)
 
(0
.3
3)
 
(0
.3
8)
 
(0
.3
4)
 
(0
.3
8)
 
(0
.3
4)
 
(0
.3
9)
 
(0
.3
3)
 
C
o
n
st
an
t 
-0
.5
2
 
-1
.1
6*
**
 
-0
.5
7
 
-1
.2
6*
**
 
-0
.5
2
 
-1
.1
4*
**
 
-0
.5
6
 
-1
.1
8*
**
 
-0
.5
1
 
-1
.1
8*
**
 
-0
.5
2
 
-1
.1
6*
**
 
-0
.5
8
 
-1
.2
3*
**
 
 
(0
.3
8)
 
(0
.4
2)
 
(0
.3
7)
 
(0
.4
3)
 
(0
.3
9)
 
(0
.4
3)
 
(0
.3
8)
 
(0
.4
2)
 
(0
.3
7)
 
(0
.4
2)
 
(0
.3
8)
 
(0
.4
2)
 
(0
.3
8)
 
(0
.4
3)
 
O
b
se
rv
at
io
n
s 
 
 
 
 
 
 
 
11
2
 
 
 
 
 
 
 
Lo
g 
Li
ke
lih
o
o
d
 F
u
ll 
 
-1
1
0
 
 
-1
0
7
 
 
-1
1
0
 
 
-1
0
9
 
 
-1
1
0
 
 
-1
1
0
 
 
-1
0
7
 
Χ
2  
 
[1
6]
5
4.
0*
*
*
 
 
[1
6]
6
3.
6*
*
*
 
 
[1
6]
5
4.
9*
*
*
 
 
[1
6]
5
6.
9*
*
*
 
 
[1
6]
5
3.
6*
*
*
 
 
[1
6]
5
5.
8*
*
*
 
 
[1
6]
5
3.
3*
*
*
 
ρ
 
 
0.
74
 
 
0.
74
 
 
0.
74
 
 
0.
73
 
 
0.
74
 
 
0.
74
 
 
0.
72
 
W
al
d
 t
es
t,
 ρ
=0
 
 
[1
]1
8.
29
**
*
 
 
[1
]1
8.
00
**
*
 
 
[1
]1
8.
96
**
*
 
 
[1
]1
8.
26
**
*
 
 
[1
]1
8.
53
**
*
 
 
[1
]1
8.
41
**
*
 
 
[1
]1
6.
66
**
*
 
N
o
te
s:
 *
**
,*
*,
*
 s
ig
n
if
ic
an
t 
at
 t
h
e 
1,
 5
 a
n
d
 1
0 
p
e
rc
e
nt
 c
o
n
fi
d
en
ce
 le
ve
l; 
d
eg
re
es
 o
f 
fr
ee
d
o
m
 in
 p
ar
e
nt
h
es
es
; d
e
gr
ee
s 
o
f 
fr
ee
d
o
m
 w
it
h
in
 s
q
u
ar
e
d
 b
ra
ck
e
ts
. F
o
r 
va
ri
ab
le
 d
ef
in
it
io
n
s,
 s
ee
 C
h
ap
te
r 
4.
 
So
u
rc
e:
 A
u
th
o
r 
w
it
h
 in
fo
rm
at
io
n
 f
ro
m
 E
N
ES
TY
C
, 2
0
05
  
 
154 1 2 
182
1
8
3
 
Ta
b
le
 8
.1
0:
 B
iv
ar
ia
te
 p
ro
b
it
 m
o
d
el
s 
fo
r 
in
te
rn
al
 a
n
d
 e
xt
er
n
al
 le
ar
n
in
g 
st
ra
te
gi
es
 f
o
r 
kn
o
w
le
d
ge
 e
xp
lo
it
at
io
n
 a
n
d
 le
ar
n
in
g 
fr
o
m
 e
xt
er
n
al
 m
ar
ke
ts
. B
y 
ex
te
rn
al
 t
ra
in
in
g 
p
ro
vi
d
e
r 
V
ar
ia
b
le
s 
rd
_e
xp
lo
re
 
ex
te
rn
al
_m
kt
 
rd
_e
xp
lo
re
 
ex
te
rn
al
_m
kt
 
rd
_e
xp
lo
re
 
ex
te
rn
al
_m
kt
 
rd
_e
xp
lo
re
 
ex
te
rn
al
_m
kt
 
rd
_e
xp
lo
re
 
ex
te
rn
al
_m
kt
 
rd
_e
xp
lo
re
 
ex
te
rn
al
_m
kt
 
rd
_e
xp
lo
re
 
ex
te
rn
al
_m
kt
 
tr
ai
n
in
g_
in
te
rn
al
 
0.
47
 
0.
15
 
0.
41
 
-0
.0
43
 
0.
51
 
0.
13
 
0
.5
4
 
0.
14
 
0.
49
 
0.
17
 
0.
53
 
0.
08
5
 
0.
48
 
0.
08
1
 
 
(0
.3
4)
 
(0
.3
3)
 
(0
.3
4)
 
(0
.3
4)
 
(0
.3
4)
 
(0
.3
3)
 
(0
.3
4)
 
(0
.3
2)
 
(0
.3
4)
 
(0
.3
4)
 
(0
.3
7)
 
(0
.3
7)
 
(0
.3
4)
 
(0
.3
1)
 
tr
ai
n
in
g_
fi
rm
 
0.
33
 
0.
01
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(0
.2
7)
 
(0
.2
9)
 
 
 
 
 
 
 
 
 
 
 
 
 
tr
ai
n
in
g_
fr
ee
la
n
ce
 
 
 
0.
61
**
 
0.
69
**
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(0
.2
8)
 
(0
.2
9)
 
 
 
 
 
 
 
 
 
 
 
tr
ai
n
in
g_
p
ri
u
n
iv
 
 
 
 
 
0.
40
 
0.
11
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(0
.3
4)
 
(0
.3
6)
 
 
 
 
 
 
 
 
 
tr
ai
n
in
g_
p
u
b
u
n
iv
 
 
 
 
 
 
 
0.
63
 
0.
48
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(0
.4
4)
 
(0
.4
1)
 
 
 
 
 
 
 
tr
ai
n
in
g_
p
u
b
ce
n
t 
 
 
 
 
 
 
 
 
0.
26
 
-0
.1
6
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(0
.3
7)
 
(0
.3
6)
 
 
 
 
 
tr
ai
n
in
g_
su
p
_m
ac
h
 
 
 
 
 
 
 
 
 
 
 
0.
01
1
 
0.
10
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(0
.2
9)
 
(0
.3
1)
 
 
 
tr
ai
n
in
g_
tr
ad
eo
rg
 
 
 
 
 
 
 
 
 
 
 
 
 
1.
53
**
* 
0.
62
*
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(0
.4
5)
 
(0
.3
2)
 
re
m
_s
iz
e 
0.
08
 
0.
08
 
0.
10
*
 
0.
09
*
 
0.
08
 
0.
08
 
0.
09
*
 
0.
08
 
0.
09
 
0.
09
 
0.
09
5*
 
0.
08
2
 
0.
06
9
 
0.
07
0
 
 
(0
.0
6)
 
(0
.0
6)
 
(0
.0
6)
 
(0
.0
5)
 
(0
.0
6)
 
(0
.0
54
) 
(0
.0
6)
 
(0
.0
5)
 
(0
.0
6)
 
(0
.0
5)
 
(0
.0
56
) 
(0
.0
54
) 
(0
.0
59
) 
(0
.0
54
) 
ru
le
_h
ir
in
g 
-0
.1
4
 
0.
43
 
-0
.3
0
 
0.
30
 
-0
.1
9
 
0.
43
 
-0
.1
8
 
0.
41
 
-0
.1
6
 
0.
44
*
 
-0
.1
5
 
0.
44
*
 
0.
14
 
0.
60
**
 
 
(0
.2
8)
 
(0
.2
6)
 
(0
.2
9)
 
(0
.2
7)
 
(0
.2
8)
 
(0
.2
6)
 
(0
.2
8)
 
(0
.2
7)
 
(0
.2
8)
 
(0
.2
7)
 
(0
.2
8)
 
(0
.2
6)
 
(0
.3
0)
 
(0
.2
8)
 
im
p
_e
m
p
o
w
er
m
en
t 
 
0.
02
 
0.
30
 
-0
.0
1
 
0.
26
 
0.
00
 
0.
30
 
0.
04
 
0.
31
 
0.
03
 
0.
31
 
0.
03
2
 
0.
30
 
-0
.0
35
 
0.
27
 
 
(0
.2
2)
 
(0
.2
2)
 
(0
.2
3)
 
(0
.2
3)
 
(0
.2
1)
 
(0
.2
2)
 
(0
.2
2)
 
(0
.2
2)
 
(0
.2
2)
 
(0
.2
2)
 
(0
.2
2)
 
(0
.2
2)
 
(0
.2
4)
 
(0
.2
2)
 
m
o
d
er
n
_p
ra
ct
ic
e
 
0.
41
 
0.
90
**
* 
0.
42
 
0.
95
**
* 
0.
43
 
0.
91
**
* 
0.
44
 
0.
92
**
* 
0.
41
 
0.
91
**
* 
0.
42
 
0.
90
**
* 
0.
34
 
0.
8
7*
**
 
 
(0
.3
3)
 
(0
.3
3)
 
(0
.3
3)
 
(0
.3
3)
 
(0
.3
2)
 
(0
.3
3)
 
(0
.3
2)
 
(0
.3
3)
 
(0
.3
2)
 
(0
.3
3)
 
(0
.3
3)
 
(0
.3
3)
 
(0
.3
4)
 
(0
.3
3)
 
ex
p
o
rt
_d
u
m
m
y 
0.
93
**
* 
0.
47
 
0.
85
**
 
0.
34
 
0.
88
**
* 
0.
44
 
0.
86
**
 
0.
40
 
0.
91
**
* 
0.
48
 
0.
91
**
* 
0.
46
 
0.
90
**
 
0.
43
 
 
(0
.3
4)
 
(0
.3
2)
 
(0
.3
4)
 
(0
.3
2)
 
(0
.3
4)
 
(0
.3
3)
 
(0
.3
4)
 
(0
.3
2)
 
(0
.3
4)
 
(0
.3
2)
 
(0
.3
4)
 
(0
.3
2)
 
(0
.3
8)
 
(0
.3
1)
 
fd
i 
-1
.3
6*
**
 
-1
.2
1*
**
 
-1
.4
1*
**
 
-1
.2
7*
**
 
-1
.3
5*
**
 
-1
.2
0*
**
 
-1
.3
8*
**
 
-1
.2
2*
**
 
-1
.3
1*
**
 
-1
.2
3*
**
 
-1
.3
5*
**
 
-1
.2
0*
**
 
-1
.4
0*
**
 
-1
.1
7*
**
 
 
(0
.4
0)
 
(0
.3
5)
 
(0
.3
9)
 
(0
.3
5)
 
(0
.4
1)
 
(0
.3
5)
 
(0
.4
1)
 
(0
.3
5)
 
(0
.4
1)
 
(0
.3
5)
 
(0
.4
2)
 
(0
.3
5)
 
(0
.4
6)
 
(0
.3
4)
 
C
o
n
st
an
t 
-1
.0
5*
*
 
-1
.1
9*
**
 
-1
.0
4*
*
 
-1
.2
9*
**
 
-0
.8
7*
*
 
-1
.1
6*
**
 
-1
.0
0*
*
 
-1
.2
0*
**
 
-0
.9
2*
*
 
-1
.2
1*
**
 
-0
.9
7*
*
 
-1
.1
8*
**
 
-1
.0
5*
*
 
-1
.2
3*
**
 
 
(0
.4
2)
 
(0
.4
3)
 
(0
.4
2)
 
(0
.4
4)
 
(0
.4
2)
 
(0
.4
4)
 
(0
.4
2)
 
(0
.4
3)
 
(0
.4
1)
 
(0
.4
4)
 
(0
.4
2)
 
(0
.4
3)
 
(0
.4
2)
 
(0
.4
3)
 
O
b
se
rv
at
io
n
s 
 
 
 
 
 
 
 
11
2
 
 
 
 
 
 
 
Lo
g 
Li
ke
lih
o
o
d
 F
u
ll 
 
-1
15
 
 
-1
13
 
 
-1
15
 
 
-1
15
 
 
-1
16
 
 
-1
16
 
 
-1
08
 
Χ
2
 
 
[1
6]
53
.2
**
*
 
 
[1
6]
59
.6
**
*
 
 
[1
6]
52
.9
**
*
 
 
[1
6]
52
.1
**
*
 
 
[1
6]
52
.6
**
*
 
 
[1
6]
51
.5
**
*
 
 
[1
6]
59
.3
**
*
 
ρ
 
 
0.
66
 
 
0.
64
 
 
0.
67
 
 
0.
66
 
 
0.
17
 
 
0.
67
 
 
0.
65
 
W
al
d
 t
es
t,
 ρ
=
0
 
 
[1
]1
5.
99
**
*
 
 
[1
]1
4.
61
**
*
 
 
[1
]1
6.
58
**
*
 
 
[1
]1
5.
47
**
*
 
 
[1
]1
6.
69
**
*
 
 
[1
]1
6.
14
**
*
 
 
[1
]1
3.
94
**
*
 
N
o
te
s:
 *
**
,*
*,
*
 s
ig
n
if
ic
an
t 
at
 t
h
e 
1,
 5
 a
n
d
 1
0
 p
er
ce
n
t 
co
n
fi
d
en
ce
 le
ve
l; 
d
eg
re
es
 o
f 
fr
ee
d
o
m
 in
 p
ar
en
th
es
es
; d
eg
re
es
 o
f 
fr
ee
d
o
m
 w
it
h
in
 s
q
u
ar
e
d
 b
ra
ck
et
s.
 F
o
r 
va
ri
ab
le
 d
ef
in
it
io
n
s,
 s
ee
 C
h
ap
te
r 
4.
 
So
u
rc
e
: A
u
th
o
r 
w
it
h
 in
fo
rm
at
io
n
 f
ro
m
 E
N
ES
TY
C
, 2
00
5 
 
 
180 
183
1
8
4
 
Ta
b
le
 8
.1
1:
 C
o
n
d
it
io
n
al
 p
ro
b
ab
ili
ti
es
 f
o
r 
m
o
d
el
s 
in
 t
ab
le
s 
8.
9
 a
n
d
 8
.1
0,
 r
es
p
ec
ti
ve
ly
; b
y 
ty
p
e 
o
f 
st
ra
te
gy
 a
n
d
 e
xt
er
n
al
 t
ra
in
in
g 
p
ro
vi
d
e
r 
V
ar
ia
b
le
s 
Ex
p
lo
it
 
Ex
p
lo
it
 
Ex
p
lo
it
 
Ex
p
lo
it
 
Ex
p
lo
it
 
Ex
p
lo
it
 
Ex
p
lo
it
 
Ex
p
lo
re
 
Ex
p
lo
re
 
Ex
p
lo
re
 
Ex
p
lo
re
 
Ex
p
lo
re
 
Ex
p
lo
re
 
Ex
p
lo
re
 
tr
ai
n
in
g_
in
te
rn
al
 
-0
.0
9
1
 
-0
.1
3
6
 
-0
.1
0
 
-0
.0
9
 
-0
.0
8
 
-0
.0
9
 
-0
.1
0
 
-0
.0
2
 
-0
.0
7
 
-0
.0
3
 
-0
.0
3
 
-0
.0
2
 
-0
.0
5
 
-0
.0
4
 
 
(0
.1
0)
 
(0
.0
9)
 
(0
.1
0)
 
(0
.1
0)
 
(0
.1
0)
 
(0
.1
0)
 
(0
.1
0)
 
(0
.1
0)
 
(0
.0
9)
 
(0
.1
0)
 
(0
.1
0)
 
(0
.1
0)
 
(0
.1
0)
 
(0
.1
0)
 
tr
ai
n
in
g_
fi
rm
 
-0
.0
0
3
 
 
 
 
 
 
 
-0
.0
4
 
 
 
 
 
 
 
 
(0
.0
9)
 
 
 
 
 
 
 
(0
.0
8)
 
 
 
 
 
 
 
tr
ai
n
in
g_
fr
ee
la
n
ce
 
 
0.
18
*
*
 
 
 
 
 
 
 
0.
15
*
 
 
 
 
 
 
 
 
(0
.0
9)
 
 
 
 
 
 
 
(0
.0
9)
 
 
 
 
 
 
tr
ai
n
in
g_
p
ri
u
n
iv
 
 
 
0.
03
 
 
 
 
 
 
 
-0
.0
2
 
 
 
 
 
 
 
 
(0
.1
2)
 
 
 
 
 
 
 
(0
.1
2)
 
 
 
 
 
tr
ai
n
in
g_
p
u
b
u
n
iv
 
 
 
 
0.
07
 
 
 
 
 
 
 
0.
08
 
 
 
 
 
 
 
 
(0
.1
1)
 
 
 
 
 
 
 
(0
.0
9)
 
 
 
 
tr
ai
n
in
g_
p
u
b
ce
n
t 
 
 
 
 
-0
.0
7
 
 
 
 
 
 
 
-0
.1
0
 
 
 
 
 
 
 
 
(0
.1
2)
 
 
 
 
 
 
 
(0
.1
3)
 
 
 
tr
ai
n
in
g_
su
p
_m
ac
h
 
 
 
 
 
 
0.
00
3
 
 
 
 
 
 
 
0.
03
 
 
 
 
 
 
 
 
(0
.1
0)
 
 
 
 
 
 
 
(0
.0
9)
 
 
tr
ai
n
in
g_
tr
ad
eo
rg
 
 
 
 
 
 
 
0.
12
 
 
 
 
 
 
 
0.
04
 
 
 
 
 
 
 
 
(0
.0
9)
 
 
 
 
 
 
 
(0
.0
9)
 
re
m
_s
iz
e
 
0.
02
 
0.
03
 
0.
02
 
0.
02
 
0.
02
 
0.
02
 
0.
02
 
0.
02
 
0.
02
 
0.
01
 
0.
02
 
0.
02
 
0.
01
 
0.
01
 
 
(0
.0
2)
 
(0
.0
2)
 
(0
.0
2)
 
(0
.0
2)
 
(0
.0
2)
 
(0
.0
2)
 
(0
.0
2)
 
(0
.0
2)
 
(0
.0
2)
 
(0
.0
2)
 
(0
.0
2)
 
(0
.0
2)
 
(0
.0
2)
 
(0
.0
2)
 
ru
le
_
h
ir
in
g 
0.
12
 
0.
08
 
0.
11
 
0.
11
 
0.
12
 
0.
12
 
0.
15
*
 
0.
1
6*
*
 
0.
14
*
 
0.
17
*
*
 
0.
16
*
*
 
0.
17
*
*
 
0.
17
*
*
 
0.
19
*
*
 
 
(0
.0
8)
 
(0
.0
8)
 
(0
.0
8)
 
(0
.0
8)
 
(0
.0
8)
 
(0
.0
8)
 
(0
.0
9)
 
(0
.0
8)
 
(0
.0
8)
 
(0
.0
8)
 
(0
.0
8)
 
(0
.0
8)
 
(0
.0
8)
 
(0
.0
8)
 
im
p
_e
m
p
o
w
e
rm
e
n
t 
0.
13
*
*
 
0.
12
*
 
0.
13
*
*
 
0.
14
*
*
 
0.
14
*
*
 
0.
13
*
*
 
0.
13
*
 
0.
10
 
0.
09
 
0.
10
 
0.
10
 
0.
10
*
 
0.
10
 
0.
10
 
 
(0
.0
7)
 
(0
.0
6)
 
(0
.0
7)
 
(0
.0
7)
 
(0
.0
7)
 
(0
.0
7)
 
(0
.0
7)
 
(0
.0
6)
 
(0
.0
6)
 
(0
.0
6)
 
(0
.0
6)
 
(0
.0
6)
 
(0
.0
6)
 
(0
.0
7)
 
m
o
d
er
n
_
p
ra
ct
ic
e 
0.
32
*
**
 
0.
33
*
**
 
0.
32
*
**
 
0.
33
*
**
 
0.
32
*
**
 
0.
32
*
**
 
0.
32
*
**
 
0.
27
*
*
 
0.
29
*
**
 
0.
27
*
*
 
0.
28
*
*
 
0.
28
*
*
 
0.
27
*
*
 
0.
28
*
*
 
 
(0
.1
1)
 
(0
.1
2)
 
(0
.1
1)
 
(0
.1
1)
 
(0
.1
1)
 
(0
.1
1)
 
(0
.1
2)
 
(0
.1
1)
 
(0
.1
1)
 
(0
.1
1)
 
(0
.1
1)
 
(0
.1
1)
 
(0
.1
1)
 
(0
.1
2)
 
ex
p
o
rt
_d
u
m
m
y 
0.
12
 
0.
08
 
0.
12
 
0.
11
 
0.
13
 
0.
12
 
0.
12
 
0.
03
 
-0
.0
0
1
 
0.
02
 
0.
02
 
0.
03
 
0.
02
 
0.
03
 
 
(0
.1
1)
 
(0
.1
1)
 
(0
.1
2)
 
(0
.1
1)
 
(0
.1
1)
 
(0
.1
1)
 
(0
.1
1)
 
(0
.1
1)
 
(0
.1
1)
 
(0
.1
1)
 
(0
.1
1)
 
(0
.1
1)
 
(0
.1
1)
 
(0
.1
1)
 
fd
i 
-0
.3
3*
*
 
-0
.3
5*
*
 
-0
.3
3*
*
 
-0
.3
4*
*
 
-0
.3
5*
*
 
-0
.3
3*
*
 
-0
.3
3*
*
 
-0
.2
3
 
-0
.2
5
 
-0
.2
2
 
-0
.2
3
 
-0
.2
4
 
-0
.2
2
 
-0
.2
3
 
 
(0
.1
4)
 
(0
.1
4)
 
(0
.1
4)
 
(0
.1
6)
 
(0
.1
4)
 
(0
.1
4)
 
(0
.1
4)
 
(0
.1
5)
 
(0
.1
5)
 
(0
.1
5)
 
(0
.1
5)
 
(0
.1
5)
 
(0
.1
5)
 
(0
.1
6)
 
N
o
te
s:
 +
 P
ro
b
ab
ili
ty
 t
h
at
 a
 f
ir
m
 p
u
rs
u
es
 a
n
 e
xt
er
n
al
 le
ar
n
in
g 
st
ra
te
gy
, p
ro
vi
d
ed
 t
h
at
 it
 a
lr
ea
d
y 
p
er
fo
rm
s 
in
te
rn
al
 t
ec
h
n
o
lo
gi
ca
l e
ff
o
rt
s;
 *
**
,*
*
,*
 s
ig
n
if
ic
an
t 
at
 t
h
e 
1
, 5
 a
n
d
 1
0
 p
er
ce
n
t 
co
n
fi
d
e
n
ce
 
le
ve
l; 
d
eg
re
es
 o
f 
fr
ee
d
o
m
 in
 p
ar
e
n
th
es
es
; F
o
r 
st
at
is
ti
cs
 o
n
 g
o
o
d
n
es
s 
o
f 
fi
t,
 s
ee
 t
ab
le
s 
9.
9 
an
d
 9
.1
0;
 E
xp
lo
it
 d
e
n
o
te
s 
co
m
b
in
at
io
n
s 
o
f 
rd
_e
xp
lo
it
 a
n
d
 e
xt
e
rn
al
_m
kt
; 
Ex
p
lo
re
 d
en
o
te
s 
co
m
b
in
at
io
n
s 
o
f 
rd
_e
xp
lo
re
 a
n
d
 e
xt
er
n
al
_
m
kt
. F
o
r 
th
e 
re
st
 o
f 
va
ri
ab
le
 d
ef
in
it
io
n
s 
se
e 
ch
ap
te
r 
4.
 
So
u
rc
e:
 A
u
th
o
r 
w
it
h
 in
fo
rm
at
io
n
 f
ro
m
 E
N
ES
TY
C
, 2
00
5
 
154 
184
Chapter 9 
Integrated view: human resource 
management practices and learning for 
innovation  
 
 
 
During the process of writing this thesis, in April 2009, a major and unprecedented 
sanitary emergency erupted in Mexico. What was the cause? Outbreak of an as yet 
unknown strain of a swine flu virus, A(H1N1). For a few weeks, and with the aim of 
mitigating against widespread contagion among the Mexican population and 
beyond its borders, local health authorities applied strict preventive measures, such 
as shutting down schools, bringing to a halt all non-critical economic and related 
activities in most affected areas, notably Mexico City; and a total suspension of all 
activities that might lead to large gatherings of people. However difficult to 
determine, the economic costs of the emergency were estimated at 0.3 percent of 
Mexico's GDP; in some provinces the expected cost was even higher. To some extent 
the scenarios helping to assess the cost built on the similar threat of the Severe 
Acute Respiratory Syndrome (SARS) in Asia. 
To a certain extent the reaction of the Mexican authorities revealed an inability 
to distinguish between people suffering from the new A(H1N1) virus, and from 
those affected by some other kind of respiratory-related disease. The new virus 
exposed some deficiencies in local health systems. More importantly, the outbreak 
highlighted great voids in terms of STI activities in the country. Mexico relied on 
laboratories and scientists from Canada and the US to identify cases of people 
affected by the virus. It took a few weeks before the country could import, install 
and operate facilities and diagnostics to support the identification of positive cases 
of A(H1N1). The situation was compounded by the already low investment in R&D, 
particularly within the health sector –see chapter 5. Slow response by Mexican 
health authorities equally underscored the limited S&T capacity of local early 
warning systems in the event of a disaster or potential epidemic. 
As international health authorities, more specifically the World Health 
Organisation (WHO), communicated the possibility of a worldwide pandemic, the 
international community was prompted to cooperate in controlling the spread of 
the virus. Efforts included the proliferation of sanitary regulations, messaging that 
urged people to restrict human contact, and sanctions on imports and travel to 
Mexico. Reaction was strong in China, where the footprint of SARS was still fresh. 
Authorities in countries such as Brazil, Cuba, Colombia and Argentina justified 
suspension of travel from and to Mexico on the grounds that they were not 
prepared to deal with a threat on this scale. Argentina, in particular, was already 
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fighting a Malaria epidemic. In addition to weaknesses in local healthcare systems, 
the fear expressed by the countries cited above, as well as other developing 
countries, reflected their own lack of scientific, technical and financial resources to 
respond to an emergency of this magnitude. After all, only “the strength of a 
country’s health system will make the biggest difference in sickness and survival 
during an influenza pandemic (...) countries, especially in the developing world, 
where populations are most vulnerable, should prepare to see more than [a] small 
number of severe cases” (Chan 2009).  
In August 2010 the World Health Organisation declared the end of the 
pandemic (WHO 2010). Daily routines are officially restored to normal, although 
risks of contagion had already diminished considerably earlier in 2010 following the 
successful development of a vaccine against the A(H1N1) virus. Important 
challenges remained however as mass producing, delivery and distribution of new 
vaccines took time and required significant resource mobilization. One should not 
forget that the mutability and recombinant capacity of viruses keeps international 
health authorities in the look out for new events.  
From the start, the new strain of the swine flue virus pushed science, on a 
global scale, to search within and outside current knowledge bases for a solution to 
the problem. As noted by WHO authorities during the early days of the contagion, 
“Scientists, clinicians, and epidemiologists are capturing abundant signals. But we 
do not have the scientific knowledge to interpret these signals with certainty. We 
have clues, many clues, but very few firm conclusions” (Chan 2009). The outbreak of 
the influenza pandemic reminded us that the best way to respond to this and any 
other future threat is for countries to build their capacities in several areas, from 
health systems, to research and other more economic-related activities. As 
discussed in chapter 4, there are strong linkages between detection and prevention 
of health needs, operation of healthcare systems, public policy and notably, 
pharmaceutical innovation–figure 4.2.  
The outbreak of the A(H1N1) virus incited debate concerning the costs of a 
global pandemic and, more specifically, on how to share the burden among the 
international community (Chan 2009).
1
 The pandemic reminded us that although 
pharmaceutical innovation is a rather cumbersome, time-consuming, resource-
draining process, it remains an attractive business. Take as an example firms such as 
Roche and GSK, the multinationals that manufacture the main antiviral used against 
swine flu: Aseltamivir (Tamiflu
TM
), and Zanamivir (Relenza
TM
). Rising sales of both of 
those products boosted the valuation of these companies in world stock markets; 
considerable profits poured in for these companies during 2009. Likewise, Sanofi 
Pasteur, one of the largest vaccine developers in the world, benefited from 
important grants from the US government for production of a bulk A(H1N1) vaccine 
valued at US$190 million (Sanofi-Pasteur 2009). The benefits for other firms were 
significant as well, as the US government was ready to invest US$1 billion in clinical 
                                                 
1 Mexican Health authorities proposed the creation of a global contingency fund, supported by the World 
Bank and the International Monetary Fund, to compensate those countries that notify promptly about 
the outbreak of a pandemic, or other major health risk with potential international diffusion (Secretaría 
de Salud 2009)  
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research and development of a new vaccine against the A(H1N1) virus (HHS 2009).  
To what extent developing countries, and particularly domestic firms, can 
benefit from a sanitary emergency like the one just described above? It was clear, 
right from the outset, the limited capacity of countries such as Mexico to participate 
more actively in the development of the new vaccine against the A(H1N1). 
Unfortunately such limitations only added to the restrictions already faced by 
Mexico and other developing countries to respond to other more common diseases 
affecting local populations. So-called neglected tropical diseases impose equally or 
even stronger, more sustained threats than the A(H1N1) for local healthcare and 
research systems. The emergency motivated significant cooperation and exchanges 
between Mexican scientists and their peers throughout the world; Mexican 
researchers participated in efforts to characterize the molecular and genomic 
structure of the virus using modern biotechnology tools (UNAM April 30 2009). 
Nevertheless the dearth of adequate scientific and related infrastructures, not to 
mention mediocre funding capacity, hindered possibilities to participate in 
subsequent actions against the swine virus.  
The vulnerability of developing countries in the face of global and domestic 
disasters aggravates by the lack of a sufficient human resources base, including both 
the knowledge and experience needed to perform more systematic R&D efforts; in 
this case to support the development of novel pharmaceutical products. At a more 
general level, the swine flu case dramatically illustrated some of the serious 
challenges developing countries face to generate the scientific and technological 
knowledge needed to meet the myriad of socioeconomic challenges they face.  
Turning back to the discussion in the introductory chapter of this thesis, there is 
room to do research on the contribution of education systems to the building of 
sound human resource bases for STI. Education, particularly at postgraduate level, 
provides individuals with capacities, tools and ways to systematically understand 
and address pressing problems faced by society. Distinct strands of literature, 
notably including that on the national systems of innovation, document several 
challenges and opportunities to strengthen the contribution of education 
organisations to social and economic progress. Noteworthy is the construction and 
improvement of the supply of highly qualified human resources.  
Equally important it is to consider the role of factors that, from the perspective 
of demand, determine the development of human resources for STI. In particular, 
firms contribute to the development of such human resource bases via the 
organisation and management of the people involved in innovation-related 
activities, notably R&D. Based on the empirical evidence used in this thesis, I will 
now discuss some of the conclusions drawn from this study. The conclusions follow 
a progressive disaggregation, from the macro view of factors influencing learning 
and innovation in a country such as Mexico, down to the more intermediate facets 
related to the local pharmaceutical industry. Finally, I analyse a number of more 
micro aspects associated with the characteristics of human resource management 
interventions inside the firm. The discussion amalgamates three kinds of findings, 
namely: those that lend support to existing literature on human resource 
management practices, learning and innovation performance at firm level; those 
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that contrast the conclusions from previous studies; and more importantly, the 
conclusions that add to the debate in the field. 
 
1. Lessons from a study on human resource management practices and 
learning for innovation in a developing country context 
 
This thesis built on the notion that the organisation and management of 
personnel inside a firm can positively influence innovation performance at firm 
level. Two major gaps were identified in the existing literature: first, traditional 
approaches to research fail to sufficiently explain the nature of the relationships 
linking human resource management practices to innovation performance. In other 
words, why and how human resource management practices influence innovation? 
Second, so far we know very little about how human resource management 
practices hold sway of innovation performance by firms in developing countries? 
This thesis advanced the discussion around these two questions. In relation to the 
first question, the thesis analysed the role of learning as intermediary factor linking 
human resource management practices to innovation performance at the firm level. 
It looked at firms within the more ample environment around them. Hence we 
found a number of factors that shape the relationships between human resource 
management practices and learning for innovation. Such factors relate to the overall 
macro environment around STI activities, the characteristics of innovation processes 
in the (local) industry, and notably, the decisions about learning strategies adopted 
by firms. As for the second question, evidence about the pharmaceutical industry in 
Mexico substantiates our main findings.  
A third relevant set of findings relate to both the identification of the human 
resource management practices likely to influence learning for innovation. We also 
explained how and why such practices do so in the context of a developing country 
such as Mexico. As we comment latter, the provision of training showed the more 
consistent and positive effects on distinct kinds of learning and learning strategies. 
The effects associated with the remaining practices included in the analysis tended 
to be weaker, somehow subordinated to firm characteristics such as export 
behaviour and origin of capital ownership. We confirmed however, the more 
notorious effects of human resource management practices as firms tend to launch 
more ambitious learning outside their customary knowledge bases.  
Socioeconomic contexts matter for learning and innovation: The discussion 
about the A(H1N1) virus demonstrated that health-related problems arising in one 
part of the world have the potential to threaten global stability. Those problems call 
for stronger coordination between systems designed to alert on emerging global 
disasters, the structure and operation of public healthcare organisations and R&D 
systems. The latter system is a core element of strategies to improve the operation 
of the former two instances. Countries such as Mexico accuse strong disconnection 
among healthcare, R&D, and productive systems; they show greater vulnerability to 
global contingencies, not to mention the capacity to fight endemic diseases. 
Reliance on knowledge generated in more developed countries implies risks of being 
always late to respond, or fail to sufficiently take into account local conditions and 
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resources. Opportunities to develop and ‘use’ a dynamic local STI workforce are 
equally low.  
From the above, this thesis documented that in Mexico the environment 
around STI activities in general, and the operation of the pharmaceutical industry in 
particular, is poorly conducive to more intense learning and innovation activities, 
particularly by domestic firms. Mexico endures a number of challenges in policy-
making and policy implementation, namely, poor incentives to R&D as the basis for 
successful business strategies, little interaction between relevant components of the 
national and sectoral systems of innovation, and scarcity in human resources and 
research infrastructure. In such an environment, the chances for the local 
pharmaceutical industry to gain relevance in global pharmaceutical innovation are 
rather bleak; the potential for human resources to contribute to a firm’s innovative 
performance in the industry is rather low. 
Firms at a micro level and, by extension, countries at a more macro level 
contribute to and benefit differently from learning and innovation in distinct 
sectors/industries. Both micro- and macroeconomic factors combine to induce 
performance among firms and countries alike. Dynamics of consumption, R&D and 
regulations around science and technology-related activities will continue to 
influence future developments of the global pharmaceutical industry. Emerging 
economies are called to play an increasingly important role; hence the importance 
of learning about the successful stories of emerging economies such as India or 
China. However, one must question the extent to which such cases can inform 
strategies intended to further advance the base of human resources for innovation 
in other developing countries. 
Understanding the nature of the R&D process, innovation more broadly defined, 
in specific industries paves the way to better appreciate the influence of human 
resource management practices on innovation performance at firm level: Chapter 1 
documented that available studies on innovation performance and human resource 
management practices have explored the relationships between those variables at a 
single point in time. Such studies look for industry and market differences leading to 
greater heterogeneity in innovation outcomes. By contrast, research has overlooked 
ways in which firms and countries contribute to innovation in specific industries, and 
how such specialisation feeds back to the characteristics of human resource 
management practices adopted by firms.  
This thesis showed that the strategic position of an industry, as driver of 
broader economic performance, determines both the incentives to do, and the 
scope of R&D and innovation. This observation calls for more careful appreciation of 
the nature of innovation processes, the environmental conditions around such 
processes, and how those factors ultimately relate to the influence of human 
resource management practices on firm’s performance. In countries such as Mexico, 
improved innovation performance begins by enhancing incentives and conditions 
for firms to carry out R&D as a basis for more formal and systematic innovation 
efforts. 
From the above, chapter 4 documented the several instances shaping 
pharmaceutical innovation, from public interest and national wellbeing, to pure 
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business opportunities. All those dimensions involve distinct agents and institutional 
frameworks to govern both individual activities and interactions within the industry. 
Perhaps more than in other industries, the innovation cycle in the pharmaceutical 
industry is long and complex, it actively involves scientific research and 
technological developments, as well as ethical considerations concerning research 
involving humans. Some such dimensions are frequently overlooked in the 
literature. As a research intensive activity, pharmaceutical innovation systematically 
involves and can significantly affect human beings. Continuous promotion of 
learning and creativity are crucial for success in pharmaceutical innovation. 
Innovation in the industry requires commitment, sustained efforts to keep up with 
new knowledge about the world and how to use it for specific purposes. Strong 
regulation of the industry shapes, often limits the scope of and potential for 
innovation by firms. 
In a country such as Mexico pharmaceutical innovation is closely related with 
drug manufacturing activities, particularly of generic drugs; it is mostly incremental 
in nature and somehow constrained by a series of factors associated with the local 
culture and overall socioeconomic conditions of the country. Firms need to enhance 
capacities to innovate even within the narrow boundaries allowed by both local 
regulation and the inherent nature of development and manufacturing of generic 
drugs. These observations take us back to the discussion about how narrowly or 
how broadly systems of innovation should be defined in the context of developing 
countries -chapter 1. Here we argued that the two approaches are complementary; 
in effect mutually reinforcing. R&D systems are strongly linked to productive 
activities and need to be responsive to societal needs; in other words, R&D and 
socio-economic problems are dimensions with strong feedback loops. Figure 4.2 
illustrated the case of pharmaceutical R&D.  
Human resource management practices as starting point for the construction of 
systems of innovation. This thesis endorsed Lorenz and Wilkinson (2003) and 
Lundvall and Valeyre (2007) who have stressed the need for more systematic and 
comparative studies on how dynamic work environments are built and how they 
impact performance in terms of innovation, learning and, in general, technical 
change. The literature draws attention to developments at the firm level; 
nevertheless, this is only to identify factors likely to influence the construction and 
dynamics of systems of innovation over time. In other words, the firm remains the 
focal point from which cumulative learning and innovation unfold. Interest in better 
understanding the dynamic processes inside the firm motivates enquiries about the 
linkages between research on human resource management practices and 
innovation. Success however remains contingent on improved understandings of the 
conditions, organisational and development requirements, and the capacities and 
aspirations of people involved in activities such as R&D.  
Chapter 2 presented some alternative approaches to research on human 
resource management practices and innovation; arguably each of those analytical 
frameworks can be used to study the case of developing countries. Extending the 
scope of the analysis implies understanding that, in general, environmental 
conditions around innovation in developing countries can be less dynamic, more 
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cumbersome than in developed countries. Moreover, it can be more difficult to 
define innovation according to commonly accepted indicators centred on patent or 
paper counts and other customary outcomes. The look at alternative views of 
innovation set the stage for some of the main contributions of this thesis to the 
literature. 
Learning as intermediary process between human resource management and 
innovation performance: This thesis focused on learning as intermediary process 
between management practices and firm performance.
2
 Learning was broadly 
interpreted as a mechanism promoting absorptive capacity and supporting 
technology capability-building. We thus explored how human resource management 
practices influence learning for pharmaceutical innovation. In order to do so we 
discarded some underlying assumption of studies about developed countries. Firms’ 
performance was not captured in terms of innovation outcomes but in terms of the 
learning dynamics, and technological accumulation through R&D.  
Firms learn by implementing different strategies: Analysis in this thesis centred 
attention on learning activities supporting technological and innovative capability 
building. Firms fulfil innovation-relevant knowledge requirements by relying on 
either internal or external technology sources or both. To the best of our 
knowledge, this is the first time such a distinction among learning strategies is made 
in the context of studies on human resource management and innovation. The split 
of the analysis in three interrelated chapters helped to study the effects of 
management practices on learning for innovation from different perspectives, but 
always along comparable theoretical backgrounds. In such a way we got closer to 
the firm’s actual decisions underpinning technological learning and innovation. This 
thesis showed that although firms in the Mexican pharmaceutical industry tend to 
pursue in-house R&D, such activities are still very much isolated from those of other 
knowledge producers in the Mexican system of innovation. Internal knowledge 
sources prevail as the main sources for pharmaceutical R&D in Mexico. By contrast, 
the use of external knowledge sources was disconnected from in-house 
technological efforts. 
Based on the empirical literature on capability building, carefully combined 
approaches to learning were expected to provide superior results than individual 
learning strategies. Although the analysis in chapter 8 granted some support to this 
observation, data limitations make it difficult to conclude with more certainty on the 
complementarity of internal and external strategies for pharmaceutical firms in 
Mexico. The notion of complementarity is an area that attracts great attention in 
current innovation literature, particularly in developing countries where scarce 
resources need to be maximized. In Mexico, interactivity is constrained at three 
levels, along a continuum. At a macro level the structure and functioning of national 
systems of innovation is poorly conducive to such dynamic interactions; the systems 
characterise by low investment in R&D, inadequate or limited research 
infrastructure and human resources. At a more disaggregated level, the structure 
and operation of firms and public research organisations respond to different, 
                                                 
2 Creativity is an alternative dimension. 
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somewhat difficult to reconcile incentives and aspirations. Last but not least 
scientific communities face limited, even contradictory incentives to interact with 
private firms. In some cases researchers need to overcome strong peer criticism as 
to the extent a balance is maintained between research goals in terms of 
commercial purposes and that of contributing to the overall pull of scientific 
knowledge.  
Learning involves different knowledge flows depending on the goals pursued by 
the firm: An additional contribution of this thesis stems from the study of the 
knowledge flows involved during the innovation process, whether for exploitation or 
exploration -an alternative view to the classical dichotomy between incremental and 
radical innovations. This is together with the relative specialisation of a firm in 
conducting searches for particular pieces of knowledge. In such a way, the 
traditional distinction between process and product innovations became only an 
additional, albeit important, category for the analysis. Perceiving innovation merely 
in terms of outcomes masks the more intricate learning processes taking place 
inside the firm. Our research strategy was in line with Delery (1998) who advised the 
use of multiple performance indicators in investigations about human resource 
management practices. In this case we introduced distinct definitions of the R&D 
variable, each of which denoted different uses of knowledge during the R&D 
process. 
Human resource management practices play different roles as determinants of 
learning for innovation: Different learning strategies on the one hand, and the 
search for distinct pieces of knowledge on the other, require mobilization of 
different kinds of resources. Such resources contribute differently to distinct 
learning strategies. As part of internal learning efforts, management practices 
support absorptive capacity building; and human beings are building blocks upon 
which such building processes unfold (Simon 1991). In addition, human resource 
management practices condition the nature of interactions between firms and other 
agents in the environment. Those practices assist in channelling, absorbing and, 
eventually, transferring knowledge from and to the external environment. If 
consideration falls onto knowledge flows, human resource management practices 
intervene in two main areas: First, they guide the mobilization and exploitation of 
knowledge already residing in the firm. Second, they steer the search and 
exploration for knowledge previously unavailable within the firm; they effectively 
contribute to enriching the knowledge base of a firm.  
The need to address more explicitly the dynamics of knowledge accumulation 
and how this is accompanied by the organisation of human resources: Identification 
of the alternative ways in which human resource management practices can 
influence learning performance supports Lorenz and Wilkinson’s criticism against 
previous studies in the field (Lorenz and Wilkinson 2003). The authors contend that 
human resource management practices conform to some innovative definitions or 
systems of practices. This is what they interpret as the one-dimensional ranking of 
firms from traditional to dynamic working environments; the more innovative such 
management practices are, the better the expected performance of a firm 
(Ichniowski et.al, 1997). Our study showed that distinct innovation outcomes 
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associate with different human resource management practices across firms. This 
reflects the different knowledge inputs required to achieve the desired goals. In 
other words, the role of management practices depends on the scale of a firm's 
technological capabilities, as measured by the type of learning processes and 
associated innovation outcomes being generated there. Open for debate is the 
extent to which advancement in technological capabilities is tied to changes in 
organisational practices and worker characteristics. 
Relevant relationship between human resource management practices and 
learning for new product innovation: The dynamism and technological complexity of 
drug innovation in Mexico is considerably more limited than that of more developed 
countries. Specialisation in generic drugs means the country’s capacity to enhance 
the technological frontier in the industry is quite limited. Limitations are more 
evident if one considers that our reference for defining novelty of innovation was 
the firm. Nonetheless, to some extent our findings support recent research 
suggesting that human resource management practices significantly impact R&D for 
new product innovation (Christensen and Lundvall 2004; Greve 2007); in this 
particular case the design of drugs that are new to the firm. Chapter 6 
demonstrated that the more novel the drug, the greater the evidence of the 
influence of human resource management interventions. Knowledge exploration 
demands more systematic learning efforts; mobilization of human resources 
becomes more formal and systematic. 
How firms, industries and countries contribute to global innovation processes 
condition the impact of management practices on learning for innovation. 
Multinational affiliates in Mexico report very dynamic management systems, clearly 
defined procedures to govern industrial relations, intensive provision of training and 
so on. Interviews with pharmaceutical affiliates corroborated this; management 
systems were much more dynamic and advanced as compared to those 
implemented by local firms. Human resource management practices within 
multinationals usually follow models developed in parent companies but with 
careful adaptation to the Mexican context. This does not necessarily mean that 
affiliates are more innovative than some more modest local firms; at least not in 
terms of in-house R&D performance. Domestic and multinational firms differ both in 
the likelihood of conducting R&D, and more importantly, in the nature and expected 
outcomes from such activities. Affiliates of pharmaceutical firms carry out R&D in 
Mexico, but with a limited technological content and novelty, as compared to the 
activities those same firms conduct at parent locations and, only exceptionally, in 
developing countries, notably India and China. Even in the case of clinical research, 
the most relevant decisions in terms of design and planning of research protocols, 
take place at the parent companies. This distinction is key between this and previous 
studies. 
Human resource management practices influence interactions between a firm 
and external knowledge providers: Placed at the centre of the system of innovation, 
firms’ bounded knowledge bases lead them to search for new ideas, new knowledge 
residing outside their cognitive, even physical boundaries. Firms incorporate 
whatever knowledge they find strategically, according to defined business strategies, 
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specific projects and so on. Pharmaceutical firms in Mexico tend to link to research 
and academic organisations mostly as means to complement whatever learning 
activity they carry out in-house. Interactions go from pure consulting activities to 
joint project development; these consider the distinct degrees of technological 
complexity existing not only between firms and research centres, but across firms. 
Our findings suggest that the provision of training by external agents and the 
adoption of rules to govern strategic hiring assist firms to achieve the objectives of 
learning from external knowledge sources. These two practices capture the state of 
development and consequently, the type of agents a firm interacts with. 
We documented the privileged position of agents directly related with the 
industry, for instance private consultants and training centres linked to the trade 
organisations of the pharmaceutical industry in Mexico. Even as technological 
efforts gained in complexity, training from traditional knowledge producers failed to 
show statistical significance. The discussion in chapters 7 and 8 highlighted some 
serious restrictions remaining in some basic areas shaping interactions between 
pharmaceutical firms and other agents in the Mexican system of innovation. More 
decisive public policy intervention is needed to tackle some of these issues—see 
below. 
Which human resource management practices matter for learning and 
innovation in pharmaceuticals in Mexico? Although difficult to identify with 
certainty –see discussion in next section; this thesis incorporated a number of 
human resource management practices expected to influence learning and thereby 
innovation at the firm level. By far, the provision of training was the practice with 
the more notorious and positive effects on different learning strategies. This 
particular finding indicates the need for continuous learning inside firms, as 
ingredient for successful learning strategies at the firm level. Additional practices 
such as worker’s remuneration, staff hiring practices and worker’s empowerment 
showed distinct degrees of relevance depending precisely on the type of learning 
activities and learning strategies endorsed by pharmaceutical firms in Mexico. 
As can be expected, this study has several limitations: 
Identification of relevant human resource management variables is subject to 
debate: A fundamental question inspired by the discussion in chapters 1 and 3 refers 
to the human resource management practices that matter the most for learning and 
innovation. The subsequent discussion of the literature illustrated some of the 
complexities faced in defining such human resource management practices. Those 
interventions are heterogeneous, a number of technological, market related, 
institutional, even idiosyncratic factors condition approaches to the organisation of 
personnel. Even more problematic is to find out exactly how human resources 
management practices enhance tacit and other kinds of knowledge underpinning a 
firm’s improved performance over time. Finding adequate indicators to capture 
cognitive and other latent processes inside the firm is problematic. The number of 
practices suitable for the analysis is rather large; interesting constructs and 
associated interactions can be left aside. Innovation studies have thus joined 
management scholars in the broad and complex debate about factors linking 
management practices to firms’ performance (Boseli et.al, 2005; Combs et.al, 2006). 
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This study offers some further insights to continue the debate.  
Limitations in the scope and structure of available data sources: Research about 
science, technology and innovation in developing countries is usually confronted 
with the lack of data, or the limited quality and reliability of relevant available 
indicators. Chapter 3 in this thesis highlighted additional shortcomings related to 
data on human resource management practices implemented by firms in developing 
countries. Both the literature and the instruments supporting data collection show 
conceptual biases towards management practices in manufacturing. By contrast, 
scant attention is given to human resource management practices shaping work 
environments around R&D and related activities. Systematic research in this area is 
therefore problematic. Whereas case studies are insightful, advancement of theory 
calls for additional efforts to improve quantitative data, notably through survey 
instruments.  
The structure of ENESTYC illustrates the aforementioned gap. This kind of 
survey collects data about general management practices but fails to capture other 
indicators such as teamwork, communication, delegation of decision-making 
capacity, let alone finer indicators on performance evaluation (publications, patent 
counts, product developments, and so on), and compensation for performance, use 
of distinct career ladders, and so on. These and related practices are prominent in 
the literature about R&D and innovation management–see approaches type 2 and 3 
in Chapter 2. Information about interactions of R&D staff with external partners 
during the performance of R&D is also missing. This is a major limitation of our 
dataset.  
Insufficient exploration of complementarities between process and product 
innovation in the pharmaceutical industry: The literature often portrays product and 
process innovations as closely related, yet driven by different factors (Rouvinen 
2002). Although difficult to test given the structure of our data, such interrelation is 
evident in pharmaceuticals. Close regulation and supervision applicable to the 
industry implies that drug manufacturing, irrespective of the degree of novelty of 
the product, has to comply with strict specifications about the productive process. 
Changes in the characteristics of a product are constrained by eventual needs to 
modify the manufacturing process; hence the risk that the manufacturing process 
will require recertification and the need to obtain new marketing authorization. This 
reduced freedom can ultimately explain the limited influence of some human 
resource management practices on learning for pharmaceutical R&D in Mexico.  
Some policy implications also emerged from the analysis: 
The need to improve the overall conditions around learning and innovation: The 
macroeconomic environment in Mexico is not conducive to more active learning 
and innovation activities. The structure of incentives provided via public 
procurement, funding of public research organisations, and the generation of 
demand for new technologies with strong local content remains a major limitation. 
Promotion of enhanced interactivity in the system requires more decisive 
interventions, particularly from organisations responsible for the implementation of 
science and technology policy, to bring together distinct agents in the system. 
Empirical and theoretical literature suggests that progress in this area requires 
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policy interventions to align with the actions, interests and contributions of the rest 
of agents in the system. Policy interventions need to promote co-evolution in the 
system (Kuruvilla et.al, 2002; Lijima and Tachiki 1994; Metcalfe 1994 and 1997).  
This thesis identified some specific barriers to academy-industry interaction for 
pharmaceutical R&D in Mexico. Such barriers relate to the type and complexity of 
the knowledge flows required, the activities performed by firms during the distinct 
stages of the R&D process. Factors such as adequacy and availability of research 
infrastructure, presence and characteristics of human resources, as well as 
incentives and perceptions of agents in the system come distinctly into play as 
factors supporting/hindering interactivity in systems of innovation. The thesis 
suggests that promoting increased interactivity requires enhanced understanding of 
the specific knowledge requirements that firms seek to fulfil and how they do so via 
interaction with agents such as universities and public research centres. The 
discussion in this thesis should also inform about the organisation of the human 
factors intervening in R&D and other connected processes; hence it is possible to 
redefine or formulate programs targeting the development of human resources 
beyond education systems.  
The importance of enhancing the export orientation of domestic pharmaceutical 
firms: Chapters 6-8 stated that participation in export markets has positive effects 
on learning for innovation in the pharmaceutical industry. The effect was especially 
perceptible in the case of R&D for new drug designs. This conclusion is consistent 
with previous studies suggesting that successful advancement of latecomer 
pharmaceutical firms has included, as a strategic element, an aggressive export 
orientation of those firms (Chaturvedi et.al, 2007; Kale and Little 2007; Kim et.al, 
1989; Singh 2007). Unfortunately, our evidence suggests that pharmaceutical firms 
in Mexico participate relatively little in export markets; the share of exports to total 
sales rounds up at ten percent or lower. This finding calls for more specific and 
targeted policy interventions via the promotion of and support to exports by local 
pharmaceutical firms. Progress in the area remains constrained however by the 
current ideological stance of the Mexican government. Debate exists about the 
success or failure of the liberalisation strategy in the country. Over the last 20 years 
or so, Mexican governments have believed that inducing stronger competition via 
liberalization of local markets should drive enhanced incentives for productivity, 
efficiency and ultimately, innovation. Tapping external demand to induce incentives 
to innovate remains insufficiently exploited. 
It is important to re-think the impulse to innovation stemming from the public 
market: Sales of Mexican pharmaceutical firms remain tied to the public sector. In 
this regard, significant opportunities to induce innovation could result from a re-
evaluation of factors such as quality, technological content and domestic origin 
during public procurement. As discussed in chapter 6, for several reasons the 
mechanisms currently in place privilege low prices over quality of products. The 
fundamentalist logic of cutting public healthcare expenditures without efforts to 
promote the development of innovation capacities among local pharmaceutical 
firms threatens sustainability of the local industry in the long-run.  
Reshape the role of multinational affiliates as sources of technology and 
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innovation capacity: It is important here to restate one of the conclusions in chapter 
9. Mexico needs to carefully reconsider its stance towards the use of foreign 
investment as a source of external technology. Global pharmaceutical firms have 
clearly defined roles for host countries within their innovation and commercial 
strategies. The experiences of countries such as South Korea, China and India show 
that complementary actions are needed. Countries need to improve the overall 
business environment, to strengthen the use of science, technology and innovation 
as core elements of development strategies. Otherwise, the possibilities for catch-
up by leaping FDI look rather poor.  
More money helps but would not solve all problems: Insufficient funding to 
science and technology is characteristic of developing countries. Increasing financial 
investment to science and technology is not the single most imperative factor. Great 
challenges relate to promoting enhanced interactivity within the system of 
innovation. Promoting the co-evolution of research agendas by pharmaceutical 
firms and public research systems, particularly in the area of health, is needed. So 
far, the agents find themselves running at very different speeds and in different 
directions. Whereas firms privilege development, universities and other similar 
organisations favour research.  
Understanding organisational environments around R&D: Programs in support 
of R&D in private firms need to better understand the organisational environments 
in which public resources will, eventually, be used. Since human beings are at the 
heart of innovative organisations, the dynamics of working environments, as created 
via human resource management interventions, can lead to the potential success or 
failure of public funding to R&D. It is our conviction that this thesis shed light on 
how, why and which human resource management practices support learning for 
innovation in developing countries such as Mexico.   
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Annex 1 
 
 
 
 
 
“Gestión y desarrollo de recursos humanos y desempeño innovador de las empresas” 
Encuesta a Empresas de la Industria Farmacéutica en México, 2007 
 
Estimado informante, el objetivo central de esta investigación es conocer la contribución de las prácticas 
de gestión de recursos humanos a las actividades de innovación en la industria farmacéutica en México. 
Toda la información será utilizada únicamente para fines estrictamente académicos y tratada con 
absoluta confidencialidad y reserva.  
El cuestionario incluye preguntas relativas a actividades de innovación en dos áreas concretas: (i) la 
manufactura de productos farmacéuticos; y, (ii) investigación y/o desarrollo tecnológico. El énfasis es en 
la estrategia que caracteriza la gestión de los recursos humanos involucrados en actividades de innova-
ción en su empresa durante los últimos cinco años. 
Actividades innovativas denotan todas aquellas acciones necesarias para el desarrollo de produc-
tos/procesos nuevos o mejorados, se puede incluir: investigación y desarrollo de nuevos produc-
tos/procesos; diseño e ingeniería; adquisición de tecnologías incorporadas a capital (maquinaria y 
equipo) y no incorporadas a capital (patentes, licencias, know-how, marcas, servicios computacionales o 
científico-técnicos relacionados con la implementación de innovaciones); modernización organizacional 
(orientadas a reducir tiempos de producción, modificaciones en el diseño de líneas de producción, justo 
a tiempo, círculos de calidad, calidad total, etc.); comercialización (actividades relacionadas con el lan-
zamiento de productos nuevos o mejorados, incluyendo investigación de mercado, gastos en publicidad, 
medios de entrega, etc.); capacitación se refiere al entrenamiento de mano de obra relacionada con las 
actividades de innovación de la empresa. 
Investigación y desarrollo (I&D): Se refiere al trabajo creativo y sistemático que incrementa el conoci-
miento, así como el uso del conocimiento para obtener nuevas aplicaciones o mejorar las ya existentes, 
incluyendo la construcción, diseño y pruebas de prototipos. 
Dudas o preguntas acerca de cómo responder a este cuestionario, por favor comuníquese con Fernando 
Santiago, a los teléfonos: 53198590 y/o 044 55-2515 9566. Correo Electrónico: rodríguez@merit.unu.edu 
 
¡Muchas gracias por su participación! 
 
 
 
 
________________________________________ 
Nombre, departamento, cargo y firma de la persona que responde al cuestionario 
 
________________________________________ 
Teléfono (incluye LADA) y correo electrónico 
 
 
¿Le interesa obtener información sobre los resultados finales de este estudio? Sí___; No___ 
 
 
 
 
  
Número de Control (uso exclusivo del grupo de investigación) 
Facultad de Contaduria, 
Administracion e Informatica, 
UNAM 
Universidad Autonoma 
Metropolitana-
Xochimilco 
Universiteit Maastricht 
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GESTION DE RECURSOS HUMANOS E INNOVACIÓN EN LA INDUSTRIA FARMACÉUTICA MÉXICO, 2007 
 
I. DATOS GENERALES 
1. Nombre o Razón Social de la empresa: 
_____________________________________________________________________ 
2. Año de inicio de operaciones en giro actual de negocio: __________ 
3. Indique el(los) producto(s) principal(es) de la empresa según su contribución a ventas 
totales en 2006: 
Número 
productos 
% 
ventas 
Total ----------- 100% 
01 Principios activos farmacéuticos   
02 Productos farmacéuticos   
(a) De patente/éticos   
(b) Innovadores cuya patente ha vencido   
(c) Genéricos intercambiables (GI)   
(d) Similares   
03 Productos de consumo (OTC)   
04 Productos auxiliares para la salud (equipos médicos, prótesis, agentes de diagnóstico, etc.)   
05 Productos químicos y reactivos farmacéuticos   
06 Biofármacos   
07 Otros ingresos (como % de ventas totales):  
(a) Producción por con-
trato___________ 
(b) Licenciamiento tec-
nología/patentes________________ 
(c) Otros (especi-
fique)_________________ 
4. Mercado principal según distribución de sus ventas 
01 Sector Gobierno ________% 02 Sector Privado ________% 03 Exportación ____% 
5. Origen del capital de la empresa 
 01 Nacional ______%  02 Extranjero _____%  03 Mixto (Indique % nacional) _______ 
6. Ordene en una escala de 1-3 todos los procesos de manufactura presentes en sus plantas en México (donde 1=más 
importante, 3=menos importante) 
01 Biológicos ________ 02 Farmacéuticos  _________ 03 Químicos _________ 
7. ¿Cuenta con certificación para manufacturar y exportar medicamentos por parte de agencias extranjeras? 
 01 Si (especifique):  
(a) FDA (EUA); (b) EMEA (Europa); (c) Otro (¿cuáles?)_______________________ 
 02 Ninguna  
8. Indique en número de personas, el empleo total y su distribución por área/departamento al 31 de diciembre de 
2006: 
Producción______ Investigación y/o desarrollo____ Departamento Médico__ Ventas______ Total____ 
9. Indique el número de personas en su empresa que cuentan actualmente con los niveles de escolaridad siguientes:  
 Doctorado Maestría Profesional Bachillerato/Técnico 
Secundaria o 
menos 
01 Produc-
ción: 
 
 
 
02 Depto 
Médico: 
 
 
03 Ventas 
(a)Gerentes 
(b)Supervisores 
(c)Obreros 
  
(d)Gerente  
(e)Personal  
 
(f)Gerente  
(g)Rep. Médico 
______ 
______ 
______ 
 
______ 
______ 
 
______ 
______ 
_______ 
_____ 
 
_____ 
_____ 
 
_____ 
_____ 
________ 
________ 
________ 
 
________ 
________ 
 
________ 
________ 
________ 
________ 
________ 
 
________ 
________ 
 
________ 
________ 
________ 
________ 
________ 
 
________ 
________ 
 
________ 
________ 
10. Volumen promedio mensual de producción en 2006 (Millones de Unidades) 
(a) Principios Activos Farmacéuticos___________________ (b) Formulaciones Farmacéuticas________________ 
11. Indique el valor total (miles de pesos) en 2006 de:  
01 Producción:______________________ 03 Inversión Bruta Fija:_________________ 
02 Activos fijos:_____________________ 04 Ventas: __________________________ 
12. En los últimos tres años el comportamiento de sus ventas ha sido: 
01 Crecimiento continuo_________ 
02 Permanecido sin cam-
bio____________ 
03 Descenso con-
tinuo__________ 
 
  
224
II. INNOVACIÓN EN LA MANUFACTURA DE PRODUCTOS FARMACÉUTICOS 
Cuadro 1 
(Por favor lea este cuadro como auxiliar para responder a las preguntas 13-16) 
Un producto o servicio nuevo puede ser nuevo para su empresa o para el mercado y cuyas características tecnológicas 
o de uso difieren significativamente de todos los productos que su empresa produce actualmente. 
Una mejora significativa de producto o servicio se refiere a un producto previamente existente cuyo desempeño fue 
sustancialmente aumentado. Un producto complejo que consiste de varios componentes o subsistemas integrados 
puede ser perfeccionado por cambios parciales en alguno de sus componentes o subsistemas. Los cambios que son 
básicamente estéticos o de estilo, no deben ser considerados. 
Un nuevo proceso de producción es un proceso recientemente incorporado a su empresa o al sector. Involucran la 
introducción de nuevos métodos, procedimientos, sistemas, maquinaria y equipo que difieren sustancialmente de los 
utilizados por su empresa. 
Una mejora significativa a los procesos de producción involucra cambios tecnológicos importantes y parciales en 
procesos ya usados. Cambios pequeños y/o de rutina no deben ser considerados. 
Una innovación organizacional denota cambios significativos en la estructura organizacional, introducción de técnicas 
avanzadas de gestión o instrumentación de estrategias de negocio nuevas o sustancialmente modificadas. En principio 
una innovación organizacional cuenta como tal sólo si ello se traduce en cambios cuantificables en la productividad o las 
ventas de la compañía. 
13. Innovaciones de producto: Señale número de productos tecnológicamente nuevos o mejorados introducidos en 
2004-2006  
Descripción por tipo de producto Éticos OTC GI Otro Ninguno 
01 Producto nuevo para su empresa, pero existente en mercado      
02 Producto nuevo para el mercado nacional      
03 Producto nuevo para el mercado internacional      
14. Señale participación porcentual de ventas de productos nuevos o significativamente mejorados introducidos en 
2004-2006 en sus ventas totales de 2006 (Si respondió “ninguno” a todos los conceptos de la pregunta 13, pase a 
pregunta 15) 
Descripción por tipo de producto Éticos OTC GI Otro  
01 Ventas nacionales de nuevos productos      
02 Ventas nacionales de productos mejorados      
03 Exportaciones de nuevos productos      
04 Exportaciones de productos mejorados     
15. Innovaciones de proceso: Señale el número de procesos tecnológicamente nuevos o mejorados introducidos en 
2004-2006, y el impacto que tuvieron sobre las operaciones de su empresa 
 
01 Proceso nue-
vo/mejorado para 
empresa, pero existen-
te en mercado 
02 Nuevo 
mercado 
mexicano 
03 Nuevo 
mercado 
int’l 
04 
Ninguno 
(a) Aumentó productividad     
(b) Incorporó nuevas líneas de productos      
(c) Redujo no conformidades por lote producido     
(d) Aumentó participación de mercado en México     
(e) Aumentó participación mercado exportación     
(f) Cumplió con regulaciones en México     
(g) Cumplió con regulaciones en mercado externo     
(h) Redujo costos laborales     
(i) Redujo costos de insumos     
(j) Otro (especifique)________________________     
16. Innovaciones organizacionales: Si su empresa realizó innovaciones organizacionales en 2004-2006, identifique el 
área donde éstas tuvieron lugar y su impacto sobre las operaciones de la empresa 
Descripción 
01 Gestión 
producción 
02 Estructura 
organizacional 
03 Ventas 04 Otro ¿cuál?  
(a) Aumentó productividad     
(b) Incorporó nuevas líneas de productos      
(c) Redujo no conformidades por lote producido     
(d) Aumentó participación mercado en México     
(e) Aumentó participación mercado exportación     
(f) Cumplió con regulaciones en México     
(g) Cumplió con regulaciones mercado externo     
(h) Redujo costos laborales     
(i) Redujo costos de insumos     
(j) Otro (especifique)_______________________     
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 GESTIÓN Y DESARROLLO DE RECURSOS HUMANOS EN LA MANUFACTURA  
Indique la importancia de los siguientes programas para el personal en el área de manufactura: (Donde: 1=no aplica; 
2=sin importancia; 3=poco importante; 4=importante; 5=muy importante) 
(a) Plan carrera: _____ (b) Plan sucesión:________ (c) Plan retención y desarrollo talentos_______ 
III.1 Trabajo en equipo en el área de manufactura 
17. Indique la afirmación que mejor describe el trabajo en equipo para la innovación en manufactura (donde 
1=organización se asemeja principalmente a la afirmación del lado izquierdo de la numeración, 5=la organización se 
asemeja principalmente a la afirmación del lado derecho de la numeración) 
01 El trabajo en equipo: 
Se promueve formal y activamente (1) (2) (3) (4) (5) 
Surge de manera informal y es-
pontánea entre el personal 
02 La conformación de los equipos de trabajo incluye:  
Sólo personal del área de manufactura (1) (2) (3) (4) (5) 
Personal de diversas áreas en 
empresa 
03 Los equipos interactúan:   
Constantemente (1) (2) (3) (4) (5) Ocasionalmente 
04 En su composición, los equipos de trabajo son: 
Estables (1) (2) (3) (4) (5) Cambian constantemente 
05 La retroalimentación para los empleados en relación con su trabajo en el equipo es: 
Frecuente y abierta (1) (2) (3) (4) (5) Esporádica e individualizada 
06 El trabajo en equipo contribuye a difundir/compartir conocimientos 
Siempre (1) (2) (3) (4) (5) Esporádicamente 
07 Los equipos de trabajo intervienen en la toma decisiones sobre diversos aspectos del trabajo 
Siempre (1) (2) (3) (4) (5) Esporádicamente 
08 El trabajo en equipo es clave para establecer objetivos de trabajo 
Siempre (1) (2) (3) (4) (5) Esporádicamente 
09 El trabajo en equipo es clave para evaluar el cumplimiento de objetivos de trabajo 
Siempre (1) (2) (3) (4) (5) Esporádicamente 
10 Los equipos de trabajo intervienen en la búsqueda de soluciones a problemas 
Siempre (1) (2) (3) (4) (5) Esporádicamente 
11 El trabajo en equipo es clave para la mejora continua de procesos  
Siempre (1) (2) (3) (4) (5) Esporádicamente 
III.2 Comunicación interna en el área de manufactura 
18. Indique afirmación que mejor describe estrategia de comunicación para sus actividades de innovación en 
manufactura (donde 1=organización se asemeja principalmente a la afirmación del lado izquierdo de la numeración, 
5=organización se asemeja principalmente a la afirmación del lado derecho de la numeración) 
01 En general la comunicación es: 
Vertical, de arriba hacia abajo según la 
jerarquía 
(1) (2) (3) (4) (5) Horizontal, independiente de jerarquía 
02 En cuanto a su frecuencia, número de participantes y duración, las reuniones de trabajo son: 
Bien delimitadas (1) (2) (3) (4) (5) Totalmente libres 
03 La información requerida para mantener/concluir los proyectos de innovación funcionando es: 
Exclusiva del líder de proyecto/jefe de 
área 
(1) (2) (3) (4) (5) Abierta para todo el personal involucrado 
04 La retroalimentación para los empleados en relación con su trabajo es: 
Frecuente y abierta (1) (2) (3) (4) (5) Esporádica e individualizada 
05 La estrategia de comunicación busca facilitar creación y difusión del conocimiento en la empresa  
Siempre (1) (2) (3) (4) (5) Esporádicamente 
06 La comunicación buscar mantener el contacto del personal de manufactura con otras áreas y especialidades 
profesionales en la empresa 
Siempre (1) (2) (3) (4) (5) Esporádicamente 
07 La estrategia de comunicación se encamina a difundir objetivos de negocio entre el personal 
Siempre (1) (2) (3) (4) (5) Esporádicamente 
08 La estrategia de comunicación busca promover el trabajo en equipo 
Siempre (1) (2) (3) (4) (5) Esporádicamente 
09 La comunicación entre el personal se encamina a encontrar solución a problemas 
Siempre (1) (2) (3) (4) (5) Esporádicamente 
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III.3 Capacitación y/o Entrenamiento al personal de manufactura 
19. ¿Cuál fue su presupuesto anual para capacitación y/o entrenamiento del personal de manufactura en 2006?  
Miles de pesos 
_____________________ 
Como % de ventas _____________ 
20. Indique el número promedio de cursos de capacitación y/o entrenamiento recibidos por el personal de manu-
factura en2006  
(a) Gerentes _________ (b) Supervisores_________ (c) Obreros _______ 
Evalúe el tipo de habilidades y/o conocimientos que mejor caracterizan la capacitación y/o entrenamiento recibi-
dos por el personal de manufactura involucrado en actividades de innovación durante 2006 (Donde: 1=no aplica; 
2=sin importancia; 3=poco importante; 4=importante; 5=muy importante) 
 Gerente Supervisor Obrero 
01 Habilidades básicas (leer, escribir, etc.)    
02 Conocimientos técnicos especializados que no conducen a 
obtención de grado académico 
   
03 Conocimientos técnicos especializados que conducen a 
obtención de grado académico 
   
04 Metodologías para el diseño y/o conducción de experimen-
tos 
   
05 Operación/mantenimiento de maquinaria y equipo    
06 Habilidades gerenciales (negociación, comunicación, trabajo 
en equipo, presentación en público) 
   
07 Procedimientos de seguridad    
08 Buenas prácticas de manufactura     
09 Operación de cuartos limpios     
10 Idiomas     
11 Otro ¿Cuál? ____________________    
21. Evalúe la relevancia del entrenamiento/capacitación recibido según agente proveedor de la capacitación en 
2006 (donde  1=no aplica; 2=sin importancia; 3=poco importante; 4=importante; 5=muy importante) 
01 Personal de la propia empresa (salón) 
02 Personal de propia empresa (en sitio de traba-
jo)  
03 Empresas de consultoría  
04 Cámaras empresariales  
(  ) 
(  ) 
(  ) 
(  ) 
05 Universidades en México  
06 Universidades en el extranjero 
07 Proveedores 
08 Otros (especifique) _____ 
(  ) 
(  ) 
(  ) 
(  ) 
III.4 Evaluación y Retribución por desempeño al personal de manufactura  
22. La evaluación formal del desempeño tiene lugar ______veces al año 
23. Por favor indique en una escala de 1-5 la afirmación que mejor describe la evaluación y retribución por 
desempeño del personal en la manufactura (donde 1=su organización se asemeja principalmente a la afirmación del 
lado izquierdo de la numeración, 5=su organización se asemeja principalmente a la afirmación del lado derecho de 
la numeración) 
01 De acuerdo con la evaluación por desempeño:  
Los objetivos deben cumplirse 
totalmente 
(1) (2) (3) (4) (5) 
Existe absoluta flexibilidad en el cumplimiento de los 
objetivos 
02 El personal participa en la definición de sus propios objetivos laborales: 
Ocasionalmente (1) (2) (3) (4) (5) Siempre 
03 La evaluación del desempeño incluye retroalimentación y guía para el trabajador: 
Ocasionalmente (1) (2) (3) (4) (5) Siempre 
04 La evaluación de desempeño involucra: 
Únicamente al jefe y al empleado evaluado (1) (2) (3) (4) (5) 
Al jefe, pares y subordinados del perso-
nal evaluado 
05 La evaluación informa planes de capacitación y/o entrenamiento: 
Ocasionalmente (1) (2) (3) (4) (5) Siempre 
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24. Indique todos los factores relevantes para informar la retribución por desempeño del personal involucrado 
en actividades de innovación en manufactura (donde  1=no aplica; 2=sin importancia; 3=poco importante; 
4=importante; 5=muy importante) 
01 Productividad 
02 Grado de cumplimiento de objetivos 
03 Mejoras introducidas al proceso de manufactura 
04 Propuestas de mejora en la calidad del producto 
05 Participación en desarrollo de nuevos productos 
y/o procesos 
(  ) 
(  ) 
(  ) 
(  ) 
(  ) 
06 Participación en programas de 
entrenamiento y/o capacitación 
07 Trabajo en equipo 
08 Puntualidad 
09 Otros (especifique) ___________ 
(  ) 
 
(  ) 
(  ) 
(  ) 
25. Valore los objetivos de la evaluación y retribución por desempeño del personal involucrado en actividades 
de innovación en el área de manufactura (donde: 1=no aplica; 2=sin importancia; 3=poco importante; 
4=importante; 5=muy importante) 
01 Facilitar cooperación y difusión del conocimiento (1)  (2)  (3)  (4)  (5) 
02 Elevar la satisfacción por el trabajo (1)  (2)  (3)  (4)  (5) 
03 Promover la iniciativa individual (1)  (2)  (3)  (4)  (5) 
04 Fomentar trabajo en equipo (1)  (2)  (3)  (4)  (5) 
05 Promover desarrollo continuo del personal (1)  (2)  (3)  (4)  (5) 
06 Retener y desarrollar talentos (1)  (2)  (3)  (4)  (5) 
07 Otro (especifique) (1)  (2)  (3)  (4)  (5) 
26. Remuneración promedio mensual (en pesos) pagada a su personal en el área de manufactura durante 
2006 (incluya sueldos, salarios, bonos y otras prestaciones) 
Gerente________ Supervisor_________ Obrero_______ Administrativo_________ Ventas________ 
27. Por favor, evalúe todos los factores considerados para contratar nuevo personal en el área de manufactura 
(donde  1=no aplica; 2=sin importancia; 3=poco importante; 4=importante; 5=muy importante) 
01 Antecedentes académicos (1)  (2)  (3)  (4)  (5) 
02 Desarrollo profesional previo  (1)  (2)  (3)  (4)  (5) 
03 Experiencia previa en la industria farmacéutica  (1)  (2)  (3)  (4)  (5) 
04 Recomendaciones personales  (1)  (2)  (3)  (4)  (5) 
05 Vínculos familiares (1)  (2)  (3)  (4)  (5) 
06 Existencia de personal en la empresa con potencial para ser promovido  (1)  (2)  (3)  (4)  (5) 
07 Aspiraciones económicas del candidato (1)  (2)  (3)  (4)  (5) 
08 Edad del candidato (1)  (2)  (3)  (4)  (5) 
09 Otro ¿cuál?______________________________________ (1)  (2)  (3)  (4)  (5) 
 
IV. INVESTIGACIÓN Y/O DESARROLLO TECNOLÓGICO 
28. ¿Su empresa realiza actividades de investigación y/o desarrollo tecnológico? (excluye investigación clínica) 
 01 Si (especifique en dónde)  
      (a) En México (continúe a pregunta 31); (b) Sólo en el extranjero (continúe a 
Sección V) 
 02 No (continúe a Sección 
V) 
29. ¿Cuál fue su inversión en investigación y/o desarrollo tecnológico en 2006? 
01 En miles de pesos__________________  02 Como % de sus ventas en México______________ 
30. Indique el lugar donde se realizan sus actividades de investigación y/o desarrollo tecnológico 
 01 Unidad/departamento especializado perteneciente a la empresa  
 02 Centro de investigación y/o desarrollo asociado a la empresa (Especifique) ___________________________ 
 03 Instalaciones de terceros (donde: 1=no aplica; 2=sin importancia; 3=poco importante; 4=importante; 5=muy 
importante): 
              (a) Universidades 
              (b) Centro Público de Investigación 
              (c) Otras empresas del grupo 
(d) Otras empresas 
(e) Otros (¿dónde?)______________ 
31. Indique los principales resultados de las actividades de investigación y/o desarrollo tecnológico en 2004-2006  
 número % de ventas en 2006 
01 Descubrimiento de nuevas moléculas   
02 Nuevas combinaciones de moléculas existentes   
03 Desarrollo de nueva/mejorada forma de dosificación   
04 Nuevas aplicaciones de terapias existentes   
05 Desarrollo de nuevos productos genéricos   
06 Desarrollo nuevos productos de consumo (OTC)   
07 Desarrollo de nuevas formas de presentación, medios de suministro, 
empaques 
  
08 Otro (especifique)____________________   
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32. Indique el número de proyectos de investigación y/o desarrollo tecnológico de su empresa en 2004-2006 
01 Total ______ 02 Concluidos con éxito _____ 03 Concluidos sin éxito _______ 04 Sin concluir ________ 
33. Número de Patentes asociadas a sus actividades de investigación y/o desarrollo tecnológico en México en 2004-
2006 
01 En proceso de solicitud (¿cuántas?)  ___________ 
02 Obtenidas______ (Especifique país): (a) EUA_____; (b) Europa_____; (c) México_____; (d) Otros (especifique)______ 
03 Ninguna ________ 
34. Número de Publicaciones obtenidas por sus actividades de investigación y/o desarrollo tecnológico en México, 
2004-2006  
01 Nacionales _______________; 02 Internacionales ________________; 03 Ninguna _________ 
35. Evalúe la importancia de las ideas provenientes de las siguientes áreas para iniciar proyectos de investigación y/o 
desarrollo tecnológico (donde: 1=no aplica; 2=sin importancia; 3=poco importante; 4=importante; 5=muy importan-
te) 
01 Casa Matriz (1)  (2)  (3)  (4)  (5) 09 Competidores  (1)  (2)  (3)  (4)  (5) 
02 Otras empresa del grupo (1)  (2)  (3)  (4)  (5) 10 Médicos (1)  (2)  (3)  (4)  (5) 
03 Departamento de investigación y 
desarrollo 
(1)  (2)  (3)  (4)  (5) 
11 Pacientes 
  (1)  (2)  (3)  (4) (5) 
04 Departamento médico 
(1)  (2)  (3)  (4)  (5) 12 Centro público de investiga-
ción 
(1)  (2)  (3)  (4)  (5) 
05 Área de manufactura (1)  (2)  (3)  (4)  (5) 13 Universidades (1)  (2)  (3)  (4)  (5) 
06 Ventas/mercadotecnia (1)  (2)  (3)  (4)  (5) 14 Oficinas de patentes (1)  (2)  (3)  (4)  (5) 
07 Clientes (1)  (2)  (3)  (4)  (5) 15 Publicaciones (1)  (2)  (3)  (4)  (5) 
08 Proveedores 
(1)  (2)  (3)  (4)  (5) 16 Regulación/normas 
locales 
(1)  (2)  (3)  (4)  (5) 
09 Socios estratégicos (1)  (2)  (3)  (4)  (5) 17 Otro (¿cuál?) (1)  (2)  (3)  (4)  (5) 
 
V. INVESTIGACIÓN CLÍNICA 
36. ¿Realiza investigación clínica? 
 01 Si (especifique en dónde)  
(a) En México (continúe a pregunta 39); (b) Sólo en el extranjero (pase a 
Sección VI) 
 02 No (pase a Sección VI) 
37. Indique el número de protocolos de investigación clínica patrocinados en 2006______________ 
38. ¿Cuál fue su inversión en investigación clínica en México en 2006? 
01 Miles de pesos________________ 02 Como % de sus ventas en México _____________ 
39. Indique quién se encarga de redactar los protocolos de investigación clínica de manera rutinaria:  
01 Si su empresa es transnacional  02 Si su empresa es nacional 
La casa matriz   
 (a) Según 
lineamientos 
de país sede 
 (b) Según 
regulación 
mexicana 
 (c) Personal de 
filial en Méxi-
co 
 Per-
sonal 
médico  
 Otro 
(¿quién?) 
__________ 
40. Evalúe por su importancia, la institución a la que recurre para llevar a cabo las actividades de investigación clínica 
(donde: 1=no aplica; 2=sin importancia; 3=poco importante; 4=importante; 5=muy importante) 
01 Universidad_ 02 Inst. Público Salud  03 Org. de investigación por contrato_____ 04 Hospital Privado___ 
41. Evalúe el tipo de proyectos de investigación clínica patrocinados por la empresa durante 2005-2006, (donde: 1=no 
aplica; 2=sin importancia; 3=poco importante; 4=importante; 5=muy importante) 
 01 Estudios Fase I (Primera evaluación de un nuevo fármaco en humanos; identificación de dosis seguras para 
realizar estudios posteriores) 
 02 Estudios Fase II (Estudios cuyo objetivo es estimar la actividad clínica y toxicidad de una nueva droga; ensa-
yos clínicas no controlados) 
 03 Estudios Fase III (Prueba de eficacia y seguridad de un nuevo fármaco en ensayos clínicos controlados, utili-
zados como herramienta de medición comparativa) 
 04 Estudios Fase IV (Estudios posteriores a la aprobación de una droga para una determinada indicación o pa-
decimiento. Se evalúan nuevas indicaciones y/o aplicaciones, además de evaluar usos terapéuticos que no hab-
ían analizado previamente) 
 05 Biodisponibilidad y Bioequivalencia  
 06 Otro(s) (especifique) _______________________________________ 
 
  
229
VI. GESTIÓN Y DESARROLLO DE RECURSOS HUMANOS EN INVESTIGACIÓN Y/O DESARROLLO 
(Si no realiza actividades de investigación y/o desarrollo tecnológico en México concluya el cuestionario) 
(Considere la estrategia de gestión característica de su empresa durante los últimos cinco años) 
42. Personal dedicado a investigación y/o desarrollo tecnológico al 31 de diciembre de 2006:  
Tiempo parcial____________; Tiempo completo____________; Total ____________ 
43. Indique la importancia de los siguientes programas para el personal involucrado en actividades de investigación 
y/o desarrollo: (Donde: 1=no aplica; 2=sin importancia; 3=poco importante; 4=importante; 5=muy importante) 
(a) Plan de carrera: _____ 
(b) Plan de suce-
sión:______ 
(c) Plan de retención y desarrollo de talentos______ 
44. Indique cuántos de sus empleados en investigación y/o desarrollo tecnológico cuentan con los siguientes niveles 
de escolaridad 
Área Investigadores 
Asistentes de 
investigación 
Directivos Monitores clínicos Administrativos 
Doctorado ________ ________ ________ ________ ________ 
Maestría/Especialidad ________ ________ ________ ________ ________ 
Profesional  ________ ________ ________ ________ ________ 
Bachillerato/Técnico ________ ________ ________ ________ ________ 
Secundaria o menor ________ ________ ________ ________ ________ 
VI.1 Trabajo en equipo en actividades de investigación y/o desarrollo tecnológico 
45. Elija la afirmación que mejor describe el trabajo en equipo relacionado con sus actividades de investigación y/o 
desarrollo (donde 1=la organización se asemeja principalmente a la afirmación del lado izquierdo de la numeración, 
5=la organización se asemeja principalmente a la afirmación del lado derecho de la numeración) 
01 El trabajo en equipo: 
Se promueve formal y activamente (1) (2) (3) (4) (5) 
Surge de manera informal y espontánea entre el 
personal 
02 En general, la conformación de los equipos de trabajo incluye: 
Sólo personal del área de investigación y 
desarrollo 
(1) (2) (3) (4) (5) Personal de diversas áreas de la empresa 
03 En su composición, los equipos de trabajo son: 
Estables (1) (2) (3) (4) (5) Cambian constantemente 
04 Los equipos de trabajo interactúan: 
Constantemente (1) (2) (3) (4) (5) Ocasionalmente 
05 La capacidad para la toma de decisiones ante problemas es: 
Exclusiva del director o supervisor (1) (2) (3) (4) (5) 
Distribuida entre los integrantes del equipo sin 
importar su jerarquía  
06 Los equipos intervienen en la decisión respecto al inicio/terminación de proyectos de investigación y/o desarrollo  
Siempre (1) (2) (3) (4) (5) Esporádicamente 
07 La retroalimentación para el personal en relación con su trabajo en el equipo es: 
Frecuente y abierta (1) (2) (3) (4) (5) Esporádica e individualizada 
08 El trabajo en equipo contribuye a difundir/compartir conocimientos 
Siempre (1) (2) (3) (4) (5) Esporádicamente 
09 El trabajo en equipo contribuye a desarrollar un lenguaje común, normas de conducta entre sus integrantes 
Siempre (1) (2) (3) (4) (5) Esporádicamente 
10 El trabajo en equipo contribuye al desarrollo profesional de los integrantes del equipo  
Siempre (1) (2) (3) (4) (5) Esporádicamente 
11 El trabajo en equipo es clave para establecer objetivos de trabajo 
Siempre (1) (2) (3) (4) (5) Esporádicamente 
12 El trabajo en equipo es clave para evaluar el cumplimiento de los objetivos de trabajo 
Siempre (1) (2) (3) (4) (5) Esporádicamente 
13 El trabajo en equipos es clave para la mejora continua de procesos  
Siempre (1) (2) (3) (4) (5) Esporádicamente 
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VI.2 Comunicación interna y externa en actividades de investigación y/o desarrollo tecnológico 
46. Por favor indique la afirmación que mejor describe la comunicación interna entre su personal en actividades de 
investigación y/o desarrollo (donde 1=su organización se asemeja principalmente a la afirmación del lado izquierdo de 
la numeración, 5=su organización se asemeja principalmente a la afirmación del lado derecho de la numeración) 
01 En general la comunicación es: 
Vertical, de arriba hacia abajo según la jerar-
quía 
(1) (2) (3) (4) (5) Horizontal, independientemente de la jerarquía 
02 En cuanto a su frecuencia, número de participantes y duración, las reuniones de trabajo son: 
Bien delimitadas (1) (2) (3) (4) (5) Totalmente libres 
03 La información requerida para mantener los proyectos de investigación y/o desarrollo funcionando es: 
Exclusiva del líder de proyecto o jefe del área (1) (2) (3) (4) (5) Abierta para todo el personal involucrado 
04 La información requerida para concluir los proyectos de investigación y/o desarrollo funcionando es: 
Exclusiva del líder de proyecto o jefe del área (1) (2) (3) (4) (5) Abierta para todo el personal involucrado 
05 La retroalimentación para los empleados en relación con su trabajo de investigación y/o desarrollo es: 
Frecuente y abierta (1) (2) (3) (4) (5) Esporádica e individualizada 
06 La estrategia de comunicación busca facilitar creación y difusión del conocimiento a lo largo de la empresa  
Siempre (1) (2) (3) (4) (5) Esporádicamente 
07 La comunicación permite al personal científico/técnico conocer necesidades de otras áreas de la empresa 
Siempre (1) (2) (3) (4) (5) Esporádicamente 
08 El personal requiere conocer el desarrollo del mercado, la técnica/ciencia internacional y traducirlos en respuestas a 
necesidades corporativas 
Siempre (1) (2) (3) (4) (5) Esporádicamente 
09 En su trabajo, el personal necesita integrar demandas de investigación, desarrollo, producción y mercadotecnia  
Siempre (1) (2) (3) (4) (5) Esporádicamente 
47. Indique la importancia de las siguientes afirmaciones respecto a la comunicación externa por parte de su personal en 
investigación y/o desarrollo (Donde: 1=no aplica; 2=sin importancia; 3= poco importante; 4=importante; 5=muy impor-
tante) 
 (a) México (b) El extranjero 
01 El personal publica su trabajo en:  (1)  (2)  (3)  (4)  (5) (1)  (2)  (3)  (4)  (5) 
02 El personal presenta su trabajo en seminarios y congresos 
en: 
(1)  (2)  (3)  (4)  (5) (1)  (2)  (3)  (4)  (5) 
03 La empresa promueve co-autorías entre su personal con 
investigadores en: 
(1)  (2)  (3)  (4)  (5) (1)  (2)  (3)  (4)  (5) 
48. Durante sus actividades de investigación y/o desarrollo el personal científico/técnico interactúa activamente con sus 
pares en  
 (a) México (b) El extranjero 
01 Otras empresas en: (1)  (2)  (3)  (4)  (5) (1)  (2)  (3)  (4)  (5) 
02 Instituciones de investigación en: (1)  (2)  (3)  (4)  (5) (1)  (2)  (3)  (4)  (5) 
03 Instituciones de educación superior en: (1)  (2)  (3)  (4)  (5) (1)  (2)  (3)  (4)  (5) 
49. Evalúe los objetivos de la comunicación interna y externa por parte de su personal en investigación y/o desarrollo 
tecnológico (Donde: 1=no aplica; 2=sin importancia; 3=poco importante; 4=importante; 5=muy importante) 
01 Facilitar creación y difusión del conocimiento (1)  (2)  (3)  (4)  (5) 
02 Encontrar solución a problemas  (1)  (2)  (3)  (4)  (5) 
03 Difundir objetivos de negocio entre el personal  (1)  (2)  (3)  (4)  (5) 
04 Integrar al personal de diferentes áreas y especialidades (1)  (2)  (3)  (4)  (5) 
05 Mantener contacto del personal técnico/científico con el resto de la empresa (1)  (2)  (3)  (4)  (5) 
06 Aumentar la reputación y reconocimiento interno de los investigadores (1)  (2)  (3)  (4)  (5) 
07 Aumentar la reputación y reconocimiento externo de los investigadores  (1)  (2)  (3)  (4)  (5) 
08 Otro (especifique)___________________________________ (1)  (2)  (3)  (4)  (5) 
 
  
231
VI.3 Capacitación y Entrenamiento del personal de investigación y/o desarrollo tecnológico 
50. Presupuesto anual para capacitación y/o entrenamiento del personal de investigación y/o desarrollo tecnológico en 
2006?  
Miles de pesos _____________________ Como % de ventas ____________________ 
51. ¿Durante 2006 recibió capacitación el personal de investigación y/o desarrollo tecnológi-
co?   
 Si  No 
52. Indique el número promedio de cursos de capacitación y/o entrenamiento recibidos por el personal de investiga-
ción y/o desarrollo tecnológico durante 2006  
(a) Directivos _______________________ 
(b) Investigadores _______________________ 
(c) Asistentes de investigación _______________________ 
(d) Administrativos  _______________________ 
(e) Monitores clínicos _______________________ 
53. Evalúe la relevancia del entrenamiento/capacitación recibido por el personal de investigación y/o desarrollo, según 
agente capacitador en 2006 (Donde: 1=no aplica; 2=sin importancia; 3=poco importante; 4=importante; 5=muy impor-
tante) 
01 Personal de la propia empresa (salón) 
02 Personal de la propia empresa (en el 
sitio de trabajo)  
03 Empresas de consultoría  
04 Cámaras empresariales  
(  ) 
(  ) 
(  ) 
(  ) 
05 Universidades en México  
06 Universidades en el extranjero 
07 Socios de investigación 
08 Otros (especifique) ________________ 
(  ) 
(  ) 
(  ) 
(  ) 
54. Evalúe las habilidades y/o conocimientos que mejor describen la capacitación y/o entrenamiento recibidos por el 
personal de investigación y/o desarrollo en 2006 (Donde: 1=no aplica; 2=sin importancia; 3=poco importante; 
4=importante; 5=muy importante) 
 
Directivo Investigador Asistente de 
investigación 
Monitor 
clínico 
Administrativo 
01 Habilidades básicas (leer, escribir, etc.)      
02 Conocimientos técnicos especializados que 
no conducen a obtención de grado académico 
     
03 Conocimientos técnicos especializados que 
conducen a obtención de grado académico 
     
04 Habilidades gerenciales (negociación, 
comunicación, trabajo en equipo)  
     
05 Buenas prácticas de manufactura       
06 Principios de buenas prácticas de laboratorio       
07 Principios de buenas prácticas clínicas       
08 Metodología para el diseño y/o conducción 
de experimentos  
     
09 Operación/mantenimiento de maquinaria y 
equipo 
     
10 Procedimientos de seguridad      
11 Idiomas      
12 Otros (especifique) ___________________      
VI.4 Evaluación y Retribución por desempeño del personal de investigación y/o desarrollo tecnológico 
55. Evaluación formal del desempeño del personal de investigación y/o desarrollo tecnológico tiene lugar ___veces al año 
56. Indique en una escala de 1-5 la afirmación que mejor describelas características de la evaluación por desempeño de su 
personal de investigación y/o desarrollo tecnológico (donde con respecto a la numeración, 1=organización se asemeja 
principalmente a la afirmación del lado izquierdo, 5= organización se asemeja principalmente a la afirmación del lado de-
recho) 
01 De acuerdo con la evaluación por desempeño:  
Los objetivos deben cumplirse totalmente (1) (2) (3) (4) (5) 
Existe absoluta flexibilidad en cumplimiento de 
objetivos 
02 El personal participa en la definición de sus propios objetivos laborales: 
Ocasionalmente (1) (2) (3) (4) (5) Siempre 
03 La evaluación del desempeño incluye retroalimentación y guía para el trabajador 
Ocasionalmente (1) (2) (3) (4) (5) Siempre 
04 La evaluación de desempeño involucra: 
Únicamente al jefe y al empleado evaluado (1) (2) (3) (4) (5) 
Al jefe, pares y subordinados del personal evalua-
do 
05  La evaluación informa planes de capacitación y/o entrenamiento:: 
Ocasionalmente (1) (2) (3) (4) (5) Siempre 
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 57. Evalúe la importancia de los siguientes factores para informar la retribución al desempeño del personal en investi-
gación y/o desarrollo tecnológico: (donde 1=no aplica; 2=sin importancia; 3=poco importante; 4=importante; 5=muy 
importante) 
01 Desarrollo de nuevos productos  (1)  (2)  (3)  (4)  (5) 06 Obtención de patentes  (1)  (2)  (3)  (4)  (5) 
02 Obtención de registros sanitarios  (1)  (2)  (3)  (4)  (5) 07 Colaboraciones externas (1)  (2)  (3)  (4)  (5) 
03 Publicación en revistas científicas 
prestigiadas 
(1)  (2)  (3)  (4)  (5) 08 Obtener financiamiento 
externo 
(1)  (2)  (3)  (4)  (5) 
04 Publicar reportes/manuales en la 
compañía 
(1)  (2)  (3)  (4)  (5) 09 Cumplir objetivos person-
ales 
(1)  (2)  (3)  (4)  (5) 
05 Presentaciones en seminar-
ios/congresos 
(1)  (2)  (3)  (4)  (5) 
10 Otro (¿cuál?) __________ 
(1)  (2)  (3)  (4)  (5) 
58.Evalúe los objetivos de la evaluación y retribución por desempeño de su personal de investigación y/o desarrollo 
tecnológico (donde 1=no aplica; 2=sin importancia; 3=poco importante; 4=importante; 5=muy importante) 
01 Facilitar cooperación y difusión del conocimiento (1)  (2)  (3)  (4)  (5) 
02 Elevar la satisfacción por el trabajo (1)  (2)  (3)  (4)  (5) 
03 Promover la iniciativa individual (1)  (2)  (3)  (4)  (5) 
04 Fomentar trabajo en equipo (1)  (2)  (3)  (4)  (5) 
05 Retener y desarrollar talentos  (1)  (2)  (3)  (4)  (5) 
06 Detectar necesidades de capacitación y/o entrenamiento (1)  (2)  (3)  (4)  (5) 
07 Otros (¿cuál?)___________________________________________ (1)  (2)  (3)  (4)  (5) 
59.Remuneración promedio mensual en pesos (incluye salario, bonos y cualquier otro pago) para personal de investiga-
ción y/o desarrollo tecnológico 
Gerente________ Investigador_______ 
Asistente Investi-
gador___ 
Monitor 
Clínico____ 
Administrativo_______ 
60. Evalúe los factores relevantes para la contratación de nuevo personal para actividades de investigación y/o 
desarrollo tecnológico (donde 1=no aplica; 2=sin importancia; 3=poco importante; 4=importante; 5=muy importante) 
01 Antecedentes académicos (1)  (2)  (3)  (4)  (5) 
02 Experiencia en investigación y desarrollo de productos farmacéuticos (1)  (2)  (3)  (4)  (5) 
03 Capacidad probada para publicar en revistas académicas de prestigio  (1)  (2)  (3)  (4)  (5) 
04 Historial de patentes obtenidas (1)  (2)  (3)  (4)  (5) 
05 Capacidad para establecer contactos en universidades/centros de investigación en México (1)  (2)  (3)  (4)  (5) 
06 Capacidad para establecer contactos en universidades/centros de investigación en el extran-
jero 
(1)  (2)  (3)  (4)  (5) 
07 Experiencia previa en la industria farmacéutica (1)  (2)  (3)  (4)  (5) 
08 Recomendaciones personales (1)  (2)  (3)  (4)  (5) 
09 Recomendaciones familiares (1)  (2)  (3)  (4)  (5) 
10 Existencia de personal en la empresa con potencial para ser promovido (1)  (2)  (3)  (4)  (5) 
11 Aspiraciones económicas del candidato (1)  (2)  (3)  (4)  (5) 
12 Edad del candidato (1)  (2)  (3)  (4)  (5) 
13 Otro (¿cuál?)___________________________________________________ (1)  (2)  (3)  (4)  (5) 
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Annex 2: Pharmaceutical firms operating in Mexico, 2007 
 CANIFARMA AMIIF ANAFAM 
Abbott Laboratories de México, S.A. de C.V. X X  
Alcon Laboratorios, S.A. de C.V.  X    
Allen Laboratorios S.A. de C.V.      
Allergan, S.A. de C.V. X    
Almirall, S.A. de C.V. X    
Alpharma     X 
Altana Pharma, S.A. de C.V./byk gulden X X  
Alvartis Pharma, S.A. de C.V.      
Antibióticos de México, S.A. DE C.V.  X    
APITEX     X 
Aplicaciones Farmacéuticas, S.A. de C.V. X    
Armstrong Laboratorios de México, S.A. de C.V. X X  
Asofarma de México, S.A. de C.V. X    
Aspid, S.A. de C.V. X    
Astrazeneca, S.A. de C.V. X X  
Atlantis     X 
Baxter, S.A. de C.V. X    
Bayer de México, S.A. de C.V. X X  
Beckman Laboratories México, S.A. de C.V. X    
Biofarma Natural CMD      
Bioresearch de México, S.A. de C.V.      
Boehringer Ingelheim Promeco, S.A. de C.V. X X  
Bristol Myers Squibb de México, S de RL de CV X X  
BRULUAGSA S.A. de C.V.       
Chinoin    X   
Compañía Internacional de Comercio, S.A. de C.V. X     
Codifarma    
Degort's Chemical S.A. de C.V       
Diba S.A.       
Distribuidora de Alimentos Naturales y Nutricionales S.A. de C.V.       
Eli Lilly y Compañía de México, S.A. de C.V. X X   
Específicos Stendhal, S.A. DE C.V. X     
Farmacéutica Wandel, S.A. de C.V.       
Farmacéuticos Ederka, S.A. de C.V.       
Farmacéuticos Rayere, AS X     
Fármacos Continentales, S.A. de C.V. X     
Ferring, S.A. DE C.V. X X   
Fersinsa/GIST Brocades, S.A. de C.V.       
Fresenius Kabi México, S.A. de C.V. X     
Galderma México, S.A. de C.V. X     
Genética Laboratorios, S.A. de C.V.       
Genzyme México, S de RL de CV X     
GlaxoSmithKline México, S.A. de C.V. X X   
Goñi’s S.R.L. de C.V.       
Grimann S.A. de C.V.       
Grisi Hermanos, SA X     
Grünenthal de México S.A. de C.V.    X   
Grupo Carbel, S.A. de C.V. X   X 
Grupo Roche Syntex de México, S.A. de C.V. X     
Hospira, S DE RLL DE CV  X     
ICN Farmacéutica, S.A. de C.V. X     
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 CANIFARMA AMIIF ANAFAM 
Importadora y Manufacturera Bruluart, SA X   X 
Industria Farmacéutica Andromaco, S.A. de C.V. X     
Industrias Suanca, S.A. de C.V.       
Instituto Bioclón, S.A. de C.V. X     
Investigación Farmacéutica, S.A. de C.V.  X     
Italmex, SA X     
Ivax Pharmaceuticals México, S.A. de C.V. X   X 
Janssen-Cilag, S.A. de C.V. X X   
Keton de México S.A. de C.V.        
Laboratorio Bioquímico     X 
Laboratorio Bioquímico Mexicano, S.A. De C.V       
Laboratorio de Especialidades Homeopáticas Millenium, S.A. de C.V. X     
Laboratorio Farmacológico Nutrimedi S.A. de C.V.  X     
Laboratorio Médico Químico Biológico, S.A. de C.V.       
Laboratorios Cryopharma, S.A. de C.V. X     
Laboratorios Grossman, SA X     
Laboratorios Hexal, S.A. de C.V. X     
Laboratorios Hormona, S.A. de C.V. X   X 
Laboratorios Kendrick, SA X   X 
Laboratorios Kener, S.A. de C.V. X   X 
Laboratorios Liomont, S.A. de C.V. X   X 
Laboratorios Manuell SA     X 
Laboratorios Pisa, S.A. de C.V. X   X 
Laboratorios Pizzard, S.A. de C.V. X     
Laboratorios Quimpharma, S.A. de C.V. X     
Laboratorios Raam de Sahuayo, S. A. de C. V       
Laboratorios Salus, S.A. de C.V. X     
Laboratorios Sanfer, S.A. de C.V. X X   
Laboratorios Sardel de Xalapa, S.A. de C.V.       
Laboratorios Serral S.A    
Laboratorios Senosiain, S.A. de C.V. X   X 
Laboratorios Servier, S.A. de C.V. X     
Laboratorios Silanes, S.A. de C.V. X   X 
Laboratorios Solfran, S.A. DE C.V. X     
Laboratorios Sophia, S.A. de C.V. X     
Laboratorios Valdecasas, SA X   X 
Laboratorios Zafiro, S.A. de C.V.       
Laboratorios Zerboni, SA X   X 
Landsteiner Scientific S.A. de C.V.     X 
Lemery, S.A. de C.V. X   X 
Lundbeck México, S.A. de C.V. X     
Marcel S.A. de C.V.       
Medix     X 
Merck Sharp & Dohme de México, S.A. de C.V. X X   
Merck, S.A. de C.V. X     
Merz   X   
Monticello Drug Company, SA X     
Novag Infancia, S.A. de C.V       
Novartis Farmacéutica, S.A. de C.V. X X   
Novo Nordisk Mexico, S.A. de C.V. X X   
NUCITEC, S.A. de C.V.       
Octapharma, S.A. de C.V. X     
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 CANIFARMA AMIIF ANAFAM 
Offenbach Mexicana, S.A. de C.V.       
Olnatura S.A. de C.V       
Organon Mexicana, S.A. de C.V. X X   
Pfizer, S.A. de C.V.-Pharmacia Upjhon X X   
Pharmacos Exakta, S.A. de C.V. X   X 
Pharmanova, S.A. de C.V. X     
Precimex S.A. de C.V.     X 
Probiomed, S.A. de C.V. X     
Productos Farmacéuticos, S.A. de C.V. X     
Productos Mavi, S.A. de C.V.  X     
Productos Químicos Naturales, S.A.       
Protein, S.A. de C.V. X     
Pro-Ventas, S.A. de C.V. X     
Provit S.A. de C.V.       
Psicofarma, S.A. de C.V. X   X 
Química y Farmacia, S.A. de C.V. X   X 
Randall laboratories, S.A. de C.V. X     
Representaciones e Investigaciones Médicas, S.A. de C.V. X   X 
Representaciones Mex-América, S.A. de C.V.       
Romsa de México, S.A. de C.V. X     
Sanofi Synthelabo de México, S.A. de C.V. X     
Sanofi-Aventis   X   
SBL Pharmaceuticals, S de RL de CV  X     
Schering Mexicana, S.A. de C.V. X X   
Schering Plough, S.A. de C.V. X X   
Schwabe México, S.A. de C.V. X     
Serono de México, S.A. de C.V. X X   
Siegfried Rhein, S.A. de C.V. X     
Stiefel Mexicana, S.A. de C.V.  X     
Streger, SA X     
Tecnofarma, S.A. de C.V. X   X 
Terapia Infantil S.A. de C.V.       
Ultra Laboratorios, S.A de C.V       
Unipharm de México, S.A. de C.V. X     
Valeant Farmacéutica, S.A. de C.V. X X   
Wermar Pharmaceuticals S.A. de C.V.       
Wyeth, S.A. de C.V. X X   
Source: Author with information from CANIFARMA, AMIIF, ANAFAM; Pharmacopea de los Estados Unidos Mexicanos; 
Internet sites of firms and other organizations specialised in the industry. See chapter 4 for a more ample discussion.  
Source: Author 
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Samenvatting 
 
 
 
Dit proefschrift draagt bij aan de literatuur over Human Resource Management 
(HRM) praktijken, en het leerproces bij innovatie in de context van ontwikke-
lingslanden. Het brengt bij elkaar literatuur over: (1) innovatie systemen, (2) HRM 
praktijken en innovatieve prestaties op bedrijfsniveau, en (3) leren door middel van 
R&D. Het proefschrift interpreteert R&D als "leren", een mechanisme ter bevorder-
ing van opname capaciteit en ter ondersteuning van de opbouw van technologische 
capaciteiten. 
Empirisch bewijs verwijst naar de farmaceutische industrie in Mexico en bouwt 
voort op twee soorten gegevens: kwalitatieve en kwantitatieve uit zowel primaire 
als secundaire bronnen. Primaire gegevens werden verzameld door zowel een en-
quête uitgevoerd door de Mexicaanse regering als door een reeks diepte-interviews 
met vertegenwoordigers van de farmaceutische industrie, medisch onderzoek, en 
regulerende organisaties. Secundaire gegevens kwamen uit uitgebreide zoekop-
drachten op archiefmateriaal en andere documentaire bronnen, het bijwonen van 
gespecialiseerde seminars, presentaties, internet, etc. 
De empirische analyse maakt onderscheid tussen leren als strategie, en het leren in 
termen van kennis inhoud. Met andere woorden, bedrijven onderschrijven verschil-
lende leerstrategieën en vereisen verschillende soorten kennis tijdens het R&D-
proces. Voor wat het voormalige betreft, kunnen bedrijven technologie produceren 
gebaseerd op interne technologische, - R&D-inspanningen -, of de externe techno-
logie markten aanboren als een exclusieve bron van kennis. Als alternatief kunnen 
ondernemingen streven naar complementariteit tussen beide leerstrategieën. 
In termen van kennis inhoud, en in overeenstemming met op kennis gebaseerde 
ondernemingstheorieën, kunnen de farmaceutische bedrijven in Mexico of de ken-
nis die binnen hun gebruikelijke kennisbasis aanwezig is exploiteren, of op zoek 
gaan naar die delen van de kennis die tot nu toe niet beschikbaar voor hen zijn. 
Verschillende kennis eisen associëren met distinctieve R&D-resultaten met verschil-
lende gradaties van noviteit, althans voor de onderneming. Derhalve onderzocht 
het proefschrift hoe de farmaceutische R&D die leidt tot de goedkeuring van verbe-
terde of nieuwe (generieke) medicijnen en/of drugs productieprocessen door HRM 
praktijken wordt onderbouwt. 
Het gebruik van leren als relevante dimensie voor de analyse is een belangrijke 
bijdrage van dit proefschrift; het bouwt verder op een aantal eerdere studies op dit 
gebied die rechtstreekse verbindingen tussen HRM praktijken en de innovatieve 
prestaties op bedrijfsniveau traceren. Hoewel dergelijke studies vaak positieve rela-
ties tussen deze variabelen aantreffen, zijn ze niet in staat om uit te leggen waarom 
dit zo is. Dit proefschrift werpt licht op hoe en waarom management praktijken, 
leren voor innovatie, onderbouwen: de verwantschappen zijn afhankelijk van facto-
ren zoals de verwachte uitkomst van R&D, of de noviteit van de vereiste kennis van 
de onderneming. De verschillende HRM interventies dragen ieder anders bij aan de 
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aanleg van de noodzakelijke opnamecapaciteit en innovatiecapaciteit van farma-
ceutische bedrijven. 
De analyse toonde aan dat de sociaal-economische context van belang is voor leren 
en innovatie; ze bepaalt hoe landen, sectoren en ondernemingen inbrengen en 
bijdragen aan de innovatie in specifieke sectoren/bedrijfstakken. Landen zoals Mex-
ico karakteriseren zich door strikte arbeids controles, beperkte R&D en een speciali-
satie in incrementele innovaties; de kenmerken van een onderneming derhalve, in 
het bijzonder de exportpositie en de oorsprong van het kapitaal bezit, verklaren 
grotendeels het leergedrag van farmaceutische bedrijven in het land. 
Niettemin, HRM praktijken grijpen in op twee belangrijke gebieden. Ten eerste 
begeleiden ze de mobilisatie en de exploitatie van kennis die al in het bedrijf aan-
wezig is. Ten tweede sturen ze het zoeken naar en verkennen van kennis die eerder 
niet beschikbaar binnen de onderneming; zij dragen bij aan de verrijking van de 
kennisbasis van een bedrijf. Verschillende HRM praktijken associëren met verschil-
lende R&D processen en verwachte resultaten van innovatie; zij beinvloeden ook 
interacties tussen een bedrijf en externe kennisaanbieders. Het aanreiken van op-
leidingen en het aannemen van regels om het strategische inhuren te besturen zijn 
management praktijken die leren door middel van R&D in de farmaceutische indus-
trie in Mexico bijstaan. 
Dit proefschrift stelt voor dat een beter begrip van organisatorische omgevingen 
rondom R&D nodig is aangezien de mens aan de basis staat van innovatieve organi-
saties; de dynamiek van de werkomgeving, zoals geschapen door HRM interventies, 
kan het leren versterken door middel van R&D. 
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